

**EHRlich II –2nd World Conference
on Magic Bullets**

**Celebrating the 100th Anniversary of the
Nobel Prize Award to Paul Ehrlich**

Nürnberg, Germany

October 3-5, 2008

Program

Welcome to Nürnberg,

We are pleased that you took the occasion of the celebration of the 100th Anniversary of the Nobel Prize awarded to Paul Ehrlich to come to Germany and to our beautiful city of Nürnberg. We hope that in spite of the large scientific program you will have some time to see our city and the area around. Likewise the Paul Ehrlich and the Penicillin Exhibition as well as the "Anniversary Celebration Party" on Saturday should give you time to relax and enjoy.

1477 international participants from 99 countries have registered for the conference making already the "2nd World Conference on Magic Bullets" a great interdisciplinary event and what it always also was meant to be which is to commemorate one of medicine's and pharmaceuticals' most prominent and multi-talented scientists: Paul Ehrlich. We thank you all for your excellent scientific contributions that make the conference that Paul Ehrlich deserves.

We are also pleased that many colleagues from smaller countries and Third World countries could make it to Germany in difficult times when visa restrictions are also beginning to affect travel of scientists. To allow participation for as many scientists as possible we accepted submissions to the very last moment; actually Sunday, September 27th, 2008, in cases where the visa was obtained Friday, September 26th !

In times of difficult funding for conferences the President's institution decided to organize the conference by itself and thus making it possible to come for many who would usually not have been able to come because of budget restrictions. A special thank to all members of the Institute for Biomedical and Pharmaceutical Research (IBMP) for making this meeting possible for a second time through their enduring energy. A true Hercules work that usually is not provided by a conference. A tremendous number of people needs to be handled and therefore we ask for patience if necessary. Presenters and chairmen are particularly requested to stay within the very tight timelines since we tried to even fit the program to individual needs of presence here.

We would like to thank the Minister-President ("Governor") of the State of Bavaria, Dr. Günther Beckstein, for taking over the patronage of the conference.

The conference is hosted by ISAP – International Society of Anti-Infective Pharmacology, German Pharmaceutics Association (DPhG) and Infektliga.

We also thank the artists of the theater play for their great enthusiasm to envisage the live of the great Paul Ehrlich.

Thanks to the Gymnasiums ("high schools") of Eckental and Lauf for their last year students' contributions and help during the preparation and performance of the conference.

And last but not least our sponsors shown on the next page without whom this meeting would not have been possible.


So we hope that this will become a great "Fest" for research and the commemoration of Paul Ehrlich at the same time.



Fritz Sörgel
Conference President



Klaus Bodmann
Co President



Manfred Schubert-Zsilavecz
Co President



Martin Wilhelm
Co President

Program coordination

Jürgen Bulitta, Buffalo, USA, Local secretariat and local organization: Martina Kinzig

Table of Content

Welcome to Nürnberg	2
Key Note Lectures	21
Symposia	24
Oral presentations.....	26
Poster presentations	149
Symposia in German	173
Satellitensymposium MSD	174
Wyeth Satellitensymposium.....	175
Lunchsymposium Pfizer.....	176
Fortbildung der Bayerischen Landesapothekerkammer.....	177
HNO-INFEKTIOLOGISCHE FORTBILDUNGSVERANSTALTUNG	178

Important Note on Scheduling Presentations and categorizing to topics

Our team has spent days and countless hours to enter all arrival and departure dates to make your stay here as pleasant as possible for you. e.g. the time of presentations to fit well without distress to get from the airport or train station to the conference. No conference had probably ever done that You will certainly realize that immediately.

Also as a consequence of this not all sessions could be organized in a way so that all topics fit into the session as well as they should. Also, sometimes very small sessions of only one or two presentations had to be made. This was the only way to meet all requirements for individualized scheduling of the talk and length of stay. Also some starting times may look a bit awkward for the same reasons.

There will be one room assigned for colleagues who can prove by their flight ticket that their flight was delayed by more than 6 hours. We will try to make the talk possible in a separate room. We don't want somebody travel to a world conference and then being unable to present because of a delayed or cancelled flight. We all have experienced that and know what pain this causes. We keep rooms available until Sunday noon for these "emergencies".

Chairmen will strictly follow the rule and stop the talk after exactly 15 minutes. A conference of this size can by no means allow extra lengths of talks.

Program at a glance – according to date and scheduled time

	Session	Duration		Room
Friday	Antineoplastic agents - New targets & compounds - Part I	8:00 AM	- 9:00 AM	206
	Antibacterials - Clinical Aspects - Part I	8:00 AM	- 9:20 AM	205
	Antibacterials - New antibiotic and antineoplastic compounds from nature - Part I	8:00 AM	- 9:40 AM	212
	Antibacterials - New compounds and mechanisms - focusing on tuberculosis and delivery	8:00 AM	- 9:40 AM	213
	Antibacterials - Resistance, surveillance, and guidelines	8:00 AM	- 9:40 AM	214
	Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part I	8:00 AM	- 9:40 AM	216
	Antibacterials - Discovery - New methods of chemical significance	8:00 AM	- 10:00 AM	207
	Antineoplastic agents - Effectiveness and resistance in patients - Part I	8:00 AM	- 10:00 AM	215
	Blood-brain barrier - History and most recent finding - Part I	10:15 AM	- 10:55 AM	212
	Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part I	10:15 AM	- 11:15 AM	214
	Antineoplastic agents - Tyrosine Kinase Inhibitors - Part I	10:15 AM	- 11:15 AM	205
	Antivirals - Mechanisms and development of antivirals - Part I	10:15 AM	- 11:35 AM	206
	Treatment of severe diseases	10:15 AM	- 11:35 AM	216
	Antibacterials - Molecular microbiology	10:15 AM	- 12:15 PM	215
	Biomarkers and their applications	10:15 AM	- 12:15 PM	207
	Treatment of diseases with involvement of the immune system - Part I	10:15 AM	- 12:35 PM	213
	Pharmaceutics - Drug delivery - Part I	10:55 AM	- 11:55 AM	212
	Antibacterials - Resistance in gram positives	11:15 AM	- 12:15 PM	214
	Massspectrometry in pharmaceutics and biochemistry	11:55 AM	- 12:15 PM	212
	Antineoplastic agents - New strategies and new compounds- Part I	11:55 AM	- 1:15 PM	215
	Vaccines - Physiology and molecular biology - Part I	1:15 PM	- 1:55 PM	406
	Antineoplastic agents - Approaches to optimize therapy - Part I	1:15 PM	- 2:15 PM	206
	Antineoplastic agents - New mechanisms & compounds - Part I	1:15 PM	- 2:35 PM	214
	Antiparasitic compounds - Therapeutic approaches	1:15 PM	- 2:35 PM	207
	Blood brain barrier physiology and diseases - Part I	1:15 PM	- 2:35 PM	213
	Recombinant Proteins - a new class of Magic Bullets- Part I	1:15 PM	- 2:35 PM	216
	Antineoplastic agents - New promising mechanisms - Part I	1:15 PM	- 3:15 PM	218
	Antivirals - General issues and their solutions - Part I	1:15 PM	- 3:15 PM	212

Program at a glance – according to date and scheduled time

	Session	Duration	Room
Friday	Biotechnology of drug delivery	1:15 PM - 3:15 PM	405
	Vaccines - Development, production and manufacturing - Part I	1:15 PM - 3:20 PM	217
	Antineoplastic agents - Compounds and approaches - Part I	1:15 PM - 3:30 PM	205
	CNS - Pharmacological options in disease of the central nervous system - Part I	1:15 PM - 3:55 PM	215
	Pharmaceutics - Nanoparticles and their latest developments - Part I	1:55 PM - 3:15 PM	406
	Antibacterials - Adverse events and mechanisms of toxicity - Part I	2:35 PM - 3:15 PM	216
	Pharmaceutics - Experimental and computational approaches - Part I	2:35 PM - 3:30 PM	207
	Professional perspectives for health professionals	3:30 PM - 4:02 AM	212
	Anti-infectives - Approaches to combat resistance	3:30 PM - 3:50 PM	206
	Nerve diseases, mechanisms, and pathophysiology - Part I	3:30 PM - 4:10 PM	214
	Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part I	3:30 PM - 4:30 PM	404
	Cytochrome P450 - in vitro studies - Part I	3:30 PM - 4:30 PM	216
	Antidepressant drugs and their mechanism of action Part I	3:30 PM - 4:37 PM	218
	Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part I	3:30 PM - 4:50 PM	217
	Clinical studies with agents of different pharmacological activity - Part I	3:30 PM - 4:50 PM	213
	Agents / diseases affecting the immune system - Part I	3:30 PM - 5:30 PM	205
	Cardiovascular - Drugs acting on the cardiovascular system - Part I	3:30 PM - 5:30 PM	207
	Antifungals - Pharmacokinetics and formulation issues	3:50 PM - 4:30 PM	206
	CNS - Pharmacological options in disease of the central nervous system - Part II	4:02 AM - 4:42 PM	212
	Pharmaceutics - Discovery of drugs and mechanisms - Part I	4:10 PM - 5:10 PM	214
	Antibacterials - Discovery - Peptide antibiotics - Part I	4:30 PM - 5:10 PM	216
	Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part II	4:50 PM - 5:10 PM	213
	Atherosclerosis, stroke & aging - mechanisms and treatment - Part I	4:50 PM - 5:30 PM	217
	Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part I	5:30 PM - 6:10 PM	213
	Transporters of physiological compounds and drugs - Part I	5:30 PM - 6:10 PM	212
	Analgesia & analgetic drugs - Part I	5:30 PM - 6:30 PM	207
	Antiparasitic compounds - Magic Bullets against various parasites	5:30 PM - 6:30 PM	214
	Treatment of asthma, COPD, and other lung diseases - Part I	5:30 PM - 6:30 PM	217

Program at a glance – according to date and scheduled time

	Session	Duration	Room
Friday	Biosimilars / Follow-on Proteins and their challenges to manufacturers and regulatory bodies - Part I	5:30 PM - 6:50 PM	216
	Cardiovascular - Drugs acting on the cardiovascular system - Part II	5:30 PM - 6:50 PM	205
	Mechanisms of inflammation and anti-inflammatory agents - Part I	5:30 PM - 6:50 PM	206
	Antivirals - Clinical effectiveness	5:30 PM - 7:30 PM	215
	Antibacterials - New mechanisms and delivery strategies - Part I	6:10 PM - 6:50 PM	212
	Antineoplastic agents - Personalized therapy - Part I	6:10 PM - 7:40 PM	213
	Drug transporters and delivery - Part I	6:30 PM - 7:10 PM	207
	Immunosuppressants - Part I	6:30 PM - 7:30 PM	217
	Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part I	6:50 PM - 7:30 PM	216
	Antineoplastic agents - Effectiveness and resistance in patients - Part II	6:50 PM - 7:50 PM	205
	Clinical studies with agents of different pharmacological activity - Part II	6:50 PM - 7:50 PM	212
	Physiology & Magic Bullets - Part I	6:50 PM - 7:50 PM	206
	Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part I	8:00 PM - 9:00 PM	217
	Blood-brain barrier - History and most recent finding - Part II	8:00 PM - 9:00 PM	218
	Pharmaceutics - Drug delivery through the skin - Part I	8:00 PM - 9:20 PM	206
	Anti-infectives - Mechanisms of bacterial resistance - Part I	8:00 PM - 9:40 PM	215
	Pharmaceutics - Pharmacokinetics and drug formulations - Part I	8:00 PM - 9:40 PM	412
	Treatment of diseases with involvement of the immune system - Part II	8:00 PM - 9:40 PM	404
	Vaccines - Antiinfectives - Malaria & Tuberculosis	8:00 PM - 9:40 PM	405
	Pharmacokinetic studies and drug metabolism	8:00 PM - 9:40 PM	212
	Vaccines - Targeting non-infectious diseases - Part I	8:00 PM - 9:40 PM	214
	Antineoplastic agents - Clinical trials and approaches- Part I	8:00 PM - 10:00 PM	216
	New drug concepts	8:00 PM - 10:00 PM	205
	Pharmaceutics - Reviews and general aspects	8:00 PM - 10:00 PM	207
	Therapeutic Proteins - clinical studies - Part I	8:00 PM - 10:00 PM	213
	Antiparasitic compounds - Malaria Therapy and approaches	9:00 PM - 10:00 PM	217
	Vaccines - Antiinfectives - Bacteria and parasites - Part I	9:20 PM - 10:00 PM	206

Program at a glance – according to date and scheduled time

Session	Duration	Room
Saturday		
Analgesia & analgetic drugs II	7:15 AM - 8:15 AM	206
Doping and performance enhancement drugs	7:15 AM - 8:15 AM	404
Illicit drugs & similar agents and addiction	7:15 AM - 8:35 AM	101
Antineoplastic agents - in vitro and in vivo	7:15 AM - 8:35 AM	214
Bioanalytics - The cutting edge of LC-MS/MS - Part I	7:15 AM - 8:35 AM	216
Recombinant Proteins - a new class of Magic Bullets- Part II	7:15 AM - 8:35 AM	406
Antineoplastic agents - how to find new Magic Bullets	7:15 AM - 8:55 AM	115
Physiology & Magic Bullets - Part II	7:15 AM - 8:55 AM	405
Clinical situations & therapy and cellular therapeutics	7:15 AM - 8:55 AM	111
Anticoagulation and heparin-based drugs	7:15 AM - 8:55 AM	212
Antifungals - Optimizing treatment in normal and special populations	7:15 AM - 8:55 AM	213
Antineoplastic agents - New mechanisms & compounds - Part II	7:15 AM - 8:55 AM	215
Clinical studies with agents of different pharmacological activity - Part III	7:15 AM - 8:55 AM	217
Pharmaceutics - Discovery of drugs and mechanisms - Part II	7:15 AM - 8:55 AM	412
Endocrinology including diabetes	7:15 AM - 9:15 AM	112
Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part III	7:15 AM - 9:15 AM	207
Antineoplastic agents - Creating Magic Bullets from natural compounds - Part I	7:15 AM - 9:15 AM	L001
Antibacterials - Tissue penetration of anti-infectives	7:15 AM - 9:29 AM	Paul Karrer Hall
Biomarkers - The thorny way to personalized medicine	7:15 AM - 9:30 AM	403
Agents / diseases affecting the immune system - Part II	7:15 AM - 9:35 AM	205
CNS - Pharmacological options in disease of the central nervous system - Part III	7:15 AM - 9:35 AM	218
Vaccines - Antineoplastic - Role of immune cells - Part I	9:30 AM - 10:10 AM	216
Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part II	9:30 AM - 10:10 AM	412
New findings on purines	9:30 AM - 10:30 AM	101
Antibacterials - Adverse events and mechanisms of toxicity - Part II	9:30 AM - 10:30 AM	214
Parkinson's disease, mechanism of disease and treatment - Part I	9:30 AM - 10:30 AM	405
Ehrlich History, Reviews and Future perspectives on Ehrlich's Research Fields	9:30 AM - 10:50 AM	207
Antifungals - New approaches and their success	9:30 AM - 10:50 AM	217

Program at a glance – according to date and scheduled time

Session	Duration	Room
Saturday Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part II	9:30 AM - 10:50 AM	403
Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part II	9:30 AM - 10:50 AM	404
Antibacterials - Peptide antibiotics and their intricacies	9:30 AM - 10:57 AM	218
Vaccines - Antiinfectives - Influenza and other viruses	9:30 AM - 11:10 AM	215
Which role does PK/PD play in drug development?	9:30 AM - 11:28 AM	L001
Vaccines - Antineoplastic - Antigen guided	9:30 AM - 11:30 AM	112
Ehrlich`s research fields: Historical aspects and latest research results	9:30 AM - 11:30 AM	115
Target site interactions and spectroscopic / computational approaches	9:30 AM - 11:30 AM	205
Antibacterials - Clinical Aspects - Part II	9:30 AM - 11:30 AM	206
Treatment of tuberculosis and other infections	9:30 AM - 11:30 AM	213
New / known targets & mechanisms - Part II	9:30 AM - 11:50 AM	111
HPLC, capillary electrophoresis, and other analytical techniques	9:30 AM - 11:50 AM	212
Vaccines - Physiology and molecular biology - Part II	9:30 AM - 11:50 AM	406
Treatment of asthma, COPD, and other lung diseases - Part II	10:10 AM - 10:05 AM	412
Antifungals - Pharmacokinetics and formulation issues	10:10 AM - 10:50 AM	216
Antibacterials - Discovery - Peptide antibiotics - Part II	10:30 AM - 11:10 AM	214
Anti-infectives - Mechanisms of bacterial resistance - Part II	10:30 AM - 11:50 AM	101
Anti-infectives - Reviews on Magic Bullets - Part I	10:50 AM - 11:30 AM	403
Anti-infectives - Approaches to combat resistance	10:50 AM - 11:50 AM	207
Antibacterials - New mechanisms and delivery strategies - Part II	10:50 AM - 11:50 AM	217
Antineoplastic agents - New targets & compounds - Part II	10:50 AM - 11:50 AM	404
Antineoplastic agents - Compounds and approaches - Part II	10:57 AM - 11:57 AM	218
Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part II	11:10 AM - 11:30 AM	214
Vaccines - Antiinfectives - Bacteria, parasites, and HPV - Part I	11:30 AM - 11:50 AM	112
Pharmaceutics - Experimental and computational approaches - Part II	11:30 AM - 11:50 AM	205
Cardiovascular - Drugs acting on the cardiovascular system - Part III	12:00 PM - 12:40 PM	217
Vaccines - Antiinfectives - Bacteria and parasites - Part II	12:00 PM - 12:40 PM	403
Antiparasitic compounds - Molecular and genomic approaches	12:00 PM - 1:00 PM	205

Program at a glance – according to date and scheduled time

	Session	Duration	Room
Saturday	Antineoplastic agents - Search and Development of new Magic Bullets - Part I	12:00 PM - 1:00 PM	406
	Vaccines - Development, production and manufacturing - Part II	12:00 PM - 1:20 PM	101
	Brain physiology, biochemistry, and drugs acting on the brain - Part II	12:00 PM - 1:20 PM	111
	Antineoplastic agents - New targets & compounds - Part II	12:00 PM - 1:20 PM	218
	Drug transporters and delivery - Part II	12:00 PM - 1:20 PM	405
	Antivirals - New compounds and their mechanisms - Part I	12:00 PM - 1:20 PM	412
	Antibacterials - PK/PD: past, presence, and future challenges	12:00 PM - 1:32 PM	112
	Vaccines - History, Reviews, and Future Perspectives - Part I	12:00 PM - 1:40 PM	207
	Antibacterials - Unexpected findings and new approaches	12:00 PM - 1:40 PM	212
	Antineoplastic agents - Balancing efficacy and toxicity	12:00 PM - 1:40 PM	214
	Vaccines - Antiinfectives - HIV - Part II	12:00 PM - 1:40 PM	216
	Steroids, Receptors & pulmonary diseases	12:00 PM - 2:00 PM	115
	Cardiovascular - Magic Bullets & the cardiovascular system - Part I	12:00 PM - 2:00 PM	206
	Antibacterials - New antibiotic and antineoplastic compounds from nature - Part II	12:00 PM - 2:00 PM	213
	Resistance - a Global Issue for diverse therapeutic areas - Part I	12:00 PM - 2:00 PM	215
	Vaccines - Targeting non-infectious diseases - Part II	12:40 PM - 1:00 PM	403
	Antidepressant drugs and their mechanism of action - Part II	12:40 PM - 2:00 PM	217
	Atherosclerosis, stroke & aging - mechanisms and treatment - Part II	1:00 PM - 2:00 PM	205
	Targets, Drugs and Carriers – Approaches to Translational Medicine, Financial support: German Research Foundation (FG463)	1:00 PM - 4:30 PM	404
	Antineoplastic agents - Personalized therapy - Part II	1:20 PM - 2:20 PM	218
	Antivirals - Mechanisms and development of antivirals - Part II	2:00 PM - 2:40 PM	218
	Vaccines - Development, production and manufacturing - Part III	2:00 PM - 3:00 PM	213
	Treatment of diseases with involvement of the immune system - Part III	2:00 PM - 3:20 PM	206
	Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part II	2:00 PM - 3:20 PM	215
	Antineoplastic agents - Old and new compounds / approaches - Part I	2:00 PM - 3:20 PM	216
	Antiparasitic compounds - Magic Bullets to treat malaria	2:00 PM - 3:20 PM	217
	Therapeutic Proteins - discovery and manufacturing - Part II	2:00 PM - 3:20 PM	403
	Antineoplastic agents - Compounds and approaches - Part III	2:00 PM - 3:40 PM	212

Program at a glance – according to date and scheduled time

Session	Duration	Room
Saturday Bioanalytics - The cutting edge of LC-MS/MS - Part II	2:00 PM - 3:40 PM	405
Pharmaceutics - Drug delivery - Part II	2:00 PM - 3:40 PM	406
Antineoplastic agents - New strategies and new compounds- Part II	2:00 PM - 3:40 PM	207
Erythropoietin - a Magic Bullet's quo vadis	2:00 PM - 4:00 PM	214
Antivirals - General issues and their solutions - Part II	2:00 PM - 4:20 PM	111
Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part II	2:00 PM - 4:20 PM	205
Antibacterials - The rise of antibacterial resistance	2:00 PM - 4:20 PM	115
Drug-drug and drug-nutrient interactions - Part I	2:00 PM - 4:20 PM	412
Antineoplastic agents - Approaches to optimize therapy - Part II	2:00 PM - 4:27 PM	112
Psychoactive drugs - Part I	2:00 PM - 4:40 PM	101
Blood brain barrier physiology and diseases - Part II	2:30 PM - 3:50 PM	Paul Ehrlich Hall
Mechanisms of inflammation and anti-inflammatory agents - Part II	3:00 PM - 4:00 PM	213
Nerve diseases, mechanisms, and pathophysiology - Part II	3:00 PM - 4:00 PM	218
Immunosuppressants - Part II	3:20 PM - 4:20 PM	206
Pharmaceutics - Drug delivery - Part III	3:20 PM - 4:20 PM	217
Vaccines - Antiinfectives - Herpes	4:45 PM - 5:45 PM	112
Antineoplastic agents - Genomic approaches to optimize therapy - Part I	4:45 PM - 5:45 PM	404
Antineoplastic agents - Tyrosine Kinase Inhibitors - Part II	4:45 PM - 6:05 PM	212
Pharmaceutics - Nanoparticles and their latest developments - Part II	4:45 PM - 6:05 PM	403
Parkinson's disease, mechanism of disease and treatment - Part II	4:45 PM - 6:05 PM	405
Sex steroids	4:45 PM - 6:05 PM	406
Antivirals - New compounds and their mechanisms - Part II	4:45 PM - 6:05 PM	412
Antiparasitic compounds - Discovery	4:45 PM - 6:05 PM	Paul Ehrlich Hall
Nerve diseases, mechanisms, and pathophysiology - Part III	4:45 PM - 6:05 PM	205
Therapy with monoclonal antibodies - Part I	4:45 PM - 6:05 PM	215
Treatment of severe infections including sepsis	4:45 PM - 6:12 PM	213
Cytochrome P450 drug metabolism	4:45 PM - 6:15 PM	216
Therapeutic Proteins - clinical studies - Part II	4:45 PM - 6:25 PM	111

Program at a glance – according to date and scheduled time

	Session	Duration	Room
Saturday	Antineoplastic agents - Biochemical approaches	4:45 PM - 6:25 PM	207
	Steroid receptor - Jensen symposium	4:45 PM - 6:25 PM	214
	Antiparasitic compounds - Leishmaniasis and its intricacies	4:45 PM - 6:25 PM	218
	Antibacterials - PK/PD of antibiotics in serious infections	4:45 PM - 6:41 PM	101
	Resistance - a Global Issue for diverse therapeutic areas - Part II	4:45 PM - 6:45 PM	115
	Antineoplastic agents - Clinical trials and approaches- Part II	4:45 PM - 6:45 PM	206
	Anti-infectives - PK/PD modeling strategies and applications	4:45 PM - 7:04 PM	217
	Antineoplastic agents - Effectiveness and resistance in patients - Part III	6:25 PM - 6:45 PM	206

Program at a glance – according to date and scheduled time

	Session	Duration	Room
Sunday	Analgesia & analgetic drugs III	8:45 AM - 9:25 AM	218
	Antibacterials - Clinical Aspects - Part III	8:45 AM - 10:05 AM	205
	Drug-drug and drug-nutrient interactions - Part II	8:45 AM - 10:05 AM	215
	Metabolic Diseases	8:45 AM - 10:05 AM	216
	Vaccines - Antiinfectives - Bacteria, parasites, and HPV - Part II	8:45 AM - 10:05 AM	404
	CNS - Pharmacological options in disease of the central nervous system - Part IV	8:45 AM - 10:25 AM	403
	Antineoplastic agents - New strategies and new compounds- Part III	8:45 AM - 10:25 AM	207
	Antineoplastic agents - Combination therapy to optimize effectiveness	8:45 AM - 10:25 AM	212
	Brain physiology, biochemistry, and drugs acting on the brain - Part I	8:45 AM - 10:25 AM	214
	Bioanalytics - The cutting edge of LC-MS/MS - Part III	8:45 AM - 10:25 AM	217
	Illicit drugs & similar agents, doping and performance enhancement drugs	8:45 AM - 10:25 AM	406
	Therapeutic Proteins - discovery and manufacturing - Part III	8:45 AM - 10:25 AM	405
	Treatment of asthma, COPD, and other lung diseases - Part III	8:45 AM - 10:25 AM	115
	Antineoplastic agents - Metal-based compounds to combat cancer	8:45 AM - 10:45 AM	206
	Antineoplastic agents - Compounds and approaches - Part IV	8:45 AM - 10:45 AM	213
	Psychoactive drugs - Part II	8:45 AM - 11:05 AM	412
	Pharmaceutics - Experimental and computational approaches - Part III	9:25 AM - 10:25 AM	218
	Therapeutic Drug Monitoring, Personalized Medicine, and immunosuppressive agents	10:05 AM - 10:45 AM	215
	Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part III	10:05 AM - 11:05 AM	205
	Treatment of diseases with involvement of the immune system - Part IV	11:15 AM - 11:35 AM	217
	Antineoplastic agents - Effectiveness and resistance in patients - Part IV	11:15 AM - 12:15 PM	207
	Antineoplastic agents - Paclitaxel - a true Magic Bullet	11:15 AM - 12:15 PM	412
	Drug-drug and drug-nutrient interactions - Part III	11:15 AM - 12:15 PM	404
	Antibacterials - Genomic strategies	11:15 AM - 12:15 PM	218
	Analgesia & analgetic drugs IV	11:15 AM - 12:35 PM	205
	Antineoplastic agents - Genomic approaches to optimize therapy - Part II	11:15 AM - 12:35 PM	406
	Anti-infectives - Reviews on Magic Bullets - Part II	11:15 AM - 12:55 PM	206
	New / known targets & mechanisms - Part I	11:15 AM - 12:55 PM	215

Program at a glance – according to date and scheduled time

Session	Duration	Room
Sunday		
Resistance - a Global Issue for diverse therapeutic areas - Part III	11:15 AM - 12:55 PM	216
Atherosclerosis and stroke - mechanisms and treatment	11:15 AM - 12:55 PM	405
Antineoplastic agents - New mechanisms & compounds - Part III	11:15 AM - 1:15 PM	212
Cardiovascular - Drugs acting on the cardiovascular system - Part IV	11:15 AM - 1:15 PM	214
Biomarkers & personalized medicine	11:15 AM - 1:55 PM	213
Recent progress and development in nanotechnology	11:35 AM - 12:35 PM	217
Antibacterials - New antibiotic and antineoplastic compounds	12:15 PM - 12:55 PM	218
Antineoplastic agents - Search and Development of new Magic Bullets - Part II	12:15 PM - 1:15 PM	412
Pharmaceutics - Pharmacokinetics and drug formulations - Part II	12:15 PM - 1:15 PM	404
Therapy with monoclonal antibodies - Part II	12:15 PM - 1:55 PM	207
Therapy with monoclonal antibodies - Part II	12:15 PM - 1:55 PM	207
Antibacterials - Adverse events and mechanisms of toxicity - Part III	12:35 PM - 1:15 PM	217
Antineoplastic agents - New promising mechanisms - Part II	12:35 PM - 1:15 PM	406
Antibacterials - Discovery - Peptide antibiotics - Part III	12:35 PM - 1:55 PM	205
Antineoplastic agents - Clinical trials and approaches- Part III	12:55 PM - 2:15 PM	206
Blood-brain barrier - History and most recent finding - Part III	2:15 PM - 2:55 PM	205
Pharmaceutics - Nanoparticles and their latest developments - Part III	2:15 PM - 2:55 PM	213
Cytochrome P450 - in vitro studies - Part II	2:15 PM - 3:15 PM	206
Vaccines - Antineoplastic - Role of immune cells - Part II	2:15 PM - 3:15 PM	215
Vaccines - History, Reviews, and Future Perspectives - Part II	2:15 PM - 3:15 PM	212
Anti-infective Magic Bullets	2:15 PM - 3:35 PM	207
Therapeutic Proteins - discovery and manufacturing - Part IV	2:55 PM - 3:35 PM	213
Cardiovascular - Magic Bullets & the cardiovascular system - Part II	2:55 PM - 3:55 PM	205
Resistance - a Global Issue for diverse therapeutic areas - Part IV	3:15 PM - 3:35 PM	206
Transporters of physiological compounds and drugs - Part II	3:35 PM - 4:35 PM	214

Program at a glance – according to topic

Session		Duration			Room
Agents / diseases affecting the immune system - Part I	Friday	3:30 PM	-	5:30 PM	205
Agents / diseases affecting the immune system - Part II	Saturday	7:15 AM	-	9:35 AM	205
Analgesia & analgetic drugs - Part I	Friday	5:30 PM	-	6:30 PM	207
Analgesia & analgetic drugs II	Saturday	7:15 AM	-	8:15 AM	206
Analgesia & analgetic drugs III	Sunday	8:45 AM	-	9:25 AM	218
Analgesia & analgetic drugs IV	Sunday	11:15 AM	-	12:35 PM	205
Antibacterials - Adverse events and mechanisms of toxicity - Part I	Friday	2:35 PM	-	3:15 PM	216
Antibacterials - Adverse events and mechanisms of toxicity - Part II	Saturday	9:30 AM	-	10:30 AM	214
Antibacterials - Adverse events and mechanisms of toxicity - Part III	Sunday	12:35 PM	-	1:15 PM	217
Antibacterials - Clinical Aspects - Part I	Friday	8:00 AM	-	9:20 AM	205
Antibacterials - Clinical Aspects - Part II	Saturday	9:30 AM	-	11:30 AM	206
Antibacterials - Clinical Aspects - Part III	Sunday	8:45 AM	-	10:05 AM	205
Antibacterials - Discovery - New methods of chemical significance	Friday	8:00 AM	-	10:00 AM	207
Antibacterials - Discovery - Peptide antibiotics - Part I	Friday	4:30 PM	-	5:10 PM	216
Antibacterials - Discovery - Peptide antibiotics - Part II	Saturday	10:30 AM	-	11:10 AM	214
Antibacterials - Discovery - Peptide antibiotics - Part III	Sunday	12:35 PM	-	1:55 PM	205
Antibacterials - Genomic strategies	Sunday	11:15 AM	-	12:15 PM	218
Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part I	Friday	3:30 PM	-	4:50 PM	217
Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part II	Saturday	11:10 AM	-	11:30 AM	214
Antibacterials - Molecular microbiology	Friday	10:15 AM	-	12:15 PM	215
Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part I	Friday	10:15 AM	-	11:15 AM	214
Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part II	Friday	4:50 PM	-	5:10 PM	213
Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part III	Saturday	7:15 AM	-	9:15 AM	207
Antibacterials - New antibiotic and antineoplastic compounds	Sunday	12:15 PM	-	12:55 PM	218
Antibacterials - New antibiotic and antineoplastic compounds from nature - Part I	Friday	8:00 AM	-	9:40 AM	212
Antibacterials - New antibiotic and antineoplastic compounds from nature - Part II	Saturday	12:00 PM	-	2:00 PM	213
Antibacterials - New compounds and mechanisms - focusing on tuberculosis and delivery	Friday	8:00 AM	-	9:40 AM	213
Antibacterials - New mechanisms and delivery strategies - Part I	Friday	6:10 PM	-	6:50 PM	212

Program at a glance – according to topic

Session		Duration			Room
Antibacterials - New mechanisms and delivery strategies - Part II	Saturday	10:50 AM	-	11:50 AM	217
Antibacterials - Peptide antibiotics and their intricacies	Saturday	9:30 AM	-	10:57 AM	218
Antibacterials - PK/PD of antibiotics in serious infections	Saturday	4:45 PM	-	6:41 PM	101
Antibacterials - PK/PD: past, presence, and future challenges	Saturday	12:00 PM	-	1:32 PM	112
Antibacterials - Resistance in gram positives	Friday	11:15 AM	-	12:15 PM	214
Antibacterials - Resistance, surveillance, and guidelines	Friday	8:00 AM	-	9:40 AM	214
Antibacterials - The rise of antibacterial resistance	Saturday	2:00 PM	-	4:20 PM	115
Antibacterials - Tissue penetration of anti-infectives	Saturday	7:15 AM	-	9:29 AM	Paul Karrer Hall
Antibacterials - Unexpected findings and new approaches	Saturday	12:00 PM	-	1:40 PM	212
Anticoagulation and heparin-based drugs	Saturday	7:15 AM	-	8:55 AM	212
Antidepressant drugs and their mechanism of action - Part II	Saturday	12:40 PM	-	2:00 PM	217
Antidepressant drugs and their mechanism of action Part I	Friday	3:30 PM	-	4:37 PM	218
Antifungals - New approaches and their success	Saturday	9:30 AM	-	10:50 AM	217
Antifungals - Optimizing treatment in normal and special populations	Saturday	7:15 AM	-	8:55 AM	213
Antifungals - Pharmacokinetics and formulation issues	Friday	3:50 PM	-	4:30 PM	206
Antifungals - Pharmacokinetics and formulation issues	Saturday	10:10 AM	-	10:50 AM	216
Anti-infective Magic Bullets	Sunday	2:15 PM	-	3:35 PM	207
Anti-infectives - Approaches to combat resistance	Friday	3:30 PM	-	3:50 PM	206
Anti-infectives - Approaches to combat resistance	Saturday	10:50 AM	-	11:50 AM	207
Anti-infectives - Mechanisms of bacterial resistance - Part I	Friday	8:00 PM	-	9:40 PM	215
Anti-infectives - Mechanisms of bacterial resistance - Part II	Saturday	10:30 AM	-	11:50 AM	101
Anti-infectives - PK/PD modeling strategies and applications	Saturday	4:45 PM	-	7:04 PM	217
Anti-infectives - Reviews on Magic Bullets - Part I	Saturday	10:50 AM	-	11:30 AM	403
Anti-infectives - Reviews on Magic Bullets - Part II	Sunday	11:15 AM	-	12:55 PM	206
Antineoplastic agents - Approaches to optimize therapy - Part I	Friday	1:15 PM	-	2:15 PM	206
Antineoplastic agents - Approaches to optimize therapy - Part II	Saturday	2:00 PM	-	4:27 PM	112
Antineoplastic agents - Balancing efficacy and toxicity	Saturday	12:00 PM	-	1:40 PM	214
Antineoplastic agents - Biochemical approaches	Saturday	4:45 PM	-	6:25 PM	207
Antineoplastic agents - Clinical trials and approaches- Part I	Friday	8:00 PM	-	10:00 PM	216
Antineoplastic agents - Clinical trials and approaches- Part II	Saturday	4:45 PM	-	6:45 PM	206

Program at a glance – according to topic

Session		Duration		Room
Antineoplastic agents - Clinical trials and approaches- Part III	Sunday	12:55 PM	- 2:15 PM	206
Antineoplastic agents - Combination therapy to optimize effectiveness	Sunday	8:45 AM	- 10:25 AM	212
Antineoplastic agents - Compounds and approaches - Part I	Friday	1:15 PM	- 3:30 PM	205
Antineoplastic agents - Compounds and approaches - Part II	Saturday	10:57 AM	- 11:57 AM	218
Antineoplastic agents - Compounds and approaches - Part III	Saturday	2:00 PM	- 3:40 PM	212
Antineoplastic agents - Compounds and approaches - Part IV	Sunday	8:45 AM	- 10:45 AM	213
Antineoplastic agents - Creating Magic Bullets from natural compounds - Part I	Saturday	7:15 AM	- 9:15 AM	L001
Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part I	Friday	5:30 PM	- 6:10 PM	213
Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part II	Saturday	9:30 AM	- 10:50 AM	404
Antineoplastic agents - Effectiveness and resistance in patients - Part I	Friday	8:00 AM	- 10:00 AM	215
Antineoplastic agents - Effectiveness and resistance in patients - Part II	Friday	6:50 PM	- 7:50 PM	205
Antineoplastic agents - Effectiveness and resistance in patients - Part III	Saturday	6:25 PM	- 6:45 PM	206
Antineoplastic agents - Effectiveness and resistance in patients - Part IV	Sunday	11:15 AM	- 12:15 PM	207
Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part I	Friday	3:30 PM	- 4:30 PM	404
Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part II	Saturday	9:30 AM	- 10:10 AM	412
Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part III	Sunday	10:05 AM	- 11:05 AM	205
Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part I	Friday	8:00 AM	- 9:40 AM	216
Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part II	Saturday	2:00 PM	- 4:20 PM	205
Antineoplastic agents - Genomic approaches to optimize therapy - Part I	Saturday	4:45 PM	- 5:45 PM	404
Antineoplastic agents - Genomic approaches to optimize therapy - Part II	Sunday	11:15 AM	- 12:35 PM	406
Antineoplastic agents - how to find new Magic Bullets	Saturday	7:15 AM	- 8:55 AM	115
Antineoplastic agents - in vitro and in vivo	Saturday	7:15 AM	- 8:35 AM	214
Antineoplastic agents - Metal-based compounds to combat cancer	Sunday	8:45 AM	- 10:45 AM	206
Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part I	Friday	8:00 PM	- 9:00 PM	217
Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part II	Saturday	2:00 PM	- 3:20 PM	215
Antineoplastic agents - New mechanisms & compounds - Part I	Friday	1:15 PM	- 2:35 PM	214
Antineoplastic agents - New mechanisms & compounds - Part II	Saturday	7:15 AM	- 8:55 AM	215
Antineoplastic agents - New mechanisms & compounds - Part III	Sunday	11:15 AM	- 1:15 PM	212
Antineoplastic agents - New promising mechanisms - Part I	Friday	1:15 PM	- 3:15 PM	218
Antineoplastic agents - New promising mechanisms - Part II	Sunday	12:35 PM	- 1:15 PM	406

Program at a glance – according to topic

Session		Duration		Room
Antineoplastic agents - New strategies and new compounds- Part I	Friday	11:55 AM	- 1:15 PM	215
Antineoplastic agents - New strategies and new compounds- Part II	Saturday	2:00 PM	- 3:40 PM	207
Antineoplastic agents - New strategies and new compounds- Part III	Sunday	8:45 AM	- 10:25 AM	207
Antineoplastic agents - New targets & compounds - Part I	Friday	8:00 AM	- 9:00 AM	206
Antineoplastic agents - New targets & compounds - Part II	Saturday	10:50 AM	- 11:50 AM	404
Antineoplastic agents - New targets & compounds - Part II	Saturday	12:00 PM	- 1:20 PM	218
Antineoplastic agents - Old and new compounds / approaches - Part I	Saturday	2:00 PM	- 3:20 PM	216
Antineoplastic agents - Paclitaxel - a true Magic Bullet	Sunday	11:15 AM	- 12:15 PM	412
Antineoplastic agents - Personalized therapy - Part I	Friday	6:10 PM	- 7:40 PM	213
Antineoplastic agents - Personalized therapy - Part II	Saturday	1:20 PM	- 2:20 PM	218
Antineoplastic agents - Search and Development of new Magic Bullets - Part I	Saturday	12:00 PM	- 1:00 PM	406
Antineoplastic agents - Search and Development of new Magic Bullets - Part II	Sunday	12:15 PM	- 1:15 PM	412
Antineoplastic agents - Tyrosine Kinase Inhibitors - Part I	Friday	10:15 AM	- 11:15 AM	205
Antineoplastic agents - Tyrosine Kinase Inhibitors - Part II	Saturday	4:45 PM	- 6:05 PM	212
Antiparasitic compounds - Discovery	Saturday	4:45 PM	- 6:05 PM	Paul Ehrlich Hall
Antiparasitic compounds - Leishmaniasis and its intricacies	Saturday	4:45 PM	- 6:25 PM	218
Antiparasitic compounds - Magic Bullets against various parasites	Friday	5:30 PM	- 6:30 PM	214
Antiparasitic compounds - Magic Bullets to treat malaria	Saturday	2:00 PM	- 3:20 PM	217
Antiparasitic compounds - Malaria Therapy and approaches	Friday	9:00 PM	- 10:00 PM	217
Antiparasitic compounds - Molecular and genomic approaches	Saturday	12:00 PM	- 1:00 PM	205
Antiparasitic compounds - Therapeutic approaches	Friday	1:15 PM	- 2:35 PM	207
Antivirals - Clinical effectiveness	Friday	5:30 PM	- 7:30 PM	215
Antivirals - General issues and their solutions - Part I	Friday	1:15 PM	- 3:15 PM	212
Antivirals - General issues and their solutions - Part II	Saturday	2:00 PM	- 4:20 PM	111
Antivirals - Mechanisms and development of antivirals - Part I	Friday	10:15 AM	- 11:35 AM	206
Antivirals - Mechanisms and development of antivirals - Part II	Saturday	2:00 PM	- 2:40 PM	218
Antivirals - New compounds and their mechanisms - Part I	Saturday	12:00 PM	- 1:20 PM	412
Antivirals - New compounds and their mechanisms - Part II	Saturday	4:45 PM	- 6:05 PM	412

Program at a glance – according to topic

Session		Duration			Room
Atherosclerosis and stroke - mechanisms and treatment	Sunday	11:15 AM	-	12:55 PM	405
Atherosclerosis, stroke & aging - mechanisms and treatment - Part I	Friday	4:50 PM	-	5:30 PM	217
Atherosclerosis, stroke & aging - mechanisms and treatment - Part II	Saturday	1:00 PM	-	2:00 PM	205
Bioanalytics - The cutting edge of LC-MS/MS - Part I	Saturday	7:15 AM	-	8:35 AM	216
Bioanalytics - The cutting edge of LC-MS/MS - Part II	Saturday	2:00 PM	-	3:40 PM	405
Bioanalytics - The cutting edge of LC-MS/MS - Part III	Sunday	8:45 AM	-	10:25 AM	217
Biomarkers - The thorny way to personalized medicine	Saturday	7:15 AM	-	9:30 AM	403
Biomarkers & personalized medicine	Sunday	11:15 AM	-	1:55 PM	213
Biomarkers and their applications	Friday	10:15 AM	-	12:15 PM	207
Biosimilars / Follow-on Proteins and their challenges to manufacturers and regulatory bodies - Part I	Friday	5:30 PM	-	6:50 PM	216
Biotechnology of drug delivery	Friday	1:15 PM	-	3:15 PM	405
Blood brain barrier physiology and diseases - Part I	Friday	1:15 PM	-	2:35 PM	213
Blood brain barrier physiology and diseases - Part II	Saturday	2:30 PM	-	3:50 PM	Paul Ehrlich Hall
Blood-brain barrier - History and most recent finding - Part I	Friday	10:15 AM	-	10:55 AM	212
Blood-brain barrier - History and most recent finding - Part II	Friday	8:00 PM	-	9:00 PM	218
Blood-brain barrier - History and most recent finding - Part III	Sunday	2:15 PM	-	2:55 PM	205
Brain physiology, biochemistry, and drugs acting on the brain - Part I	Sunday	8:45 AM	-	10:25 AM	214
Brain physiology, biochemistry, and drugs acting on the brain - Part II	Saturday	12:00 PM	-	1:20 PM	111
Cardiovascular - Drugs acting on the cardiovascular system - Part I	Friday	3:30 PM	-	5:30 PM	207
Cardiovascular - Drugs acting on the cardiovascular system - Part II	Friday	5:30 PM	-	6:50 PM	205
Cardiovascular - Drugs acting on the cardiovascular system - Part III	Saturday	12:00 PM	-	12:40 PM	217
Cardiovascular - Drugs acting on the cardiovascular system - Part IV	Sunday	11:15 AM	-	1:15 PM	214
Cardiovascular - Magic Bullets & the cardiovascular system - Part I	Saturday	12:00 PM	-	2:00 PM	206
Cardiovascular - Magic Bullets & the cardiovascular system - Part II	Sunday	2:55 PM	-	3:55 PM	205
Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part I	Friday	6:50 PM	-	7:30 PM	216
Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part II	Saturday	9:30 AM	-	10:50 AM	403
Clinical situations & therapy and cellular therapeutics	Saturday	7:15 AM	-	8:55 AM	111
Clinical studies with agents of different pharmacological activity - Part I	Friday	3:30 PM	-	4:50 PM	213

Program at a glance – according to topic

Session		Duration	Room
Clinical studies with agents of different pharmacological activity - Part II	Friday	6:50 PM - 7:50 PM	212
Clinical studies with agents of different pharmacological activity - Part III	Saturday	7:15 AM - 8:55 AM	217
CNS - Pharmacological options in disease of the central nervous system - Part I	Friday	1:15 PM - 3:55 PM	215
CNS - Pharmacological options in disease of the central nervous system - Part II	Friday	4:02 AM - 4:42 PM	212
CNS - Pharmacological options in disease of the central nervous system - Part III	Saturday	7:15 AM - 9:35 AM	218
CNS - Pharmacological options in disease of the central nervous system - Part IV	Sunday	8:45 AM - 10:25 AM	403
Cytochrome P450 - in vitro studies - Part I	Friday	3:30 PM - 4:30 PM	216
Cytochrome P450 - in vitro studies - Part II	Sunday	2:15 PM - 3:15 PM	206
Cytochrome P450 drug metabolism	Saturday	4:45 PM - 6:15 PM	216
Doping and performance enhancement drugs	Saturday	7:15 AM - 8:15 AM	404
Drug transporters and delivery - Part I	Friday	6:30 PM - 7:10 PM	207
Drug transporters and delivery - Part II	Saturday	12:00 PM - 1:20 PM	405
Drug-drug and drug-nutrient interactions - Part I	Saturday	2:00 PM - 4:20 PM	412
Drug-drug and drug-nutrient interactions - Part II	Sunday	8:45 AM - 10:05 AM	215
Drug-drug and drug-nutrient interactions - Part III	Sunday	11:15 AM - 12:15 PM	404
Ehrlich History, Reviews and Future perspectives on Ehrlich's Research Fields	Saturday	9:30 AM - 10:50 AM	207
Ehrlich's research fields: Historical aspects and latest research results	Saturday	9:30 AM - 11:30 AM	115
Endocrinology including diabetes	Saturday	7:15 AM - 9:15 AM	112
Erythropoietin - a Magic Bullet's quo vadis	Saturday	2:00 PM - 4:00 PM	214
HPLC, capillary electrophoresis, and other analytical techniques	Saturday	9:30 AM - 11:50 AM	212
Illicit drugs & similar agents and addiction	Saturday	7:15 AM - 8:35 AM	101
Illicit drugs & similar agents, doping and performance enhancement drugs	Sunday	8:45 AM - 10:25 AM	406
Immunosuppressants - Part I	Friday	6:30 PM - 7:30 PM	217
Immunosuppressants - Part II	Saturday	3:20 PM - 4:20 PM	206
Massspectrometry in pharmaceuticals and biochemistry	Friday	11:55 AM - 12:15 PM	212
Mechanisms of inflammation and anti-inflammatory agents - Part I	Friday	5:30 PM - 6:50 PM	206
Mechanisms of inflammation and anti-inflammatory agents - Part II	Saturday	3:00 PM - 4:00 PM	213
Metabolic Diseases	Sunday	8:45 AM - 10:05 AM	216

Program at a glance – according to topic

Session		Duration			Room
Nerve diseases, mechanisms, and pathophysiology - Part I	Friday	3:30 PM	-	4:10 PM	214
Nerve diseases, mechanisms, and pathophysiology - Part II	Saturday	3:00 PM	-	4:00 PM	218
Nerve diseases, mechanisms, and pathophysiology - Part III	Saturday	4:45 PM	-	6:05 PM	205
New / known targets & mechanisms - Part I	Sunday	11:15 AM	-	12:55 PM	215
New / known targets & mechanisms - Part II	Saturday	9:30 AM	-	11:50 AM	111
New drug concepts	Friday	8:00 PM	-	10:00 PM	205
New findings on purines	Saturday	9:30 AM	-	10:30 AM	101
Parkinson's disease, mechanism of disease and treatment - Part I	Saturday	9:30 AM	-	10:30 AM	405
Parkinson's disease, mechanism of disease and treatment - Part II	Saturday	4:45 PM	-	6:05 PM	405
Pharmaceutics - Discovery of drugs and mechanisms - Part I	Friday	4:10 PM	-	5:10 PM	214
Pharmaceutics - Discovery of drugs and mechanisms - Part II	Saturday	7:15 AM	-	8:55 AM	412
Pharmaceutics - Drug delivery - Part I	Friday	10:55 AM	-	11:55 AM	212
Pharmaceutics - Drug delivery - Part II	Saturday	2:00 PM	-	3:40 PM	406
Pharmaceutics - Drug delivery - Part III	Saturday	3:20 PM	-	4:20 PM	217
Pharmaceutics - Drug delivery through the skin - Part I	Friday	8:00 PM	-	9:20 PM	206
Pharmaceutics - Experimental and computational approaches - Part I	Friday	2:35 PM	-	3:30 PM	207
Pharmaceutics - Experimental and computational approaches - Part II	Saturday	11:30 AM	-	11:50 AM	205
Pharmaceutics - Experimental and computational approaches - Part III	Sunday	9:25 AM	-	10:25 AM	218
Pharmaceutics - Nanoparticles and their latest developments - Part I	Friday	1:55 PM	-	3:15 PM	406
Pharmaceutics - Nanoparticles and their latest developments - Part II	Saturday	4:45 PM	-	6:05 PM	403
Pharmaceutics - Nanoparticles and their latest developments - Part III	Sunday	2:15 PM	-	2:55 PM	213
Pharmaceutics - Pharmacokinetics and drug formulations - Part I	Friday	8:00 PM	-	9:40 PM	412
Pharmaceutics - Pharmacokinetics and drug formulations - Part II	Sunday	12:15 PM	-	1:15 PM	404
Pharmaceutics - Reviews and general aspects	Friday	8:00 PM	-	10:00 PM	207
Pharmacokinetic studies and drug metabolism	Friday	8:00 PM	-	9:40 PM	212
Physiology & Magic Bullets - Part I	Friday	6:50 PM	-	7:50 PM	206
Physiology & Magic Bullets - Part II	Saturday	7:15 AM	-	8:55 AM	405
Professional perspectives for health professionals	Friday	3:30 PM	-	4:02 AM	212

Program at a glance – according to topic

Session		Duration	Room
Psychoactive drugs - Part I	Saturday	2:00 PM - 4:40 PM	101
Psychoactive drugs - Part II	Sunday	8:45 AM - 11:05 AM	412
Recent progress and development in nanotechnology	Sunday	11:35 AM - 12:35 PM	217
Recombinant Proteins - a new class of Magic Bullets- Part I	Friday	1:15 PM - 2:35 PM	216
Recombinant Proteins - a new class of Magic Bullets- Part II	Saturday	7:15 AM - 8:35 AM	406
Resistance - a Global Issue for diverse therapeutic areas - Part I	Saturday	12:00 PM - 2:00 PM	215
Resistance - a Global Issue for diverse therapeutic areas - Part II	Saturday	4:45 PM - 6:45 PM	115
Resistance - a Global Issue for diverse therapeutic areas - Part III	Sunday	11:15 AM - 12:55 PM	216
Resistance - a Global Issue for diverse therapeutic areas - Part IV	Sunday	3:15 PM - 3:35 PM	206
Sex steroids	Saturday	4:45 PM - 6:05 PM	406
Steroid receptor - Jensen symposium	Saturday	4:45 PM - 6:25 PM	214
Steroids, Receptors & pulmonary diseases	Saturday	12:00 PM - 2:00 PM	115
Target site interactions and spectroscopic / computational approaches	Saturday	9:30 AM - 11:30 AM	205
Targets, Drugs and Carriers – Approaches to Translational Medicine, Financial support: German Research Foundation (FG463)	Saturday	1:00 PM - 4:30 PM	404
Therapeutic Drug Monitoring, Personalized Medicine, and immunosuppressive agents	Sunday	10:05 AM - 10:45 AM	215
Therapeutic Proteins - discovery and manufacturing - Part II	Saturday	2:00 PM - 3:20 PM	403
Therapeutic Proteins - discovery and manufacturing - Part III	Sunday	8:45 AM - 10:25 AM	405
Therapeutic Proteins - discovery and manufacturing - Part IV	Sunday	2:55 PM - 3:35 PM	213
Therapeutic Proteins - clinical studies - Part I	Friday	8:00 PM - 10:00 PM	213
Therapeutic Proteins - clinical studies - Part II	Saturday	4:45 PM - 6:25 PM	111
Therapy with monoclonal antibodies - Part I	Saturday	4:45 PM - 6:05 PM	215
Therapy with monoclonal antibodies - Part II	Sunday	12:15 PM - 1:55 PM	207
Therapy with monoclonal antibodies - Part II	Sunday	12:15 PM - 1:55 PM	207
Transporters of physiological compounds and drugs - Part I	Friday	5:30 PM - 6:10 PM	212
Transporters of physiological compounds and drugs - Part II	Sunday	3:35 PM - 4:35 PM	214
Treatment of asthma, COPD, and other lung diseases - Part I	Friday	5:30 PM - 6:30 PM	217
Treatment of asthma, COPD, and other lung diseases - Part II	Saturday	10:10 AM - 10:05 AM	412
Treatment of asthma, COPD, and other lung diseases - Part III	Sunday	8:45 AM - 10:25 AM	115

Program at a glance – according to topic

Session		Duration		Room
Treatment of diseases with involvement of the immune system - Part I	Friday	10:15 AM	- 12:35 PM	213
Treatment of diseases with involvement of the immune system - Part II	Friday	8:00 PM	- 9:40 PM	404
Treatment of diseases with involvement of the immune system - Part III	Saturday	2:00 PM	- 3:20 PM	206
Treatment of diseases with involvement of the immune system - Part IV	Sunday	11:15 AM	- 11:35 AM	217
Treatment of severe diseases	Friday	10:15 AM	- 11:35 AM	216
Treatment of severe infections including sepsis	Saturday	4:45 PM	- 6:12 PM	213
Treatment of tuberculosis and other infections	Saturday	9:30 AM	- 11:30 AM	213
Vaccines - Antiinfectives - Bacteria and parasites - Part I	Friday	9:20 PM	- 10:00 PM	206
Vaccines - Antiinfectives - Bacteria and parasites - Part II	Saturday	12:00 PM	- 12:40 PM	403
Vaccines - Antiinfectives - Bacteria, parasites, and HPV - Part I	Saturday	11:30 AM	- 11:50 AM	112
Vaccines - Antiinfectives - Bacteria, parasites, and HPV - Part II	Sunday	8:45 AM	- 10:05 AM	404
Vaccines - Antiinfectives - Herpes	Saturday	4:45 PM	- 5:45 PM	112
Vaccines - Antiinfectives - HIV - Part II	Saturday	12:00 PM	- 1:40 PM	216
Vaccines - Antiinfectives - Influenza and other viruses	Saturday	9:30 AM	- 11:10 AM	215
Vaccines - Antiinfectives - Malaria & Tuberculosis	Friday	8:00 PM	- 9:40 PM	405
Vaccines - Antineoplastic - Antigen guided	Saturday	9:30 AM	- 11:30 AM	112
Vaccines - Antineoplastic - Role of immune cells - Part I	Saturday	9:30 AM	- 10:10 AM	216
Vaccines - Antineoplastic - Role of immune cells - Part II	Sunday	2:15 PM	- 3:15 PM	215
Vaccines - Development, production and manufacturing - Part I	Friday	1:15 PM	- 3:20 PM	217
Vaccines - Development, production and manufacturing - Part II	Saturday	12:00 PM	- 1:20 PM	101
Vaccines - Development, production and manufacturing - Part III	Saturday	2:00 PM	- 3:00 PM	213
Vaccines - History, Reviews, and Future Perspectives - Part I	Saturday	12:00 PM	- 1:40 PM	207
Vaccines - History, Reviews, and Future Perspectives - Part II	Sunday	2:15 PM	- 3:15 PM	212
Vaccines - Physiology and molecular biology - Part I	Friday	1:15 PM	- 1:55 PM	406
Vaccines - Physiology and molecular biology - Part II	Saturday	9:30 AM	- 11:50 AM	406
Vaccines - Targeting non-infectious diseases - Part I	Friday	8:00 PM	- 9:40 PM	214
Vaccines - Targeting non-infectious diseases - Part II	Saturday	12:40 PM	- 1:00 PM	403
Which role does PK/PD play in drug development?	Saturday	9:30 AM	- 11:28 AM	L001

Key Note Lectures

08:00 AM - 05:00 PM Friday October 3rd, 2008

Room: Sir Henry Dale Hall

Time	Abstr. No.	Title
10:00 AM	1678	Optimizing Leishmaniasis therapy BOGDAN C. Mikrobiologisches Institut-Universitätsklinikum Erlangen, Wasserturmstraße 3, 91054 Erlangen, Germany
11:00 AM	1784	Stellenwert der EGFR-Inhibition in der Therapie des fortgeschrittenen Pankreaskarzinoms HEINEMANN V. University of Munich, Marchioninstr. 15, 81377 Munich, Germany
01:00 PM	1811	Erythropoietin - a therapeutic protein magic bullet LAPPIN TRJ Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast
02:00 PM	1809	From Bark to Bullet: A personal history of the discovery and development of Taxol WANI MC Research Triangle Institute, Research Triangle Park, NC 27709, USA
03:00 PM	1634	Prevention of bacterial resistance - 21st century strategies to prevent a public healthcare disaster DRUSANO G Orday Research Institute, 150 New Scotland Ave, Albany, NY 12208, USA
04:00 PM	1755	Uncovering tumor systems biology by biomodulatory therapy strategies REICHLE A Department of Hematology and Oncology, University Hospital Regensburg, Germany

09:00 AM - 06:00 PM Saturday October 4th, 2008

Room: Sir Henry Dale Hall

Time	Abstr. No.	Title
09:00 AM	1632	Four Decades of Anti-infective PK/PD - Progress & Future Perspectives CRAIG WA University of Wisconsin- Madison, William S. Middleton Memorial VA Hospital, 2500 Overlook Terrace, 53705 Madison, USA
10:00 AM	1783	Paul Ehrlich's 'Magic Bullet' Revisited, the emerging role of arsenic compounds in antineoplastic therapy. FREIREICH EJ University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 55, 77030 Houston, USA
11:00 AM	1623	Chronic myeloid leukemia: biological basis of therapy in 2008 GOLDMAN J. Imperial College, Du Cane Road, W12 0NN, London, UK
12:00 PM	1637	Corticosteroids - Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, and disease Progression JUSKO W University at Buffalo, 565 Hochstetter Hall, Buffalo, NY, USA
01:00 PM	1469	Signal transduction therapy of cancer LEVITZKI A Unit of Cellular Signaling, Department of Biological Chemistry. The Alexander Silberman Institute of Life Sciences. The Hebrew University of Jerusalem, Jerusalem 91904, Israel
02:00 PM	233	The Contribution of Alternative Approach to Understanding Steroid Hormone Action JENSEN VE John and Gladys Strauss Professor of Cancer Research at University of Cincinnati Medical Center's Vontz Center for Molecular Studies, Cincinnati, USA
03:00 PM	416	The Development of Influenza Virus Sialidase Inhibitors as Anti-Influenza Drugs VON ITZSTEIN M Institute for Glycomics, Griffith University, Gold Coast Campus, Queensland, Australia
04:00 PM	1759	Optimising outcomes of hospital infections through appropriate empirical antimicrobial therapy LODE H Berlin, Germany
05:00 PM	1660	The New York Connection: Paul Ehrlich and the Rockefeller Institute for Medical Research STAPLETON D Rockefeller University, 25 Wolden Road, 10562 Ossining USA

09:00 AM - 04:00 PM Sunday October 5th, 2008

Room: Sir Henry Dale Hall

Time	Abstr. No.	Title
09:00	1803	Toward biosimilar monoclonal antibodies - To what extent is the existing framework for biosimilars in Europe likely to be applicable to monoclonal antibodies? SCHNEIDER C Paul-Ehrlich-Institut, Federal Agency for Sera and Vaccines, Paul-Ehrlich-Str. 51-59, 63225 Langen, German
10:00 AM	10000	Glucocorticoids, COPD, Asthma (Samstag) WELTE T Depart. of Respiratory Medicine, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
11:00 AM	1806	Immunotherapy vs. Small Molecules in Haematology NIEDERWIESER D Abt. Hämatologie/Onkologie/Hämostaseologie, Universitätsklinikum Leipzig AöR, Johannisallee 32 A, Leipzig, Germany
12:00 PM	1551	Understanding and Predicting the Role of Transporters in Drug Absorption and Elimination BENET L. Department of Biopharmaceutical Sciences, University of California San Francisco, 533 Parnassus Avenue, Room U-68, San Francisco, CA 94143-0912, USA
01:00 PM	1803	Bioequivalence regulations - bar or driving force for scientific progress? BLUME H. SocraTec R&D GmbH, Feldbergstr. 27-29, D-61440 Oberursel, Germany
02:00 PM	1804	The Mould that Changed the World: Alexander Fleming and Penicillin Eighty Years On BROWN K Alexander Fleming Laboratory Museum (Imperial College Healthcare NHS Trust), St Mary's Hospital, Praed Street, W2 1Ny London, UK
02:30 PM	1804	More than "Geduld, Geschick, Geld and Gluck": Paul Ehrlich, Almroth Wright and Alexander Fleming BROWN K Alexander Fleming Laboratory Museum (Imperial College Healthcare NHS Trust), St Mary's Hospital, Praed Street, W2 1Ny London, UK

Symposia

**Symposium on: Targets, Drugs and Carriers – Approaches to Translational
Medicine**

Samstag, 4.10.2008 13.00 - 16.30 Uhr

Room 404

Section: Targets, Drugs and Carriers – Approaches to Translational Medicine
Financial support: German Research Foundation (FG463)

Symposium Date: **October 4, 2008**

Speakers and topics (in part to be confirmed)

13.00 – 13.15 Uhr

Introduction:

Schäfer-Korting M. (FU Berlin)

13.15-13.45 Uhr

Kleuser B., Reißig H.-U. (FU Berlin)

Sphingosin 1-phosphate signalling and therapeutic implications

13.45-14.15 Uhr

Dernedde J., Tauber R. (Charité-Universitätsmedizin Berlin)

Multivalency as action principle for the suppression of inflammatory processes

14.15-14.45 Uhr

Danker K., Reutter W. (Charité-Universitätsmedizin Berlin)

Glycosidic Phospholipids: Inhibitors of cell proliferation and migration

14.45-15.15 Uhr

Korting H.C., Kocsch B., Höltje H.-D. (LMU München, FU Berlin, HHU Düsseldorf)

Inhibitors of secreted aspartic proteinases for the treatment and prevention of candidoses

15.15-15.45 Uhr

Dathe M. (FMP Berlin)

Targeting of blood vessels by small ApoE-like peptides

15.45-16.15 Uhr

Schäfer-Korting M., Mehnert W. (FU Berlin)

From fundamental research in carrier-related skin penetration to polymerase-alpha inhibitors for skin tumor therapy

16.15 Uhr

Concluding remarks

Schäfer-Korting M. (FU-Berlin)

Oral presentations

08:00 - 09:00 AM Antineoplastic agents - New targets & compounds - Part I

Room: 206

Chairman: CC Diaconu, Brussels, Belgium

Time	Abstr. No.	Title
08:00 AM	142	Breast and Prostate Tumor Cell Destruction by Genetically Altered Salmonella with Preferential Targeting of Mitochondria SCHATTEN H¹ , ZHONG Z ¹ , KAZMIERCZAK RA ² , DINO A ² , KHREIS R ² , EISENSTARK A ² ¹ University of Missouri, Columbia, MO 65211, USA ² Cancer Research Center, Columbia, MO, 65201, USA
08:20 AM	194	Targeting Mutated Janus Kinases In Myeloproliferative Neoplasms Drug Discovery DIACONU CC¹ , DUSA A ² , PEQUET C ² , CHIVU M ¹ , DRAGOMIR L ¹ , CONSTANTINESCU SN ² ¹ Stefan S. Nicolau, Institute of Virology, Bucharest, Romania; ² Ludwig Institute for Cancer Research Brussels Branch, Christian de Duve Institute, Universite Catholique de Louvain, Brussels, Belgium.
08:40 AM	1494	Selective Stimulation Of Human Natural Killer Cells Proliferation By Novel Fucosylated Acidic Glycan Drugs: Possible Therapeutic Use For Treating Cancer And Viral/Retroviral Infections MISEVIC GN , MISEVIC NJ, SUMANOVSKI LT Gimmune GmbH, Zug, Switzerland

08:00 - 09:20 AM Antibacterials - Clinical Aspects - Part I

Room: 205

Chairmen: NB. Basnet, Kathmandu, Nepal
H. Ashraf, Dhaka, Bangladesh

Time	Abstr. No.	Title
08:00 AM	434	Erythromycin: Magic Bullet for Sore Throat and its Consequences in Children BASNET NB^{1,2} , BASNET SB ¹ ¹ Children's Medical Diagnosis Center (CMDC), Kathmandu, Nepal; ² Durga Bhawani Polyclinic, Kathmandu, Nepal.
08:20 AM	875	Randomized Controlled Clinical Trial of Day-Care Based and Hospitalized Management of Severe Childhood Pneumonia by Injection Ceftriaxone in Dhaka, Bangladesh ASHRAF H¹ , ALAM NH ¹ , GYR N ² ¹ International Centre for Diarrhoeal Disease Research (ICDDR,B), Dhaka, Bangladesh, ² University of Basel, Switzerland
08:40 AM	910	Management of Deep Space Neck Infection. Five Year Experience. CIZMAREVIC B , DEBEVC D, LEVART P Univ. Clinical Center Maribor, Department for otorhinolaryngology and maxillofacial surgery, Maribor, Slovenia.
09:00 AM	726	Alveolar Echinococcosis: The Impact Of Chemotherapy And Surgery On Survival MÜLLHAUPT B^{1,2} , TORGERSON PR ³ , DEPLAZES P ³ , AMMANN RW ⁴ ¹ Gastroenterology and Hepatology and ² Swiss HBP Center University Hospital of Zurich, Zurich, Switzerland, ³ Institute of Parasitology, University of Zurich, Zurich, Switzerland

**08:00 - 09:40 AM Antibacterials - New antibiotic and antineoplastic compounds from nature
- Part I**

Room: 212

Chairmen: F. von Nussbaum, Wuppertal, Germany
 J. Berdy, Budapest, Hungary
 S. Hoshina, Minato-ku, Japan

Time	Abstr. No.	Title
08:00 AM	143	Chemical Postevolution of Antibacterial Natural Products VON NUSSBAUM F Bayer Schering Pharma AG, Medicinal Chemistry Europe, D-42096 Wuppertal, Germany
08:20 AM	838	Natural Products (NP) - Microbial Metabolites (MM) - Antibiotics (AB): History, Facts and Problems, Where Now ? BÉRDY J Budapest, Hungary, e-mail: jberdy@t-online.hu
08:40 AM	1420	Dioxin like compounds for anti-infective agents of know as its degrading enzyme from its resistant <i>Geobacillus midousuji</i> thermophile HOSHINA S, YOSHIDA H Department of Laboratory Medicine, Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Tokyo, Japan.
09:00 AM	522	Disinfectant effect of Garcinia kola extract on Staph. Aureus EGWUATU TO,*¹ OGUNSOLA FT;¹ AGOMO AN;¹ AREWA DG;¹ BAMIDELE TJ²; EGWUATU CA³ ¹ Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria. ² Biotechnology Division, Department of Genetics, Federal Institute, of Research and Industrial Oshodi, Lagos Nigeria. ³ Lifegate Specialist Hospital, Ogba, Lagos Nigeria
09:20 AM	594	Drug Potential of Nigerian MedicinE Related Plants: A SURVEY BOBOYE B AND AKHARAIYI F Department Of Microbiology, Federal University Of Technology, P. M. B. 704, Akure, Ondo State, Nigeria.

**08:00 - 09:40 AM Antibacterials - New compounds and mechanisms - focusing on
tuberculosis and delivery**

Room: 213

Chairmen: K. Makino, Noda, Japan
 A.O. Tastan Bishop, Pretoria, South Africa
 T. Ishikawa, Tsukuba, Japan

Time	Abstr. No.	Title
08:00 AM	86	Pulmonary Drug Delivery System For Efficient Treatment Of Tuberculosis MAKINO K^{1,3}, TERADA H² ¹ Faculty of Pharmaceutical Sciences, ² Center for Drug Delivery Research, ³ Institute of Colloid and Interface Science, Tokyo University of Science, Noda, Japan
08:20 AM	1266	Mode of Action of a Naphthoquinone on Tuberculosis TASTAN BISHOP AO¹, MEYER JJM² ¹ University of Pretoria, Bioinformatics and Computational Biology Unit, Pretoria, South Africa; ² University of Pretoria, Department of Plant Science, Pretoria, South Africa.
08:40 AM	362	Discovery of a Novel Anti-MRSA Agent, TAK-599 (Ceftaroline Fosamil): An <i>N</i> -Phosphono Water-Soluble Prodrug for Intravenous Injection ISHIKAWA T, HASHIGUCHI S, AND IIZAWA Y Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd.

- 09:00 AM 463 Interactions of liposomal vesicles with bacterial cells and antimicrobial activity of liposomal antibiotics.
DRULIS-KAWA Z¹, DOROTKIEWICZ-JACH A¹, and GUBERNATOR J²
¹Institute of Genetics and Microbiology, University of Wrocław, Przybyszewskiego 63/77 51-148 Wrocław, Poland,
²Institute of Biochemistry and Molecular Biology, University of Wrocław, Przybyszewskiego 63/77, 51-148 Wrocław, Poland,
³Academic Centre for Biotechnology of Supramolecular Lipid Aggregates, Przybyszewskiego 63/77, 51-148 Wrocław, Poland
- 09:20 AM 1009 A diarylquinoline targeting the energy supply of *M. tuberculosis*
ANDRIES K, KOUL A, LOUNIS N, GUILLEMONT J*, JARLIER V**
Tibotec NV, Beerse, Belgium, *Tibotec NV, Val de Reuil, France, **Pitié-Salpêtrière School of Medicine, Paris, France

08:00 - 09:40 AM Antibacterials - Resistance, surveillance, and guidelines

Room: 214

Chairmen: V. Randhawa, New Delhi, India
G. Rodrigues, MANIPAL, India
K. Scott, Aberdeen, United Kingdom

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 08:00 AM | 497 | Ciprofloxacin Resistance Profile In <i>Klebsiella Pneumoniae</i> Isolates During 2002-2007 In Paediatric Septicaemic Cases Of A Tertiary Care Hospital In India
RANDHAWA VS , GUPTA LK*, MEHTA G
Deptt. Of Microbiology and Pharmacology*, Lady Hardinge Medical College and associated Kalawati Saran Children's Hospital New Delhi, India |
| 08:20 AM | 193 | Antimicrobial Prophylaxis In Surgery And Emergence Of Super Bugs: Dilemma In Developing Countries
RODRIGUES G ¹ , KHAN S ²
¹ Kasturba Medical College and ² Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India |
| 08:40 AM | 823 | Bacterial Tetracycline Resistance: Prevalence, Evolution and Dissemination of Genes
SCOTT KP , PATTERSON AJ, KAZIMIERCZAK K
Microbial Ecology Group, Rowett Institute of Nutrition and Health, University of Aberdeen, Greenburn Road, Bucksburn, Aberdeen, UK. AB21 9SB |
| 09:00 AM | 430 | Dentistry and Antibiotic Resistance: The Need to Set Guidelines and Improve Prescribing Practices.
DAR-ODEH NS ¹ , ABU-HAMMAD OA ²
¹ Department of Oral Surgery, Oral Medicine, and Periodontics, Faculty of Dentistry, University of Jordan, Amman, Jordan; ² Department of Prosthodontics, Faculty of Dentistry, University of Jordan, Amman, Jordan |
| 09:20 AM | 422 | Clinical Importance of Antimicrobial Resistance
PRASAD KN , SEN M.
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India |

08:00 - 09:40 AM Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part I

Room: 216

Chairmen: J.V. Moller, Aarhus, Denmark
R. Wu, Taipei, Taiwan
K. Liu, Guangzhou, China

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 08:00 AM | 1176 | Development of SERCA Inhibitors Targeted towards Prostate Cancer Cells
MØLLER JV ¹ , BRØGGER CHRISTENSEN S ³ , OLESEN C ¹ , WINTER AML ² , SØHOEL H ³ , LIU H ³ , NISSEN P ²
¹ Institute of Physiology and Biophysics, ² Department of Molecular Biology, PUMPKIN Research Center, Aarhus University; ³ Department of Medicinal Chemistry, University of Copenhagen |

08:20 AM	652	The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma MEI SC¹ WU RT^{1,2} ¹ Institute of Biopharmaceutical Science and ² Research Center for Drug Discovery, School of Pharmaceutical Science, National Yang-Ming University, Shih-Pai, Taipei, Taiwan, Republic of China
08:40 AM	699	Monitor of Chemosensitivity by Bcl-2 Transcript Kinetics in Acute Myeloid Leukemias LIU KS¹, KREUZER KA², LASS U², SCHMIDT CA² ¹ Univ. Jinan, Guangzhou, China; ² Univ. Humboldt, Berlin, Germany.
09:00 AM	322	Proton Transport Inhibitors (PTI) as Selective Anticancer Agents HARGUINDEY S Institute of Clinical Biology and Metabolism, c) Postas 13 - 01004 Vitoria, Spain.
09:20 AM	98	The Many Lives of Hsp10: From Early Pregnancy Factor to Potential Antitumoral Agent. New Proteomic Data and a Review of the Literature Focusing on Its Immunologic Properties LA ROCCA G¹, ANZALONE R¹, CAPPELLO F¹, CORRAO S¹, TIMPERIO AM², ZOLLA L², CONWAY DE MACARIO E³, MACARIO AJ³, FARINA F¹, ZUMMO G¹. ¹ DIMES, University of Palermo, Italy; ² DISA, University of Viterbo, Italy; ³ COMB, University of Maryland, Baltimore, USA.

08:00 - 10:00 AM Antibacterials - Discovery - New methods of chemical significance

Room: 207

Chairmen: J. Primeau, Waltham , USA
 T. Chang, Logan, USA
 N. Demirbas, Trabzon, Turkey

Time	Abstr. No.	Title
08:00 AM	1128	The Discovery of New Scaffold Antibacterial Agents PRIMEAU J AstraZeneca R&D Boston
08:20 AM	1246	Neomycin, Kanamycin and Pyranmycin: Synthesis, Antibacterial Activity and New Applications CHANG CWT Department of Chemistry and Biochemistry, Utah State University, Logan, Utah 84322, USA
08:40 AM	941	Synthesis of Some New 1,3,4-Thiadiazol-2-ylmethyl-1,2,4-Triazole Derivatives and Investigation of Their Antimicrobial Activities DEMIRBAS N^a, DEMIRBAS A, SAHIN D, BAYRAK H, KARAOGLU S ^a Karadeniz Technical University, Department of Chemistry 61080 Trabzon-Turkey
09:00 AM	264	Synthesis, In Silico ADME-Tox Study And Antimicrobial Evaluation Of Some Small Molecules MOORTHY NSHN, VITTAL UB, KARTHIKEYAN C, TRIVEDI P School of Pharmaceutical Sciences, RGPV, Bhopal, MP, India
09:20 AM	108	An Entry to Clavams from Chiral Vinyl Ethers and Chlorosulfonyl Isocyanate CHMIELEWSKI M Institute of Organic Chemistry of the Polish Academy of Sciences, 01-224 Warsaw, Kasprzaka 44/52, Poland, e-mail:chmiel@icho.edu.pl
09:40 AM	1190	A Simple Microwave-assisted Synthesis of Sulfonamides directly from Sulfonic Acids DE LUCA L¹, GIACOMELLI G¹ ¹ Univ. of Sassari, Sassari, Italy;

08:00 - 10:00 AM Antineoplastic agents - Effectiveness and resistance in patients - Part I

Room: 215

Chairmen: A. Driedger, Ingersoll, Canada
F. Nadali, Isfahan, Iran
C. Lingwood, Toronto, Canada

Time	Abstr. No.	Title
08:00 AM	1244	Molecular guidance systems for nuclear-tipped magic bullets: Clinical experiences in thyroid cancer treatment using recombinant TSH DRIEDGER AA Division of Nuclear Medicine, University of Western Ontario, London, Canada
08:20 AM	503	Multidrug Resistance Inhibition in Acute Myeloblastic leukemia by Antisense Oligonucleotide NADALI.F¹ , POURFATHOLLAH.A.A. ² , ALI- MOGHADDAM.K ³ , DIZAJI.A ⁴ , ZOMORODIPOUR.A ⁴ , AZIZI.E ⁵ , ROSTAMI.SH ³ , GHAVAMZADEH.A ³ Pathology Department, School of Medicine, Isfahan university of Medical Sciences, Isfahan, IRAN. ¹ nadalifa@yahoo.com Hematology Department, School of Medical Sciences, Tarbiat Modares University ² , Hematology-Oncology & BMT Research Center, Shariati Hospital, Tehran University / Medical Sciences ³ , National Institute for Genetic Engineering and Biotechnology ⁴ , Toxicology Department, Faculty of Pharmacy, University of Tehran /Medical Science
08:40 AM	1148	"Verotoxin (Shiga toxin) binding to its receptor glycolipid, globotriaosyl ceramide, provides a new antineoplastic tool and physiologically-based approaches to tumour cell drug resistance" LINGWOOD C Research Institute, Hospital for Sick Children, Toronto, Canada
09:00 AM	1391	Experimental Evidence for Killing the Resistant Cells and Raising the Efficacy of Cytostatics by a New Anticancer Drug Candidate (Culevit Infusion) Developed on the Basis of the Passive Antitumor Defence System KULCSAR G¹ , GAAL D ² , TOTH Z ¹ , KULCSAR PI ¹ , OSZ E ¹ , BERENTE Z ¹ , HALASZ H ¹ ¹ Univ. Pecs, Pecs, Hungary ² National Institute of Oncology, Budapest, Hungary
09:20 AM	1077	The urokinase system is a natural inducer of cancer cell drug resistance CHUN MH , HOFFMANN MK ApoTech, Seocho gu, Banpo dong, Gu-ganpo 106-505, Seoul Korea
09:40 AM	1269	Safe and Effective Delivery of Paclitaxel through Amphiphilic Beta-Cyclodextrin Nanoparticles BILENSOY E¹ ¹ Univ. Hacettepe, Fac. of Pharmacy, Dept. Pharmaceutical Technology, Ankara, Turkey

10:15 - 10:55 AM Blood-brain barrier - History and most recent finding - Part I

Room: 212

Chairman: J-J Dreifuss, Geneva, Switzerland

Time	Abstr. No.	Title
10:15 AM	476	The blood-brain barrier and its magic transporters – a pharmacokinetic perspective on how to optimize drug delivery to the brain HAMMARLUND-UDENAES M Division of Pharmacokinetics and Drug Therapy, Uppsala University, Sweden
10:35 AM	625	Circumventing the blood-brain-barrier. Soviet attempts during World War 2. DREIFUSS J-J , TIKHONOV N University Medical Centre, CH-1211 Geneva 4, Switzerland.

10:15 - 11:15 AM Antineoplastic agents - Tyrosine Kinase Inhibitors - Part I

Room: 205

Chairman: H. Reh, Augsburg Germany

Time	Abstr. No.	Title
10:15 AM	859	Transcriptional Changes Induced by Imatinib and Nilotinib in the Chronic Myelogenous Leukemia (CML) Cell Line K562 BRUENNERT D , KOCH A, GATTERMANN N, KRONENWETT R, HAAS R, NEUMANN F Heinrich-Heine-University, Duesseldorf, Germany
10:35 AM	276	Receptor Tyrosine Kinases As Therapeutic Targets In Malignant Glioma, Present Status And Application In China REN H ¹ , JIANG T ² , RAINOV NG ³ ¹ Harbin Medical Univ., Harbin, China; ² Tian Tan Hosp., Beijing, China; ³ Klinikum Augsburg, Augsburg, Germany
10:55 AM	854	The critical role of IL-15 <i>trans</i> -presentation in the antitumor effects mediated by the combination therapy with Imatinib and IL-2 ULLRICH E ^{1,2} , MIGNOT G ¹ , BONMORT M ¹ , TEMRE M ¹ , CHAPUT N ¹ , ZITVOGEL L ¹ ¹ INSERM U805, Institut Gustave Roussy, Villejuif, France; ² Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany

10:15 - 11:15 AM Antibacterials - New and innovative approaches to discover and develop antimicrobials – Part 1

Room: 214

Chairman: F. Van Bambeke, Brussels, Belgium

Time	Abstr. No.	Title
10:15 AM	460	Perspective Chemotherapeutic Combination to Combat Flu GALABOV AS , SIMEONOVA L, GEGOVA G The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria
10:35 AM	110	One target, two bullets : from erythromycin to telithromycin, what makes the difference ? VAN BAMBEKE F Pharmacologie cellulaire et moléculaire, Univ. catholique de Louvain, Brussels, Belgium
10:55 AM	1364	The Use of DNA-based Therapies to Restore Clinical Efficacy of Antibiotics MCARTHUR M , MOORE J, BIBB MJ Department of Molecular Microbiology, John Innes Centre, Norwich, NR4 7UH, UK

10:15 - 11:35 AM Antivirals - Mechanisms and development of antivirals - Part I

Room: 206

Chairmen: S. Menne, Ithaca, USA
L. Nikolaeva-Glomb, Sofia, Bulgaria

Time	Abstr. No.	Title
10:15 AM	156	Antiviral Effect Of Lamivudine, Emtricitabine, Adefovir Dipivoxil, And Tenofovir Disoproxil Fumarate, Administered Orally Alone And In Combination, To Woodchucks With Chronic Woodchuck Hepatitis Virus Infection MENNE S ¹ , BUTLER SD ¹ , GEORGE AL ¹ , TOCHKOV IA ¹ , ZHU Y ² , XIONG S ² , GERIN JL ³ , COTE PJ ³ , TENNANT BC ¹ ¹ Cornell University, College of Veterinary Medicine, Department of Clinical Sciences, Ithaca, NY, USA; ² Gilead Sciences, Inc., Durham, NC, USA; ³ Georgetown University Medical Center, Department of Microbiology and Immunology, Washington, DC, USA
10:35 AM	351	The Potential Of Oxoglaucine, A New Antiviral Compound, To Inhibit Enterovirus Replication When Applied Alone Or In Combination NIKOLAEVA-GLOMB L ¹ , FILIPOV S ² , GALABOV AS ¹

- 10:55 AM 663 Nitric Oxide and Zidovudine Potentiate Oxidative Response of Stimulated Macrophages
KOMAROV AM, WEGLICKI WB
The George Washington University Medical Center, Washington, DC, USA
- 11:15 AM 1754 Non-steroidal Anti-inflammatory Drugs; a Potential New Way to Treat Human
Cytomegalovirus (HCMV) Disease
SCHRÖER J^{1,2}, SHENK TE²
¹ University Regensburg, Regensburg, Germany; ²Princeton University Princeton, NJ, USA

10:15 - 11:35 AM Treatment of severe diseases

Room: 216

Chairman: F. Simon, Ulm, Germany

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 10:15 AM | 1749 | Low-dose steroids in critically ill patients: Who should be treated and when?
BRIEGEL J
Munich, Germany |
| 10:35 AM | 1687 | H ₂ S-induced suspended animation during porcine aortic occlusion-induced ischemia
reperfusion injury
SIMON F ^{1,2} , WAGNER F ¹ , BAUMGART K ¹ , HAUSER B ¹ , GRÖGER M ¹ , CALZIA E ¹ ,
RADERMACHER P ¹ , SCHELZIG H ² , GEORGIEFF M ¹
¹ Klinik für Anästhesiologie und ² Thorax- und Gefäßchirurgie, Universitätsklinikum, Ulm,
Germany |
| 10:55 AM | 1761 | Red blood cell omega-3 fatty acids and the risk of ventricular arrhythmias in patients with
heart failure
WILHELM M
University of Erlangen, Ulmenweg 18, 91054 Erlangen, Germany |
| 11:15 AM | 1260 | Anti-IgE Therapy In The Management Of Asthma: Present Use And Possible Future
Applications
MARCUS P
NY College of Osteopathic Medicine, Old Westbury, NY, USA; St. Francis Hospital, Roslyn,
NY, USA |

10:15 AM - 12:15 PM Antibacterials - Molecular microbiology

Room: 215

Chairmen: G. Ehrlich, Pittsburgh, USA
F. Hu, Pittsburgh, USA
H. Grasmann, Toronto, Canada

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 10:15 AM | 1248 | Prediction of species-specific targets for the development of STAMPs based on analyses of
bacterial species-level supragenomes
EHRlich GD , HOGG JS, JANTO B, AHMED, A, HILLER NL, BOISSY R, POWELL E, YU
S, POST JC, HU FZ
Center for Genomic Sciences, Allegheny Singer Research Institute 320 E North Ave,
Pittsburgh, PA, 15212, USA |
| 10:35 AM | 1245 | Development of species-specific STAMPs (specific targeted antimicrobial peptide) that
target and kill only <i>Streptococcus pneumoniae</i> within a polymicrobial community
HU FZ , ² SHI W, ¹ HILLER NL, ¹ HOGG JS, ¹ JANTO B, ¹ AHMED A, ¹ BOISSY R, ¹ POWELL
E, ¹ YU S, ¹ POST JC, ¹ EHRlich GD,
¹ Center for Genomic Sciences (CGS), Allegheny Singer Research Institute, 320 E North
Ave, Pittsburgh, PA, 15212, USA; ² Department of Oral Biology, UCLA School of Dentistry, 10833
Le Conte Ave, Los Angeles, CA 90095, USA |

10:55 AM	576	Augmenting Endogenous Nitric Oxide Production to Kill Multiresistant <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Lung Disease. GRASEMANN H Hospital for Sick Children Research Institute, and Division of Respiratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada
11:15 AM	109	Can We Make Eucaryotic Cells Resistant To Antibiotics? Correlation Between Multidrug Resistance-Associated Protein (Mrp) Efflux Pump Expression And Fluoroquinolones Accumulation In J774 Macrophages MARQUEZ B, VALLET C, MINGEOT-LECLERCQ MP, TULKENS PM, VAN BAMBEKE F Unité de Pharmacologie cellulaire et moléculaire, Université catholique de Louvain, Brussels, Belgium
11:35 AM	690	The Unexpected Hidden Face Of The Cephalosporin Antibiotic Cefazidime: From Biological To Chemical And Physical Activities Against Oxidant Species Produced By Phagocytes MOUITHYS-MICKALAD A¹, DEBY-DUPONT G^{1,2}, MATHY-HARTERT¹ M, LAMY M^{1,2}, SERTEYN D^{1,3}, DEBY C¹ ¹ Centre for oxygen, R&D (CORD), Institute of Chemistry B6a ² Department of Anesthesiology and Intensive Care Medicine, ³ Equine Clinic, University of Liège, Liège, Belgium
11:55 AM	1285	Serotonin Transporter: Mechanisms of Inhibition by Enteropathogenic <i>E. coli</i> (EPEC) GILL R, ESMAILI A, NAZIR S, BORTHAKUR A, TURNER J, ALREFAI W, HECHT G, DUDEJA P Dept. of Medicine, University of Illinois at Chicago, Medical Research Service (600/151), Jesse Brown VA Medical Center, 820 South Damen Avenue, Chicago, IL 60612, USA

10:15 AM- 12:15 PM Biomarkers and their applications

Room: 207

Chairmen: E. Marrer, Basel, Switzerland
M. Yamaguchi, Morioka, Japan
J. STYCZYNSKI, BYDGOSZCZ, Poland

Time	Abstr. No.	Title
10:15 AM	346	Success Story Of The First Regulatory Approval Of Safety Biomarkers, Part I: From Identification To Biological Qualification MARRER E, DIETERLE F Novartis Institutes for BioMedical Research, Basel, Switzerland
10:35 AM	665	Noninvasively Evaluation on Human Stress Using Salivary Biomarker YAMAGUCHI M Iwate University, Morioka, Japan
10:55 AM	987	Strategic Role of Prednisolone, Vincristine and Asparaginase in Pediatric Leukemia as a Paradigm of Success in Oncology: Individualized Tumor Response Testing and Microarray Analysis STYCZYNSKI J Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
11:15 AM	249	Cell Hydration as a Universal and Extra-Sensitive Biomarker for Determination of the Functional State of the Organism AYRAPETYAN S UNESCO Chair-Life Sciences International Postgraduate Educational Center, Yerevan, Armenia
11:35 AM	783	Pivotal Evaluation of the Accuracy of a Diagnostic Biomarker: the PRoBE Study Design FENG M-G, NAVAR LG Tulane University, New Orleans, LA. USA
11:55 AM	743	Inhibition of experimental Sjögren's syndrome through immunization with Hsp 60kDa and its peptide aa437-460 - predicting treatment efficacy using multi-plex biomarker profiling DELALEU N¹, MADUREIRA AC¹, IMMERSVOLL H^{2,3}, JONSSON R^{1,4,5} ¹ Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, ² Section of Pathology, The Gade Institute, University of Bergen, Bergen, Norway, ³ Department of Pathology, Haukeland University Hospital, Bergen, Norway, ⁴ Department of Rheumatology and ⁵ Department of Otolaryngology, Head and Neck Surgery, Haukeland University Hospital, Bergen, Norway.

10:15 AM - 12:35 PM Treatment of diseases with involvement of the immune system - Part I

Room: 213

Chairmen: E. Kmonickova, Prague, Czech republic
D. Gladstone, Miller Place, USA
S. Grygorczuk, Bialystok, Poland

Time	Abstr. No.	Title
10:15 AM	360	Novel Generation of Antivirotics: Combination of Antimetabolic and Immunostimulatory Modes of Action KMONICKOVÁ E¹ , HOLÝ A ² , ZÍDEK Z ¹ ¹ Inst. Experimental Medicine, Acad. Sci., Prague, Czech Rep; ² Inst. Organic Chemistry and Biochemistry, Acad. Sci., Prague, Czech Rep.
10:35 AM	1183	High-dose cyclophosphamide is active in immune-mediated illnesses. GLADSTONE D Stony Brook University, New York, USA
10:55 AM	1252	Expression of Fas on human T lymphocytes under stimulation with <i>Borrelia burgdorferi</i> sensu lato. GRYGORCZUK S¹ , OSADA J ² , SWIERZBINSKA R ¹ , CHMIELEWSKI T ³ , ZAJKOWSKA J ¹ , KONDRUSIK M ¹ , PANCEWICZ S ¹ , DABROWSKA M ² , TYLEWSKA-WIERZBANOWSKA S ³ ¹ Department of Infectious Diseases and Neuroinfections, Medical University in Bialystok, Poland; ² Department of Haematologic Diagnostics, Medical University in Bialystok, Poland; ³ Department of Rickettsiae, Chlamydiae and Zoonotic Spirochetes, National Institute of Hygiene, Warsaw, Poland
11:15 AM	1363	Novel Immuno - Potency Drugs KALAVI K* , MOHAGHEGH HAZRATI S** Golestan University of Medical Sciences and Golestan Research Center of Gastroenterology & Hepatology, **Dr. Mohaghegh's foundation researches on Industrial Biotechnology
11:35 AM	7	Prevention of Inflammatory Leukocyte Adhesions for Treatments in Acute Sepsis Condition by Anti-CD18 sFv Single-Chain Antibody LUK JM , WONG KF Dept of Surgery, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
11:55 AM	1175	Genetic immunization: comparison of water-in-oil liposome-based delivery of cDNAs with <i>in vivo</i> electroporation. DAFTARIAN P^{1,2} , MANSOUR M ³ , CHOWDHURY R ¹ , BROWN RG ³ , KENYON N ¹ , LEMMON V ⁴ 1. Wallace H. Coulter Center for Translational Research, University of Miami Miller School of Medicine, Miami, FL. 2. Department of Microbiology & Immunology, University of Miami Miller School of Medicine, Miami, FL. 3. ImmunoVaccine Technologies Inc. Halifax NS, Canada. 4. Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL.
12:15 PM	144	Rheumatoid arthritis, <i>Proteus</i> and "magic bullets". EBRINGER A , RASHID T. Analytical Sciences Group, King's College, 150 Stamford Street, LONDON SE1 9NN, U.K.

10:55 - 11:55 AM Pharmaceutics - Drug delivery - Part I

Room: 212

Chairman: C. Martins-Lopes, Porto, Portugal

Time	Abstr. No.	Title
10:55 AM	492	Cyclotides, ultrastable peptide frameworks for magic bullet drug delivery DALY NL¹ , GUNASEKERA S ¹ , FOLEY F ¹ , CLARK RJ ¹ , FABRI, L ² , CRAIK DJ ¹ ¹ Institute for Molecular Bioscience, University of Queensland. 4072 Australia. ² CSL Richmond Victoria, Australia.

11:15 AM	817	Optimizing A Therapeutic With Nsaids: Intelligent Design For Delivery Systems MARTINS LOPES C ¹ , COELHO PB ¹ , SANTOS D ² , OLIVEIRA R ¹ , SOUTO E ¹ ¹ Faculty of Health Sciences, FCS, Fernando Pessoa University, Porto, Portugal; ² Faculty of Pharmacy, Porto University, Porto, Portugal
11:35 AM	992	Targeted Delivery of Cytotoxic Drugs by Means of Protein Vectors SEVERIN SE Moscow Research Institute of Medical Ecology, Moscow, Russia

11:15 AM - 12:15 PM Antibacterials - Resistance in gram positives

Room: 214

Chairmen: S. Lemaire, Brussels, Belgium
P. Munsch-Alatossava, Helsinki, Finland

Time	Abstr. No.	Title
11:15 AM	127	Magic Activity Of Beta-Lactam Antibiotics Against Intracellular Methicillin-Resistant <i>S. Aureus</i> (MRSA): Role Of Acidic pH Lemaire S , Van Bambeke F Tulkens PM Université Catholique de Louvain, Brussels, Belgium.
11:35 AM	1247	Antibiotic Resistance Of Psychrotrophs Spoiling Raw Milk MUNSCH-ALATOSSAVA P , ALATOSSAVA T University of Helsinki, Dept. of Food Technology, Helsinki, Finland
11:55 AM	365	Susceptibilities of rickettsiae to antimicrobials. BENABDELLAH A , BENSSADOUN F-Z, BENSSAD M, KOUIDAD-BELKADI S-A Service des maladies infectieuses et tropicales, CHU.Oran, Oran 31000, Algeria

11:55 - 12:15 AM Masspectrometry in pharmaceutics and biochemistry

Room: 212

Time	Abstr. No.	Title
11:55 AM	1541	Masspectrometry in pharmaceutics and biochemistry HOPFGARTNER, G. , Geneva, Switzerland

11:55 AM - 12:55 PM Antineoplastic agents - New strategies and new compounds- Part I

Room: 215

Chairman: A. Reichle, Regensburg, Germany

Time	Abstr. No.	Title
11:55 AM	455	Selenium Derivatives as Cancer Preventive Agents ABOUL-FADL T Departments of Pharmaceutical Chemistry, King Saud University, Riyadh, Saudi Arabia.
12:15 PM	895	Heterocyclic hydrazones induce radical formation and dissipation of mitochondrial membrane potential HOFMANN J ¹ , JENNYM ¹ , HERMANN ¹ , EASMON J ² , PUERSTINGER G ² , HEINISCHG1, SHTIL AA ³ , CONDORELLI DF ⁴ , SCIRÉS ⁴ , MUSUMARRA G ⁴ ¹ Innsbruck Medical University, Innsbruck, Austria; ² University of Innsbruck, Innsbruck, Austria; ³ Blokhin Cancer Center, Moscow, Russia; ⁴ Università di Catania, Catania, Italy.
12:35 PM	234	Retargeting anticancer drugs to drug resistant cancers by using polymer Biotransport technology. Clinical proof of the concept ALAKHOV VY Suptarek Pharma Inc., Montreal, Canada

01:15 - 01:55 PM Vaccines - Physiology and molecular biology - Part I

Room: 406

Chairman: Y. Madhavi, New Delhi, India

Time	Abstr. No.	Title
01:15 PM	969	Resolution of cancer and infection induced wounding is an essential factor in immune enhancement. The answers to why and how revealed SMITH GR Perses Biosystems Ltd, Warwick Science Park, Coventry, UK
01:35 PM	1014	Vaccines: The Magic wand of Indian Public Health?" MADHAVI Y. National Institute of Science, Technology and Development Studies (NISTADS, CSIR), NPL Campus, New Delhi, India

01:15 - 02:15 PM Antineoplastic agents - Approaches to optimize therapy - Part I

Room: 206

Chairman: B. Anilanmert, Kayseri, Turkey

Time	Abstr. No.	Title
01:15 PM	37	Cytochrome P450 Dependent Drug Response In Oncology RODRÍGUEZ-ANTONA C Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), C/ Melchor Fernández Almagro, 3, 28029 Madrid, Spain
01:35 PM	1022	The Chemical Interaction of the Anticancer Drugs Irinotecan-HCl and Epirubicin-HCl in the Same Infusion Solution ÖZDEMİR FA ¹ , ANILANMERT B ² , PEKIN M ¹ ¹ Marmara Univ. Faculty of Pharmacy, Istanbul, Turkey; ² Erciyes Univ. Faculty of Pharmacy, Kayseri, Turkey
01:55 PM	724	KIT-deficient mouse and KIT-targeted drug KITAMURA K ¹ , TAKEGAMI S ¹ , OMRAN AA ^{1,2} , KITADE T ¹ ¹ Kyoto Pharmaceutical University, Kyoto, Japan, ² Al-Azhar University, Assiut, Egypt

01:15 - 02:35 PM Antiparasitic compounds - Therapeutic approaches

Room: 207

Chairmen: I. Francischetti, Bethesda, USA
Z. Taoufiq, Paris, France

Time	Abstr. No.	Title
01:15 PM	1095	Ixostatin, a Novel Tick Salivary Protein that Specifically Binds to the Somatomedin B Domain of Vitronectin and Prevents its Interaction with Integrin alphavbeta3 and Urokinase Receptor FRANCISCHETTI I National Institutes of Health, Bethesda, USA.
01:35 PM	1116	Fasudil: the New "Magic Bullet" to Thwart Malaria Mortality? TAOUFIQ Z ^{1,2} , and MAZIER D ^{1,2,3} . ¹ : INSERM U511, Laboratoire d'Immunobiologie Cellulaire et Moléculaire des Infections Parasitaires, Paris, France. ² : Université Pierre et Marie Curie-Paris6, UMR S511, Paris 75013, France. ³ : Groupe hospitalier Pitié-Salpêtrière, Service de Parasitologie-Mycologie, Paris, France
01:55 PM	439	Mediterranean spotted fever(MSF) in Oran (Algeria) BESTAOUI L , BENABDELLAH A, BENSADOUN F-Z, KOUIDED-BELKADI S-A, BENSAAID M Service des maladies infectieuses et tropicales, CHU.Oran, ORAN 31000, Algeria

02:15 PM 297 Plasmodium Heme Crystallization: Methylene Blue to the Quinolines
SULLIVAN DJ
Dept Molecular Microbiology and Immunology and Infectious Diseases
Johns Hopkins Bloomberg School of Public Health

01:15 - 02:35 PM Blood brain barrier physiology and diseases - Part I

Room: 213

Chairmen: D. Focosi, Pisa, Italy
M. Lagarde, Villeurbanne, France

Time	Abstr. No.	Title
01:15 PM	167	5-HT _{2a} antagonists as a new treatment for JCV-associated progressive multifocal leukoencephalopathy FOCOSI D¹ , MAGGI F ¹ , KAST RE ² , GALIMBERTI S ¹ , CECCHERINI-NELLI L ¹ , PETRINI M ¹ . ¹ Division of Hematology, University of Pisa, Italy ² Division of Psychiatry, University of Vermont, USA
01:35 PM	942	Blood Choline Phospholipids As Preferential Sources Of Docosahexaenoic Acid To The Brain LAGARDE M Université de Lyon, UMR 870 Inserm / Insa-Lyon, 69621 Villeurbanne, France.
01:55 PM	378	Hierarchy of Immune Responses behind the Blood-Brain-Barrier (BBB) in the Normal Brain: Implications for the development of CNS Diseases and Treatment HARLING-BERG CJ¹ , KNOPF PM ¹ ¹ Brown University, Providence RI 02912, USA
02:15 PM	396	Pathogenesis Of Blood-Brain Barrier Breakdown Following Brain Injury: Windows For Therapeutic Intervention NAG S , MANIAS J, ¹ STEWART D.J. Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON Canada, ¹ Terrance Donnelly Heart Center, St. Michael's Hospital, University of Toronto, ON Canada.

01:15 - 02:35 PM Antineoplastic agents - New mechanisms & compounds - Part I

Room: 214

Chairmen: R. Auerbach, Madison, USA
S.J. Yeung, Houston, USA

Time	Abstr. No.	Title
01:15 PM	979	The Role of Endothelial Cell Heterogeneity in the Search for Anti-angiogenic Agents AUERBACH R , AUERBACH W Laboratory of Developmental Biology, Department of Zoology and Institute on Aging, University of Wisconsin, Madison, WI 53706 USA
01:35 PM	1241	Antineoplastic effects of an aurora B kinase inhibitor against breast cancer YEUNG SJ , GULLY C, YEUNG JA, LEE MH Department of General Internal Medicine, Ambulatory Treatment & Emergency Care, Department of Molecular & Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
01:55 PM	1756	Rituximab Maintenance Therapy in CD20+ B-Cell Non-Hodgkin-Lymphoma – First results of a multicenter prospective randomised Phase II study WITZENS-HARIG M , HENSEL M, SCHMIER JW, NEBEN K, BENNER A, DREGER P, KUHN C, SCHMIDT-WOLF I, KRÄMER A, HO AD
02:15 PM	1165	Molecular Mechanism of Action and Cellular Consequences of the DNA Minor Groove Alkylating Agent S23906-1. LENGLET G¹ , DEPAUW S ¹ , DAVID-CORDONNIER M-H¹ ¹ INSERM U837-Centre de Recherches Jean-Pierre Aubert (JPARC), Team 4 "Molecular and Cellular Targeting for Cancer Treatment", Institut de Recherche sur le Cancer de Lille, Place de Verdun, F-59045 Lille cedex, France.

01:15 - 02:35 PM Recombinant Proteins - a new class of Magic Bullets- Part I

Room: 216

Chairmen: L. Gaziola de la Torre, Campinas, Brazil
Y. Endo, Matsuyama, Japan

Time	Abstr. No.	Title
01:15 PM	1369	Synergy between structural stability and DNA-binding controls the antibody production in EPC/DOTAP/DOPE vesicles and DOTAP/DOPE lipoplexes LUCIMARA GAZIOLA DE LA TORRE¹, ROGÉRIO SILVA ROSADA², ARLETE A.M. COELHO-CASTELO², CELIO LOPES SILVA², MARIA HELENA ANDRADE SANTANA¹ ¹ Departamento de Processos Biotecnológicos, Faculdade de Engenharia Química
01:35 PM	947	Discovery of Malaria Vaccine Candidates – Application of the HT Cell-Free Protein Production System Born of the Study on Ricin Toxin ENDO Y Ehime University, Matsuyama, Japan.
01:55 PM	1138	The Impact of Inflammatory Responses on Taste Bud Cell Turnover and Function. WANG H¹, ZHOU M¹, BRAND J¹, HUANG L¹, ¹ Monell Chemical Senses Center, Philadelphia, USA.
02:15 PM	1347	Wheat and barley for celiac patients by molecular silencing of the immunogenic endosperm proteins VON WETTSTEIN D^{A,B,C,D}, BRUEGGEMANA R, GAMINI C. KANNANGARAA, NII ANKRAHA, RUSTGIA S, LANGENC G, KOGELC KH, PANGD J, LIUD B ^a Department of Crop and Soil Sciences and ^b School of Molecular Biosciences, Washington State University, Pullman WA 99164-6420, USA, ^c Institute for Phytopathology and Applied Zoology, Justus-Liebig-University, Giessen, D-35392, ^d Key Laboratory of Molecular Epigenetics, Institute of Genetics and Cytology, Northeast Normal University, Changchun 130024, P.R. China

01:15 - 03:15 PM Antivirals - General issues and their solutions - Part I

Room: 212

Chairmen: S. Pathak, Manipal, India
G. Berencsi, Budapest, Hungary
P. Pungpo, Warinchumrap, Thailand

Time	Abstr. No.	Title
01:15 PM	882	Differential roles of physiological and physicochemical parameters on low and variable bioavailability of Saquinavir- hurdles of effective drug treatment PATHAK SM, MUSMADE P., UDUPA N Department of pharmaceutical Quality Assurance, Manipal College of pharmaceutical Sciences, Manipal-University, Manipal-576104, INDIA
01:35 PM	1076	Possible Consequences of Transplacental Transfer of Viruses in Healthy Pregnants (Review) BERENCSI GY, ÖRDÖG K, CSIRE M, KAPUSINSZKY B, YOUNES SA Division of Virology, National Center for Epidemiology, Gyáli Str. 2-6, H-1097 Budapest, Hungary
01:55 PM	661	Elucidating Inhibitor-enzyme Interaction of Highly Potent Non-nucleoside Reverse Transcriptase Inhibitors Active Against Wild-type and Mutant HIV-1 Strains: Computer-aided Molecular Design Approaches PUNGPO P¹, PUNKVANG A¹, SAPARPAKORN P², WOLSCHANN P³, HANNONGBUA S² ¹ Faculty of Science, Ubonratchathani University, Warinchamrap, Ubonratchathani, Thailand; ² Faculty of Science, Kasetsart University, Bangkok, Thailand; ³ Institute for Theoretical Chemistry, University of Vienna, Vienna, Austria
02:15 PM	775	HIV/AIDS and Malarial/Toxoplasmosis Co-Infections: a Magic Bullet Approach to Drug Development FIALHO AM¹ and CHAKRABARTY AM² ¹ Instituto Superior Tecnico, Lisbon, Portugal; ² University of Illinois, Chicago, USA

- 02:35 PM 1389 Buletprooves to Abacavir-related Hypersensitivity Reaction in HIV-1-infected Population
CHOLEWINSKA G
Hospital for Infectious Diseases. Warsaw, Poland
- 02:55 PM 620 New neutralizing monoclonal antibodies from HIV-1 subtype C and CRF02_AG infected people.
BALLA-JHAGJHOORSINGH S ¹, CORTI D ², LANZAVECCHIA A ², **DAVIS D** ³ and The
BMGF CAVD UCL Vaccine Discovery Consortium.
1. Institute of Tropical Medicine, Antwerp, Belgium; 2. Institute for Research in Biomedicine,
Bellinzona, Switzerland; 3. Biomedical Primate Research Centre, Rijswijk, the Netherlands.

01:15 - 03:15 PM Antineoplastic agents - New promising mechanisms - Part I

Room: 218

Chairmen: M. Soory, London, United Kingdom
FH Jansen, TURNHOUT, Belgium
D. Scheel-Toellner, Birmingham, United Kingdom

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 01:15 PM | 27 | Oxidative stress in periodontal diseases and associated neoplasias: a role for antioxidants?
SOORY M
King's College London Dental Institute, UK |
| 01:35 PM | 1053 | Clusters of Free Radicals from Dihydroartemisinin Cure Several Parasitic and Viral Diseases. They Attack Cancers by Activating a Series of Apoptotic Pathways and by Causing Strong Angiogenesis Inhibition
JANSEN FH ¹ , SOOMRO SA ¹ , EFFERTH T ² ; RULISA S ³
¹ Department of Research and Development, Dafra Pharma R&D, Turnhout, Belgium,
² Institut für Krebsforschung Heidelberg, Germany and ³ Department of Gynaecology, Kigali, Rwanda. |
| 01:55 PM | 1086 | Depending on PKC-theta Expression, the Novel PKC Activator PEP005 can Either Increase or Decrease Apoptosis of Hemopoetic cells
LEE WY , HAMPSON P , SALMON M , LORD JM , SCHEEL-TOELLNER D .
School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK |
| 02:15 PM | 715 | Vascular Directed Tumour Therapy by a Novel Pyrazole that Inhibits the Ras-Net (Elk-3) Pathway and Affects Microtubules
WASYLYK B ¹ , WASYLYK C ¹ , ZHENG H ¹ , CASTELL C ² , DEBUSSCHE L ² , MULTON M-C ²
¹ Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Illkirch, France; ² Sanofi-Aventis, Vitry-sur-seine, France |
| 02:35 PM | 1226 | Folate-Targeted Chemotherapy
LEAMON, C.P. , REDDY, J.A. , VETZEL, M. , DORTON, R. , WESTRICK, E. , PARKER, N. , WANG, Y. and VLAHOV, I.R.
Endocyte Inc., West Lafayette, USA |
| 02:55 PM | 1225 | Design and Synthesis of Folate Targeted Chemotherapeutics
VLAHOV IR , WANG Y , KLEINDL PJ , and LEAMON CP
Endocyte Inc., 3000 Kent Ave, Suite A1-100, West Lafayette, IN 47906, USA |

01:15 - 03:15 AM Biotechnology of drug delivery

Room: 405

Chairmen: H. Kohler, Lexington, US
M. Lee, Cambridge, USA
N. Misevic, Zug, Switzerland

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 01:15 PM | 1096 | Enhanced Potency of Antibodies using biologically active Peptides
KOHLER H , MULLER S , BRYAN, AJ
Univ. of Kentucky, Lexington, USA; |

01:35 PM	405	Systematic Discovery of Novel Multi-Target Therapeutics: Finding the New Magic Bullets LEE MS¹ , RICKLES R ¹ , JOHANSEN L ¹ , AVERY W ¹ , GIORDANO T ¹ , ¹ CombinatoRx, Incorporated, Cambridge, MA, USA.
01:55 PM	178	Selective Stimulation Of Human Natural Killer Cells Proliferation By Novel Fucosylated Acidic Glycan Drugs: Possible Therapeutic Use For Treating Cancer And Viral/Retroviral Infections MISEVIC GN , MISEVIC NJ, SUMANOVSKI LT Gimmune GmbH, Zug, Switzerland
02:15 PM	148	Discovery Of Dual-Targeting Ligands KNOX AJS , FLOOD CT, LLOYDD DG Molecular Design Group, School of Biochemistry & Immunology, Trinity College Dublin, Dublin, Ireland
02:35 PM	3	Designing Bone-Seeking Proteins ULUDAG H University of Alberta
02:55 PM	26	Intracellular and organelle-specific drug delivery: The new frontier for Magic Bullets" WEISSIG V Midwestern University College of Pharmacy Glendale, Glendale, AZ 85308, USA

01:15 - 03:15 PM Vaccines - Development, production and manufacturing - Part I

Room: 217

Chairmen: D. Lalosevic ,Novi Sad, Serbia
 A. Gedvilaite, Vilnius, Lithuania
 P. Lobo, Charlottesville, USA

Time	Abstr. No.	Title
01:15 PM	1215	Selection Of Cell Culture Substrate For Human Viral Vaccines LALOSEVIC D¹ , KNEZEVIC I ² , LALOSEVIC V ³ , LAZAREVIC-IVANC LJ ⁴ ¹ Faculty of Medicine, Novi Sad, Serbia; ² World Health Organization, Geneva, Switzerland; ³ Faculty for Agriculture, Novi Sad, Serbia; ⁴ Pasteur Institute, Novi Sad, Serbia.
01:35 PM	746	Recombinant virus-like particles and their application for vaccine development and diagnostics GEDVILAITE A , SLIBINSKAS R, ZVIRBLIENE A, SASNAUSKAS K Institute of Biotechnology, Vilnius, Lithuania.
01:55 PM	572	Inhibition of HIV-1 through an Innate Humoral Mechanism – a Potential for Vaccine Development LOBO PI , SCHLEGEL KH, YUAN W, TOWNSEND GC, WHITE JA Center for Immunity Inflammation and Regenerative Medicine, Division of Infectious Diseases and International Health, and Myles H. Thaler Center for AIDS and Human Retrovirus Research, University of Virginia Health System, Charlottesville, VA 22908
02:15 PM	1779	Therapeutic Vaccination Followed By Antiretroviral Therapy Interruption (TI): Results From A Single Blind, Randomized, Controlled, Multicenter Phase II Study With An MVA-Nef Vaccine In HIV-1 Infected Patients HARRER T Med. Klinik III, Krankenhausstraße 12, 91054 Erlangen, Germany
02:35 PM	963	Search for the Perfect Synthetic Isoprenoid-Glycolipid Vaccine Adjuvant SPROTT GD¹ , WHITFIELD DM ² ^{1,2} National Research Council, Ottawa, Canada
02:55 PM	986	A cost-effective Haemophilus Influenzae type b conjugate vaccine in combination with DTwP-Hep B vaccine for developing countries – A perspective YADAV S¹ , LALWANI S ² , CHAKRAVARTY A ¹ , BHARDWAJ S ³ , SHARMA H ³ ¹ Maulana Azad Medical College & Hospital, New Delhi. ² Bharti Vidyapeeth Hospital, Pune ³ Serum Institute of India Ltd., Pune

01:15 - 03:30 PM Antineoplastic agents - Compounds and approaches - Part I

Room: 205

Chairmen: A. De Kroon, Utrecht, The Netherlands
E. Kondo, Okayama, Japan
E. MINGOMATAJ, TIRANA, Albania

Time	Abstr. No.	Title
01:15 PM	1020	The High Cytotoxicity of Cisplatin Nanocapsules in Ovarian Carcinoma Cells Depends on Uptake by Caveolae-Mediated Endocytosis HAMELERS IH, DE KROON AI Utrecht University, Utrecht, The Netherlands.
01:35 PM	870	Experimental Approach For Growth Inhibition Of Human Malignancies By The Highly Efficient Anti-Tumor Peptides Delivery System KONDO E¹ ¹ Dept. of Pathology, OKAYAMA Univ., Okayama, Japan
01:55 PM	250	Enigmatic Eosinophil As Magic Bullet: Eosinophil-Induced Prognosis Improvement Of Solid Tumors Could Be Enabled By Their Vesicle-Mediated Barrier Permeability Induction MINGOMATAJ EÇ Mother Theresa School of Medicine, Tirana, Albania
02:15 PM	983	Vitamin A and D Derivatives; Potential MAGIC BULLETS with Antithrombotic and Antineoplastic Applications KOYAMA T, CHUNG J Tokyo Medical & Dental University, Tokyo, Japan. (1) Department of Internal Medicine Division of nephrology and dialysis. Hyogo College of Medicine. (2) Chugai pharmaceutical CO., LTD.
02:35 PM	694	The Potential of Orally Presented Mistletoe Lectins in Cancer Therapy. PRYME IF University of Bergen, N-5009 Bergen, Norway.
02:55 PM	614	Screening Of Antioxidants For Inhibitory Activity Against Lung Metastasis Of Murine Colon Cancer Cells In Mice OGASAWARA M^{1,2}, MATSUNAGA T¹, NAGAI Y², TAKATSU K^{1,2} ¹ Toyama Prefectural Institute for Pharmaceutical Research, Toyama, Japan; ² University of Toyama, Toyama, Japan.
03:15 PM	557	Anti-neoplastic properties of tea catechins are associated with pro-differentiation caspase 14 gene expression: implementation for novel therapies DULEBOHN R¹, DICKINSON D¹, HUFF F¹, KODANI I², WU M³, MESSER R¹, AL-SHABRAWY M¹, TEWFIK A¹, OGBUREKE K¹, LEWIS J¹, AND HSU S¹. ¹ Medical College of Georgia, Augusta. USA. ² Totorri University Hospital, Yonago, Japan. ³ Zhejiang University, Hangzhou, China.

01:55 - 03:15 PM Pharmaceuticals - Nanoparticles and their latest developments - Part I

Room: 406

Chairmen: S. Mohammadi-Samani, Shiraz, Iran
B. Sarmiento, Porto, Portugal

Time	Abstr. No.	Title
01:55 PM	260	Magnetic Nanoparticles For Controlled Delivery Of Methotrexate MOHAMMADI-SAMANI S^{1*}, NEMATI ZA², MIRI R³, SOTOUDEH S⁴ ¹ Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz university of Medical Sciences, Shiraz, Iran, ² Materials Science and Engineering Department, Sharif University of Technology, Tehran, Iran, ³ Faculty of Pharmacy, Shiraz university of Medical Sciences, Shiraz, Iran, ⁴ Science and Research Branch of Azad University, Tehran, Iran
02:15 PM	421	Chitosan-stealth polymeric nanoparticles for mucosal insulin delivery SARMENTO B^{1,2}, TEIXEIRA J¹, NEVES R¹, MARTINS S¹, FERREIRA D¹ ¹ Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Porto, Portugal ² Department of Pharmaceutical Sciences, CICS-Instituto Superior de Ciências da Saúde, Gandra, Portugal

02:35 PM	1236	Biocompatible Nanoparticles, Carriers Of The Magic Bullet LACKO AG ¹ , NAIR M ¹ , PARANJAPÉ S ¹ , MOOBERRY L ¹ , McCONATHY WJ ² ¹ University of North Texas Health Science Center, Fort Worth TX, USA ² Texas Tech University Health Science Center, Permian Basin, Odessa, USA.
02:55 PM	1778	G-Protein Coupled Receptors – New Portals for Nanoparticles in Cellular Drug Targeting? HILD W Lehrstuhl Pharmazeutische Technologie, Universität Regensburg, Germany

02:35 - 03:15 PM **Antibacterials - Adverse events and mechanisms of toxicity - Part I**

Room: 216

Chairman: BC. Vakharia, Surat, India

Time	Abstr. No.	Title
02:35 PM	10000	Aminoglycosides as a paradigm of multidisciplinary approach to drug toxicity TULKENS P. , Bruxelles, Belgium
02:55 PM	458	Prevention of hepatotoxicity in patients undergoing anti tuberculosis treatment: A novel integrative approach VAKHARIA BC ¹ , ADHVARYU MR ² , REDDY MN ² ¹ Bhuma Research in Ayurvedic and Herbal Medicine, Surat, India; ² Veer Narmad South Gujarat University, Surat, India

02:35 - 03:30 PM **Pharmaceutics - Experimental and computational approaches - Part I**

Room: 207

Chairman: MF Cerda, Montevideo, Uruguay

Time	Abstr. No.	Title
02:35 PM	305	New Development of Drug Solubilization ZHANG H ¹ , Maroju R ¹ , Menger F ² ¹ Mercer University, Atlanta, GA USA; ² Emory University, Atlanta, GA USA
02:55 PM	241	Electrochemical Behavior of Flavonoids in the Presence of Metal Ions CERDÁ MF ¹ , KREMER C ² , TORRES J ² , HEINZEN H ² , BERTUCCI A ² , DOMINGUEZ S ³ ¹ Facultad de Ciencias, UdelaR, Montevideo, Uruguay; ² Facultad de Química, UdelaR, Montevideo, Uruguay; ³ Universidad de La Laguna, España
03:15 PM	435	Fundamental Understanding on Interactions of Bisphosphonates with Bone (by Use of Different Techniques, Including Computational Modelling). CUKROWSKI I University of Pretoria, Department of Chemistry, Pretoria 0002, South Africa.

03:30 - 03:50 PM **Anti-infectives - Approaches to combat resistance**

Room: 206

Time	Abstr. No.	Title
03:30 PM	1376	Developing a magic bullet against P-glycoprotein-mediated drug resistance by exploiting mechanism TOMBLINE G ^{1,3} , HOLT JJ ³ , GANNON MK ³ , SAWADA G ² , RAUB TJ ² , DONNELLY D ³ , Wetzell B ³ , Ye M ³ , Nygren CL ³ , and Detty MR ³ ¹ Univ. of Rochester, Microb. & Immunol., Rochester NY, USA; ² Eli Lilly, Drug Disposition, Indianapolis IN, USA; ³ Univ. at Buffalo, Chemistry, Buffalo NY, USA.

01:15 - 03:55 PM CNS - Pharmacological options in disease of the central nervous system - Part I

Room: 215

Chairmen: JI. Borrell, Barcelona, Spain
JH. Tapia-Perez, Magdeburg, Germany
H. Gallagher, Dublin, Ireland

Time	Abstr. No.	Title
01:15 PM	1375	Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors PETERSSON S¹, PÉREZ-NUENO V¹, ROS-BLANCO L¹, CLOTET B², CLOTET-CODINA I², ARMAND-UGÓN M², ESTÉ J², TEIXIDÓ J¹, BORRELL JI¹ ¹ IQS, Universitat Ramon Llull, Barcelona, Spain; ² Retrovirology Laboratory IrsiCaixa, Badalona, Spain.
01:35 PM	437	The clinical role of the statins in surgical neurosciences TAPIA-PÉREZ JH^{1,2,3}, SÁNCHEZ-AGUILAR M¹, TORRES-CORZO J G², GORDILLO-MOSCOSO A¹, MANDEVILLE P¹, CHALITA-WILLIAMS J², FIRSCHING R³ ¹ Universidad Autónoma de San Luis Potosí. San Luis Potosí, Mexico ² Hospital Central "Dr. Ignacio Morones Prieto". San Luis Potosí, México ³ Universitätsklinikum Magdeburg. Magdeburg, Germany
01:55 PM	295	Multiple Mechanisms of Action and Pharmacological Activities of Valproate GALLAGHER HC School of Medicine and Medical Science, Conway Institute, University College Dublin, IRELAND.
02:15 PM	818	Are The Substituted Phenethylamines Magic Bullets? Benefits And Harms Of Amphetamines And Related Compounds MENDELSON J, GALLOWAY G, BAGGOTT M Addiction Pharmacology Research Laboratory, St Luke's Hospital, California Pacific Medical Center Research Institute, San Francisco, CA, USA
02:35 PM	739	Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease and Pesticide Poisoning. GUPTA RC Murray State University, Hopkinsville, KY; Dejan Milatovic, Vanderbilt University, Nashville, TN, USA.
02:55 PM	443	Zolpidem after brain Damage CLAUSS RP¹, NEL HW² ¹ Royal Surrey County Hospital, Guildford, Surrey, UK, ² Family Practice, Springs, South Africa
03:15 PM	827	Structure and Function of the Ubiquitous TRPC channels: Targets in Need of Magical Bullets. BIRNBAUMER L Laboratory of Neurobiology, National Institute of Environmental Health Sciences, NIH, DHHS, Research Triangle Park, North Carolina 27708 USA
03:35 PM	1140	Crosstalk Between TNF α and NGF: Potential Implications for Alzheimer's Disease and Neuroblastoma YOSHINORI TAKEI and RONALD LASKEY MRC Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road Cambridge CB2 0XZ, UK.

03:30 - 04:10 PM Nerve diseases, mechanisms, and pathophysiology - Part I

Room: 214

Chairman: KG. Petry, Bordeaux, France

Time	Abstr. No.	Title
03:30 PM	1181	Protective Effect of Dimebon on the TNF- α Induced Lipid Disorders in Mice Brain ALESSENKO AV¹, KARATASSO YO¹, SHEVTSOVA EF², *SHINGAROVA LN¹, BACHURIN SO² ¹ Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia, ² Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernogolovka, Russia.

03:50 PM 714 MRI monitoring of blood brain barrier alterations in inflammatory lesions of Multiple Sclerosis: Tools to evaluate disease activity, efficacy of treatments and to develop new therapeutic strategies
PETRY KG, BOIZIAU C, BROCHET B, DOUSSET V
EA2966 Neurobiology of myelin disorders, University of Bordeaux 2, 146, rue Léo-Saignat, 33076 BORDEAUX – France

03:30 - 04:02 PM Professional perspectives for health professionals

Room: 212

Time	Abstr. No.	Title
03:30 PM	1812	Professional perspectives for health professionals: meeting a pharmaceutical company's top manager FRITZ H Essex Pharma GmbH, Munich, Germany

03:30 - 04:30 PM Cytochrome P450 - in vitro studies - Part I

Room: 216

Chairman: I. Spasojevic, Durham, USA

Time	Abstr. No.	Title
03:30 PM	1341	Using Chimeras With C-Terminal Tails Of Noss For Probing Of The Electron Traffic In CYPOR JÁCHYMOVÁ M ^{1,2} , MARTÁSEK P ³ , SHEA TM ² , ROMAN LJ ² , MASTERS BS ² ¹ Institute of Clinical Biochemistry and Laboratory Diagnostic, Charles University 1 st Medical Faculty, Prague, Czech Republic ² Department of Biochemistry, University of Texas Health Science Center, San Antonio, Texas ³ Department of Pediatrics, Charles University 1 st Medical Faculty, Prague, Czech Republic
03:50 PM	892	Metalloporphyrins are Versatile and Powerful Therapeutics: Biomimetics of SOD, Peroxyredoxin, and cyt P450 SPASOJEVIC I ¹ , SHENG H ² , WARNER DS ² , BATINIC-HABERLE I ³ Departments of Medicine ¹ , Anaesthesiology ² , and Radiation Oncology ³ Duke University Medical Center, Durham, NC 27710, USA.
04:10 PM	451	Physico-Chemical Insights in Biological Conversions; the Role of H ₂ O as driving Force in Cytochrome P450 catalysis VEEGER C ¹ , RIETJENS IMCM ¹ , ZAKHARIEVA O ² ¹ Dept. of Biochemistry, Wageningen Univ. Research Centre, Dreijenlaan 3, 6703 HA Wageningen, the Netherlands. ² Inst. für Physik, Univ. of Lübeck, Ratzeburger Allee 169, D-23538, Lübeck, Germany

03:30 - 04:30 PM Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part I

Room: 404

Chairman: H. Uemura, Yokohama, Japan

Time	Abstr. No.	Title
03:30 PM	197	Anticancer Effects of Statins VÍTEK L Institute of Clinical Biochemistry and Laboratory Diagnostics and 4 th Department of Internal Medicine, 1 st Faculty of Medicine, Charles University in Prague, Czech Republic

- 03:50 PM 630 Antitumor potency of angiotensin II receptor blocker for prostate cancer
UEMURA H, ISHIGURO H, HOSHINO K, KUBOTA Y
Department of Urology, Yokohama City University Graduate School of Medicine,
Yokohama, Japan
- 04:10 PM 482 Cardioprotective Anthracycline PKC Activators for The Treatment of Drug-Resistant Tumors
LOTHSTEIN L, HOFMANN PA, ISRAEL M, SWEATMAN TW
University of Tennessee Health Science Center Memphis USA

03:30 - 04:37 PM Antidepressant drugs and their mechanism of action Part I

Room: 218

Chairman: KP Bøgesø, Valby, Denmark

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 03:30 PM | 55 | New Features of Antidepressant Drugs - Modification of Histamine Kinetics
IRMAN-FLOREJANC T, RAJTAR S
Department of Pharmacology and Experimental Toxicology, Faculty of Medicine, University
of Ljubljana, Ljubljana, Slovenia |
| 03:50 PM | 602 | Escitalopram-the first ASRI. A Magic Bullet in the treatment of depression and anxiety.
BØGESØ KP
Lundbeck Research DK, Ottiliavej/9, DK 2500 Valby, Denmark |
| 04:17 PM | 799 | Photophysics, Photochemistry and induced-Photoallergy of Tricyclic Antidepressants
GALINDO-SEVILLA N¹, MARTINEZ-ROJANO H^{2,3}, MANCILLA-RAMIREZ J^{1,2},
QUIÑONEZ-DIAZ L^{2,4}
¹ Instituto Nacional de Perinatología, Mexico City, Mexico; ² Escuela Superior de Medicina,
Instituto Politecnico Nacional, Mexico City; ³ Hospital de Gineco-Pediatría 3A, IMSS, Mexico
City; ⁴ UJAT, Villahermosa, Tabasco. |

03:30 - 04:50 PM Clinical studies with agents of different pharmacological activity – Part I

Room: 213

Chairmen: S. He, Stockholm, Sweden
D. Dougherty, San Antonio, USA

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 03:30 PM | 1388 | Increase of fibrin network porosity and the consequent fibrinolysis as an anticoagulant effect
of acetylsalicylic acid
HE S¹⁺², BARK N², WANG HY², SVENSSON JE², BLOMBÄCK M¹⁺²
Karolinska Institutet: ¹ Dept of Clinical Sciences, Danderyds Hospital; ² Dept of Molecular
Medicine & Surgery /Coagulation Research, Sweden, Stockholm |
| 03:50 PM | 1315 | L-tryptophan as a Research Compound and Therapeutic Agent
DOUGHERTY DM¹, RICHARD DM¹, MATHIAS CW¹, HILL-KAPTURCZAK N¹, DAWES MA¹,
BADAWY A.A-B²
¹ University of Texas Health Science Center San Antonio, Psychiatry, Division of Alcohol and
Drug Addiction, NRLC
² The Cardiff School of Health Sciences, University of Wales Institute Cardiff (UWIC) |
| 04:10 PM | 217 | Sulfasalazine Revisited: A Multi-Targeted Magic Bullet
JANSEN G, VAN DER HEIJDEN JW, DIJKMANS BAC
Dept. of Rheumatology, VU University Medical Ctr, Amsterdam, The Netherlands |

- 04:30 PM 253 Long-Term Sequential Deferiprone-Deferoxamine Versus Deferiprone Alone For Thalassaemia Major Patients: A Randomised Clinical Trial
RESTIVO PANTALONE G¹, MAGGIO A¹, VITRANO A¹, CAPRA M², CUCCIA L², GAGLIARDOTTO F², FILOSA A², ROMEO MA², MAGNANO C², CARUSO V², ARGENTO C², GERARDI C², CAMPISI S², VIOLI P², MALIZIA R², CIANCIULLI P², RIZZO M², D'ASCOLA DG², QUOTA A², PROSSOMARITI L², FIDONE C², ROCCAMO G², LOMBARDO T², CIANCIO A², MEO A², COMMENDATORE F², CAROLLO A², GIUGNO R², GIUFFRIDA G², GALATI M², RIGANO P¹, PEPE A², D'AMICO G², MORABITO A² and GLUUD C³
¹U.O.C.Ematologia II con Talassemia, A.O. "V. Cervello",Palermo,Italy; ²Members of the Italian Society for Thalassaemia and Haemoglobinopathy,Italy; ³Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

03:30 - 04:50 PM Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part I

Room: 217

Chairmen: K. Abo-EL-Sooud, Giza, Egypt
H. Wetzstein, Monheim am Rhein, Germany

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 03:30 PM | 54 | EFFECT OF FLUNIXIN ON ENROFLOXACIN CLEARANCE AND STEADY-STATE SERUM CONCENTRATIONS IN CALVES
ABO-EL-SOUD K¹ , AL-ANATI L ²
¹ Pharmacology Department, Faculty of Veterinary Medicine, Cairo University, Giza 12211, Egypt;
² Dept. of Veterinary Basic Sciences, Faculty of Veterinary Medicine, Jordan University of Science and Technology, Jordan. |
| 03:50 PM | 1015 | Magic Bullets: Once Fired – How are They Recaptured? On Metabolic Transformation and Environmental Fate of the Veterinary Fluoroquinolone Enrofloxacin
WETZSTEIN HG
Bayer Animal Health GmbH, Leverkusen, Germany |
| 04:10 PM | 242 | Effect of gentamicin on serum digoxin level in patients with congestive heart failure.
ALKADI HO , MAJED AN, YAHIA AR
Univ. Sana'a , Sana'a, Yemen |
| 04:30 PM | 1249 | Controlled Release Amoxicillin Therapy In Veterinary Medicine
LAVY E , FRIEDMAN M, HOFFMAN A
School of Veterinary Medicine, Rehovot, Israel. |

03:30 - 05:30 PM Agents / diseases affecting the immune system - Part I

Room: 205

Chairmen: H. Rahamimoff, Jerusalem, Israel
FS. Kubrusly , São Paulo, Brasil
V. Korenbaum, Vladivostok, Russia

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 03:30 PM | 1007 | The Immunosuppressive Drugs- Cyclosporin A, FK506 And Rapamycin Modulate The Functional Expression Of The Na ⁺ -Ca ²⁺ Exchangers In An Isoform Specific Manner
ELBAZ B^{1,2} , DAVIDOV G ¹ , GOTTESMAN MM ² , KIMCHI-SARFATY C ³ , RAHAMIMOFF H^{1,2}
¹ Department of Biochemistry Hebrew University – Hadassah Medical School, Jerusalem, Israel, ² Laboratory of Cell Biology, NCI, NIH, Bethesda MD, USA, ³ Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA |
| 03:50 PM | 1411 | Polyclonal Rabbit Antiserum Against Porcine-SP-A Able to Detect Human SP-A Using Immunochemical Methods
KUBRUSLY FS¹ ; SAKAUCHI D² , DIAS SC ¹ , IOURTOV D ³ , GEBARA VCBC ¹ , HORTON DSPQ ² , PIAZZA RM F ⁴ , PRECIOSO AR ^{1,5} , MASCARETTI RS ^{1,5} , REBELLO CM ^{1,5} & RAW I ¹
¹ Centro de Biotecnologia; ² Serviço de Controle de Qualidade; ³ Laboratório de Surfactante Pulmonar; ⁴ Laboratório Especial de Microbiologia; Unidade de Pesquisa Experimental da Faculdade de Medicina. ^{1,2,3,4} Instituto Butantan, ⁵ USP, São Paulo, Brasil |

04:10 PM	719	Electronic Homeopathic Preparations (EHPs) as Potential "Magic Bullet": Pilot Study on Biologic Model KORENBAUM VI ¹ , CHERNYSHEVA TN ² , SHIN SN ¹ , DEMENOK VN ¹ ¹ Pacific Oceanological Institute FEB RAS, Vladivostok, Russia; ² Clinics of functional medicine "Manus", Vladivostok, Russia.
04:30 PM	1119	Alpha 1 Antitrypsin (AAT) for the Treatment of Autoimmune Diseases SONG S Department of Pharmaceutics, University of Florida
04:50 PM	1359	New perspectives in the treatment of melanoma by a glycobiological approach: results in mouse experimental model VANNUCCI L , KULDOVA M, ROSSMANN P, KREN V, BEZOUSKA K, SAIH M, ULLMANOVA-BENSON V, KLEMENSOVA K, GROBAROVA V, and FISEROVA A. Institute of Microbiology, Czech Academy of Sciences v.v.i., Prague, CZ.
05:10 PM	473	Helicobacter Cysteine-Rich Proteins A And -C, Two Novel Signalling Molecules Form The Family Of Sel1-Like Repeat Proteins Involved In The Modulation Of Pathogen/Host Interactions MITTL P Biochemisches Institut, Universität Zürich, Schweiz

03:30 - 05:30 PM Cardiovascular - Drugs acting on the cardiovascular system - Part I

Room: 207

Chairmen: M. Grunnet, Ballerup, Denmark
Z. Todorovic, Belgrade, Serbia
V. Pittala, Catania, Italy

Time	Abstr. No.	Title
03:30 PM	909	Increased repolarization reserve as a new anti-arrhythmic principle GRUNNET M , DINESS TG, OLESEN SP, HANSEN RS NeuroSearch A/S and Department of Biomedical Sciences, University of Copenhagen, Denmark
03:50 PM	247	The Acute Effects of Statins in an Experimental Model of Renal Ischemia-Reperfusion Injury TODOROVIC Z , NESIC Z, PROSTRAN M, STOJANOVIC R, VUCKOVIC S, DIVAC N Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Belgrade, Serbia
04:10 PM	1380	In Search of the Magic Bullets: Discovery of RN5 and its Structural Modifications for Targeting Selectively α_1 Adrenoceptors PITTALA V ¹ , SALERNO L ¹ , MODICA M ¹ , SIRACUSA MA ¹ , ROMEO G ¹ ¹ Università di Catania, Catania, Italy
04:30 PM	300	Effect Of Insulin Resistance On In-Stent Restenosis After Coronary Stenting In Type 2 Diabetic Patients NISHIO K ^{1,2} , KOBAYASHI Y ¹ ¹ Univ. SHOWA, Tokyo, Japan; ² Yamanashi red-cross Hosp, Yamanashi, Japan
04:50 PM	1752	Effects of Small-volume Resuscitation Using Hyperosmolar Saline Colloid Solution on Regional Blood Flow and Ischemic Tissue Injury KREIMEIER U ¹ , MESSMER K ² ¹ Dept. Anaesthesiology, ² Dept. Surgical Research; Univ. Hospital Munich, Germany
05:10 PM	1773	Potential use of denosumab in the treatment of giant cell tumor of bone KUBITZ KM Masonic Cancer Center and University of Minnesota, Minneapolis, MN, USA

03:50 - 04:30 PM Antifungals - Pharmacokinetics and formulation issues

Room: 206

Chairman: B. Biner Orhaner, Edirne, Turkey

Time	Abstr. No.	Title
03:50 PM	213	Pharmacokinetics and Pharmacodynamics of Amphotericin B and its Lipid Formulations BELLMANN R Department of Internal Medicine I, Innsbruck Medical University, Innsbruck, Austria
04:10 PM	797	The Pharmacokinetics (PK) of Voriconazole in Children BINER ORHANER B Univ. Trakya, Pediatric Hematology, Edirne, Turkey.

04:10 - 05:10 PM Pharmaceutics - Discovery of drugs and mechanisms - Part I

Room: 214

Chairman: T. Ema, Okayama, Japan

Time	Abstr. No.	Title
04:10 PM	30	The design of drugs which do not create resistance: folding inhibitors BROGLIA RA^{1,2,3} AND TIANA G^{1,2} ¹ Department of Physics, University of Milano, Milano, Italy ² INFN, sez. di Milano, Italy ³ The Niels Bohr Institute, University of Copenhagen. Copenhagen, Denmark
04:30 PM	131	Process Research on a Key Synthetic Intermediate of Clopidogrel EMA T Okayama Univ., Okayama, Japan
04:50 PM	20	Key Aspects for the Compilation and Enhancement of a Comprehensive Chemogenomics and Drug Discovery Compound Screening Collection JACOBY E Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland

04:22 - 04:42 PM CNS - Pharmacological options in disease of the central nervous system - Part II

Room: 212

Chairman: JG. Ortiz, San Juan, Puerto Rico

Time	Abstr. No.	Title
04:02 PM	1342	Effect of <i>Valeriana officinalis</i> in [³ H]Glutamate Binding LISA M. DEL VALLE-MOJICA¹, YOSHIRA M. AYALA-MARÍN², BIANCA A. TORRES-HERNÁNDEZ¹ AND JOSÉ G. ORTÍZ¹ ¹ University of Puerto Rico - School of Medicine, San Juan, PR; ² University of Puerto Rico – Humacao Campus; Humacao, Puerto Rico. ² Universidade Estadual de Campinas, UNICAMP, CP 6066, 13083-970, Campinas-SP, Brasil; ² Núcleo de Pesquisas em Tuberculose, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 14049-900, São Paulo, Brasil.
04:22 PM	1346	Interactions Between NE And EAAT ORTIZ JG, BERRIOS-CARTAGENA N, RUBIO-DAVILA M Department of Pharmacology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico

04:30 - 05:10 PM Antibacterials - Discovery - Peptide antibiotics - Part I

Room: 216

Chairman: MA Sari, GIF/YVETTE, France

Time	Abstr. No.	Title
04:30 PM	621	Designing Peptidic Magic Bullets Against Bacteria SAHAL D ¹ , DEWAN PC, ANANTHARAMAN A, CHAUHAN VS International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India
04:50 PM	1310	Production of cystine rich peptides and protein in <i>E. coli</i> : hepcidin, the iron-regulating hormone GAGLIARDO B ¹ , FAYE A ² , KUBAT N ² , JAOUEN M ¹ , DESCHEMIN JC ² , CANONNE-HERGAUX F ³ , VAULONT S ² , SARI MA ¹ ¹ Université PARIS DESCARTES, CNRS UMR 8601, 45 rue des Saints-Pères, 75006 PARIS, FRANCE. ² Université PARIS DESCARTES, CNRS UMR 8104, INSERM U567, PARIS, FRANCE. ³ ICSN-CNRS, GIF/YVETTE, FRANCE

04:50 - 05:10 PM Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part II

Room: 213

Time	Abstr. No.	Title
04:50 PM	68	Silencing Cell-Cell Communication: The New Bullets in Anti-Infectives PLOTKIN BJ ¹ , KONAKLIEVA MI, ² GREEN JM ¹ Midwestern University, Downers Grove Illinois, U.S.A.; American University, Washington, D.C., U.S.A

04:50 - 05:30 PM Atherosclerosis, stroke & aging - mechanisms and treatment - Part I

Room: 217

Chairman: S. Sharma, Bakersfield, USA

Time	Abstr. No.	Title
04:50 PM	550	Modification of the Infarct Size Limiting Effects of Statins by Antiplatelet Drugs BIRNBAUM Y ^{1,2} , YE Y ^{1,2} , PEREZ-POLO J.R. ² . ¹ The Division of Cardiology, ² The Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas.
05:10 PM	1195	Intragraft Administration Of Abciximab And Verapamil Combined With Direct Stenting Prevents Slow-Flow And No-Reflow Phenomenon In Saphenous Vein Graft Percutaneous Coronary Intervention SHARMA S , LARDIZABAL JA, ANTONESCU A, BHAMBI B, NYITRAY W, DESAI K, ISHIMORI T Cardiology, Bakersfield Heart Hospital/Central Cardiology, 2901 Sillect Avenue, Ste # 100, Bakersfield, CA 93308, USA

05:30 - 06:10 PM Transporters of physiological compounds and drugs – Part I

Room: 212

Chairman: T. Katsuragi, Fukuoka, Japan

Time	Abstr. No.	Title
05:30 PM	232	Aminoglycoside Derivatives as Drug Transporters: Delivery Magic Bullets? TOR Y University of California, San Diego, Department of Chemistry and Biochemistry, La Jolla, California, U.S.A.
05:50 PM	586	Ca ²⁺ -signal transducing system from the endoplasmic reticulum to mitochondria involved in the caffeine-inducible ATP transport KATSURAGI T Medical Research Center, Fukuoka University, Fukuoka, Japan

05:30 - 06:10 PM Antineoplastic agents - Delivering a Magic Bullet to its target(s) - Part I

Room: 213

Chairman: N. Oku, Shizuoka, Japan

Time	Abstr. No.	Title
05:30 PM	1317	New multifunctional pharmacophores and biocompatible nanocomposites for targeting drug delivery and cancer diagnosis Wang X State Key Lab of Bioelectronics, Southeast University, Nanjing 210096, China
05:50 PM	871	Efficient Cancer Therapy By Use Of Neovascular-Targeted Liposomes OKU N¹, ASAI T¹, SHIMIZU K¹ ¹ Sch. of Pharm. Sci., Univ. of Shizuoka, Shizuoka, Japan

05:30 - 06:30 PM Analgesia & analgetic drugs - Part I

Room: 207

Chairman: A. Ayar, Elazig, Turkey

Time	Abstr. No.	Title
05:30 PM	1028	Cardiotoxicity Plagues Bupivacaine HEAVNER JE TTUHSC, Lubbock, TX, USA
05:50 PM	413	Levetiracetam in the Treatment of Neuropathic Pain: Evidence from Cellular and Behavioral Pain Models AYAR A¹, OZCAN M² Firat University, Faculty of Medicine, Departments of ¹ Physiology, ² Biophysics, Elazig, Turkey.
06:10 PM	593	Under-treated painful condition may lead patients to opioid abuse ¹SAEIDIAN SR, ²SAIIAH BM Jundishapour University of medical sciences, Ahwzaz Iran

05:30 - 06:30 PM Antiparasitic compounds - Magic Bullets against various parasites

Room: 214

Chairmen: M. Müller, Abu Dhabi, United Arab Emirates

Time	Abstr. No.	Title
05:30 PM	192	Diagnosis And Innovative Therapy Of Human Specific <i>Enterocytozoon Bieneusi</i> Genotype D Strain In Falcons (<i>Falconiformes</i>) MÜLLER MG ¹ Abu Dhabi Falcon Hospital, Abu Dhabi, United Arab Emirates
05:50 PM	1045	The fecundity of <i>Schistosoma japonicum</i> was impaired by administration of low dose cyclophosphamide CHUANXIN YU ¹ , QI G ¹ , XUREN Y ¹ , KIKUCHI M ² , KENJI H ² 1 Jiangsu Institute of Parasitic Diseases, Wuxi city, Jiangsu Province, P.R. China 2 Institute of Tropical Medicine, Nagasaki University, Nagasaki city, Japan.
06:10 PM	1464	Percutaneous absorption of crotamiton in man following single and multiple dosing. DIKA E ¹ , TOSTI A ¹ , FANTI ¹ , MAIBACH H ² . 1. Università degli Studi di Bologna, Dipartimento di Medicina Clinica Specialistica e Sperimentale Sezione di Clinica Dermatologica, Italy. emi.dika@tin.it 2. University of California, San Francisco

05:30 - 06:30 PM Treatment of asthma, COPD, and other lung diseases - Part I

Room: 217

Chairman: R. Bansal, Glasgow, United Kingdom

Time	Abstr. No.	Title
05:30 PM	299	Budesonide - Breath-giving innovation for asthma patients VOLOVITZ B Schneider Children's Medical Center of Israel, Petach Tikva, Israel
05:50 PM	431	Synthesis of a Series of 8-(Substituted-Phenyl)xanthines and a Study on the Effects of Substitution Pattern of Phenyl Substituents on Affinity for Adenosine A ₁ and A _{2A} Receptors- The Magic of Theophylline BANSAL R ¹ , KUMAR G ¹ , GANDHI D ¹ , YOUNG CL ² , HARVEY AL ² ¹ Panjab University, Chandigarh, India; ² University of Strathclyde, Glasgow, United Kingdom

05:30 - 06:50 PM Cardiovascular - Drugs acting on the cardiovascular system - Part II

Room: 205

Chairmen: A. Rodriguez, Buenos Aires, Argentina
J. Arsenal, WENO, MICRONESIA (FSM)

Time	Abstr. No.	Title
05:30 PM	125	Systemic Immunosuppressive Therapy With Oral Sirolimus After Bare Metal Stent Implantation: The Missing Alternative To Prevent Restenosis Following Percutaneous Coronary Interventions RODRIGUEZ AE On behalf of the ORAR III Investigators. Cardiovascular Research Center (CECI), Otamendi Hospital, Buenos Aires School of Medicine, Buenos Aires, Argentina
05:50 PM	239	Cardiac tamponade from slingshot metal darts in Chuuk: a retrospective review of cases. ARSENAL JC , REMIT K , YICHIRO O . C/- Chuuk State Hospital, Federated States of Micronesia. jcars3@yahoo.com
06:10 PM	321	Structure Based Design of Second Generation PDE5 Inhibitors PALMER MJ , BELL AS , FOX DNA , BROWN DG Sandwich Discovery Chemistry, Pfizer Global Research and Development, Sandwich, Kent, U.K.

06:30 PM 304 Pharmacokinetic-Pharmacodynamic Modeling of Calcium Channel Blockers in Animal Models of Hypertension.
HÖCHT C, BERTERA F, MAYER M, OPEZZO JAW, TAIRA CA.
Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.

05:30 - 06:50 PM Mechanisms of inflammation and anti-inflammatory agents - Part I

Room: 206

Chairmen: J. Ruyschaert, BRUXELLES, Belgium
M. Noda, Fukuoka, Japan

Time	Abstr. No.	Title
05:30 PM	23	Cationic Liposomes:How A Magic Bullet Turns Into An Anti-Inflammatory Agent LONEZ C,VANDENBRANDEN M, RUYSSCHAERT JM Laboratoire de Structure et Fonctions des Membranes Biologiques, Université Libre de Bruxelles – Brussels, Belgium
05:50 PM	1212	Brain's Immune Cells And Anti-Inflammatory Effects Of Neuropeptides NODA M, IFUKU M, OKUNO Y, YAMAKAWA Y Laboratory of Pathophysiology, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Japan
06:10 PM	308	Magic Microspheres for Joint Treatment. Why Doxycycline? HAERDI-LANDERER MC¹, STEINER A², SUTER MM², GANDER BA¹ ¹ ETH Zurich, Switzerland; ² Vetsuisse-Faculty Berne, Switzerland.
06:30 PM	406	Methotrexate in Dermatology through 50 Years ZACHARIAE H University of Aarhus, Denmark

05:30 - 06:50 PM Biosimilars / Follow-on Proteins and their challenges to manufacturers and regulatory bodies - Part I

Room: 216

Chairmen: C. Schneider, Langen, Germany
W. Jusko, Buffalo, USA

Time	Abstr. No.	Title
05:30 PM	1803	Biosimilars - EMEA's point of view SCHNEIDER CK Paul-Ehrlich-Institut, Federal Agency for Sera and Vaccines, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany
05:50 PM	10000	Phase I - study of an erythropoietin biosimilar SÖRGEL F IBMP - Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, 90562 Nürnberg-Heroldsberg, Germany
06:10 PM	10010	Bioequivalence of biosimilars - is pharmacodynamic equivalence sufficient? W. JUSKO University at Buffalo, 565 Hochstetter Hall, Buffalo, NY, USA
06:30 PM	10000	Developing a biosimilar BROCKMEYER C. Hexal Biotech Forschungs GmbH, Keltenring 1 + 3, 82041 Oberhaching, Germany

05:30 - 07:30 PM Antivirals - Clinical effectiveness

Room: 215

Chairmen: E. Gigi, Greece
 G. Kotwal, Louisville, USA
 M. Serin, Mersin, Turkey

Time	Abstr. No.	Title
05:30 PM	510	Treatment of Intravenous Drug Users with Chronic Hepatitis C: Treatment Response, Compliance and Side Effects GIGI ?¹ , SINAKOS ? ¹ , LALLA ? ^{H1} , VRETTOU E ² , ORPHANOU E ¹ , RAPTOPOULOU M ¹ ¹ 2 nd Dpt of Medicine, Thessaloniki University Medical School, Greece, ² Dpt of Pathology, Thessaloniki University Medical School, Greece.
05:50 PM	669	Enveloped Virus Neutralizing Compounds (EVNCs), The Magic Bullets against a Broad Spectrum of Deadly Viruses Causing a Billion Infections Annually Around the globe KOTWAL GJ Division of Infectious Diseases, University of Massachusetts Medical School, Worcester, MA, USA, Kotwal Bioconstling, LLC, Louisville, USA and KBiotech pvt.ltd., Cape Town, South Africa.
06:10 PM	828	Detection Of Lamivudine And Adefovir Resistant Hepatitis B Virus Polymerase Gene Variants During Two Years Antiviral Therapy Of Chronic Hepatitis B Patients In The South Of Turkey SERIN MS¹ , BEKIROGLU E ¹ , TEZCAN S ² , ASLAN G ² , SEZGIN O ³ , ALTINTAS E ³ , EMEKDAS G ² , POLAT S ¹ ¹ Mersin University, Phaculty of Pharmacy, Dept. Pharmaceutical Microbiology, Mersin, TURKIYE ² Mersin University, Phaculty of Medicine, Dept. Medical Microbiology, Mersin, TURKIYE ³ Mersin University, Phaculty of Medicine, Dept. Gastroenterology, Mersin, TURKIYE
06:30 PM	282	Ganciclovir treatment of infants with cytomegalovirus infection and central nervous system involvement. DUNIN-WASOWICZ D¹ , JÓZWIAK S ¹ , KASZPRZYK-OBARA J ¹ The Children's Memorial Health Institute, Warsaw, Poland
06:50 PM	564	Spectrum And Risk For HIV-1 Associated Mutations And The Efficacy Of Antiretroviral Therapy Among Infected Pediatric Patients MALHOTRA A , GAUR S, WHITLEY-WILLIAMS PN, PETROVA A Department of Pediatrics, Division of Infectious Disease, University of Medicine and Dentistry of New Jersey (UMDNJ) – Robert Wood Johnson Medical School New Brunswick, New Jersey, 08903 USA
07:10 PM	536	Residue Networks and Drug Resistance in Hepatitis C Virus Antiviral Therapy WELSCH C^{1,2} , DOMINGUES FS ² , ALBRECHT M ² , LENGAUER T ² , SARRAZIN C ¹ , ZEUZEM S ¹ ¹ J. W. Goethe University Hospital, Frankfurt/Main, Germany; ² Max Planck Institute for Informatics, Saarbrücken, Germany

06:10 - 06:50 PM Antibacterials - New mechanisms and delivery strategies - Part I

Room: 212

Chairman: K. Iwabuchi, Urayasu, Japan

Time	Abstr. No.	Title
06:10 PM	279	Effect of antineoplastic agents on the surface properties of bacterial cells de CARVALHO CCCR IBB-Institute for Biotechnology and Bioengineering, Centre for Biological and Chemical Engineering, Instituto Superior Técnico, 1049-001 Lisbon, Portugal. Tel. +351218419594; Fax: +351218419062; E-mail: ccarvalho@ist.utl.pt
06:30 PM	781	The role of lipid rafts in host-pathogen interactions: Involvement of lactosylceramide-enriched lipid rafts in innate immunity and ycobacterial infection- IWABUCHI K^{1,2} , NAKAYAMA H ¹ , IWAHARA C ¹ , TAKAMORI K ¹ , OGAWA H ¹ ¹ Inst. Env. Gender Specific Med. Juntendo Univ. Grad. Sch. Med., ² Infect. control Nurs., Juntendo Univ. Grad. Sch. of Health Care and Nurs.

06:10 - 07:40 PM Antineoplastic agents - Personalized therapy - Part I

Room: 213

Chairmen: U. Fuhr, Cologne, Germany
Q. Dai, Nashville, USA

Time	Abstr. No.	Title
06:10 PM	10001	Application of pharmacokinetics of individualize antineoplastic therapy FUHR U Department of Pharmacology, Clinical Pharmacology Unit, University Hospital of Cologne, Germany
06:40 PM	980	Personalized Prevention of Colorectal Neoplasia: High Magnesium and Low Calcium among People with a Functional Polymorphism in the Magnesium Transporter DAI Q, SHRUBSOLE M, NESS RM, SCHLUNDT D, CAI Q, SMALLEY WE, LI M, SHYR Y, ZHENG W Vanderbilt University, Nashville, USA
07:00 PM	555	When More is Not Necessarily Better: Interdisciplinary Inquiry into the Implications of U-Shaped Dose Responses for Personalizing Anticancer Interventions WATERS DJ Purdue University Center on Aging and the Life Course, and the Gerald P. Murphy Cancer Foundation, West Lafayette, IN, USA
07:20 PM	251	Characterised Nanomaterials for Biomarker Profiling Based Cancer Detection HUCK CW, RAINER M, HEIGL N, BONN GK Institute of Analytical Chemistry and Radiochemistry, Leopold-Franzens University, Innsbruck, Austria

06:30 - 07:10 PM Drug transporters and delivery - Part I

Room: 207

Chairman: SW Paine, Loughborough, UK

Time	Abstr. No.	Title
06:30 PM	1217	Transporter Mediated Drug-Drug Interactions: Modulation Of Drug Absorption By Environmental Toxicants OOSTERHUIS B¹, VUKMAN K¹, VÁGI E¹, GLAVINAS H¹, JABLONKAI I², KRAJCSI P¹ ¹ Solvo Biotechnology, Budaörs, Hungary; ² Institute of Biomolecular Chemistry, Chemical Research Centre, Hungarian Academy of Sciences, Budapest, Hungary
06:50 PM	684	Predicting the Impact of Hepatic Transporters on the Pharmacokinetics of Statins in the Liver PAINE SW, SOARS M, WEBBORN P, GRIME K, RILEY RJ AstraZeneca, Loughborough, UK

06:10 - 07:10 PM Immunosuppressants - Part I

Room: 217

Chairman: J. Wagner, Basel, Switzerland

Time	Abstr. No.	Title
06:30 PM	885	Pharmacogenetic and pharmacokinetic approaches after kidney and liver transplantation MOURAD M Department of Surgery, Surgery and Abdominal Transplantation Division, Université Catholique de Louvain, Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium. Michel.Mourad@chir.ucl.ac.be

- 06:50 PM 1208 NVP-AEB071: Oral and Specific Inhibitor of T Cell Activation for the Prevention of Graft Rejection and the Treatment of Autoimmune Diseases
WAGNER J
Novartis Institutes for BioMedical Research, Basel, CH-4002 Switzerland
- 07:10 PM 248 Blocking Effect of an Immuno-Suppressive Agent, Cynarin, on CD28 of T-Cell Receptor Found by a Novel Pharmaceutical Method
CHEN HM
National Nano Device Laboratories, HsinChu, Taiwan, R.O.C.

06:50 - 07:30 PM Cardiovascular - Pharmacological action in the cardiovascular system from small molecules to peptides and vaccines - Part I

Room: 216

Chairman: W. Friess, Munich, Germany

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 06:50 PM | 1180 | Absorption, Kinetics, Metabolism and Disposition of the Renin Inhibitor Drug Aliskiren
WALDMEIER F¹ , GLAENZEL U ¹ , WIRZ B ¹ , OBERER L ¹ , SCHMID D ¹ , SEIBERLING M ² , VALENCIA J ³ , RIVIERE GJ ⁴ , END P ¹ , VAIDYANATHAN S ³
¹ Novartis Pharma AG, Basel, Switzerland; ² Swiss Pharma Contract, Allschwil, Switzerland; ³ Novartis Pharmaceuticals Corp, East Hanover, New Jersey USA ⁴ Novartis Pharma SAS, Rueil-Malmaison, France |
| 07:10 PM | 1751 | Formulation Challenges in Biologics
FRIESS W
Ludwig-Maximilian-University; Department of Pharmacy; Pharmaceutical Technology and Biopharmaceutics |

06:50 - 07:50 PM Antineoplastic agents - Effectiveness and resistance in patients - Part II

Room: 205

Chairman: L. Liebes, Scarborough, USA

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 06:50 PM | 1066 | Exercise as a Modality to Identify Therapeutic Molecules for Treatment & Prevention of Cancer-Associated Cachexia: Possible Enhancement of Anti-inflammatory Cytokines Through an Intermittant Activation of the Stress-Response Pathways
ARDIES, CM
Northeastern Illinois University, Chicago, USA. |
| 07:10 PM | 893 | Enhancement Of Radiation Or Chemotherapeutic Effects Of Para-Aminobenzoic Acid (PABA) And A Novel Analog On Melanoma: Preclinical Studies And Phase I Studies
LIEBES L¹ , PAVLICK ¹ A, MUGGIA F ¹ , HARDIN E ¹ , MENDOZA S ¹ , ROTH J ² , BROOKS P ²
¹ NYU Langone School of Medicine, New York, NY, ² Maine Medical Center Research Inst., Scarborough, USA. |
| 07:30 PM | 1033 | Spectroscopic study on the interaction of the antitumoral drug emodin with bovine serum albumin: fluorescence, circular dichroism, SERS, SEF and stopped-flow techniques
SEVILLA P^{1,2} , GARCIA-BLANCO F ¹ , SANCHEZ-CORTES S ² , GARCIA-RAMOS J.V ^{1,2}
¹ Univ. Complutense de Madrid, Madrid, ES; ² CSIC, Madrid, ES |

06:50 - 07:50 PM Clinical studies with agents of different pharmacological activity - Part II

Room: 212

Chairman: J. Varkonyi, Budapest, Hungary

Time	Abstr. No.	Title
06:50 PM	358	25-Years Of Sight Saving By Preventing Postoperative Scarring With Local Use Of Antimetabolites OPHIR A Hillel-Yaffe Medical Center, Hadera and the Ruth and Bruth Rappaport Faculty of Medicine, the Technion, Haifa, Israel
07:10 PM	930	Preliminary results of the Semmelweis Budapest Mastocytosis Center VARKONYI J ¹ , CSOMOR J ² , FULE T ² , SHÖNLEBER J ² , FARKAS H ¹ , VARGA L ¹ , SRETER L ¹ , MARSCHALKO M ³ , HIDVEGI B ³ , DARVAS ZS ⁴ , FALUS A ⁴ 1. 3 rd Department of Internal Medicine (Hematology Division) 2. Department of Pathology and Cancer Research 3. Department of Dermatology 4. Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary
07:30 PM	1074	Vitamin C In Intravenous Nutritive Solution: Double-Edge Effect For Premature Newborn Infants LAVOIE JC, CÔTÉ F, ROULEAU T Departments of pediatrics & nutrition, Sainte-Justine hospital, University of Montréal.

06:50 - 07:50 PM Physiology & Magic Bullets - Part I

Room: 206

Chairman: AG Assounga, Boston, USA

Time	Abstr. No.	Title
06:50 PM	1030	Isoproterenol And Insulin: The Ying-Yang Of Regulation Of Mg ²⁺ Homeostasis In Mammalian Cells ROMANI A Department of Physiology and Biophysics – Case Western Reserve University, Cleveland, USA
07:10 PM	696	Transcription of Major Histocompatibility Complex Class I (K ^b) and Transporter Associated with Antigen Processing 1 and 2 genes is up-regulated with age. ASSOUNGA AG ^{1,2} , WARNER CM ¹ 1. Department of Biology, Northeastern University, Boston, MA 02115. 2. Department of Medicine, University of KwaZulu-Natal, Durban, South Africa.
07:30 PM	1769	Ion channels as biomolecular drug targets. ZEILINGER

08:00 - 09:00 PM Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part I

Room: 217

Chairman: Y. Suzuki, Tokyo, Japan

Time	Abstr. No.	Title
08:00 PM	182	TLN-4601, a novel anticancer agent, inhibits Ras signaling through c-Raf degradation GOURDEAU H, BOUFAIED N, WIOLAND M-A, DESROCHERS F, FALARDEAU P Thallion Pharmaceuticals Inc., Montreal, Canada
08:20 PM	13	L-type calcium channels in non-excitabile cells: critical roles in cell survival SUZUKI Y, YOSHIMARU T, INOUE T, RA C Nihon University Graduate School of Medical Science, Tokyo, Japan

08:40 PM 769 Calcium Signaling And Angiogenesis
MUNARON L, FIORIO PLA A
Department of Animal and Human Biology, Nanostructured Interfaces and Surfaces Centre of Excellence (NIS), and Center for Complex Systems in Molecular Biology and Medicine – SysBioM, University of Torino, Italy

08:00 - 09:00 PM Blood-brain barrier - History and most recent finding - Part II

Room: 218

Chairman: O. Braissant, Lausanne, Switzerland

Time	Abstr. No.	Title
08:00 PM	343	Brain cholesterol? Long secret life behind a barrier BJÖRKHEM I Karolinska Institutet, Karolinska University Hospital Huddinge, Division of Clinical Chemistry, 14186 Huddinge, Sweden
08:20 PM	19	Poor permeability of blood brain barrier for creatine: Autonomous brain synthesis of creatine, and consequences for creatine deficiency syndromes BRAISSANT O Inborn Errors of Metabolism, Clinical Chemistry Laboratory, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1011 - Lausanne, Switzerland.
08:40 PM	1001	Peculiarities of Blood-Brain-Barrier Penetration of Pralidoxime KALASZ H, TEKES, K Semmelweis University, Budapest, Hungary

08:00 - 09:20 PM Pharmaceutics - Drug delivery through the skin - Part I

Room: 206

Chairmen: C. Squier, Iowa City, USA
A. Stinchcomb, Lexington, USA

Time	Abstr. No.	Title
08:00 PM	150	Penetration of Bioactive Proteins and Peptides across Stratified Mucosae in a Porcine Ex-Vivo Model SQUIER CA, KREMER M Institute for Dental Research, University of Iowa, Iowa City, IA 52242, USA
08:20 PM	113	Transdermal Delivery of Naltrexone, In Vitro Testing to Human Volunteers STINCHCOMB AL University of Kentucky College of Pharmacy, Lexington, KY USA; AllTranz Inc., Lexington, KY USA
08:40 PM	631	Fentanyl: How Delivery System Can Modify Clinical Properties Of Molecule LECYBYL R Royal Free Hospital, London, UK.
09:00 PM	1177	Hydrogels for Sustained and Selective Release of Diclofenac ALVAREZ-LORENZO C Univ. Santiago de Compostela, Santiago de Compostela, Spain.

08:00 - 09:20 PM Pharmacokinetic studies and drug metabolism

Room: 212

Chairmen: H. Amini, Gorgan, Iran
C. Cook, Round Lake, USA

Time	Abstr. No.	Title
08:00 PM	540	Pharmacokinetic study of rivastigmine in Iranian healthy subjects following 3 and 4.5 mg dosing using a simple and sensitive HPLC-UV method AMINI H¹ , AHMADIANI A ² ¹ Golestan University of Medical Sciences, Gorgan, Iran; ² Beheshti University of Medical Sciences, Tehran, Iran.
08:20 PM	1031	Role of Drug Metabolism in the Development of Eplerenone (EP): A Lesson Learned from Spironolactone (SP). COOK CS¹ , BERRY LM ² ZHANG L ³ ¹ Baxter Healthcare, Round Lake IL, USA, ² Amgen Inc Cambridge MA, USA, ³ Pfizer Inc, Groton CT, USA
08:40 PM	1302	Chemotherapy of advanced colorectal carcinoma under hemodialysis AKIYAMA S , TANAKA M Mitsukaido Sakura Hospital, Mitsukaido, IB, Japan.
09:00 PM	679	Indocyanine Green: Revisiting An Old Friend MUKHERJEE S , ROGERS MA, BUNIAK B Liver Gallbladder Pancreas Center, Section of Gastroenterology and Hepatology, Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York, USA
09:20 PM	1085	Microdialysis with Moderately Lipophilic Drugs: What Is Essential to Know for Voriconazole and its Drug Product to be applicable in Pre-/Clinical Microdialysis Settings? SIMMEL F , KLOFT C Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany.

08:00 - 09:40 PM Vaccines - Targeting non-infectious diseases - Part I

Room: 214

Chairmen: Y. Katoh , Sapporo, Japan
A. Cirila, CREMONA, Italy

Time	Abstr. No.	Title
08:00 PM	1256	EMY162 Protein As A Vaccine Candidate To Reduce Level Of Alveolar Hydatid Disease KATOH Y1 , KOUGUCHI H 1), MATSUMOTO J2), SUZUKI T 1), YAGI K1) 1) Hokkaido Institute of Public Health, Sapporo, Hokkaido, Japan, 2) College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan
08:20 PM	816	Treatment and relocation of wheat flour sensitized workers by an allergenic vaccine CIRLA AM , LORENZINI RA, CIRLA PE Italian Center Environmental Occupational Health (CIMAL), Milan-Cremona, Italy
08:40 PM	903	Psoriasis [Ps]: A Possinle Candidate for Vaccination FRY L BAKER BS Imperial College, London W2 1PG
09:00 PM	956	The Modified Vaccination Technique developed by Barabas provides the "magic bullet" for the prevention and cure of chronic ailments such as autoimmune disorders and cancer specifically, without side effects BARABAS AZ¹ , COLE CD ² , LAFRENIERE R ¹ ¹ Department of Surgery, University of Calgary, Health Sciences Centre, Calgary, Alberta, Canada ² Department of Neurosurgery, University of Utah, Salt Lake City, Utah, USA

09:20 PM 756 Sculpting the Immunological Response to Dengue Fever by Polytopic Vaccination
DEEM MW
Rice University, Houston, TX, USA

08:00 - 09:40 PM Anti-infectives - Mechanisms of bacterial resistance - Part I

Room: 215

Chairmen: G. Kumarasinghe, Singapore, Singapore
X. Peng, Guangzhou, China
O. Ozgumus, Rize, Turkey

Time	Abstr. No.	Title
08:00 PM	162	Resistance, Including Carbapenem Resistance, Among Enterobacteriaceae In a University Hospital In Singapore KUMARASINGHE G, JAYASURYA A, JUREEN R, LIN RTP National University Hospital, Singapore
08:20 PM	1294	Modifying cytoplasmic protein complexome involved in energy metabolism as a strategy of <i>Escherichia coli</i> against ceftriaxone XUAN-XIAN PENG¹, JIAN-YI PAN², SAN-YING WANG², HUI LI¹, BIN JIANG¹, BAO-CHENG WANG¹, WEN-JIAO XU¹ ¹ Center for Proteomics, State key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, University City, Guangzhou, 510006, China; ² School of Life Sciences, Xiamen University, Xiamen, 361005, China
08:40 PM	1047	A Molecular Perspective On Integron-Associated And Transferable Antibiotic Resistance In Clinical And Aquatic Isolates Of Gram-Negative Bacteria In Northern Region Of Turkey OZGUMUS OB¹, SANDALLI C¹, CAYLAN R², TOSUN I³, AYDIN K², KOKSAL I², SEVIM A¹, SEVIM-CELIK E¹, ALPAY-KARAOGLU S¹, COLAKOGLU F¹, SIVRI N⁴, KOLAYLI F⁵, YESILGIL-ATASOY P¹ ¹ Microbiology & Molecular Biology Research Laboratory, Department of Biology, Faculty of Arts & Sciences, Rize University, Rize, ² Department of Clinical Microbiology & Infectious Diseases, Faculty of Medicine, Karadeniz Technical University, Trabzon, ³ Department of Microbiology & Clinical Microbiology, Faculty of Medicine, Karadeniz Technical University, Trabzon, ⁴ Department of Environmental Engineering, Faculty of Engineering, Istanbul University, Istanbul, ⁵ Department of Medical Microbiology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
09:00 PM	140	Bacterial Drug Efflux Pumps: Significance for Antibiotic Resistance and Pathogenicity SHAHER WM^{1,2}, WARNER D³, ZALUCKI Y^{1,2}, JOHNSON P^{1,2}, JERSE AE³ ¹ VA Medical Center, Decatur, Georgia, U.S.A., ² Emory University School of Medicine, Atlanta, Georgia, U.S.A., ³ Uniformed Services University of the Health Sciences, Bethesda, Maryland, U.S.A
09:20 PM	1313	Mechanism of Fluoroquinolone resistance in Shigella and Salmonella species TALUKDER KA, Ishrat J. Azmi, Bijay K. Khajanchi, Zhahirul Islam, Abdus S. Mondol, Mohammad Aslam, D. K. Dutta, A.S.G Faruque, D. Ahmed, M. A. Hossain, Haruo Watanabe, David A. Sack, Hubert P. Endtz and Alejandro Cravioto ICDDR, B, GPO Box-128, Dhaka-1000, Bangladesh

08:00 - 09:40 PM Treatment of diseases with involvement of the immune system - Part II

Room: 404

Chairmen: A. Avunduk, Trabzon, Turkey
A. Joseph, Framingham, USA
C. Malemud, Cleveland, USA

Time	Abstr. No.	Title
08:00 PM	1141	The Effect of Melatonin and Zinc on the Immune Response in Experimental Toxoplasma Retinochoroiditis AVUNDUK AM¹, AVUNDUK MC², BALTACI AK², MOGULKOC R² ¹ Karadeniz Technical University, Trabzon, Turkey ² Selçuk University, Konya, Turkey

08:20 PM	293	Short-term, low dose methotrexate for immune tolerance induction JOSEPH A , MUNROE K, HOUSMAN M, GARMAN R, RICHARDS S Immunology Laboratory, Biologics R&D, Genzyme Corporation, Framingham, USA
08:40 PM	1130	Potential Of JAK/STAT Inhibitors For Treating RA MALEMUD CJ Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University, Cleveland, Ohio (USA)
09:00 PM	39	Oral Tolerance as a Method of Suppression of Immunological Response in Experimental Autoimmune Encephalomyelitis KWIATKOWSKA-PATZER B ¹ , MICHALKIEWICZ J ² , ZIELINSKA J ¹ , KASSARELLO K ¹ , KURZEPA K ³ , LIPKOWSKI AW ^{1,3} ¹ Medical Research Center, Polish Academy of Sciences, Warsaw, Poland, ² Children's Memorial Health Institute, Warsaw, Poland, ³ Industrial Chemistry Research Institute Warsaw, Poland.
09:20 PM	1032	Mechanisms of anti-CD20 immunotherapy: Why Type II mAb are better BEERS SA ¹ , CHAN CHT ¹ , JAMES S ¹ , FRENCH RR ¹ , ATTFIELD KE ¹ , BRENNAN CM ¹ , AHUJA A ² , SHLOMCHIK M ² , GLENNIE MJ ¹ and CRAGG MS ¹ ¹ Cancer Sciences Division, Southampton University School of Medicine, UK ² Yale University School of Medical, CT, USA

08:00 - 09:40 PM **Pharmaceutics - Pharmacokinetics and drug formulations - Part I**

Room: 412

Chairmen: T. Hermann, Poznan, Poland
 M. Otagiri, Kumamoto, Japan
 J. Kennedy, Cork, Ireland

Time	Abstr. No.	Title
08:00 PM	938	Which gliclazide (GLC) formulation tablets, immediate (IR) or modified release (MR), are better therapeutic choice? RESZTAK M ¹ , HERMANN TW ¹ , MIKOLAJCZAK P ¹ , PASZUN S ¹ , SAWICKI W ² ¹ Univ. Med. Sci., Poznan, Poland; ² Medcal Academy, Gdansk, Poland.
08:20 PM	52	Reduction Of Flubiprofen-Induced Gastric Toxicity By Prodrug Formation And Enhancement Of Oral Bioavailability Of Flubiprofen By Chitosan Complexation OTAGIRI M , IMAI T Graguate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan
08:40 PM	907	Drug Absorption From The Small Intestine In Immediate Postoperative Patients KENNEDY JM ^(1,2,3) , VAN RIJ AM ⁽²⁾ ⁽¹⁾ School of Pharmacy, ⁽²⁾ Department of Surgery, University of Otago, Dunedin, New Zealand, ⁽³⁾ School of Pharmacy UCC, Cork, Ireland
09:00 PM	1372	Controlling of Systemic Absorption of Gliclazide through Incorporation into Alginate Beads. AL-KASSAS RS ¹ , AL-GOHARY OM ² , AL-FAADHEL MM ² ¹ Univ. AUK, Auckland, New Zealand; ² Univ. KS, Riyadh, Saudi Arabia
09:20 PM	118	The Use of Permeability and Reference Compound Data for Predictions and Understanding of Human Pharmacokinetics. FAGERHOLM U AstraZeneca R&D, Södertälje, Sweden.

08:00 - 09:40 PM **Vaccines - Antiinfectives - Malaria & Tuberculosis**

Room: 405

Chairmen: M. Haile, Solna, Sweden
 M. Andrade Santana, Campinas, Brazil
 P. Cardona, Badalona, Spain

Time	Abstr. No.	Title
08:00 PM	1182	Studies on new tuberculosis vaccine candidates in animal models HAILE M ¹ , PAWLOWSKI A ¹ , SVENSON SB ² . ¹ Swedish Institute for Infectious Disease Control, Stocholm, Sweden; ² Swedish University for Agricultural Sciences, Uppsala, Sweden.

- 08:20 PM 1303 Construction -Dependent DNA Liposome Effectiveness on Tuberculosis Vaccination
GAZIOLA DE LA TORRE L²; ROSADA RS¹; COELHO-CASTELO AAM¹; SILVA CL¹,
SANTANA MHA² *
¹Núcleo de Pesquisas em Tuberculose, Faculdade de Medicina de Ribeirão Preto,
Universidade de São Paulo, Brazil; ² Departamento de Processos Biotecnológicos,
Faculdade de Engenharia Química, Universidade Estadual de Campinas, Brazil
- 08:40 PM 1011 The dynamic hypothesis of latent tuberculosis infection offers a new rational to develop
future therapeutic strategies.
CARDONA P-J
Unitat de Tuberculosi Experimental. Institut Germans Trias i Pujol. Universitat Autònoma de
Barcelona. Badalona. Catalonia. Spain. www.ute.galenicom.com; e-mail:
pjcardona.igtp.germanstrias@gencat.cat
- 09:00 PM 329 Status of BCG Vaccine at the Beginning of the 21st Century
PESUT DP^{1,2}
¹Univ. of Belgrade School of Medicine, Belgrade, Serbia; ²Research and Epidemiology
Department, Institute of Lung Diseases and Tuberculosis, Belgrade, Serbia
- 09:20 PM 761 Severing the Gordian Knot: Are Glycolipids the solution for Effective Vaccines against
Malaria and HIV?
LI X*, LIANG PH, WU D, IMAMURA M, FUJIO M, WONG CH, **TSUJI M***
*HIV and Malaria Vaccine program, Aaron Diamond AIDS Research Center, The
Rockefeller University, New York, NY, USA: #The Scripps Research Institute, La Jolla, CA,
USA: +The Genome Research Center, Academia Sinica, Taipei, Taiwan

08:00 - 10:00 PM New drug concepts

Room: 205

Chairmen: K. Degtyarenko, Hinxton, United Kingdom
W. Koppenol, Zürich, Switzerland
R. Honkanen, Mobile, USA

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 08:00 PM | 921 | Open Chemical Databases and Ontologies in the Genomic Age
DEGTYARENKO KN
European Bioinformatics Institute, Cambridge, UK |
| 08:20 PM | 1016 | Energetics Of Cytochrome P450 Hydroxylations: Making Sense Of <i>In Silico</i> :
KOPPENOL WH , BOUNDS PL
Institute of Inorganic Chemistry, Department of Chemistry and Applied Biosciences, ETH
Zürich, Zürich, Switzerland |
| 08:40 PM | 959 | Inhibitors of Serine/Threonine Protein Phosphatases at the Dawn of a Clinical Era.
HONKANEN RE
Dept. of Biochem and Mol. Biol., University of South Alabama, Mobile, AL USA. |
| 09:00 PM | 1197 | Combinatorial Nanobiotechnology – A Paradigm Shift in Chemistry and Material Science
PETRENKO VA
Department of Pathobiology, Auburn University, Auburn, AL 36849, U.S.A. |
| 09:20 PM | 638 | Alpha1-Antitrypsin Augmentation Therapy: New Insights Into The Molecular Basis Of
Efficacy
JANCIAUSKIENE S , NITA I
Wallenberg Laboratory Entrance 46, 2nd floor, Lund University, University Hospital Malmö,
20502 Malmö, Sweden |
| 09:40 PM | 261 | What Sort of Light Is At the End Of the Tunnel In Anti-Allergic Drugs?
HORAK F
Medical University of Vienna, ENT Dptm., Vienna, Austria |

08:00 - 10:00 PM Pharmaceuticals - Reviews and general aspects

Room: 207

Chairmen: R. Kondaj, Tirana, Albania
 G. Gonzales, Lima, Peru
 P. Pezehk, Iran

Time	Abstr. No.	Title
08:00 PM	913	The Pharmaceutical Policy In Context Of Health Care System In Albania KONDAJ R Albanian Centre For Equity In Health
08:20 PM	616	Medicinal effects of maca: Experimental data on reproduction, memory and learning GONZALES GF¹, VILLEGAS L¹, GONZALES C¹, GONZALES-CASTAÑEDA C¹, GASCO M¹, YUCRA S¹, RUBIO J¹. ¹ Faculty of Sciences and Philosophy, Universidad Peruana Cayetano Heredia, Lima, Peru.
08:40 PM	897	A Cost-Benefit Approach to Sample Size Determination for Clinical Trials with Binary Responses PEZESHK H¹, NEMATOLLAHI N² and MAROUFY V³ ¹ School of Mathematics, Statistics and Computer Science and Center of Excellence in Biomathematics University of Tehran, Tehran, Iran. ^{2,3} Department of Statistics, Allameh Tabatabaie University, Tehran, Iran
09:00 PM	722	Exploiting Plant Sources for Potential Drugs. Alpinumisoflavones in Perspective KINGSFORD-ADABOH UNIVERSITY OF GHANA, DEPARTMENT OF CHEMISTRY, ACCRA, GHANA
09:20 PM	1511	Retinoic Acid Regulates the Expression of the Anti-Apoptotic Protein PKCδVIII PATEL NA^{1,2} AND COOPER DR^{1,2} James A. Haley Veterans Hospital ¹ and College of Medicine, Department of Molecular Medicine ² , University of South Florida, Tampa, FL
09:40 PM	1345	The Role of Ancient Iraqi People (Sumerian, Assyrian, Babylonian and Arabian) in the Development of Medicine as Viewed by Western Writers AL MOSAWI AJ University Hospital in Al Kadhimiya, Baghdad, Iraq.

08:00 - 10:00 PM Therapeutic Proteins - clinical studies - Part I

Room: 213

Chairmen: R. Idro, Kampala, Uganda
 W. Wong, Hong Kong, China
 M. Shimura , Sendai, Japan

Time	Abstr. No.	Title
08:00 PM	452	Can Erythropoietin Be Used To Prevent Brain Injury In African Children With Cerebral Malaria? IDRO R^{1,2}, CASALS-PASCUAL C³, DAY R⁴, NEWTON CRJC^{2,5} ¹ Makerere University, Kampala, Uganda; ² Kenya Medical Research Council, Kilifi, Kenya; ³ Medical Research Council Labs, Fajara, Gambia; ⁴ Oxford University, Oxford, UK; ⁵ UCL Institute of Child Health, London, UK.
08:20 PM	103	Applications of recombinant human epidermal growth factor in the treatment of hard-to-heal wounds WONG WKR Hong Kong University of Science and Technology, Department of Biochemistry, Clear Water Bay, Kowloon, Hong Kong
08:40 PM	1311	A Bevacizumab, An Anti-VEGF Antibody, As A MAGIC BULLET for Retinal Disease? SHIMURA M Department of Ophthalmology, NTT East Japan Tohoku Hospital

- 09:00 PM 1231 Optimized Productions Of Recombinant Human Proteins, An Enzyme And Two Cytokines, In Fermentor Cultures Of The Yeast, *Pichia Pastoris*
MURASUGI A
Product Development Department, Meiji Dairies Corporation, Tokyo, Japan
- 09:20 PM 786 Commercialization of Recombinant Human Epidermal Growth Factor – A Nobel Prize Winning Molecule with Diverse Therapeutic Applications.
VADREU KM (*) and V K Srinivas,
Bharat Biotech International, Hyderabad, India
- 09:40 PM 1263 Designing Drugs for Neurological Disorders: TRH-based Neurotherapeutics
GREGG DJ¹, SCALABRINO GA¹, BOYLE NT¹, SLATOR GR¹, WILLIAMS CH¹, TIPTON KF¹, HOGAN N², O'BOYLE KM², BAUER K³, **KELLY JA**¹
¹School of Biochemistry and Immunology and Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland; ²UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Ireland; ³Leibniz Institute for Age Research, Jena, Germany

08:00 - 10:00 PM Antineoplastic agents - Clinical trials and approaches- Part I

Room: 216

Chairmen: H. Nishida, Kanazawa city, Japan
C. da Fonseca, Rio de Janeiro, Brazil
H. Wiela, Wroclaw, Poland

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 08:00 PM | 1518 | Cryoimmunology Induced After Reimplantation Of Malignant Bone Tumor Treated With Liquid Nitrogen
NISHIDA H ^{1,2} , TSUCHIYA H ¹ , KAWANO M ¹ , TOMITA K ¹
¹ Kanazawa Univ., Kanazawa, Japan; ² Fujii Hosp., Kanazawa, Japan |
| 08:20 PM | 92 | Ras as a target for exploratory study of monoterpene perillyl alcohol intranasal administration in patients with recurrent gliomas
DA FONSECA CO
Associate Professor of Neurosurgery, Universidade Federal Fluminense, Brazil. |
| 08:40 PM | 328 | Methotrexate – the past and the present
WIELA-HOJENSKA A
Medical University, Wroclaw, Poland |
| 09:00 PM | 591 | Magic bullet and magic shield: a new strategy to target Survivin in human cancers
WANG Q , BEREZOV A, FREUDENBERG JA, CAI Z, ZHANG H, MURALI R, GREENE MI
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA |
| 09:20 PM | 1314 | Estrogen Metabolites In The Control Of Osteosarcoma
MARAN A , DADSETAN M, BROPHY CM, YASZEMSKI MJ
Mayo Clinic, Rochester, MN, USA |
| 09:40 PM | 466 | Prevention of Mucositis and Improvement in Compliance of Head & Neck Cancer Patients undergoing Radio-Chemotherapy by Curcumin
ADHVARYU MR ¹ , VAKHARIA BC ² , REDDY MN ¹ , SRIVASTAV SP ³
¹ Veer Narmad South Gujarat University, Surat, India; ² Shree Gurudev Sarvajanic Charitable trust, Surat, India; ³ Lions Cancer Research Center, Surat, India. |

09:00 - 10:00 PM Antiparasitic compounds - Malaria Therapy and approaches

Room: 217

Chairman: S. Kongpatanakul, Bangkok, Thailand

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 09:00 PM | 1080 | Antibacterial, Antisecretory and Antihemorrhagic Activity of <i>Azadirachta indica</i> Used to Treat Cholera and Diarrhea in India
BAG PK ¹ , THAKURTA P ¹ , BHOWMIK P ¹ , MUKHERJEE S ¹ , HAJRA TK ¹ , PATRA A ²
¹ Department of Biochemistry, ² Department of Chemistry, University of Calcutta, Kolkata, India |

- 09:20 PM 993 Comparative Study of Dihydroartemisinin and Artesunate Safety in Healthy Thai Volunteers
KONGPATANAKUL S¹, CHATSIRICHARONKUL S¹, KHUHAPINANT A¹, ATIPAS S¹,
KAEWKUNGWAL J²
¹Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ²Faculty of
Tropical Medicine, Mahidol University, Bangkok, Thailand.
- 09:40 PM 1125 Antimalarial drug resistance in Indonesia: A molecular analysis
SYAFRUDDIN D¹, ASIH PBS¹, TAUFIK AS², MULYANTO^{2,3}
¹Eijkman Institute for Molecular Biology, Jakarta, Indonesia, ²Immunobiology Laboratory,
School of Medicine, University of Mataram, Mataram, Indonesia, ³
West Nusa Tenggara Hepatitis Laboratory, Mataram, Indonesia

09:20 - 10:00 PM Vaccines - Antiinfectives - Bacteria and parasites - Part I

Room: 206

Chairman: V. Baker, Nijmegen, Nigeria

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 09:20 PM | 1170 | Malaria vaccines for the better
SAUERWEIN RW
Dept. of Medical Microbiology, Radboud University Nijmegen Medical Centre . Nijmegen,
The Netherlands |
| 09:40 PM | 955 | Cytokine-associated neutrophil extracellular traps and antinuclear antibodies in Plasmodium
falciparum infected children under the age of six
BAKER V¹ , IMADE G ² , MOLTA N ³ , PAM S ² , OBADOFIN M ² , SAGAY S ² , EGAH D ² , IYA D ² ,
AFOLABI B ⁴ , BAKER M ⁵ , FORD K ⁶ , FORD R ⁶ , ROUX K ⁷ , KELLER T ⁷
¹ Chipola College, FL, ² JUTH Medical School, Nigeria; ³ Jos University, Nigeria; ⁴ Nigerian
Institute of Medical Research, Nigeria; ⁵ Jackson Hospital, FL, ⁶ World Health Mission, PA,
⁷ Florida State University, FL |

07:15 - 08:03 AM Analgesia & analgetic drugs II

Room 206

Chairman: F. Simonin, Illkirch, FRANCE

Time	Abstr. No.	Title
07:15 AM	801	Valproic Acid (VA) May Be Effective in the Treatment of Headaches Associated with Reactivation of Cerebral Toxoplasmosis (CT) PRANDOTA J Dpt of Social Pediatrics, University Medical School, Wroclaw, Poland
07:35 AM	204	Neuropeptide FF receptors: a novel target for pain treatment SIMONIN F Institut Gilbert Laustriat, UMR 7175-LC1 CNRS-ULP, Illkirch, FRANCE
07:55 AM	717	Genetic aspects of tramadol PK and PD SLANAR O Institute of Pharmacology, 1st Faculty of Medicine, CharlesUniversity, Albertov 4, Praha 2, 128 00 Czech Republic

07:15 - 08:15 AM Doping and performance enhancement drugs

Room 404

Chairman: LV Serdoz, Milan, Italy

Time	Abstr. No.	Title
07:15 AM	270	Growth Hormone: how to catch the magic bullet of the modern athlete HOLT RIG on behalf of the GH-2004 project team University of Southampton, UK
07:35 AM	595	Illicit Drugs and Cardiac Arrhythmias in Athletes FURLANELLO F(*/**), SERDOZ LV(*) , CIOFFI G(**), DE AMBROGGI L (*), CAPPATO R(*) * Arrhythmias and Electrophysiology Center, Department of Cardiology, IRCCS Policlinico San Donato, University of Milan, Italy; ** Clinica Villa Bianca – Trento, Italy
07:55 AM	991	Myostatin Inhibiting Peptide Works as a Magic Bullet to Increase Skeletal Muscle Mass and to Ameliorate Muscle Pathology in Muscular Diseases by Transgenic Expression TSUCHIDA K, NAKATANI M, UEZUMI A Institute for Comprehensive Medical Science, Fujita Health Univ., Toyoake, Aichi, Japan

07:15 - 08:35 AM Antineoplastic agents - in vitro and in vivo

Room 214

Chairmen: V. Schepkin, Tallahassee, USA
T. Chou, New York, USA

Time	Abstr. No.	Title
07:15 AM	935	Sodium and Diffusion MRI as Biomarkers of Initial Tumor Response to Therapy in Rodents SCHEPKIN VD¹, LEVENSON CW², BREY WW¹, FIGUEIROA SM², GOR'KOV PL¹, CHENEVERT TL³, REHEMTULLA A³, ROSS BD³ ¹ National High Magnetic Field Laboratory/FSU, Tallahassee, FL, USA; ² Florida State University, Tallahassee, FL, USA, ³ University of Michigan Medical School, Ann Arbor, MI, USA
07:35 AM	59	The Therapeutic "Cure" of Xenograft Tumors by the Third Generation Epothilone: Iso-oxazole-Fludelone CHOU TC Memorial Sloan-Kettering Cancer Center, New York, NY, USA
07:55	725	Evidence for Anti-Cancer activity for the Antidepressant Sertraline, <i>In-Vitro</i> and <i>In-Vivo</i> Effect in Nude Mice Xenografted with HT29 cells. GIL-AD I¹, ZOLOKOV A¹, LOMNITSKI L², TALER M, BAR M¹, WEIZMAN A¹, ¹ Lab Biological Psychiatry, Tel-Aviv University, Felsenstein Institute, Campus Rabin, Petah-Tiqva, Israel, and ² Perrigo Israel Pharmaceuticals Ltd. Bnei Brak, Israel

08:15 AM 751 The Pharmacokinetics (PK) and Pharmacodynamics (PD) of Platinum (Pt) Analogs in Birds
FILIPPICH LJ, CHARLES BG
Univ. of Queensland, St. Lucia, Australia.

07:15 - 08:35 AM Bioanalytics - The cutting edge of LC-MS/MS - Part I

Room 216

Chairmen: Y. Zhao, Potters Bar, UK
R. Bischoff, Groningen, The Netherlands

Time	Abstr. No.	Title
07:15 AM	16	The combined use of HPLC, Gel-LC-MS/MS and microarray in monitoring product quality and safety for gene therapy ZHAO Y, KEATING K, WHEELER J, DOLMAN C, THORPE R Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), Blanch Lane, Herts, UK
07:35 AM	63	LC-MS for Label-Free Biomarker Discovery HORVATOVICH P ¹ , GOVORUKHINA N ¹ , SOBCZAK-ELBOURNE I ¹ , KEMPERMAN R ^{1,4} , CHRISTIN C ¹ , HOEKMAN B ¹ , VAN DER ZEE A ² , SUITS F ³ , MUSKIET F ² , HOEFSLOOT H ⁴ , SMILDE A ⁴ , BISCHOFF R¹ ¹ University of Groningen, Groningen, The Netherlands ² University Medical Center Groningen, Groningen, The Netherlands ³ IBM TJ Watson Research Center, Yorktown Heights, NY, USA ⁴ University of Amsterdam, Amsterdam, The Netherlands
07:55 AM	619	Drug Screening Of Preserved Oral Fluid By Liquid Chromatography-Tandem Mass Spectrometry ØIESTAD EL, JOHANSEN U, YTTREDAL B, CHRISTOPHERSEN AS Norwegian Institute of Public Health, Oslo, Norway
08:15 AM	339	Liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its two glucuronide metabolites in human plasma and serum TRONTELJ J, BOGATAJ M, MARC J and MRHAR A Faculty of Pharmacy, University of Ljubljana, Aškerceva 7, 1000 Ljubljana SI- 1000, Slovenia

07:15 - 08:35 AM Illicit drugs & similar agents and addiction,

Room 101

Chairmen: M. Liechti, Basel, Switzerland
C. Loland, Copenhagen, Denmark

Time	Abstr. No.	Title
07:15 AM	643	Ecstasy – The Pharmacology of Happiness LIECHTI ME Clinical Pharmacology, University Hospital, Basel, Switzerland.
07:35 AM	915	Identification of the cocaine binding site on the dopamine transporter LOLAND CJ¹, BEUMING T², KNIAZEFF J¹, NEWMAN AH³, KATZ JL³, WEINSTEIN H², GETHER U¹ ¹ Dept of Neuroscience and Pharmacology, Univ. of Copenhagen, Copenhagen, Denmark. ² Dept. of Physiology and Biophysics, Cornell Univ., New York, USA. ³ Medications Discovery Research Branch, National Institute on Drug Abuse, Baltimore, USA
07:55 AM	802	Dopamine transporter as the target and carrier of illicit and therapeutic drugs – PK/PD approaches to develop MAGIC BULLETS for cocaine abuse GU H The Ohio State University College of Medicine, Columbus, OH, USA
08:15 AM	361	Political Economy and Societal Consequences of Methamphetamine Epidemic in the United States KEDIA S University of Memphis

07:15 - 08:35 AM Recombinant Proteins - a new class of Magic Bullets- Part II

Room 406

Chairmen: P. Oestergaard, Bagsvaerd, Denmark
 M. Tini, London, Canada
 K. Kuwata; Gifu City, Japan

Time	Abstr. No.	Title
07:15 AM	642	Kinetic Properties Of Recombinant Factor VIIa (rFVIIa) And The Complexity Relating These To Treatment Response OESTERGAARD P, ERHARDTSEN E Novo Nordisk A/S, Bagsvaerd, Denmark
07:35 AM	662	Dissecting the DNA Base Excision Repair Pathway: Implications for Cancer Therapy MOHAN RD, TINI M University of Western Ontario, London, Ontario, Canada
07:55 AM	984	Dynamics Based Design of Anti-Prion Compounds Uncovered the Hot Spots for Prion's Pathogenic Conversion Reaction KUWATA K, Matsumoto T, Kamatari YO, Muto JH, Nakamura HK Center for Emerging Infectious Diseases, Gifu Univ., Gifu City, Japan.
08:15 AM	807	Epitopic Peptides With Low-Similarity To The Host Proteome. Towards The Magic Bullets. KANDUC D Department of Biochemistry and Molecular Biology, University of Bari, Italy

07:15 - 08:55 AM Anticoagulation and heparin-based drugs

Room 212

Chairmen: J. Liu, Chapel Hill, USA
 V. Laux, Wuppertal, Germany
 J. Liu, Toronto, Canada

Time	Abstr. No.	Title
07:15 AM	345	An enzymatic approach for developing heparan sulfate-based drugs LIU Jian Division of Medicinal Chemistry and Natural Products, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
07:35 AM	462	Innovation in Anticoagulation: Discovery and Development of Novel Small-Molecule Coagulation Inhibitors as New Treatment Options for Thromboembolic Diseases LAUX V Bayer Schering Pharma, Wuppertal, Germany
07:55 AM	772	Trans-lymphatic Chemotherapy LIU J Princess Margaret Hospital, Toronto, ON, Canada
08:15 AM	1374	A Therapeutic Conundrum: Low Molecular Weight Heparins in Patients with Kidney Dysfunction. BROPHY DF Virginia Commonwealth University, Richmond, VA, U.S.A.
08:35 AM	106	Antithrombotics that do not induce bleeding: the "holy grail" found by interfering with von Willebrand factor DECKMYN H, VANHOORELBEKE K Laboratory for Thrombosis Research, KU Leuven campus Kortrijk, E. Sabbelaan, 53, B-8500 Kortrijk, Belgium

07:15 - 08:55 AM Antifungals - Optimizing treatment in normal and special populations

Room 213

Chairmen: D. Dhar, Uxbridge, United Kingdom
W. Rhomberg, Bludenz, Austria
K. Thongprasom, Bangkok, Thailand

Time	Abstr. No.	Title
07:15 AM	1088	Antifungal therapy in cardiothoracic transplant recipients in a new prescribing era DHAR D , NAZARETH D, LYSTER H, HALL A, BANNER NR, CARBY M
07:35 AM	1297	Vindesine And Razoxane, An Effective Drug Combination For Soft Tissue Sarcomas RHOMBERG W ¹ , EITER H ¹ , SCHMID F ² , SAELY C ³ ¹ Department of Radiation Oncology, Academic Teaching Hospital, Feldkirch; and in behalf of the Austrian Society of Radiation Oncology [OEGRO], ² Internal Med., General Hospital, Bregenz, ³ Internal Medicine, Gen. Hosp. Feldkirch, Austria
07:55 AM	1143	Antifungals in the Treatment of Candidiasis Eruption in Oral Autoimmune Diseases THONGPRASOM K ¹ , KANJANABUD P ¹ , PIBOONRATANAKIT P ¹ , SERERAT T ¹ , LAOTHUMTHUT T ² ¹ Chulalongkorn University, Bangkok, Thailand; ² Mahidol University, Bangkok, Thailand
08:15 AM	841	Newer antifungal drugs in kidney transplant recipients VEROUX M , CORONA D Department of Surgery, Transplantation and Advanced Technologies, Organ Transplant Unit, University Hospital of Catania, Italy
08:35 AM	641	Treating fungal infections with CYP53A15 inhibitors PODOBNIK B ^{a,b} , STOJAN J ^c , LAH L ^b , KRAŠEVEC N ^b , KOMEL R ^{b,c} ^a Lek Pharmaceuticals d.d., Verovškova 57, SI-1000 Ljubljana, Slovenia; ^b National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; ^c Faculty of Medicine, University of Ljubljana, Institute of Biochemistry, Vrazov trg 2, SI-1000 Ljubljana, Slovenia

07:15 - 08:55 AM Antineoplastic agents - New mechanisms & compounds - Part II

Room 215

Chairmen: R. Momparler, Montreal, Canada
J. Moll, Nerviano (Mi), Italy
R. Injac, Ljubljana, Slovenia

Time	Abstr. No.	Title
07:15 AM	1110	Epigenetic Therapy Using 5-Aza-2'-Deoxycytine: A Potential Magic Bullet Against Cancer MOMPARLER RL Université de Montréal & Centre de recherche, Hôpital Sainte-Justine, Montreal, Quebec, Canada
07:35 AM	132	Cell Cycle Kinases As Molecular Targets In Anticancer Therapy CARPINELLI C, MONTAGNOLI A, VALSASSINA B, BERIA I, FANCELLI D, PULICI M, VANOTTI E, MOLL J Nerviano Medical Sciences Srl., Nerviano (Mi), Italy
07:55 AM	117	Carbon Bullet«: Fullerenol C ₆₀ (OH) ₂₄ As Organo-Protector Against Doxorubicin-Induced Toxicity INJAC R ¹ , ŠTRUKELJ B ¹ , ĐORĐEVIĆ A ² ¹ Univ. Ljubljana, Ljubljana, Slovenia; ² Univ. Novi Sad, Novi Sad, Serbia
08:15 AM	1334	Reloading Ehrlich's Magic Redox Bullets: Targeting the Redox Achilles Heel of Melanoma Using Phenothiazinium Dyes WONDRAK GT , TUCSON AZ University of Arizona, College of Pharmacy & Arizona Cancer Center, USA
08:35 AM	138	Acridine orange found in Ehrlich's era could become a "Magic Bullet" against cancer under photon energy KUSUZAKI K ¹ , MURATA H ³ , MATSUBARA T ² , SATONAKA H ² , NAKAMURA T ² , MATSUMINE A ² , UCHIDA A ² ¹ Odai Kosei Hospital, Taki Mie Japan, ² Mie University Faculty of Medicine, Tsu, Mie, Japan, ³ Kyoto Prefectural University of Medicine, Kyoto, Japan.

07:15 - 08:55 AM Clinical studies with agents of different pharmacological activity - Part III

Room 217

Chairmen: H. Cerwenka, Graz, Austria
K. Shrivastava, Delhi, India
M. Brunner, Vienna, Austria

Time	Abstr. No.	Title
07:15 AM	44	Treatment of Hepatic Abscess: Magic Bullets and Beyond CERWENKA H Department of Surgery, Medical University of Graz, Austria.
07:35 AM	1284	Prospective Magic Bullet Cobalt: Its Effect, Mode of Action and Utility for Hypoxic Study SHRIVASTAVA K * , ANJU B ¹ , MUSTOORI S ¹ , LILY G*, GOVINDASWAMY I.* *Expt. Biol. Div., DIPAS, DRDO, Lucknow Road, Delhi-110054, India. ¹ Biologicals E Ltd. Hyderabad, India
07:55 AM	521	Magic bullets for the treatment of inflammatory bowel disease – yet to come? BRUNNER M Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
08:15 AM	315	Genetic Polymorphisms Of Cytochromes P450 Influence The Leflunomide Treatment And Toxicity In Rheumatoid Arthritis Patients ROZMAN B¹ , LOGAR D ¹ , TOMŠIĆ M ¹ , PRAPROTNIK S ¹ , ŠUPUT D ¹ , GRABAR I ² , MRHAR A ² , BOHANEK GRABAR P ³ , DOLŽAN V ³ ¹ Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, Ljubljana, Slovenia, ² Faculty of Pharmacy, University of Ljubljana, Aškerceva 7, Ljubljana, Slovenia, ³ Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, Slovenia
08:35 AM	368	Deferoxamine and Defersirox as magic bullets against iron overload CHOUDHRY VP (M.D. FIAP, FIMSA, FISHTM, FIACM) Director, SUNFLAG PAHUJA CENTRE FOR BLOOD DISORDERS, Sunflag Hospital, Faridabad, Haryana-121002, India.

07:15 - 08:55 AM Pharmaceutics - Discovery of drugs and mechanisms - Part II

Room 412

Chairmen: S. Bogdanova, Sofia, Bulgaria
T. Walles, Stuttgart, Germany
A. Díaz Perales, Madrid, Spain

Time	Abstr. No.	Title
07:15 AM	789	Purposeful Drug-Excipients Physico-Chemical Interactions – What does that mean for Optimization of Drug Delivery and Safety? BOGDANOVA S¹ , PAJEVA I ² , AVRAMOVA N ³ , HRISTOVA Y ² ¹ Faculty of Pharmacy, Medical University-Sofia, Bulgaria; ² Bulgarian Academy of Sciences, Bulgaria; ³ Faculty of Chemistry, Sofia University, Bulgaria
07:35 AM	327	Bioartificial Human Tissues as Model Systems for Pharmaceutical Target Screening and Drug Development WALLES T^{1,2} , SCHANZ J ² , HAMPEL M ² , MICHAELIS J ² , HANSMANN J ² , MERTSCHING H ² ¹ Schillerhöhe Hospital, Gerlingen, Germany; ² Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB), Stuttgart, Germany
07:55 AM	1150	Cross-Reactivity and Identification of T and B Epitopes in Plant Food Allergens: Peach Pru p 3 as a Model DÍAZ-PERALES A^{1*} , TORDESILLAS L ¹ , SANCHEZ-MONGE R ¹ , SALCEDO G ¹ ¹ Departamento de Biotecnología, ETS Ingenieros Agrónomos, Universidad Politécnica, Madrid, Spain. *araceli.diaz@upm.es FAX: 34 913363985
08:15 AM	139	Transient Drugs As Magic Bullets: A New Approach To Drug Discovery OHLSON S School of Pure and Applied Natural Sciences, University of Kalmar, Kalmar, Sweden

- 08:35 AM 154 Modulation Of The Structure Of A Lipid Membrane For Selective Interactions With A Drug
NIKOLELIS DP, NIKOLELI GP, RAFTOPOULOU G, PSAROUDAKIS N
Laboratory of Environmental Chemistry, Department of Chemistry, University of Athens,
Panepistimiopolis-Kouponia, Athens, Greece
- 08:55 AM 147 High Throughput Screening for In Vitro Toxicity Screening: A Gradual Acceptance of New
Test Methods
SCHOONEN WGEJ, WESTERINK WMA, HORBACH GJ
Pharmacology, Schering-Plough, Oss, The Netherlands

07:15 - 08:55 AM Clinical situations & therapy and cellular therapeutics

Room 111

Chairmen: H. Maeda, Fukuoka, Japan
R. Kummoona, Baghdad, Iraq
E. Bieberich, Augusta, USA

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 07:15 AM | 1036 | Calcium-Releasing Agent Exhibits Bioactive Effects In Endodontic Therapy
MAEDA H¹ , TOMOKIYO A ¹ , FUJII S ¹ , WADA N ² , MONNOUCHI S ¹ , HORI K ¹ , AKAMINE A ¹
¹ Kyushu Univ., Fukuoka, Japan; ² Univ. Adelaide, Adelaide, Australia |
| 07:35 AM | 91 | Missile Injuries of Orofacial Region, Primary and Secondary Phase Managements
KUMMOONA R
Professor of maxillofacial surgery, Chairman Council of maxillofacial surgery, IRAQI BOARD
FOR MEDICAL SPECIALIZATIONS, BAGHDAD, IRAQ |
| 07:55 AM | 1326 | The Insulin-Stem Cell Connection: What Insulin Does To Stem Cells And How We Get It
From Them
BIEBERICH E¹
¹ Medical College of Georgia, GA, U.S.A. |
| 08:15 AM | 1149 | The Psychological Outcome Of Male Constitutional Delay Short Stature
MOBBS EJ
The Royal Alexandra Hospital for Children, Westmead, Sydney, NSW Australia |
| 08:35 AM | 1254 | Adult stem cells are a source of paracrine factors for tissue regeneration.
DORONIN SV¹ , POTAPOVA IA ¹ , GAUDETTE GR ² , BRINK PR ¹ , ROBINSON RB ³ ,
ROSEN MR ³ , COHEN IS ¹
¹ Department of Physiology and Biophysics, Institute of Molecular Cardiology, State
University of New York at Stony Brook, Stony Brook, NY 11794, USA ; ² Department of
Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA 01609, USA ;
³ Center for Molecular Therapeutics& Departments of Pharmacology and Pediatrics,
Columbia University, New York, NY 10032 USA |

07:15 - 09:29 AM Antibacterials - Tissue penetration of anti-infectives

Room Paul Karrer Hall

Chairmen: U. Theuretzbacher, Vienna, Austria
M. Zeitlinger, Vienna, Austria
J. Karjagin, Tartu, Estonia

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 07:15 AM | 203 | Evaluating our Performance: Tissue Penetration Paradigm Shift
THEURETZBACHER U
Center for Anti-Infective Agents, Vienna, Austria |
| 07:42 AM | 10014 | Pharmacokinetics of Macrolides and Ketolides – where is the drug and how do we measure
it?
Zeitlinger M
Medical University of Vienna, Währingergürtel 18-20, 1090 Vienna, Austria |

08:09 AM	530	Infection Site Concentration of Metronidazole (MTZ) and Meropenem (MER) in Patients with Septic Shock (SS) KARJAGIN J, STARKOPF J Tartu Univ., Tartu, Estonia
08:29 AM	933	Serum and Alveolar Concentrations of Antibiotics during the Treatment of Ventilator-Associated Pneumonia BOSELLI E^{1,2}, BREILH D^{3,4}, ALLAOUCHICHE B^{1,2} ¹ Hosp. Édouard Herriot, Lyon, France; ² Univ. of Lyon, Lyon, France; ³ Hosp. Haut-Lévêque, Pessac, France, ⁴ Univ. of Bordeaux II, Bordeaux, France.
08:49 AM	130	The Ocular Penetration Of Antibiotics Using A Rabbit Model That Emulates Human Topical Dosing OWEN GR, BROOKS AC, BERNAL-PEREZ LF, CAMPBELL-FURTICK MB Alcon Research Ltd., Fort Worth, TX, USA
09:09 AM	1710	Bone Penetration of Antibiotics – Review and Future Perspectives including Bayesian Population PK / PD Methods Landersdorfer C University at Buffalo, NY, USA

07:15 - 09:15 AM Antibacterials - New and innovative approaches to discover and develop antimicrobials - Part III

Room 207

Chairmen: U. Holzgrabe, Wuerzburg, Germany
 J. Severa, Prague, Czech Republic
 M. Biava, Rome, Italy

Time	Abstr. No.	Title
07:15 AM	1609	The piggy back approach or how to find new lead structures for antiinfective or antiviral drugs HOLZGRABE U, TISCHER M Institute of Pharmacy, University Wuerzburg, Germany
07:35 AM	1159	The new biocidal agents with the high sporicidal efficiency SEVERA J¹, KLABAN VI¹, SEDLACKOVA M¹ Decomkov Prague Ltd., Laboratories Hradec Králové, Czech Republic
07:55 AM	179	New derivatives of BM 212 with improved antimycobacterial activity. BIAVA M[*], PORRETTA GC¹, POCE G¹, POMPEI R², DE LOGU A², MANETTI F³, BOTTA M³ ¹ Università "La Sapienza", Rome, Italy. ² Università degli Studi di Cagliari, Cagliari, Italy; ³ Università degli Studi di Siena, Siena, Italy.
08:15 AM	686	Rediscovering antibiotics of alternative medicine: case of apitherapy BOUKRAA L; HAMMOUDI SM; BENBAREK H; BENHANIFIA MB; AISSAT S; AHMED M; MESLEM A Laboratory of Microbiology, Department of Veterinary Sciences, Tiaret University, Algeria
08:35 AM	673	Desining Novel Antiinfective Concepts Combining Nanotechnology, Bioplastics and Natural Products LAGARON JM¹, TORRES-GINER S¹, OCIO MJ^{1,2}, BUSOLO M³, JACKSON J⁴, BURT H⁴, PLACKETT D⁵ ¹ CSIC, Burjassot, Spain, ² Faculty of Pharmacy, University of Valencia, Valencia, Spain; ³ Nanobiomatters S.L., Valencia, Spain; ⁴ Faculty of Pharmaceutical Sciences, UBC, Canada; ⁵ Risoe DTU, Roskilde, Denmark.
08:55 AM	1507	A new "quasi-adaptive" response to alkylating agents in E. coli cells due to posttranslational modification in S- nitrosylated Ada protein VASILIEVA SV Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia

07:15 - 08:55 AM Physiology & Magic Bullets - Part II

Room 405

Chairmen: E. Belyaeva, St.-Petersburg, Russia
 S. Sherlina, Saint-Petersburg, Russia

Time	Abstr. No.	Title
07:15 AM	809	Mitochondrial Respiratory Chain (MRC) and Mitochondrial Permeability Transition (MPT) Effectors against Heavy Metal-induced Cytotoxicity: State-of-the-art and Perspective BELYAEVA EA Sechenov Institute of Evolutionary Physiology and Biochemistry, St.-Petersburg, Russia
07:35 AM	804	POSTIRRADIATION activation of LINE DNA Retroposition in realization of the adaptive response SHERLINA S, VLADIMIROV V (Scientific Research Institute of Military Medicine, S. Petersburg, Russia) mobile LINE, resistance, retroposition
07:55 AM	808	Fluoride and Aluminum Interactions: AlFx as the MAGIC BULLETS Producing Aberration of G Proteins STRUNECKA A Laboratory of Neuropharmacology, Institute of Medical Biochemistry, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
08:15 AM	151	A Role of Lysosomal Phospholipase A2 in Cationic Amphiphilic Drug-induced Phospholipidosis ABE A¹, KELLY R¹, KOLLMAYER J¹, HIRAOKA M², SHAYMAN JA¹ ¹ University of Michigan, Ann Arbor, MI, USA, ² Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo, Japan
08:35 AM	1087	Snake and Snail Neurotoxins – Magic Tools for Targeting Different Subtypes of Nicotinic Acetylcholine Receptors TSETLIN VI, UTKIN YuN, OSIPO vAV, KASHEVEROV IE Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

07:15 - 08:55 AM Antineoplastic agents - how to find new Magic Bullets

Room 115

Chairmen: G. Mezo, Budapest, Hungary
 T. Kumagai, Tokyo, Japan
 M. Tacke, Dublin, Ireland

Time	Abstr. No.	Title
07:15 AM	168	Novel Antineoplastic Agent – Peptide Conjugates As Drug Delivery Systems For Targeted Chemotherapy MEZO G¹, BAI KB¹, SZABÓ I¹, MANEA M², ORBÁN E¹, GAÁL D³, BOSZE S¹ ¹ Research Group of Peptide Chemistry, Budapest, Hungary; ² Laboratory of Analytical Chemistry, Univ. Konstanz, Konstanz, Germany; ³ National Institute of Oncology, Budapest, Hungary
07:35 AM	1243	Anticancer activities of vitamin D analogs KUMAGAI T^{1,2}, KOEFFLER HP² ¹ Department of Hematology, Ohme Municipal General Hospital, Tokyo, Japan ² Division of Hematology/Oncology, Department of Medicine Cedars-Sinai Medical Center, Los Angeles, US
07:55 AM	1162	Titanium-Based Magic Bullets Against Renal-Cell Cancer TACKE M UCD School of Chemistry and Chemical Biology, Belfield, Dublin 4, Ireland.
08:15 AM	172	Asparagine Synthetase Inhibitors With Nanomolar Potency: An Unexplored Approach To Treating Drug-Resistant Leukemia RICHARDS NGJ¹, GUTIERREZ-AMOS JA¹, PAN XY¹, MEYER ME¹, HUMKEY RN¹, KILBERG MS¹, HIRATAKE J² ¹ University of Florida, Gainesville, USA; ² Institute for Chemical Research, Kyoto, Japan

08:35 AM 88 Investigation of Dibenzyl Trisulphide (Dts) Isolated from *Petiveria Alliacea* as an Immunomodulator with Cytotoxic/Anti- Proliferation Activity
WILLIAMS LAD¹, **KRAUS W**², **ROSNER H**³
¹The Natural Products Unit of the Scientific Research Council, P.O. Box 350, Hope Gardens, Kingston 6, Jamaica, West Indies; The University of Hohenheim, Institutes for Bio-organic Chemistry² and Zoology³, Garbenstr 30, D-70593 Stuttgart, Germany

07:15 - 09:15 AM Endocrinology including diabetes,

Room 112

Chairmen: H. Koga, Kurume, Japan
V. Stefanovic, Nis, Serbia
G. Kudolo, San Antonio, USA

Time	Abstr. No.	Title
07:15 AM	155	Targeting Cell Cycle Progression by Troglitazone KOGA H, SATA M Division of Gastroenterology, Department of Internal Medicine, Kurume University, Japan
07:35 AM	36	Dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus STEFANOVIC V University of Nis, and Serbian Academy of Sciences and Arts, Belgrade, Serbia
07:55 AM	1205	Towards a Magic Bullet for the Metabolic Syndrome – Use of the Ginkgo Biloba Extract KUDOLO GB University of Texas Health Science Center, San Antonio, TX, USA.
08:15 AM	1082	Drug discovery related to vaspin, visceral adipose tissue-derived serine protease inhibitor, a novel adipokine with insulin-sensitizing effects WADA J, NAKATSUKA A, MAKINO H Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Okayama, Japan
08:35 AM	1485	Insulin, IGF-1 and Rosiglitazone: How Do They Effect The Glucose Metabolism and Insulin Resistance in Human SH-SY5Y Cells with Alzheimer Key Proteins? AYCAN (YERER) MB ¹ , ECKERT A ² ¹ University of Erciyes, Faculty of Pharmacy, Department of Pharmacology, 38039, Kayseri, Turkey. ² Psychiatric Univ. Clinics, Neurobiol lab. for Brain Aging, Basel, Switzerland.
08:55 AM	752	The Importance of Appropriate Animal Models for Evaluating Agents for Proliferative Retinopathy: Failure of Combretastatin to inhibit Diabetes-Like Proliferative Retinopathy in the Galactose-Fed Dog. KADOR PF , ^{1,2} BLESSING K ^{1,2} , WYMAN M ¹ ¹ Laboratory of Ocular Therapeutics, National Eye Institute, National Institutes of Health, Bethesda, MD, USA and ² Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE USA

07:15 - 09:15 AM Antineoplastic agents - Creating Magic Bullets from natural compounds - Part I

Room L001

Chairmen: MM Alauddin, Houston, USA
F. Gago, Alcalá de Henares, Spain
M. Jung, Seoul, Korea

Time	Abstr. No.	Title
07:15 AM	1069	Novel reporter probes for HSV1- <i>tk</i> gene expression ALAUDDIN MM Center for Advanced Biomedical Imaging Research (CABIR), The University of Texas M D Anderson Cancer center, Houston, TX, USA.

07:35 AM	1059	Trabectedin: a new anticancer bullet from the sea GAGO F Departamento de Farmacología, Universidad de Alcalá, E-28871 Alcalá de Henares, Spain.
07:55 AM	158	Discovery & Development of Antineoplastic Magic Bullets from Natural Products JUNG M Yonsei University, Seoul, Korea
08:15 AM	654	Retinoic Acid Regulates the Expression of the Anti-Apoptotic Protein PKCdVIII PATEL NA ^{1,2} AND COOPER DR ^{1,2} James A. Haley Veterans Hospital ¹ and College of Medicine, Department of Molecular Medicine ² , University of South Florida, Tampa, FL
08:35 AM	563	Chemopreventive and Renal Protective Effects for Epigallocatechin-Gallate (EGCG) and Resveratrol (RSLV) in Human and Animal Cancer Models EL-MOWAFY AM ¹ , ELMESERY M ¹ , ALKHALAF M ³ , AL-GAYYAR M ¹ , SALEM HA ² Departments of ¹ Biochemistry and ² Pharmacology, Faculty of Pharmacy, Mansoura Univ., Mansoura, Egypt and ³ Dept. of Biochemistry, FOM, HSC, Kuwait Univ., Kuwait
08:55 AM	1232	Optimizing New Therapeutic Discoveries from Ethnomedical and Ethnobotanical Data ELVIN-LEWIS M Washington University, St Louis Mo 63130, USA
09:15 PM	491	Application of Saffron and Its Ingredients as a Known Pharmacological Herb from Ancient Times and the Mechanisms of Their Action BATHAIE SZ ¹ , MOUSAVI SZ ² , HOSHYAR R ¹ AND ASHRAFI M ¹ ¹ Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; ² Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

07:15 - 09:55 AM Agents / diseases affecting the immune system - Part II

Room 205

Chairmen: S. Paczesny, ANN ARBOR, USA
 D. Adams, Dunedin, New Zealand
 P. Stenberg, Malmö, Sweden

Time	Abstr. No.	Title
07:15 AM	1129	A biomarker panel for acute graft versus host disease PACZESNY S. ^{1,2} , KRIJANOVSKI O ¹ , BRAUN TM ¹ , CHOI S ¹ , CLOUTHIER SG ¹ , KUICK R ¹ , MISEK DE ¹ , COOKE KR ¹ , KITKO CL ¹ , WEYAND A ¹ , BICKLEY D ¹ , JONES D ¹ , WHITFIELD J ¹ , REDDY P ¹ , LEVINE JE ¹ , HANASH SM ² , AND FERRARA JLM ¹ . ¹ University of Michigan, Ann Arbor, MI, 48109, USA and ² Fred Hutchinson Cancer Center, Seattle, WA, 98103, USA.
07:35 AM	25	Magic Bullets against the Autoimmune Diseases ADAMS DD University of Otago Medical School, Dunedin, New Zealand
07:55 AM	728	The Pathogenesis of Autoimmune Diseases: New Possibilities for Drug Developmen Stenberg P , ROTH EB Hospital Pharmacy, Malmö University Hospital, S-205 02 Malmö, Swed
08:15 AM	1035	Differently Directed Changes in Interferon-? Production Depending on Radioadaptive Response. ARKHIPOVA EN , ALCHINOVA IB, KARGANOV MYu Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russia
08:55 AM	427	Toll-Like Receptor (TLR) Agonists And The Induction Of The Innate Immune Response MITCHELL WM ¹ , STRAYER DS ² , CARTER WA ² ¹ Vanderbilt University, Nashville, USA; ² Hemispherx Biopharma, Philadelphia, USA
09:15 AM	1211	Pharmacodynamic Monitoring of Calcineurin Inhibition Therapy VAN ROSSUM HH ¹ , DE FIJTER JW ² , VAN PELT J ¹ Departments of Clinical Chemistry ¹ and Nephrology ² , Leiden University Medical Center, Leiden, Netherlands

07:15 - 09:35 AM Biomarkers - The thorny way to personalized medicine

Room 403

Chairmen: W. Fierz, Kilchberg, Switzerland
A. During, Louvain la Neuve, Belgium
M. Guvakova, Philadelphia, USA

Time	Abstr. No.	Title
07:15 AM	610	It's not only genes - The many dimensions of personalized medicine FIERZ W¹ ¹ LogoLab AG, Kilchberg, Switzerland
07:35 AM	831	Current knowledge on membrane transporters of vitamin A and its precursors DURING A¹ , HARRISON EH ² ¹ Université catholique de Louvain, Louvain-la-Neuve, Belgium; ² The Ohio State University, Columbus, USA.
07:55 AM	1402	Transient Activation of the Small GTPase Rap1 is Functionally Required for the Regulation of Breast Cancer Cell Motile Responses to IGF-I GUVAKOVA MA , LEE WSY, FURSTENAU DK Univ. of Pennsylvania, Philadelphia, PA, USA
08:15 AM	65	Personalized Management Of Breast Cancer ROUKOS DH Surgical Oncology Research Unit, Department of Surgery, Ioannina University School of Medicine, Ioannina, Greece
08:35 AM	77	Personalized Medication with Estramustine Phosphate for Advanced Prostate Cancer after Screening of the CYP1A1 gene polymorphisms MOTOFUMI SUZUKI , TAKAYUKI KUROSAKI, MIAO LIU, YUTAKA ENOMOTO, HIROAKI NISHIMATSU, YUKIO HOMMA, TADAICHI KITAMURA Department of Urology, The University of Tokyo, Tokyo, Japan
08:55 AM	152	Pharmacogenomic Targeting Of Ehrlich's Magic Bullet LI-WAN-PO A National Genetics Education and Development Centre, Morris House, Birmingham Women's Hospital, Edgbaston, Birmingham, UK, Centre for Evidence-Based Pharmacotherapy, Nottingham, UK.
09:15 AM	1265	New Biomarkers And Targeted Therapies For Breast Cancer O'DRISCOLL L National Institute for Cellular Biotechnology, Dublin City University, Dublin 9; School of Pharmacy & Pharmaceutical Sciences, Trinity College, Dublin 2, Ireland

07:15 - 09:35 AM CNS - Pharmacological options in disease of the central nervous system - Part III

Room 218

Chairmen: I. Decimo, Verona, Italy
K. Köves, Budapest, Hungary
C. Kaur, Singapore, Singapore

Time	Abstr. No.	Title
07:15 AM	1401	Neuronal trafficking of proteins involved in synaptic plasticity: a GFP-based approach DECIMO I.*¹ , FORMAGGIO E. ¹ , BERSAN E. ¹ , RONCARATI R. ³ , M CLEMENS ² , CHIAMULERA C. ¹ , FUMAGALLI G. ¹ . ¹ Sect. Pharmacology, Dept. Medicine & Public Health, Univ. of Verona (Italy); ² INAF, National Institute for Astrophysics Astronomical Observatory of Padua, Padova (Italy); ³ Sienabiotech, Discovery research Via Fiorentina 1, 53100 Siena, Italy
07:35 AM	1394	Secretin and Autism KÖVES K¹ , HEINZLMAN A ¹ , SZABÓ G ² ¹ Semmelweis University, Budapest and ² Albert Szent-Györgyi Medical University, Szeged, Hungary.

07:55 AM	62	Melatonin-a possible magic bullet in reducing hypoxic brain injury KAUR C¹, SINGH J², LING EA¹ 1. Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 2. Civil Aviation Medical Board, Civil Aviation Authority of Singapore, Singapore Changi Airport, Singapore
08:15 AM	1040	Magic Bullets For The Treatment Of Oxidative Stress-Induced Neurodegenerative Disorders ATLAS D Dept. Biological Chemistry The Hebrew University, Jerusalem 91904, Israel
08:35 AM	267	Lacosamide is a Novel Antinociceptive and Antiepileptic Drug with a Dual Mode of Action BERKELS R¹, BEYREUTHER B², KREBSFAENGER N², FREITAG J², LEES G³, ERRINGTON A³, STÖHR T² ¹ UCB GmbH, Monheim, Germany; ² SCHWARZ BioSciences GmbH, Monheim, Germany; ³ University of Otago, Dunedin, New Zealand; ⁴ UCB, Inc., Smyrna, GA, US
08:55 AM	798	Caffeine sets the brain's excitability by priming the activation of the endogenous cannabinoid system ISOKAWA M The University of Texas at Brownsville, Department of Biological Sciences, U.S.A.
09:15 AM	1309	Atorvastatin protects spinal motor neurons from glutamate mediated neurotoxicity YASUO I Department of Neurology Toho University Omori Hospital 6-11-1 Omorinishi Otaku Tokyo JAPAN

09:30 - 10:10 AM Vaccines - Antineoplastic - Role of immune cells - Part I

Room 216

Chairman: AB Heimberger Philipsburg, New Jersey

Time	Abstr. No.	Title
09:30 AM	479	RNA-modified dendritic cells as therapeutic cancer vaccines: Dressed for success ? VAN TENDELOO VF, VAN DRIESSCHE A, VAN DE VELDE A, STEIN B, NIJS G, VERMEULEN K, PIETERS K, SCHROYENS WA, COOLS N, BERNEMAN ZN University of Antwerp – Vaccine & Infectious Disease Institute
09:50 AM	1117	EGFRvIII-targeted vaccine (CDX-110) induces immune responses and prolongs survival when given with temozolomide in GBM patients HEIMBERGER AB³, ARCHER GE^{1,2}, BIGNER DD², DAVIS T⁴, FRIEDMAN HS^{1,2}, KELER T⁴, MITCHELL DA¹, REARDON D¹, SAWAYA R³, SAMPSON JH^{1,2} ¹ Departments of Neurosurgery, ² Pathology, Duke University Medical Center, Durham, North Carolina; ³ Department of Neurosurgery, University of Texas, M. D. Anderson Cancer Center, Houston, Texas; ⁴ CellDex Therapeutics, Philipsburg, New Jersey

09:30 - 10:10 AM Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part II

Room 412

Chairman: M. Wijtmaans, Amsterdam, The Netherlands

Time	Abstr. No.	Title
09:30 AM	120	The Development of Tumor-Inhibiting Metal Complexes: (Multinuclear) Metal Complexes and Mode-of-Action Studies HARTINGER CG^{1,2}, NAZAROV AA^{1,2}, MENDOZA-FERRI M-G¹, DYSON PJ², KEPPLER BK¹ ¹ University of Vienna, Vienna, Austria; ² EPFL, Lausanne, Switzerland.
09:50 AM	149	The Anti-Tumor Action of the Hybrid Drug Nitric Oxide-Donating Aspirin Relies on the 'Passive' Linker and not on Nitric Oxide Nor on Aspirin: An Overview of an Interesting Twist HULSMAN N^{1,2}, MEDEMA J P¹, BOS C¹, JONGEJAN A², LEURS R², SMIT M², DE ESCH I², RICHEL D¹, WIJTMANS M² ¹ University of Amsterdam, Amsterdam, The Netherlands. ² Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

09:30 - 10:30 AM Antibacterials - Adverse events and mechanisms of toxicity - Part II

Room 214

Chairman: A. Sidoroff, Innsbruck, Austria

Time	Abstr. No.	Title
09:30 AM	845	The Proarrhythmic Potential of Macrolides: The Role of Interactions. A Review SIMKÓ J1 , LORINCZ I2 1Ssemelweis Hospital, Health Center of Miskolc, Hungary; 2Medical and Health Science Center, University of Debrecen, Hungary
09:50 AM	1288	When "Magic Bullets" Cause Collateral Damage (SJS/TEN and AGEP) SIDOROFF A ¹ for the RegiSCAR Study Group ¹ Medical University of Innsbruck, Department of Dermatology and Venereology, Innsbruck, Austria
10:10 AM	1122	Enerceutical Mediated Activation Of The Alternative Cellular Energy Pathway In The Therapy Of Infectious Diseases MARTIN WJ Institute of Progressive Medicine, Burbank, CA, USA

09:30 - 10:30 AM Parkinson's disease, mechanism of disease and treatment - Part I

Room 405

Chairman: M Cyr, Qué., Canada

Time	Abstr. No.	Title
09:30 AM	1605	Rasagiline, a Selective Suicide Inhibitor of Monoamine Oxidase B, Increases Striatal Extracellular Fluid Dopamine Levels and Locomotor Stimulation Following L-dopa Without a Corresponding Increase in Dyskinetic Movements in a Parkinsonian Rat Model. FINBERG JPM , LOBODA L, SADER-MAZBAR O Rappaport Faculty of Medicine, Technion, Haifa, Israel
09:50 AM	1060	Behavioural and cellular consequences of excessive amounts of the powerful brain chemical dopamine. LEBEL M and CYR M Neuroscience Research Group, UQTR, Trois-Rivières, Qué., Canada.
10:10 AM	381	Is Levodopa The Magic Bullet For Parkinson's Disease? JANKOVIC J Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas

09:30 - 10:30 AM New findings on purines

Room 101

Chairman: M. Hofer, Brno, Czech Republic

Time	Abstr. No.	Title
09:30 AM	866	P2X Purinergic Receptor Modulation Of Excitatory Nociceptive Transmission Involve NMDA Receptors JENNINGS EJ ² , WILLIAMS MC ² , CHO H-J ² , SESSLE BJ ¹ ¹ University of Toronto, Toronto, ON, Canada ² University of Melbourne, Vic, Australia
09:50 AM	599	Non-Selective and Selective Adenosine Receptor Agonists in the Treatment of Radiation- and Chemotherapy-Induced Myelosuppression HOFER M , POSPIŠIL M Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic

10:10 AM 949 Adenosine-Based Therapies for Hearing Loss
VLAJKOVIC SM¹, GUO CX¹, WONG A¹, LEE KH¹, GUPTA R¹, HOUSLEY GD^{1,2}, THORNE PR¹
¹The University of Auckland, Auckland, New Zealand; ²University of New South Wales, Sydney, Australia

09:30 - 10:50 AM Ehrlich History, Reviews and Future perspectives on Ehrlich's Research Fields

Room 207

Chairmen: B. Van der Zeijst, Bilthoven, The Netherlands
D. Warhurst, London, United Kingdom

Time	Abstr. No.	Title
09:30 AM	45	Passive Immunization for the Protection of our Global Society against Emerging Infections VAN DER ZEIJST B ¹ ¹ Netherlands Vaccine Institute, The Netherlands
09:50 AM	420	The legacy of Paul Ehrlich To antimalarial chemotherapy WARHURST D London School of Hygiene and Tropical Medicine
10:10 AM	1279	Two vaccines too far: the poliovaccine fiasco of 1935 WYATT HV University of Leeds, Leeds, U.K
10:30 AM	736	Mast cell today. GRAEVSKAYA E Department of Biophysics, Biological Faculty, Lomonosov Moscow State University, Moscow, Russia

09:30 - 10:50 AM Antifungals - New approaches and their success

Room 217

Chairmen: A. Pauli, Zirndorf, Germany
P. Mardh, Lund, Sweden

Time	Abstr. No.	Title
09:30 AM	166	(-)-a-Bisabolol – a Specific Ergosterol Biosynthesis Inhibitor ? PAULI A ¹ , SCHILCHER H ² ¹ ReviewScience, Zirndorf, Germany; ² Immenstadt, Germany
09:50 AM	1216	Mannose-Binding Lectin In The Defence Against Genital Candida Infections MÅRDH PE , HENIC E, THIEL S Dept of Obstetrics and Gynecology, Lund University, Sweden and Dept. of Medical Microbiology and Immunology, Aarhus University, Denmark
10:10 AM	273	<i>In Vitro</i> Fungicidal Properties of the Plant Saponin, CAY-1, with (1) Two CAY-1 Structurally Related Saponins and (2) Synergism with Silver. DE LUCCA AJ ¹ , BOUE SM ¹ , SIEN T ² , WALSH TJ ² ¹ U.S. Department of Agriculture, New Orleans, LA, USA. ² National Institutes of Health, Bethesda, MD, USA.
10:30 AM	1101	Vulvovaginal Colonization by Aspergillus Species in Nonimmunocompromised Women BAGGISH MS , VENTOLINI G Department of Obstetrics and Gynecology, Good Samaritan Hospital, Cincinnati, OH. Department of Obstetrics and Gynecology, Wright State University, Boonshoft School of Medicine, Dayton, OH

09:30 - 10:50 AM Antineoplastic agents - Delivering a Magic Bullet to its target(s) – Part II

Room 404

Chairmen: K. Avgoustakis, PATRAS, Greece
S. Kondo, Gifu, Japan

Time	Abstr. No.	Title
09:30 AM	496	Targeted delivery of cisplatin using polymeric nanoparticles AVGOUSTAKIS K¹ ¹ Univ. of Patras, Patras, Greece
09:50 AM	948	pH Dependent 5-Fluorouracil Release System using Polymeric Micelles KONDO S¹, KUZUYA M² ¹ Gifu Pharmaceutical Univ., Gifu, Japan; ² Matsuyama Univ., Matsuyama, Japan
10:10 AM	944	Design Of Folate-Linked Liposomal Doxorubicin To Its Antitumor Effect In Mice MAITANI Y, YAMADA A, TANIGUCHI Y, KAWANO K, HATTORI Y Hoshi University, Tokyo, Japan
10:30 AM	1684	New Applications for Micro- and Nanoscaled Drug Delivery Systems COESTER C Ludwig Maximilians University, Munich, Germany

09:30 - 10:50 AM Vaccines - Antiinfectives - Influenza and other viruses

Room 215

Chairmen: B. Jiang, Atlanta, USA
S. Li, Washington, USA

Time	Abstr. No.	Title
09:30 AM	966	Development of an Inactivated Rotavirus Vaccine for the Global Immunization Agenda JIANG B¹, WANG Y¹, GLASS RI^{1,2} ¹ Centers for Disease Control and Prevention, Atlanta, Georgia and ² National Institutes of Health, Bethesda, Maryland, USA.
09:50 AM	891	Funding New Technologies For The Development Of Seasonal And Pandemic Influenza Vaccines LI S Biomedical Advanced Research and Development Authority, US Department of Health and Human Services
10:10 AM	74	Vaccination in Patients with Cancer: Strategies to Prevent Influenza and Pneumococcal Disease SAFDAR A M.D. Anderson Cancer center
10:30 AM	997	High Uptake Of Vaccines – A „Magic Bullet” In Control The Burden Of Hospitalisation Attributable To Childhood Mumps And Rotavirus Infections OLDAK E¹, ROZKIEWICZ D¹, SZAFRAN D², SULIK A¹ ¹ Medical University, Bialystok, Poland; ² University Children's Hospital, Bialystok, Poland

**09:30 - 10:50 AM Cardiovascular - Pharmacological action in the cardiovascular system
from small molecules to peptides and vaccines - Part II**

Room 403

Chairmen: D. Mager, Buffalo, USA
B. Sood, Detroit, MI, USA

Time	Abstr. No.	Title
09:30 AM	60	Pharmacokinetic-Pharmacodynamic Modeling Of Aliskiren Effects On Biomarkers Of The Renin-Angiotensin System In Humans MAGER DE ¹ , HONG Y ^{1,2} , DINGEMANSE J ³ ¹ University at Buffalo, SUNY, Buffalo, NY, USA; ² Bristol Myers Squibb Co., Princeton, NJ, USA; ³ Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
09:50 AM	1139	Targeted Pulmonary Delivery of Aerosolized PGE1: A "Magic Bullet" for Neonatal Pulmonary Hypertension? SOOD BG ¹ , MADDIPATI KR ¹ , SHEN Y ¹ , LATIF Z ¹ , JOSHI A ¹ , SLOVIS TL ¹ , HAACKE EM ¹ ¹ Wayne State University, Detroit, MI, USA
10:10 AM	1351	Trimetazidine Revisited: Current And Future Applications Of Metabolic Modulation Of The Heart ONAY-BESIKCI A , GUNER S, ARIOGLU E, OZAKCA I, OZCELIKAY AT, ALTAN VM Ankara University, Faculty of Pharmacy, Ankara, Turkey
10:30 AM	1042	The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis ASSY N ^{1,2,5} , KAYAL M, ³ MEJIRISKY Y, ³ GORENBERG M, ⁴ HUSSEIN O, ² AND SCHLESINGER S ² ¹ Liver Unit, Sieff Hospital, Safed, Israel, ² Department of Internal Medicine A, Sieff Hospital, Safed, Israel ³ Department of Internal Medicine B, Sieff Hospital, Safed, Israel. ⁴ Department of Nuclear Medicine, Sieff Hospital, Safed, Israel. ⁵ Faculty of Medicine, Technion Institute of Technology, Haifa, Israel

09:30 - 10:57 AM Antibacterials - Peptide antibiotics and their intricacies

Room 218

Chairmen: V. Tam, Houston, USA
R. Daugelavicius, Vilnius, Lithuania

Time	Abstr. No.	Title
09:30 AM	10012	Antibacterials & Peptide antibiotics Tam V University of Houston, 1441oursund Street, TX 77030 Houston, Texas, USA
09:57 AM	541	Polymyxin B: how this Magic Bullet kills Gram-negative Bacteria? DAUGELAVICIUS R Vilnius University, Lithuania.
10:17 AM	447	Polymyxin B Sulphate: A Brief Overview RANGASWAMY V , HIREMATH A, GUDURI B Reliance Life Sciences, Industrial Biotechnology Group, DALC, Navi Mumbai, India
10:37 AM	613	Magic Bullets - the Lantibiotic approach COTTER PD ¹ , FIELD D ¹ , DRAPER LA ¹ , LAWTON EM ¹ , O'CONNOR PM ^{2,3} , ROSS RP ^{2,3} , HILL C ^{1,3} ¹ Department of Microbiology, University College Cork, Cork, Ireland; ² Teagasc Dairy Products Research Centre, Moorepark, Fermoy, County Cork, Ireland; ³ Alimentary Pharmabiotic Centre, Cork, Ireland.

09:30 - 11:28 AM Which role does PK/PD play in drug development?

Room: L001

Chairmen: H. Derendorf, Gainesville, USA
H. Schütz, Vienna, Austria

Time	Abstr. No.	Title
09:30 AM	10000	Streamlining drug development using modeling and simulation DERENDORF H² University of Florida, Gainesville, FL, USA
10:23 AM	10000	Bioequivalence - Still an Applied Science or already a Cookbook? SCHÜTZ H. BEBAC, Vienna, Austria
10:34 AM	10000	Modeling and Simulation for Optimal Drug Development in Pediatric Populations MOUKSASSI S. Pharsight, Montreal, Canada
11:01 PM	1638	You can ignore PK/PD - but it does not ignore you! KIRKPATRICK CMJ Univ. of Queensland, Queensland, Australia

09:30 - 11:30 AM Target site interactions and spectroscopic / computational approaches

Room 205

Chairmen: A. Kulikov, Novosibirsk, Russia
J. Frelek, WARSAW, Poland
G. La Hoste, New Orleans, USA

Time	Abstr. No.	Title
09:30 AM	999	New Animal Models for Psychotropic Drug-Drug Interactions KULIKOV AV , BAZOVKINA DV, OSIPOVA DV Institute of Cytology and Genetics, Russian Academy of Sciences, 630090 Novosibirsk, Russia.
09:50 AM	975	Circular dichroism spectroscopy in stereochemical studies of ? -lactam antibiotic analogues FRELEK J Institute of Organic Chemistry of the Polish Academy of Sciences, Kasprzaka 44/52 01-224 Warszawa, Poland. E-mail: frelek@icho.edu.pl
10:10 AM	1333	Interactions Between Drug Target Binding Sites and the Remarkable Story of Dopamine D1/D2 Synergism LaHOSTE GJ University of New Orleans, New Orleans, LA, U.S.A.
10:30 AM	847	Dissociation of Multi-molecular Drug Complexes and Multi-site Binding to 7-TM Receptors: Protection, Delivery and Enhancement of Adrenergic Activation by Ascorbate. DILLON PF and ROOT-BERNSTEIN RS. Department of Physiology, Michigan State University.
10:50 AM	996	Consideration Of Metachromatic Spectral Changes Of Toluidine Blue Staining Of DNA Depending On Its Helical Structure MATSUMOTO S¹ , SATO S ¹ , FREIVALDS T ² , ERENPREISA J ³ ¹ Yokohama Natl. Univ., Yokohama, Japan; ² Univ. of Latvia and ³ Biomed. Centre, Riga, Latvia
11:10 AM	1115	Molecular Modelling of Inhibitor-Kinase Interactions. 'Icy', Highly Polarized Water Molecules Can Tip the Relative Energy Balances of Competing Inhibitors. de COURCY B ¹ , PIQUEMAL JP ² , GARBAY C ¹ , GRESH N¹ ¹ Laboratoire de Pharmacochimie Moléculaire et Cellulaire, U648 INSERM, UFR Biomédicale, Université Paris Descartes, 45, rue des Saints-Pères, 75006 Paris, France, ² Laboratoire de Chimie Théorique, UMR 7616 CNRS, Université Pierre-et-Marie-Curie, 4, place Jussieu, F75252 Paris

09:30 - 11:30 AM Antibacterials - Clinical Aspects - Part II

Room 206

Chairmen: F. Ram, Auckland, New Zealand
 R. Jashari, Brussels, Belgium
 N. Radhakrishnan, ROCHDALE, United Kingdom

Time	Abstr. No.	Title
09:30 AM	9	Effectiveness Of Antibiotics In The Management Of Acute Exacerbations Of Chronic Obstructive Pulmonary Disease. Do Antibiotics Improve Patient Outcomes – Evidence To Date RAM FSF¹ , RODRIGUEZ-ROISIN R ² , GRANADOS-NAVARRETTE A ² , GARCIA-AYMERICH J ² , BARNES NC ³ ¹ Massey University, Auckland, New Zealand; ² University of Barcelona, Barcelona, Spain; ³ London Chest Hospital, London, United Kingdom
09:50 AM	857	Decontamination of Cardiovascular Allografts in European Homograft Bank (EHB). Comparison of different Antibiotic Cocktails in low Concentration low Temperature Conditions JASHARI R European Homograft Bank, International Association, Brussels, Belgium
10:10 AM	927	Addition Of Local Antiseptic Spray To Antibiotic Regime Reduces The Incidence Of Stomal Infection Following Percutaneous Endoscopic Gastrostomy (PEG) – A Randomised Controlled RADHAKRISHNAN NV , SHENOY AH, CARTMILL I, SHARMA RK, GEORGE R, FOSTER DN, QUEST LJ Rochdale Infirmary, Acute Pennine Hospitals Trust, Rochdale, Lancs, UK
10:30 AM	1100	Antibiotic Treatment For Clostridium Difficile-Associated Diarrhea In Adults NELSON R Department of Surgery, Northern General Hospital, Sheffield, UK. S5 7AU
10:50 AM	393	New Silver Compounds as Wound Healing Material Problems and Opportunities ABU-YOUSSEF M^A , GOHAR Y ^B , ÖHRSTRÖM L ^{C,D} , LANGER V ^C , MASSOUD A ^{A,C} ^a Department of Chemistry, Faculty of Science, Alexandria University, P.O. Box 426 Ibrahimia, 21321 Alexandria, EGYPT, ^b Department of Microbiology, Faculty of Science, Alexandria University, 21321 Alexandria, EGYPT, ^c Department of Chemical and Biological Engineering, Chalmers University of Technology, SE-412 96 Gothenburg, SWEDEN, ^d Rebact, Stena Center 1C, 412 92 Göteborg, SWEDEN.
11:10 AM	527	Reduction Of Surgical Site Infections During Paediatric Cardiac Surgery IODICE F , KELLEHER A, SHEARER H Royal Brompton Hospital, London, UK

09:30 - 11:30 AM Ehrlich`s research fields: Historical aspects and latest research results

Room 115

Chairmen: A. Chakrabarty, Chicago, USA
 A. Gorenstein, Tel Aviv, Israel
 HH. Liu, Bryn Mawr, USA

Time	Abstr. No.	Title
09:30 AM	104	Magic Bullets Versus Shotgun Drugs in Cancer Therapy and Prevention CHAKRABARTY AM¹ , FIALHO AM ² ¹ University of Illinois, Chicago, USA, ² Instituto Superior Tecnico, Lisbon, Portugal
09:50 AM	1026	How did the MAGIC BULLETS drop the Knife out of the Surgeon's Hand. GORENSTEIN A^{1,3} , SOMEKH E ^{2,3} , SEROUR F ^{1,3} ¹ Department of Pediatric Surgery, Wolfson Medical Center, Holon, Israel; ² Pediatric Infectious/Immunology Unit, Wolfson Medical Center, Holon, Israel; ³ Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

10:10 AM	78	Antibiotic "Magic Bullets": The Promise and the Reality of the Past Thirty Years LIU HH Bryn Mawr Medical Specialists & Thomas Jefferson University, Philadelphia, PA, USA
10:30 AM	312	From immunity theory to anti-infectious chemotherapy. Why awarding two Nobel prices in 1908 to Paul Ehrlich (from Germany) and Elie Metchnikoff (from France). What consequences for medical research? DEBUE-BARAZER C EHESS Paris, France.
10:50 AM	611	Globalization and influence of Nobel prize winners for medicine and physiology to development of modern medicine during 20th and 21st century MASIC I Medical faculty, University of Sarajevo, B&H, Sarajevo, Bosnia and Herzegovina
11:10 AM	187	Receptors For Magic Bullets. Ehrlich, Precursor Of Receptor-Mediated Drug Action. Application To Age-Related Pathologies. A Review ROBERT L, LABAT-ROBERT J Ophthalmol. Res. Lab, Hotel Dieu Hosp, Univ Paris v, Paris, France

09:30 - 11:30 AM Vaccines - Antineoplastic - Antigen guided

Room 112

Chairmen: S. Gnjatic, New York, USA
 F. Grizzi, Rozzano, Italy
 C. La Porta, Milan, Italy

Time	Abstr. No.	Title
09:30 AM	1123	Antibody responses in cancer vaccines and immunotherapies: from cancer/testis antigens to new targets discovered by protein arrays GNJATIC S¹ , ODUNSI K ² , ALTORKI NK ³ , RITTER G ¹ , BUECHLER MW ⁴ , JAEGER D ⁴ , OLD LJ ¹ ¹ Ludwig Institute for Cancer Research, New York NY, USA; ² Roswell Park Cancer Institute, Buffalo NY, USA; ³ Weill Medical College of Cornell University, New York NY, USA; ⁴ Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
09:50 AM	973	Cancer-testis antigens: effective molecules for developing successful immunotherapeutic strategies in the light of cancer complexity GRIZZI F¹ ¹ Laboratories of Quantitative Medicine, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy.
10:10 AM	688	Melanoma Initiating Cells: New Perspectives For Therapy MONZANI E, BAZZOTTI R, LA PORTA CAM^a ^a Department of Biomolecular Science and Biotechnology, University of Milan, Italy
10:30 AM	632	AdCD40L Cancer Vaccine – From Experimental Models to Clinical Application LOSKOG A¹ , LINDQVIST C ¹ , FRANSSON M ¹ , MANGSBO S ¹ , WANDERS A ² , GARDMARK T ² , MALMSTROM PU ² , and TOTTERMAN TH ¹ . ¹ Uppsala University, Uppsala, Sweden. ² University Hospital, Uppsala, Sweden.
10:50 AM	763	Direct Lentiviral Injection Induces Potent Anti-CEA Immunity In CEA Transgenic Mice LOISEL-MEYER S ¹ , FOLEY JE ² , KAMMERER R ^{3,4} , MIZUE N ¹ , KEEFE R ⁵ , MCCART JA ^{6,8} , ZIMMERMANN W ³ , DROPULIC B ⁵ , FOWLER DH ² , MEDIN JA^{1,6,7,8} ¹ Ontario Cancer Institute, UHN, Toronto, Canada; ² ETIB, NCI, NIH, Bethesda, USA; ³ Tumor Immunology Laboratory, LIFE-Center, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, Germany; ⁴ Institute für Immunologie, Friedrich-Loeffler-Institut, Tübingen, Germany; ⁵ Lentigen Corp., Baltimore, USA; ⁶ TGRI, UHN, Toronto, Canada; ⁷ Department of MBP and the ⁸ Institute of Medical Sciences, Univ. of Toronto, Canada.
11:10 AM	925	Fusion Proteins For Flexible Vaccine Antigen Targeting To Cell Surface Receptors KRATZER R^{1,2} , MAUVAIS FX ^{1,2} , VAN ENDERT P ^{1,2} ¹ INSERM U580, Paris, France; ² Université Paris Descartes, Paris, France.

09:30 - 11:30 AM Treatment of tuberculosis and other infections

Room 213

Chairmen: J. Liu, Toronto, Canada
R. Greenstein, New York City, USA
W. Yew, HONG KONG, China

Time	Abstr. No.	Title
09:30 AM	1004	Intrinsic antibiotic resistance mechanism of Mycobacteria LIU Jun Department of Molecular Genetics, University of Toronto
09:50 AM	1058	The “antiinflammatory” 5-ASA, “immune-modulators” azathioprine, 6-MP, methotrexate & thalidomide and “immune-suppressants” Cyclosporine A, Rapamycin & Tacrolimus are all unsuspected “Magic Bullets” the inhibit <i>M. avium</i> subspecies <i>paratuberculosis</i> growth in culture GREENSTEIN RJ VAMC Bronx NY USA
10:10 AM	1093	Fluoroquinolones in the Treatment of Tuberculosis: Current Status and Future Issues YEW WW¹ ¹ Grantham Hospital, Hong Kong, China
10:30 AM	709	Improving Treatment Of Urinary Tract Infections In Elderly: Roles And Functions Of Information Technologies To Suggest Antibiotic Prescriptions And To Measure Their Effects OBEZ C¹, MONDAIN V², CHATELIER W¹, KOUBI C¹, PROTS L³ ¹ Clinique Les Sources Nice France, ² Infectious Dpt CHU de Nice France; ³ Lab. Ronchèse, Nice, France
10:50 AM	323	Tetracyclines: A Historical Pitfall And Additional Concept On The Treatment Of Rickettsial Diseases MAHARA F¹, IWASAKI H² ¹ Mahara Hospital, Tokushima, Japan; ² Univ. of Fukui, Fukui, Japan
11:10 AM	1003	From 1-4 Weeks Of Treatment Down To A Single Application: A Novel Terbinafine Topical Treatment Of Tinea Pedis KIENZLER JL¹, de CHAUVIN MF², ORTONNE JP³ ¹ Novartis, Nyon, Switzerland; ² Hôpital Saint-Louis, Paris, France; ³ Hôpital l'Archet 2, Nice, France

09:30 - 11:50 AM HPLC, capillary electrophoresis, and other analytical techniques

Room 212

Chairmen: T. Huang, Rochester, NY, USA
S. Al-Kindy, Muscat, Oman
K. Michalska, Warsaw, Poland

Time	Abstr. No.	Title
09:30 AM	1133	Application of Electrochemical Detection to the Determination of (A) Trace Amounts Minoxidil in Hamster Ear Skin Follicles (Magic Bullet-like Delivery) and (B) Residual Hydrogen Peroxide Present in the Minoxidil Formulation Excipients HUANG T¹, GARCEAU ME², RAMSTAD T³, STEHLE RG⁴, GAO P⁵ ¹ Bausch & Lomb, Rochester, USA; ² Washington Univ. St. Louis, USA ; ³ Pfizer, Kalamazoo, USA; ⁴ Covance, Madison, USA ; ⁵ Abbott Laboratories, Chicago, USA.
09:50 AM	34	Pharmaceutical Analysis using Sequential Injection Analysis (SIA): A review of present Applications and future possibilities AI-KINDY SMZ, SULIMAN FO Sultan Qaboos University, Muscat, Oman
10:10 AM	222	Analysis Of Linezolid Chiral And Achiral Impurities By Capillary Electrophoresis MICHALSKA K¹, TYSKI S^{1,2} ¹ Department of Antibiotics and Microbiology, National Medicines Institute, Warsaw, Poland; ² Department of Pharmaceutical Microbiology, Medical University of Warsaw, Warsaw, Poland
10:30 AM	968	Amperometric Biosensor Development And Their Clinical Application NAGY L, NAGY G University of Pecs, Pecs, Hungary

10:50 AM	211	Angiotensin Converting Enzyme Inhibitors Determination in Plasma by Enzyme Kinetic and High-Performance Liquid Chromatography THONGNOPNUA P¹ , BOTTCHER C² ¹ Chulalongkorn University, Bangkok, Thailand; ² Charite (Campus Mitte), Berlin, Germany
11:10 AM	1257	Laser-based Stable Isotope Tracing in Human Breath BARTLOME R and SIGRIST MW ETH Zurich, Zurich, Switzerland
11:30 AM	568	Introduction of supercritical fluid extraction as a new sample-preparation procedure for isolation and identification of a pharmaceutical from biological fluids: Application to disposition kinetics ABD EL-ATY AM^{1,2} , CHOI JH³ , KO MW³ , KHAY S³ , GOUDAH A² , SHIN HC¹ , SHIM JH³ ¹ Konkuk University, Seoul, Republic of Korea; ² Cairo University, Giza, Egypt; ³ Chonnam National University, Gwangju, Republic of Korea

09:30 - 11:50 AM Vaccines - Physiology and molecular biology - Part II

Room 406

Chairmen: A. Alfsen, Paris, France
K. Amemiya, Fort Detrick, Frederick, USA
L. Germeroth, Göttingen, Germany

Time	Abstr. No.	Title
09:30 AM	598	The Role of cell membrane lipid environment in antigenic peptide structure-function ALFSEN, A. ^{1,2} , YU, H.F. ^{1,2} and BOMSEL, M. ^{1,2} ¹ Entrée muqueuse du VIH et Immunité muqueuse; Département de Biologie Cellulaire, Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), Paris, France; ² Inserm, U567, Paris.
09:50 AM	760	The F1-V Plague Vaccine Can Activate the Innate Immune Response Through Toll-Like Receptor2 and 4 but Does Not Need Them for an Antibody Response to the Vaccine AMEMIYA K U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA
10:10 AM	445	Adoptive immunotherapy with Streptamer-selected HCMV specific T-cells after allogeneic stem cell transplantation GRIGOLEIT GU¹ , BUSCH DH² , ODENDAHL M² , ANDERL F² , GERMEROOTH L³ , EINSELE H¹ , TONN T⁴ IBA GmbH, Rudolf-Wissell-Str. 28, D-37079 Göttingen, Germany
10:30 AM	289	Anti-Idiotypic Vaccines Against Autologous Antigens: Designed Ankyrin Repeat Proteins as Scaffolds to Break Self Tolerance? KRICEK F^C , VOGEL M^A , KELLER-GAUTSCHI E^A , BAUMANN M^A , RUF C^C , EFFENBERGER F^C , AMSTUTZ P^B , STADLER BM^A . ^a Institute of Immunology, Inselspital, CH-3010 Bern, Switzerland ^b Molecular Partners, University Zürich, Winterthurerstr. 190, CH-8057 Zürich, Switzerland ^c Novartis Institute for Bio Medical Research GmbH & Co KG, Brunner Strasse 59, 1235 Wien Austria
10:50 AM	849	MHC Molecules as Antigen Receptors? LÜ NQ Jiangsu Family Planning Research Institute, Nanjing, Jiangsu 210036, China.
11:10 AM	38	Virus-Like Particles As Magic Bullets For Immune System PUMPENS P , GRENS E Latvian Biomedical Research and Study Centre, Riga, Latvia.
11:30 AM	659	Innovative Method For Quality Control of High Molecular Weight Semi-synthetic Vaccines TIETZ D¹ ¹ DJT Consultants, 8167 Shoal Creek Drive, Laurel MD 20724, USA

09:30 - 11:50 AM New / known targets & mechanisms - Part II

Room 111

Chairmen: C. Ofner III, Philadelphia, USA
D. Steele, Leeds, England
F. Bornancin, Basel, Switzerland

Time	Abstr. No.	Title
09:30 AM	967	Macromolecular Conjugates For Passive Tumor Targeting: <i>In Vitro</i> Studies With A Gelatin-Methotrexate Conjugate OFNER CM III, CHEN CS, PICA K University of the Sciences in Philadelphia, USA
09:50 AM	1018	A Common Molecular Basis For Ryanodine Receptor Dysfunction Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) And Malignant Hyperthermia (MH) Provides Opportunities For Novel Therapeutic Strategies STEELE DS¹, IKEMOTO N², YANG Z¹ ¹ Univ. of Leeds, Leeds, UK; ² Boston Biomedical Research Institute, Boston, USA
10:10 AM	1312	Control of ceramide levels by ceramide kinase: evidence from knockout animals and use of a novel potent inhibitor GRAF C, BOATH A, ROVINA P, SCHANZER A, NIKOLAY R, REUSCHEL, R, NIWA, S, BORNANCIN F. Novartis Institutes for BioMedical Research, Brunnerstrasse 59, A-1235 Vienna (Austria)
10:30 AM	226	Dual mechanistic anorexigenic and anti-adipogenic therapeutic for the treatment of obesity CHIN KV^{1,4,5}, QASEM A¹, SAUNDERS RA¹, SZLUDLAREK, M¹, CHIN A¹, BOSIO RM², WU Q¹, SHAPIRO J¹, NAJJAR S^{3,4} Department of Medicine ¹ , Department of Surgery ² , Department of Physiology, Pharmacology, Metabolism, and Cardiovascular Sciences ³ , Center for Diabetes and Endocrine Research ⁴ , and Department of Biochemistry and Cancer Biology ⁵ , The University of Toledo, College of Medicine, 3000 Arlington Avenue, Toledo, Ohio 43614, USA.
10:50 AM	1258	Differential Targeting Of Immune Response After Antigen Encounter At Different Mucosal Sites – A Tool For Vaccine Development KANTELE A Div. of Infect. Dis., Helsinki Univ. Central Hosp. and Univ. of Helsinki, Finland
11:10 AM	957	Prostones as ClC-2 Channel Activators for Treatment of Diseases and Disorders. CUPPOLETTI J¹ and UENO R² ¹ University of Cincinnati College of Medicine, Cincinnati, OH USA; and ² Sucampo Pharmaceuticals Inc, Bethesda, MD USA
11:30 AM	2	New targets for new drug discovery opportunities. CHENE P Oncology Research, Druggability-Enzymology-Profiling Unit, Novartis, Basel, Switzerland.

10:10 - 10:50 AM Antifungals - Pharmacokinetics and formulation issues

Room 216

Chairman: AH Al-Marzouqi, Mansoura, Egypt

Time	Abstr. No.	Title
10:10 AM	281	Pharmacokinetics of Antimycotic Drugs during Continuous Renal Replacement Therapy FUHRMANN V¹, SCHENK P¹, THALHAMMER F² ¹ Medical University Vienna, Internal Medicine 3, Vienna, Austria ² Medical University Vienna, Internal Medicine 1, Vienna, Austria
10:30 AM	367	Complexation of Itraconazole with Cyclodextrins for Enhanced Solubility, Dissolution and Bioavailability AL-MARZOUQI AH¹, JOBE B¹, SHEHATTA I², HASSAN HA¹, HAMZA AA¹ ¹ UAE University, Al-Ain, United Arab Emirates; ² Mansoura University, Mansoura, Egypt.

10:10 - 11:30 AM Treatment of asthma, COPD, and other lung diseases - Part II

Room 412

Chairmen: J. Seidegard, Lund, Sweden
VA Varney, Surrey, UK

Time	Abstr. No.	Title
10:10 AM	1383	Variability of the Systemic Availability of Budesonide in Man when Administered Locally at Different Levels in the Gut with Different Doses of Ketoconazole SEIDEGÅRD J¹, BORGÅ O², NYBERG L² ¹ AstraZeneca R&D Lund; ² Bioperm AB, Lund, Sweden
10:30 AM	1268	Cotrimoxazole, an old "magic bullet" finds a new target and benefit in advanced fibrotic lung disease VARNEY VA, PARNELL H, SALISBURY DT, RATNATHEEPAN S, TAYAR R St Helier Hospital, Wrythe Lane, Carshalton, Surrey, UK
10:50 AM	214	Omalizumab: The First Real Magic Bullet for the Treatment of Allergic Asthma? FOX H Novartis Horsham Research Centre, Horsham, West Sussex, UK
11:10 AM	834	New Horizons In Respiratory Allergy Therapy And "Magic Bullets": Could It Be Possible To Include Antiprotozoal Drugs? MARTÍNEZ-GIRÓN R Protozoal Respiratory Pathology Research Unit, Fundación INCLINICA, Oviedo, Spain

10:30 - 11:10 AM Antibacterials - Discovery - Peptide antibiotics - Part II

Room 214

Chairman: P. Valenti, Rome, Italy

Time	Abstr. No.	Title
10:30 AM	1113	Antimicrobial Peptides From Bacteria: Towards Novel Magic Bullet Strategies? REBUFFAT S, PEDUZZI J, ZIRAH S Muséum National d'Histoire Naturelle-CNRS, Chimie et biochimie des substances naturelles, Paris, France
10:50 AM	976	Lactoferrin Acts against Infection and Inflammation through its Influence on Systemic Iron Homeostasis VALENTI P¹, PIETROPAOLI M², PAESANO R¹ ¹ University of Rome, SAPIENZA, Rome, Italy; ² Biotechnology Company, MICROBO srl, Rome, Italy

10:50 - 11:30 AM Anti-infectives - Reviews on Magic Bullets - Part I

Room 403

Chairman: RHH Nelwan, Ljubljana, Jakarta, Indonesia

Time	Abstr. No.	Title
10:50 AM	920	Ear Surgery – Place for Topical use of Mitomycin C BATTELINO S, ZARGI M University Medical Centre Ljubljana, Ljubljana, EU-Slovenia.
11:10 AM	658	Levofloxacin For Typhoid Fever : An Unparalleled Local Success Story NELWAN RHH Division of Tropical and Infectious Diseases, Department of Internal Medicine, Medical Faculty University of Indonesia, Jakarta, Indonesia

10:30 - 11:50 AM Anti-infectives - Mechanisms of bacterial resistance - Part II

Room 101

Chairmen: P. Oelschlaeger, Pomona, USA
KJ Linton, London UK

Time	Abstr. No.	Title
10:30 AM	124	A Computationally Designed Mutant Of The Metallo- β -Lactamase IMP-1 Exhibits Enhanced Catalytic Efficiency OELSCHLAEGER P¹ , PLEISS J ² , MAYO SL ³ ¹ California State Polytechnic Univ., Pomona, CA, USA; ² Univ. of Stuttgart, Germany; ³ California Institute of Technology, Pasadena, CA, USA.
10:50 AM	624	Dodging the bullets: an update on the multi-drug efflux pump P-glycoprotein ZOLNERCIKS JK, LINTON KJ MRC Clinical Sciences Centre, Imperial College, Hammersmith Hospital, Du Cane Road, London, UK.
11:10 AM	1295	Counteracting drug resistance by nutritional management and genetic improvement of disease resistance - lessons from in-silico studies for nematode infections of sheep DOESCHL-WILSON AB¹ , VAGENAS D ¹ , BISHOP SC ² , KYRIAZAKIS I ³ ¹ Scottish Agric. College, Edinburgh, UK; ² Roslin Biocentre, Edinburgh, UK; ³ Univ. of Thessaly, Karditsa, Greece
11:30 AM	444	Do we need a smaller Magic Bullet for combating Staphylococcal infections? : Mechanism of vancomycin-resistance in vancomycin-intermediate <i>S. aureus</i> CUI L Department of Bacteriology & Infection Control Science, Juntendo University, 2-1-1 Bunkyo-Ku, Tokyo, Japan 113-8421

10:50 - 11:50 AM Anti-infectives - Approaches to combat resistance

Room 207

Chairman: S. Schwarz, Neustadt-Mariensee, Germany

Time	Abstr. No.	Title
10:50 AM	1278	IgY (Immunglobuline from egg-Yolk) - a "magic bullet" to fight antibiotic resistance KOLLBERG H (1) , NILSSON, E(2), WEJÄKER P-E (2), LARSSON A (2). 1). CF Centre, University Children's Hospital, Uppsala, Sweden, 2). Dep. Med sciences, University Hospital, Uppsala, Sweden.
11:10 AM	356	Transferable Resistance to Five Different Classes of Protein Biosynthesis Inhibitors Including Oxazolidinones Mediated by the Gene <i>cfr</i> in Staphylococci KEHRENBURG C¹ , LONG K ² , POEHLGAARD J ³ , VESTER B ³ , SCHWARZ S¹ ¹ Institute of Farm Animal Genetics (FLI), Neustadt-Mariensee, Germany; ² University of Copenhagen, Copenhagen, Denmark; ³ University of Southern Denmark, Odense, Denmark
11:30 AM	1240	Trans-Cinnamaldehyde From <i>Cinnamomum Zeylanicum</i> Bark Essential Oil Reduces The Clindamycin Resistance Of Clostridium Difficile <i>In Vitro</i> SHAHVERDI AR¹ , MONSEF-ESFAHANI HR ² , TAVASOLI F ¹ , ZAHERI A ¹ , MIRJANI R ² , MOLLAZADEH MOGHADDAM K¹ ¹ Department of Pharmaceutical Biotechnology and Pharmaceutical Sciences Research Center and ² Department of Pharmacognosy,, Faculty of Pharmacy, Medical Sciences/University of Tehran, Tehran, Iran

10:50 - 11:50 AM Antibacterials - New mechanisms and delivery strategies - Part II

Room 217

Chairman: KS Jeong, Los Angeles, USA

Time	Abstr. No.	Title
10:50 AM	919	Gut Health-Promoting Adhesion Of Enteropathogens To Dietary Polysaccharides BECKER PM ¹ , GALLETTI S ^{1,2} ¹ Wageningen UR, Lelystad, The Netherlands; ² University of Milan, Milan, Italy
11:10 AM	954	Perspective of chromatin structure on Topoisomerase II: Exclusive dynamics between the nucleosome and the drug target in <i>Saccharomyces cerevisiae</i> JEONG KS , SPERLING A, GRUNSTEIN M Univ. California, Los Angeles, USA
11:30 AM	864	The impact of a mixture of doxycycline, an acid and a detergent on root canal débridement SHABAHANG S ¹ , TORABINEJAD M ¹ ¹ Loma Linda University, Loma Linda, USA

10:50 - 11:50 AM Antineoplastic agents - New targets & compounds - Part II

Room 404

Chairman: MP Costimp, Windsor, Modena,Italy

Time	Abstr. No.	Title
10:50 AM	651	Targeting the vulnerability of cancer cell mitochondria to selectively induce apoptosis: Evaluating the efficacy of Pancratistatin as a non-toxic anti-cancer agent PANDEY S , GRIFFIN C, SIEDLAKOWSKI P, KARNIK A AND MCNULTY J * Department of Chemistry & Biochemistry, University of Windsor, Windsor, Ontario, Canada. *Department of Chemistry, McMaster University, Hamilton, Ontario, Canada
11:10 AM	1192	Small Peptides Challenge Thymidylate Synthase Dimerization and Inhibit Ovarian Cancer Cells Growth. COSTI MP ¹ , STEFANO M ² , WADE R ³ , MORUZZI MS ⁴ , MARVERTI G ⁴ ¹ Dipartimento di Scienze Farmaceutiche, Università di Modena e Reggio Emilia, via Campi 183, 41100 Modena, Italy. ² Dipartimento di Chimica, Università degli Studi di Siena, Via Moro 1, 53100 Siena, Italy. ³ EML Research gGmbH Villa Bosch Schloss-Wolfsbrunnengasse 33 D-69118 Heidelberg, Germany ⁴ Dipartimento di Scienze Biologiche, Università di Modena e Reggio Emilia, via Campi 187, 41100 Modena, Italy. Presenting author: mariapaola.costi@unimore.it
11:30 AM	1120	Novel Clinically Relevant Proteasome Inhibitors and HDAC Inhibitors CHANDRA J ¹ , MILLER C ¹ , RIVERA N ¹ , ¹ Children's Cancer Hospital University of Texas M.D. Anderson Cancer Center. Houston, Texas, U.S.A.

10:57 - 11:57 AM Antineoplastic agents - Compounds and approaches - Part II

Room 218

Chairman: K. Yazaki, Uji, Japan

Time	Abstr. No.	Title
10:57 AM	543	The natural steroidal withanolide Withaferin A is a novel promising chemosensitising compound in B-cell chronic lymphocytic leukemia and metastatic breast cancer VANDEN BERGHE W ¹ , LUST S ¹ , KAILEH M ^{1,4} , GERLO S ¹ , BOELEN J ¹ , OFFNER F ¹ , PHILIPPÉ J ¹ , GANEFF C ² , DEJARDIN E ² , HILLAERT U ¹ , VAN CALENBERGH S ¹ , ESSAWI T ³ , HAEGEMAN G ¹ ¹ UGent, Gent, Belgium, ² ULG, Liège, Belgium ³ University Birzeit, Palestine, ⁴ National Institute on Aging, Baltimore, USA

- 11:17 AM 1171 Membrane transport of alkaloids and anticancer drugs in plants: specificity and analogy to mammalian cells
YAZAKI K
RISH, Kyoto Univ., Uji, Japan
- 11:37 AM 1750 Pathogenesis And Targeted Treatment Of *BCR-ABL* Negative Myeloproliferative Neoplasms
REITER A
III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany

11:10 - 11:30 AM Antibacterials - Looking at the fate of anti-infectives in- and outside the body - Part II

Room 214

- Time Abstr. No. Title
- 11:10 AM 271 Quinolones and Metal Ions- Friends or Enemies?
TUREL I
University of Ljubljana, Faculty of Chemistry and Chem. Technology, Askerceva 5, Ljubljana, Slovenia

11:30 - 11:50 AM Pharmaceutics - Experimental and computational approaches - Part II

Room 205

- Time Abstr. No. Title
- 11:30 AM 970 Modern quantum chemical descriptors for QSAR/QSPR
POPELIER PLA¹, HARDING A¹ and ROY K²
¹MIB, Univ. of Manchester, 131 Princess Str., Manchester M1 7DN, Great Britain; ²Drug Theoretics and Cheminformatics Lab, Dept. of Pharm. Techn., Jadavpur University, Kolkata 700 032, India

11:30 - 11:50 AM Vaccines - Antiinfectives - Bacteria, parasites, and HPV – Part I

Room 112

- Time Abstr. No. Title
- 11:30 AM 1065 Nasal Vaccination against Bacterial Toxins
ZENG M
University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

12:00 - 12:40 PM Cardiovascular - Drugs acting on the cardiovascular system - Part III

Room 217

Chairman: J. Torzewski, Ulm, Germany

- Time Abstr. No. Title
- 12:00 PM 1078 Targeting Dexamethasone-Loaded anti-E-selectin Liposomes Prevents Glomerulonephritis Progression: The Potential of Vascular Bed-Specific Drug Delivery
ÁSGEIRSDÓTTIR SA, KAMPS JAAM, HEERINGA P, RUITERS MHJ, MOLEMA G
University Medical Center Groningen, University of Groningen, The Netherlands, Dept of Pathology & Medical Biology, Laboratory for Endothelial Biomedicine & Vascular Drug Targeting Research

12:20 PM 1757 Generating C-reactive protein inhibitors for the treatment of cardiovascular disease
TORZEWSKI J
Department of Internal Medicine II-Cardiology, Robert Koch Str. 8, 89081 Ulm, Germany,
Phone: + 49 731 500-45026, Fax: + 49 731 500-45005

12:00 - 12:40 PM Vaccines - Antiinfectives - Bacteria and parasites - Part II

Room 403

Time	Abstr. No.	Title
12:00 PM	687	Applied Reverse Vaccinology: A Meningococcal Serogroup B Vaccine For Infants OSTER P¹, BORROW R³, FINLOW J³, POLLARD AJ⁴, SNAPE M⁴, MILLER E² ¹ Novartis Vaccines, Siena, Italy, ² Immunisation Department, Health Protection Agency, London, UK, ³ Vaccine Evaluation Unit, Health Protection Agency, Manchester, UK, ⁴ Department of Paediatrics, University of Oxford, Oxford, UK

12:00 - 01:00 PM Antiparasitic compounds - Molecular and genomic approaches

Room 205

Chairman: C Neveu, Nouzilly, France

Time	Abstr. No.	Title
12:00 PM	1308	Antibody based protein-function analysis on the ryanodine receptor and troponin isoforms in <i>Caenorhabditis elegans</i> KAGAWA H¹, AMINN MD. Z^{1,2}, HAMADA, T^{1,3} ¹ Okayama Univ., Okayama, Japan; ² Sir Salimullah Med. Col., Dhaka, Bangladesh; ³ BBRI, Boston, USA
12:20 PM	748	Levamisole Resistance In Parasitic Nematodes Investigated At The Molecular Level NEVEU C, CHARVET C, FAUVIN A, CORTET J, CABARET J French National Institute for Agricultural Research (INRA), UR1282, Infectiologie Animale et Santé Publique, Centre de recherche de Tours, Nouzilly, France
12:40 PM	765	A Genomic Parasite in the Evolution of Metazoan Development Evolvability and Evolutionary Constraints as Fingerprints of Selection HOENIGSBERG H Instituto de Genética Evolutiva & Biología Molecular and Instituto de Genética Ecológica Y Biodiversidad del Trópico Americano. Bogotá D.C., Colombia

12:00 - 01:00 PM Antineoplastic agents - Search and Development of new Magic Bullets - Part I

Room 406

Chairman: M. Caraglia, Rome, Italy

Time	Abstr. No.	Title
12:00 PM	653	A Potential Tumor Cell-Penetrating Peptide, CRGD ₂ CF(K[H-J]KKK) ₆ , for the Delivery of Antisense and siRNA Oligonucleotides AOKI Y^{1,2}, NISHIO S², MIYAMOTO T², KUMAGAI M¹, HASHIZUME K² ¹ Department of Internal Medicine, Matsumoto National Hospital, Matsumoto, Japan; ² Department of Aging Medicine and Geriatrics, Institute on Aging and Adaptation, Shinshu University Graduate School, Matsumoto, Japan
12:20 PM	1172	Molecular strategies to improve the anti-tumour activity of Zoledronic acid in prostate cancer cells CARAGLIA M¹, MARRA M¹, ZAPPAVIGNA S¹, LOMBARDI A¹, SANTINI D², ABBRUZZESE A¹ Department of Biochemistry and Biophysics, Second University of Naples, Via Costantinopoli 16, 80138, Naples; ² Campus Biomedico University, Section of Oncology, Rome, Italy. * Corresponding author

12:40 PM 174 Apoptin Magics: Bullet Or Sensor?
NOTEBORN MHM¹, PENG D², SUN J², QU S², BACKENDORF C¹
¹University Leiden, Leiden, the Netherlands; ²Huazhong University of Science and
Technology, Wuhan, PR China

12:00 - 01:20 PM Vaccines - Development, production and manufacturing - Part II

Room 101

Chairmen: O. Ouerfelli, New York, USA
L. Smith, Fort Detrick, USA

Time	Abstr. No.	Title
12:00 PM	1395	Complex Carbohydrate-Based Cancer Vaccines: Magic Bullets In The Making? YANG G ¹ , SPASSOVA MK ¹ , QIAN W ² , ZHU J ² , LEE D ² , CAO C ¹ , RAGUPATHI G ³ , LIVINGSTON PO ³ , DANISHEFSKY SJ ^{2,4} , OUERFELLI O ¹ ¹ Organic Synthesis Core Laboratory, ² The Laboratory for Bioorganic Chemistry, Molecular Pharmacology and Chemistry Program, ³ Laboratory of Tumor Vaccinology, Clinical Immunology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, ⁴ Department of Chemistry, Columbia University, Havemeyer Hall, New York
12:20 PM	1013	Finding a New Vaccine in a Ricin Protein Fold SMITH LA Senior Research Scientist, Medical Countermeasures Technology, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA, Telephone: 301-619-4238 FAX: 301-619-2348 E-Mail: leonard.smith@amedd.army.mil
12:40 PM	906	Single Chain Antibodies (ScFvs) and Immunoconjugates: Computational and Functional Approaches ARCANGELI C ¹ , PUGNALI M ² , SPERANDEI M ² , CANTALE C ² , BUCHER M ³ , GIANESE G ⁴ , ROSATO V ^{1,4} , GALEFFI P ² ¹ ENEA, Dept. FIM-CAMO Rome, Italy; ² ENEA, Dept. BAS-BIOTEC Rome, Italy; ³ Univ. Cologne Cologne, Germany; ⁴ Ylichron S.r.l. c/o ENEA, Rome, Italy.
01:00 PM	566	Enhanced Depot Vaccine Formulations, Vaccimax [®] And Depovax [™] , For Cancer And Pandemic Influenza Applications KARKADA, M, MACDONALD L, FUENTES-ORTEGA A, WEIR G, MANSOUR M Immunovaccine Technologies Inc., Halifax, Canada

12:00 - 01:20 PM Antineoplastic agents - New targets & compounds - Part II

Room 218

Chairmen: M. Pines, Bet Dagan, Israel
E. Flescher, Tel Aviv, Israel

Time	Abstr. No.	Title
12:00 PM	692	Targeting the Tumor Microenvironment as a Modality to Combat Cancer – Effect of Halofuginone PINES M Institute of Animal Sciences, Volcani Center, Bet Dagan, Israel
12:20 PM	629	Jasmonates Kill Cancer Cells Selectively by Dissociating Hexokinase from Mitochondrial VDAC FLESCHER E , GOLDIN N Tel Aviv University, Tel Aviv, Israel
12:40 PM	316	mTOR Inhibitors for Hepatocellular Cancer (HCC) - A moving Target - TREIBER G ¹ ¹ Zollernalb Clinic, Dep Internal Medicine, Academic Teaching Hospital Tuebingen University, Balingen, Germany
01:00 PM	1052	Micro RNA As A Novel Drug For Cancer Metastasis: Suppression Of Lung Metastasis Of Osteosarcoma In <i>In Vivo</i> Model OSAKI M ^{1,2} , TAKESHITA F ¹ , OSHIMURA M ² , OCHIYA T ¹ ¹ Sec. Meta. Natl. Cancer Ctr. Res. Inst., Div. Mol. Genet. Biofact. Tottori Univ. Grad Sch Med. Sci.

12:00 - 01:20 PM Antivirals - New compounds and their mechanisms - Part I

Room 412

Chairmen: H. Ohrui, Yokohama, Japan
 P. Sinko, Piscataway, USA

Time	Abstr. No.	Title
12:00 PM	800	Development Of Highly Anti-HIV Active And Lowly Toxic 4'-C-Ethynyl-2'-Deoxy-2-Fluoroadenosine And A Proposal Of The Way To Develop Highly Active And Lowly Toxic Antiviral Modified Nucleosides OHRUI H Yokohama College of Pharmacy, Yokohama, Japan
12:20 PM	1103	Targeting HIV Reservoir & Sanctuary Sites Using Peptide Backbone Polyethylene Glycol (PEG) Nanocarriers SINKO PJ* , STEIN S, WAN L, POOYAN S, ZHANG X, SAMIZADEH M, CHEN P Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey USA 08854
12:40 PM	1151	Virostatics: a new class of immunomodulators with dual antiviral and cytostatic properties to inhibit viruses and protect the immune system from hyperactivation during chronic infections LORI F¹ ¹ ViroStatics srl, Sassari, Italy.
01:00 PM	890	Identification Of Novel Hepatitis C Virus Polymerase NS5B Inhibitors Through Structure-Based Virtual Screening And 3-D QSAR Studies RAGNO R¹ , MUSMUCA I ¹ , CAROLI A ¹ , SIMEONI S ¹ , MAI A ¹ , KRISHNAN R ² , KAUSHIK-BASU N ² ¹ "La Sapienza" University, Rome, IT, ² UMDNJ-New Jersey Medical School, Newark, New Jersey, US

12:00 - 01:20 PM Drug transporters and delivery - Part II

Room 405

Chairmen: S. Ohtsuki, Sendai, Japan
 J. Almqvist, Stockholm, Sweden

Time	Abstr. No.	Title
12:00 PM	1206	Reconstruction Of <i>In Vivo</i> P-Glycoprotein Activity From <i>In Vitro</i> Information By Targeted Absolute Proteomics OHTSUKI S , UCHIDA Y, TERASAKI T Grad. Sch. of Pharm. Sci., Tohoku Univ., Sendai, Japan
12:20 PM	1262	Molecular Dynamics Simulations of human membrane transport proteins from the Major Facilitator Superfamily. ALMQVIST J (A), HUANG Y (B), HOVMÖLLER S (A), LAAKSONEN A (C) AND WANG D-N (D). (a) Division of Structural Chemistry, Arrhenius Laboratory, Stockholm University, Sweden. (b) Department of Molecular Biology, Uppsala Biomedical Center, Swedish University of Agricultural Sciences, Sweden. (c) Division of Physical Chemistry, Arrhenius Laboratory, Stockholm University, Sweden. (d) Kimmel Center for Biology and Medicine at the Skirball Institute of Biomolecular Medicine and Department of Cell Biology, New York University School of Medicine, USA.
12:40 PM	274	Hypothesis on the physiological significance of the expression of the drug transporters mdr1 and Abcg2 during normal tissue regeneration and after cancer therapy ISRAELI D Genethon, CNRS FRE 3087, Evry, France
01:00 PM	311	Delivery of specific targeted drugs into the cells by TAT-technology GRDISA M , MIKECIN A-M Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka cesta 54, 10 000 Zagreb, Croatia.

12:00 - 01:20 PM Brain physiology, biochemistry, and drugs acting on the brain - Part II

Room 111

Chairmen: P. Szot, Seattle, USA
H. Hashimoto, Osaka, Japan

Time	Abstr. No.	Title
12:00 PM	1062	Treating the Untreatable: Alpha 1-Adrenoreceptor Antagonist Prazosin for PTSD, Disruptive Agitation in AD and Alcohol Dependence SZOT P , SIMPSON T, PESKIND E, RASKIND M Mental Illness, Research Education and Clinical Center (MIRECC), VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle WA 98108
12:20 PM	1124	PACAP Signaling: A Promising Drug Target for Neuropsychological Disorders HASHIMOTO H ^{1,2} , HASHIMOTO R ² , SHINTANI N ¹ , TAKEDA M ² , BABA A ¹ ¹ Grad Sch of Pharmaceutical Sciences; ² Grad Sch of Medicine, Osaka Univ., Suita, Osaka, Japan
12:40 PM	1051	A novel view of the pathophysiology of psychiatric disorders and development of pharmacotherapy based on brain energy metabolism UEHARA T , SUMIYOSHI T, MATSUOKA T, SUZUKI M Univ. TOYAMA, Dept. Neuropsychiatry, Toyama, Japan
01:00 PM	578	How Prolonged Exposure to Caffeine Can Affect Dopaminergic Transmission: Evidence from Rats Subchronically Treated with Caffeine and Possible Implications SIMOLA N ¹ , TRONCI E ¹ , PINNA A ^{1,2} , SEEMAN P ³ , MORELLI M ^{1,2} ¹ Univ. Cagliari, Cagliari, Italy; ² CNR Neuroscience Institute, Cagliari, Italy; ³ Univ. Toronto, Toronto, ON, Canada

12:00 - 01:40 PM Antibacterials - Unexpected findings and new approaches

Room 212

Chairmen: J. Tanzer, Farmington, USA
P. Dudeja, Chicago, USA
H. Majeed, Medreshet Ben Gurion, Israel

Time	Abstr. No.	Title
12:00 PM	850	Xylitol Resistance of Streptococcus mutans Appears To Be An Unexpected Benefit to The Human or Rodent Host TANZER JM ¹ , THOMPSON AS ¹ , WENZT ² ¹ Univ. Connecticut, Farmington, CT and ² Louisiana State Univ, New Orleans, LA, USA.
12:20 PM	1239	Pathophysiology of Enteropathogenic E. coli-induced diarrhea: Potential Therapeutic Role of Probiotics DUDEJA PK , GILL R, HODGES K, BORTHAKUR A, RAMASWAMY K, TURNER JR, HECHT GA Univ. of Illinois at Chicago, Univ. of Chicago and Jesse Brown VA Medical Center, Chicago, IL 60612
12:40 PM	1549	Competitive Interactions In <i>Escherichia Coli</i> Populations: The Role Of Bacteriocins MAJEED H ¹ , RILEY MA ² and GILLOR O ¹ ¹ Department of Environmental Hydrology & Microbiology Zuckerberg Institute. Ben-Gurion University, Sede Boker, Israel; ² Department of Biology, University of Massachusetts, Amherst, USA
01:00 PM	869	Stimulation Of Proline Uptake And Growth Of <i>Escherichia Coli</i> CSH4 And Its Mutants Under High Salinity Through Moderate Salinity Stress Treatment NAGATA S ¹ , WANG Y ¹ , SASAKI H ² , OSHIMA A ³ , ISHIDA A ⁴ ¹ Kobe Univ., Kobe, Japan; ² Iwaki Meisei Univ., Iwaki, Japan; ³ Shimane Univ., Matsue, Japan; ⁴ Kumamoto Univ., Kumamoto, Japan.

01:20 PM 723 Silkworm infection models to evaluate the therapeutic effects of antibiotics
SEKIMIZU K, HAMAMOTO H, ASAMI Y, HORIE R, MATSUMOTOY, NAGATA M, KAITO C
Lab. of Microbiology, Grad. Sch. Pharm. Sci., Univ. of Tokyo

12:00 - 01:40 PM Vaccines - History, Reviews, and Future Perspectives - Part I

Room 207

Chairmen: G. Rundblad, London, United Kingdom
A. Harandi, Gothenburg, Sweden
Y. HORIUCHI, Chiyoda-ku, Japan

Time	Abstr. No.	Title
12:00 PM	904	Dissemination And Communication: "Selling" Vaccines To Peers And The General Public RUNDBLAD G King's College London, London, United Kingdom
12:20 PM	1221	Vaccine Adjuvants for Sexually Transmitted Infections: Recent Developments and Future Challenges HARANDI AM Department of Microbiology & Immunology, Institute of Biomedicine, University of Gothenburg, Sweden. e-mail: ali.harandi@gu.se
12:40 PM	1168	The success story of Japanese DTaP control and a further development of vaccine evaluation HORIUCHI Y ^{1,2} , KATAOKA M ¹ , YAMAMOTO A ¹ , OCHIAI M ¹ , HARASHIMA A ¹ , NAGATA N ¹ , HASEGAWA H ¹ , KURATA T ¹ ¹ National Institute of Infectious Diseases, ² Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
01:00 PM	1050	The VesiVax [®] System: Vaccinology's Magic Bullet? FUJII, G ¹ , ERNST WA ¹ , ADLER-MOORE, J ² ¹ Molecular Express, Inc., Rancho Dominguez, USA; ² California State Polytechnic University Pomona, Pomona, USA.
01:20 PM	206	The Vienna Vaccine Safety Initiative (Vivi) – An International Scientific Forum Aiming To Promote Evidence-Based Vaccine Safety Research And Communication RATH B , LAIMER T, VYHNANEK P, ROTH-MANGEL S, MAURER W, POLLAK A Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Austria

12:00 - 01:40 PM Antineoplastic agents - Balancing efficacy and toxicity

Room 214

Chairmen: E. Hiyama, Hiroshima, Japan
M. Bayram, Ankara, Turkey
P. Pereira, Aveiro, Portugal

Time	Abstr. No.	Title
12:00 PM	1465	Effectiveness and complications of treatment for childhood liver tumors – from the experience of JPLT (Japanese Study Group for Pediatric Liver Tumor) study HIYAMA E ^{1,2} , YAMAOKA H ^{1,2} , NISHIMURA S ^{1,2} , HISHIKI T ² , HIYAMA K ^{1,2} , SASAKI F ² , HORIE H ² , OHNUMA N ² ¹ Hiroshima Univ., Hiroshima, Japan; ² Japanese Study Group for Pediatric Liver tumor, Japan
12:20 PM	916	Light (LM) and electron microscope (EM) examination of the effects of methotrexate (MTX) on the endosalpinx. BAYRAM M ¹ , OZOGUL C ² , DURSUN A ³ , ERCAN ZS ⁴ , ISIK I ³ , DILEKOZ E ⁴ Gazi University, Faculty of Medicine, ¹ Department of Gynecology and Obstetrics, ² Department of Hystology and Embryology, ³ Department of Pathology, ⁴ Department of Pharmacology

12:40 PM	278	Adverse Reactions of Titanium-based Chemotherapeutic Agents on Male Reproductive Organs PEREIRA ML ¹ , GARCIA E COSTA F ² ¹ Department of Biology, CICECO, Univ. Aveiro, Portugal; ² CIISA, Faculty of Veterinary Medicine, Technical Univ. Lisbon, Portugal
01:00 PM	1034	Possible role for human leukocyte antigen haplotypes in hepatotoxicity and/or pancreotoxicity associated with chemotherapy SATO K ¹ , TAKAGI H ¹ , MORI M ¹ ¹ Gunma University, Maebashi, Japan
01:20 PM	1343	Novel Targeted Anticancer Prodrugs of Phosphoramidate Mustard HU L Department of Pharmaceutical Chemistry, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854; The Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA

12:00 - 01:40 PM Vaccines - Antiinfectives - HIV - Part II,

Room 216

Chairmen: C. Hioe, New York, USA
 O. Tarasenko, Little Rock, USA
 G. Vyas, San Francisco, USA

Time	Abstr. No.	Title
12:00 PM	833	Using Immune Complexes to Enhance Antigenicity and Immunogenicity of a Neutralizing Epitope on HIV-1 Envelope gp120 HIOE CE ¹ , VISCIANO ML ¹ , GORNY MK ¹ , TUEN M ¹ ¹ New York University School of Medicine and VA New York Harbor Healthcare System, New York, USA.
12:20 PM	1224	Bait bullets controlling Bacillus anthracis: from spore inhibition to toxins neutralization and prevention of spore- and/or toxin-induced cell death O. TARASENKO ¹ , SCOTT A ¹ , RODRIGUEZ N ¹ , ALUSTA P ¹ , SODERBERG L ² ¹ University of Arkansas at Little Rock, ² University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
12:40 PM	1399	Synthesis of a Novel Subunit Vaccine against HIV-1: Native Envelope Proteins in Lipid Bilayer of Inactivated Virions Devoid of p24, RT and Viral Nucleic Acids VYAS GN. Univ. of California, San Francisco, CA, U.S.A.
01:00 PM	490	Current Medical Countermeasures (Vaccines- Antibodies- Antibiotics) to Protect Humans from the Anthrax Bioterrorism. BOUZIANAS DG Technological Educational Institute of Thessaloniki, Thessaloniki-Macedonia, Greece.
01:20 PM	1779	Interactions between the HIV-specific Immune Response and the Development of Resistance to Antiretroviral Drugs. HARRER

12:00 - 01:52 PM Antibacterials - PK/PD: past, presence, and future challenges

Room 112

Chairmen: J. Schentag, Amherst, USA
 WHF Goessens, Rotterdam, The Netherlands

Time	Abstr. No.	Title
12:00 PM	10011	PK/PD in patients - Learning from our Failures Schentag J University at Buffalo, School of Pharmacy and Pharm Sciences, 3980 Sheridan Drive, Suite 501, 14226 Amherst, New York, USA

12:32 PM	349	Changing the dosing frequency of ceftazidime transforms this "Daisy cutter" into an antibiotic with limited collateral damage while retaining its efficacy GOESSENS WHF¹ , MOUTON JW ² , TEN KATE MT ¹ , OTT A ¹ , BAKKER-WOUDENBERG IAJM ¹ ¹ Erasmus University Medical Center Rotterdam, Rotterdam; ² Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands
12:52 PM	10007	Pharmacometric Tools to Optimize Modeling and Control of Drug Therapy for Patient Care NEELY
01:12 PM	1796	Decoding infections - How to use „administrative“ data for clinical quality improvement WILKE MH Dr. Wilke GmbH, Werner-Eckert-Str. 12, 81829 Munic, Germany

12:00 - 02:00 PM Cardiovascular - Magic Bullets & the cardiovascular system - Part I

Room 206

Chairmen: E. Nalivaiko, Callaghan, Australia
A. Scheen, LIEGE, Belgium
G. Weitz-Schmidt, Basel, Switzerland

Time	Abstr. No.	Title
12:00 PM	161	Central Sympatholytic and Anti-arrhythmic Effects of Serotonin-1A Agonists NALIVAIKO E¹ , MASTORCI F ² , SGOIFO A ² ¹ Univ. of Newcastle, Newcastle, NSW, Australia; ² Univ. of Parma, Parma, Italy
12:20 PM	483	Rimonabant, First CB1 Receptor Antagonist, a Potential Magic Bullet to Reduce Cardiometabolic Risk in Patients with Abdominal Obesity SCHEEN AJ University of Liege, Liege, Belgium
12:40 PM	262	Beyond cholesterol lowering: Immunomodulatory effects of lovastatin WEITZ-SCHMIDT G , DAWSON J, HOMMEL U, KALLEN J, MEINGASSNER J, WELZENBACH K Novartis Institutes for BioMedical Research, Basel, Switzerland
01:00 PM	745	Novel targets and magic bullets for treating cardiovascular disease BROOKS G University of Reading, Berkshire, UK
01:20 PM	655	Hyaluronan Mixed Esters of Butyric and Retinoic Acids: Multicomponent-Multitarget Drugs with Differentiating and Paracrine Logics for Cardiovascular Repair with Human Mesenchymal Stem Cells VENTURA C , CAVALLINI C, BIANCHI F, LIONETTI V, SCARLATA I, CANTONI S Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems at the Cardiovascular Department, University of Bologna, Italy
01:40 PM	373	Nifedipine, the most cited, studied, experienced and debated ca-antagonist: where has it gone? KRAGTEN JA , Dunselman PHJM Atrium medical centre Parkstad, Heerlen, The Netherlands.

12:00 - 02:00 PM Antibacterials - New antibiotic and antineoplastic compounds from nature - Part II

Room 213

Chairmen: V. Prabha, Chandigarh, India
V. Sperandio, Dallas, USA
R. Sockett, Nottingham, United Kingdom

Time	Abstr. No.	Title
12:00 PM	803	Sperm immobilization factor: potential candidate for fertility control and antibacterial targeting bacterial motility PRABHA V Panjab University, Chandigarh, India

12:20 PM	839	Inter-kingdom cell-to-cell inhibitors: a novel target for antimicrobial drugs RASKO DA¹, MOREIRA CG¹, LI DR¹, READING NC¹, RITCHIE JM², WALDOR MK², WILLIAMS N¹, TAUSSIG R¹, WEI S¹, ROTH M¹, HUGHES DT¹, HUNTLEY J¹, FINA M¹, FALCK J¹, SPERANDIO V¹ ¹ UT Southwestern Medical Center, Dallas, USA. ² Harvard Medical School, Boston, USA
12:40 PM	1174	Predatory Bdellovibrio Bacteria as Living Antibiotics-Nature's Magic Bullets to Treat Antibiotic-Resistant Gram-Negative Infections SOCKETT RE, LAMBERT C, WOODS R, CAPENESS M, HOBLEY L, CHANG C Institute of Genetics, School of Biology, University of Nottingham Medical School, QMC Nottingham NG7 2UH UK
01:00 PM	1287	A Series of Antibacterial Proteins Made from Inactive Cyt-Like ORF of <i>Bacillus thuringiensis</i> subsp. <i>israelensis</i> Using The Microgene Polymerization Reaction ITSKO M^{1,2}, ZARITSKY A¹ ¹ Department of Life Sciences, Ben-Gurion University of the Negev, POB 653, Be'er-Sheva 84105, Israel, ² Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
01:20 PM	1155	Exploring Anti-Microbial Herbs Of Chinese Medicine LEUNG PC¹, SREEDHAR B¹, FUNG KP¹, YIP M² Institute of Chinese Medicine, 1& Department of Microbiology, 2 The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
01:40 PM	363	Auxins: Effects on Bacteria and Tumours PERICA MC¹, ESTER K², KRALJ M² ¹ Univ. of Zagreb, Faculty of Science, ² Rudjer Boskovic Institute, Bijenicka 54, Zagreb, Croatia

12:00 - 02:00 PM Resistance - a Global Issue for diverse therapeutic areas - Part I ,

Room 215

Chairmen: J. Erenpreisa, Riga, Latvia
 C. Gomes, Coimbra, Portugal
 C. IONESCU , Bucharest , Romania

Time	Abstr. No.	Title
12:00 PM	208	The Cancer Cell Life-Cycle: Providing Mechanism for Genotoxic Resistance ERENPREISA J¹ and CRAGG MS² ¹ Latvian Biomedicine Research and Studies Centre, Riga, Latvia; ² Tenovus Research Laboratory, Southampton University, UK
12:20 PM	622	Molecular Imaging of Multidrug Resistance by ABC Transporters in Osteosarcoma GOMES CMF¹, WELLING MM², QUE I², HENRIQUEZ N², PLUIJM G², ROMEO S², ABRUNHOSA AJ¹, BOTELHO MF¹, HOGENDOORN PCW², PAUWELS EKJ², CLETON-JANSEN AM² ¹ IBILI-Faculty of Medicine, Coimbra, Portugal ² Leiden University Medical Center, Leiden, The Netherlands
12:40 PM	1169	Insulin resistance: between myth and reality IONESCU-TÎRGOVISTE C National Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. NC Paulescu", Bucharest, Romania.
01:00 PM	720	Mechanism of Resistance in Non Hodgkin's Lymphoma- Expression of Fas Ligand on Endothelial Cells Lining Blood Vessels TUCKER CA^{1,2}, HOFFMAN BG¹, KYLE AH^{1,2}, WILSON IM^{1,2}, WALKER DC^{1,3}, BALLY MB^{1,2} ¹ British Columbia Cancer Agency, Vancouver, BC, Canada; ² University of British Columbia, Vancouver, BC, Canada; ³ St-Paul's Hospital, Vancouver, BC, Canada
01:20 PM	852	Battling pharmacoresistance in epilepsy patients: pharmacodynamic and pharmacokinetic approaches DECKERS C SEIN Zwolle, the Netherlands
01:40 PM	504	Aspirin Non-responders in Thai Ischemic Stroke/TIA Patients DHARMASAROJA P, Faculty of Medicine, Thammasat University, Pathumthani, Thailand

12:00 - 02:00 PM Steroids, Receptors & pulmonary diseases

Room 115

Chairmen: M. Johnson, Uxbridge, United Kingdom
R. Michalides, Amsterdam, The Netherlands
S. Barker, London, United Kingdom

Time	Abstr. No.	Title
12:00 PM	830	Cytochrome P450 Inactivation by Pharmaceuticals and Phytochemicals: Therapeutic Relevance JOHNSON WW Drug Metabolism and Pharmacokinetics, OSI Pharmaceuticals, Boulder, CO 80301, USA
12:20 PM	1012	Predicting Optimal Endocrine Treatment Of Hormone-Dependent Breast Cancer Through The Right Bullets And Targets MICHALIDES R, ZWART W, NEEFJES J, KOK M, LINN S The Netherlands Cancer Institute, Amsterdam
12:40 PM	70	Allosteric modulation of hormone receptors in cancer treatment BARKER S, PUDDEFOOT JR, VINSON GP. School of Biological and Chemical Sciences, Queen Mary, University of London, London, United Kingdom.
01:00 PM	1234	Estrogen Receptor Beta may be a Novel Target for the Beneficial Effects of Estrogens in Females, and Androgens in Males, for Anxiety, Depression, and Cognitive Function FRYE CA¹⁻⁴, WALF AA¹ ¹ Psychology, ² Biology, ³ Center for Neuroscience, ⁴ Center for Life Science Research, Univ. at Albany-SUNY, Albany, NY, USA
01:20 PM	896	Molecular Prediction Of The Therapeutic Response To Preoperative Chemotherapy With Paclitaxel In Breast Cancer NAGASAKI K, SHIMOJI T, MATSUURA M, NODA T, MIKI K Genome Ctr., The Cancer Inst. (Japanese Foundation for Cancer Research) Tokyo, Japan
01:40 PM	998	Cell-specific delivery of kinase inhibitors using lysozyme: A novel approach to treat renal fibrosis PRAKASH J¹, KOK RJ¹, VAN GOOR H², POELSTRA K¹ ¹ University of Groningen, The Netherlands; ² University Medical Centre Groningen, The Netherlands.

12:40 - 01:00 PM Vaccines - Targeting non-infectious diseases - Part II

Room 403

Time	Abstr. No.	Title
12:40 PM	426	Allergy vaccines: dreams and reality CRAMERI R¹, KÜNDIG T² ¹ Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270 Davos, Switzerland ² Unit for Experimental Immunotherapy, Department of Dermatology, University Hospital, CH-8091 Zurich, Switzerland

12:40 - 02:00 PM Antidepressant drugs and their mechanism of action - Part II

Room 217

Chairmen: P. D'Aquila, Sassari, Italy
D. Smith, Risskov, Denmark

Time	Abstr. No.	Title
12:40 PM	191	Dopamine transmission and the search for the ideal antidepressant drug D'AQUILA PS, SERRA G Department of Drug Sciences, University of Sassari, Sassari, Italy.
01:00 PM	33	[C11]Mirtazapine: Magic Bullet for PET Brain Imaging of Antidepressants SMITH DF Center for Psychiatric Research, Psychiatric Hospital of Aarhus University, Skovagervej 2, 8240 Risskov, Denmark
01:20 PM	1187	Ocular Infections: Impact of Resistance to Fluoroquinolones and Other Antibiotics on Topical Therapies SCHLECH BA, STROMAN DW Alcon Research, Ltd. Ft. Worth, Texas USA
01:40 PM	853	Emergence of Colistin Resistance during Therapy of Infections by Multi-drug Resistant Gram Negative Pathogens in the Critically Ill PLACHOURAS D¹, KONTOPIDOU FV¹, GALANI I¹, KORATZANIS E¹, PONTIKIS K², ARMAGANIDIS A², GIAMARELLOU H¹ ¹ 4 th Department of Internal Medicine and ² 2 nd Department of Critical Care, Medical School, University of Athens, Greece

01:00 - 02:00 PM Atherosclerosis, stroke & aging - mechanisms and treatment - Part II

Room 205

Chairman: SS Jeyaraj, Chennai, India

Time	Abstr. No.	Title
01:00 PM	4	The Utility of the Cholesterol:Cholesterol Ratio in Predicting LDL-Cholesterol response to Atorvastatin 80 mg: A paradigm for individualized lipid-lowering therapy HOENIG MR, WALKER PJ. Department of Vascular Surgery, Royal Brisbane & Women's Hospital Australia.
01:20 PM	1473	Effect of Fish Oil with Garlic Oil Supplementation on the Anthropometric Measurements, Serum lipid Profile and Blood Pressure in Women with Hypercholesterolemia and Hypertension JEYARAJ SS, SHIVAJI G Women's Christian College, Chennai, India
01:40 PM	456	Peptides Against Ageing KHAVINSON VKH, MALININ VV Saint Petersburg Institute of Bioregulation and Gerontology of the NW Branch of the Russian Academy of Medical Sciences

01:20 - 02:20 PM Antineoplastic agents - Personalized therapy - Part II

Room 218

Chairman: JK Lee, Charlottesville, USA

Time	Abstr. No.	Title
01:20 PM	777	Prognostic value of total AgNOR area/Nucleus area per cell in urinary bladder carcinoma via two-dimensional image analysis CUCER N¹, IMAMOGLU N², TOZAK H³, DEMIRTAS H¹, SARAC F², TATLISEN A⁴, OZTURK F⁵ Erciyes University, Kayseri, Turkey, ¹ Medical Faculty, Medical Biology Department, ² Halil Bayraktar Health Services Vocational College, Biomed. Tech. Prog., ³ Medical Faculty, Histology, ⁴ Medical Faculty, Urology Department, ⁵ Medical Faculty, Pathology Department

- 01:40 PM 727 COXEN: A New Strategy For Predicting The Chemosensitivity Of Human Cancers And Its Application To Drug Discovery
LEE JK
University of Virginia School of Medicine, Charlottesville, USA.
- 02:00 PM 419 Personalized Medicine - a Paradigm Shift in the Treatment of Cancer
JØRGENSEN J T
CMC Contrast AB, Lyngby, Denmark.

02:00 - 03:00 PM Vaccines - Development, production and manufacturing - Part III

Room 213

Chairman: MHV Van Regenmortel, Strasbourg, CNRS, France

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 02:00 PM | 589 | Challenges And Potential Solutions To Innovative Vaccine Development In Developing Countries
MILSTIEN JB
University of Maryland School of Medicine, Center for Vaccine Development, Department of Geographic Medicine, Baltimore, MD USA |
| 02:20 PM | 701 | Antibody polyreactivity and ill-defined antigen mimicry hamper the search for effective peptide-based vaccine immunogens
VAN REGENMORTELMHV
Biotechnology School of the University of Strasbourg, CNRS, France |
| 02:40 PM | 105 | Rabies in Bats and Protective Treatments of Humans in Europe
STANTIC PAVLINIC M¹, HOSTNIK P²
¹ Institute of Public Health of Ljubljana, Zaloška 29, 1000 Ljubljana, Slovenia; ² Veterinary Faculty, Department on Virology, University of Ljubljana, Gerbiceva 60, 1000 Ljubljana, Slovenia |

02:00 - 02:40 PM Antivirals - Mechanisms and development of antivirals - Part II

Room 218

Chairman: B. Macchi, Rome, Italy

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 02:00 PM | 1073 | Combinational therapeutics Targeting Laboratory and Clinical Isolates of HIV-1
HUANG RC, ABD-ELAZEIM IS, GNABRE J
Johns Hopkins University, Baltimore, MD, U.S.A |
| 02:20 PM | 618 | Antiviral Chemotherapy In HTLV-1 Infection: Highlights From In Vitro Studies
BALESTRIERI E¹, ASCOLANI A², MATTEUCCI C¹, BALZARINI J³, MASTINO A⁴, MACCHI B²
¹ Dept Exp Med Bioch Sci ; ² Dept Neuroscience Univ Tor Vergata Rome, Italy; ³ Rega Institute for Medical Research, K.U. Leuven, Leuven, Belgium; ⁴ Department of Life Sciences, Section of Microbiological, Genetic and Molecular Sciences, University of Messina, Messina, Italy |

02:00 - 03:20 PM Treatment of diseases with involvement of the immune system - Part III

Room 206

Chairmen: P. Slos, Strasbourg, France
D. Fuchs, Innsbruck, Austria

- | Time | Abstr. No. | Title |
|----------|------------|--|
| 02:00 PM | 981 | Cancer Immunotherapy with Adenovirus-IFN? (TG1042)
SLOS P, BATAILLE V, ACRES B, DE MEYER M, PICHON C, S. HERMANN S, DERBIJ A, LUSKY M
Transgene SA, 11, rue de Molsheim, 67082 Strasbourg cedex, France.
slos@transgene.fr |

02:20 PM	268	Role of antiproliferative enzyme indoleamine (2,3)-dioxygenase in the impaired immune function in infectious diseases BRANDACHER G, ¹ SCHROECKSNADEL K, ² SUCHER R, ¹ MARGREITER R, ¹ FUCHS D ² ¹ Center of Operative Medicine, Department of Visceral, Transplant, and Thoracic Surgery, and ² Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Austria
02:40 PM	626	Novel biologic therapies for psoriasis PROHIC A Department of Dermatovenerology, University Clinical Center, Sarajevo, Bosnia and Herzegovina
03:00 PM	1199	Hormone-Immunotherapy Significantly Prolongs Clinical Benefit And Median Overall Survival Of Metastatic Endocrine Dependent Breast Cancer Patients NICOLINI A ¹ , FERRARI P ¹ , ANSELMINI L ¹ , CONTE M ¹ , BERTI P ¹ , MICCOLI P ¹ ¹ University of Pisa, Pisa, Italy

02:00 - 03:20 PM Antineoplastic agents - New approaches to antineoplastic therapy and cell survival - Part II

Room 215

Chairmen: K. Chadha, Buffalo, USA
A. Iamaroon, Chiang Mai, Thailand

Time	Abstr. No.	Title
02:00 PM	1137	Anti-Angiogenic and Anti-Neoplastic Potential of Prostate-Specific Antigen (PSA) CHADHA KC Roswell Park Cancer Institute, Buffalo, NY, USA
02:20 PM	495	Oral Cancer: Molecular Pathogenesis And Novel Therapeutic Approach IAMAROON A. , KRISANAPRAKORNKIT S. Chiang Mai University, Chiang Mai, Thailand
02:40 PM	1135	Is GRP78/BiP, a Master-Regulator of Defensive Unfolded Protein Response, a New "Magic Target"? GRP78/BiP-targeting Cytotoxin and ER Stress-Inducing Drugs Synergize to Kill Cancer Cells BACKER MV ¹ , PATON AW ² , PATON JC ² , BACKER JM ¹ ¹ Sibtech, Inc., Brookfield, CT 06804 USA; ² School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, 5005, Australia
03:00 PM	520	Heparin as anti-inflammatory and anti-metastatic drug- new potentials of an old player CELIE JW ¹ , BEELEN RH ¹ ¹ Dept. Molecular Cell Biology & Immunology, VU University Medical Center, Amsterdam, the Netherlands.

02:00 - 03:20 PM Antineoplastic agents - Old and new compounds / approaches - Part I

Room 216

Chairmen: O. Merkel, Salzburg, Austria
T. Samoylova, Auburn, USA

Time	Abstr. No.	Title
02:00 PM	453	Arsenic Trioxide Induces Apoptosis Preferentially In B-CLL Cells Of Patients With Unfavorable Prognostic Factors Including Del17p13 MERKEL O ¹ , HEYDER C ¹ , ASSLABER D ¹ , HAMACHER F ¹ , TINHOFER I ¹ , HOLLER C ¹ , STÖCHER M ¹ , PROKESCH A ² , PAAR C ² , SCHEIDELER M ² , TRAJANOSKI Z ² , GREIL R ¹ ¹ Laboratory for Immunological and Molecular Cancer Research, IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology of the Paracelsus Medical University Salzburg, Salzburg, Austria, ² Institute for Genomics and Bioinformatics, Graz University of Technology
02:20 PM	294	Phage Display: Opportunities for Development of Personalized Anti-Cancer Therapeutics SAMOYLOVA TI , COX NR Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36830, USA

- 02:40 PM 672 Chemotherapeutic agents for Merkel cell carcinoma (MCC) of skin – past, present and future
TAI P¹, YU E², ASSOULINE A³, JOSEPH K⁴, KRZISCH C³.
¹Univ. Saskatchewan, Regina, Canada; ²Univ. Western Ontario, London, Canada; ³Centre
Hospitalier Universitaire d' Amiens, Amiens, France; ⁴Cross Cancer Institute, Edmonton,
Canada.
- 03:00 PM 1519 Cell Penetrating Antibody Delivery To Intracellular Targets
MULLER S, KOHLER H, ZHAO, Y
Univ. of Kentucky, Lexington, KY USA

02:00 - 03:20 PM Antiparasitic compounds - Magic Bullets to treat malaria

Room 217

Chairmen: R. Gosling, London, United Kingdom
K. Saliba, Canberra, Australia

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 02:00 PM | 1041 | Sulfadoxine- Pyrimethamine: Dead or Alive for Malaria Control?
GOSLING RD¹ , ROPER C ¹ , CHANDRAMOHAN D ¹
¹ Department of Infectious and Tropical Disease, London School of Hygiene and Tropical
Medicine, Keppel Street, London WC1E 7HT, United Kingdom |
| 02:20 PM | 1350 | Vitamin utilisation pathways as antimalarial drug targets
SALIBA KJ
The Australian National University, Canberra, ACT, 0200, Australia |
| 02:40 PM | 1385 | Structure and Antimalarial Activity of Immunomodulator P-MAPA
DURÁN M ¹ , MARCATO PD ¹ , COSTA FTM ² , DURÁN N ¹ , TASIC L¹
¹ IQ, UNICAMP, Campinas, Brazil; ² IB, UNICAMP, Campinas, Brazil. |
| 03:00 PM | 1079 | Bis(2-aminoimidazolium)diphenyl Compounds as DNA Minor Groove Binders with <i>in Vivo</i>
Antitrypanosomal and Antimalarial Activity: the cation is important.
DARDONVILLE C¹ ; MASCARAQUE A ¹ ; NIETO L ¹ ; RODRÍGUEZ F ² ; ROZAS I ² ; KAISER
M ³ ; BRUN R ³ ; NGUYEN B ⁴ ; WILSON WD ⁴
¹ Institute of Medicinal Chemistry, CSIC, Madrid, Spain; ² School of Chemistry, Trinity College
Dublin, Ireland; ³ Swiss Tropical Institute, Basel, Switzerland; ⁴ Department of Chemistry,
Georgia State University, Atlanta, USA. |

02:00 - 03:20 PM Therapeutic Proteins - discovery and manufacturing - Part II

Room 403

Chairmen: K. Hefferon, Trumansburg, USA
M. Maines, Rochester, USA

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 02:00 PM | 397 | Biopharmaceuticals in plants; toward the next century of medicine.
HEFFERON KL
Cornell Research Foundation, Cornell University, Ithaca, NY, 14850 |
| 02:20 PM | 960 | The Critical Functions Of Biliverdin Reductase (BVR) In Insulin/Insulin Growth Factor-1
(IGF-1) And MAPK Signaling Pathways: A Potential Therapeutic Application In Treatment Of
Diabetes And Cancer
MAINES MD
University of Rochester, Rochester, USA |
| 02:40 PM | 487 | Recombinant therapeutic proteins - - from the viewpoint of a biotechnologist
SUGIURA T
Daiichi-Sankyo Co., Ltd. |

03:00 PM 1196 Spider silk proteins – a new generation of bioimplantable materials.
ENGSTRÖM W¹, JOHANSSON J¹, VADGAMA P², HATTON P³, WAGEMAKER G⁴, SKAER N⁵, VOLLRATH F⁶, LARHED A⁷, HABIBOVIC P⁸, VON AULOCK S⁹.
SPIDERMAN CONSORTIUM. 1) Swedish University of Agricultural Sciences, 2) Queen Mary University of London, UK, 3) Sheffield University, UK, 4) Erasmus University, Rotterdam, the Netherlands, 5) Oxford Biomaterials, Newbury, UK, 6) University of Oxford, UK, 7) Q-Med Uppsala, Sweden, 8) University of Twente, The Netherlands, 9) University of Konstanz, Germany

02:00 - 03:40 PM Antineoplastic agents - Compounds and approaches - Part III

Room 212

Chairmen: D. FitzGerald, Bethesda, USA
L. Borsig, Zürich, Switzerland
R. Carlson, Salt Lake City, USA

Time	Abstr. No.	Title
02:00 PM	592	Recombinant Immunotoxins for the Treatment of Cancer. FitzGerald DJ , Pastrana DV, Hassan R, Kreitman RJ and Pastan I Lab of Molecular Biology, CCR, National Cancer Institute, NIH. Bethesda, MD.
02:20 PM	481	Heparin as an inhibitor of cancer progression; the role of selectins BORSIG L ¹ , VARKI A ² ¹ Univ. of Zürich, Zürich, Switzerland; ² Univ. of California, San Diego, U.S.A.
02:40 PM	82	Vascular disruption: an old mechanism rediscovered for targeting tumor blood supply CARLSON RO , PLEIMAN CP, BAICHWAL V, MATHER G, SWABB E, YU M Myriad Pharmaceuticals, Inc., Salt Lake City, UT, USA
03:00 PM	1328	Cancer stem cells - towards a new generation of antineoplastic drugs HATINA J ¹ ¹ Charles University, Medical Faculty in Pilsen, Institute of Biology Plzen, Czech Republic
03:20 PM	353	Synergistic Action of Resveratrol and its Polyhydroxylated Derivative with Cytarabine in HL-60 Human Promyelocytic Leukemia Cells BAGO-HORVATH ZS ¹ , SAIKO P ¹ , MURIAS M ² , ERKER T ² , HANDLER N ² , MADLENER S ³ , JAEGER W ² , GRUSCH M ⁴ , FRITZER-SZEKERES M ¹ , KRUPITZA G ³ , SZEKERES T ¹ ¹ Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Austria, ² Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Austria, ³ Institute of Clinical Pathology, Medical University of Vienna, Austria and ⁴ Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria

02:00 - 03:40 PM Antineoplastic agents - New strategies and new compounds- Part II

Room 207

Chairman: FA Badria, Mansoura, Egypt

Time	Abstr. No.	Title
02:00 PM	10000	[Title will be available soon] VAVANASI
02:20 PM	298	AntiNeoplaston: Synthesis, Biological, and Clinical Evaluation in Egypt BADRIA FA [*] , ABOU-ZEID L ² , MOWAFY A ³ , HAWAS S ⁴ , KHAFAGY Y ⁵ , MABED M ⁶ Pharmacognosy ¹ , Medicinal Chemistry ² , and Biochemistry ³ Departments, Faculty of Pharmacy Immunology ⁴ , Surgery ⁵ , and Oncology ⁶ Departments, Faculty of Medicine Mansoura University, Mansoura, Egypt 35516
02:40 PM	1325	Novel Anti-Cancer Peptides That Cause Reversion, Lysis And Necrosis Of Tumor Cells But Have No Effect On Normal Cells MICHL J , YAZDI ES, ADLER V, SOOKRAJ K, ZENILMAN M, BOWNE W, PINCUS MR Departments of Pathology, Anatomy and Cell Biology, Microbiology and Immunology, and Surgery, SUNY Downstate Medical Center, Brooklyn, NY; Departments of Clinical Laboratory Medicine and Surgery, VA Harbor View Medical Center, Brooklyn, NY, USA

- 03:00 PM 744 Anticancer Gold Compounds: Mechanistic Insights
MESSORI L
METMED Laboratory, Department of Chemistry, Univ. Florence, Florence, Italy
- 03:20 PM 744 A Promising Future for Cancer Immunotherapy in an Oil-Rich Country like Kuwait: An Invitation for Pharmaceutical and Non-Pharmaceutical International Collaboration
SALEH F
Faculty of Medicine, Kuwait University, Kuwait

02:00 - 03:40 PM Bioanalytics - The cutting edge of LC-MS/MS - Part II

Room 405

Chairmen: C. Sauber, Waldbronn, Germany
W. Chen, Singapore, Singapore
Y. Hsieh, Bridgewater, USA

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 02:00 PM | 10000 | Microfluidics-driven HPLC-Chip / Triple Quadrupole Mass spectrometry - shattering the sensitivity barrier for small animal pharmacokinetic studies
Sauber C
LC/MS Business manager, Agilent Technologies, Waldbronn, Germany |
| 02:20 PM | 440 | iTRAQ-coupled 2D LC-MS/MS Analysis of Proteomics Profile in Cells Incubated with S- or R-enantiomers of Chiral Drugs: from Metabolic Pathways to Biomarker Discovery
CHING CB, SUI JJ, ZHANG JH, CHEN WN
School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore |
| 02:40 PM | 133 | The Role of Metabolism, Pharmacokinetics and Mass Spectrometry in Selection of a Thrombin Receptor Antagonist for Development
HSIEH Y
Drug metabolism and pharmacokinetic department, Schering-Plough Research Institute, Kenilworth, USA |
| 03:00 PM | 507 | LC-MS/(MS) Strategies For Increased Metabolite Coverage In Metabolomics
NORDSTRÖM A ¹ , LEHTIÖ J ¹ , LEWENSOHN R ¹ ; SIUZDAK G ²
¹ Karolinska Biomics Center, Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital, Solna, Stockholm Sweden ; ² The Scripps Research Institute, Department of Molecular Biology, Scripps Center for Mass Spectrometry, North Torrey Pines Rd., CA, USA |
| 03:20 PM | 215 | LC-MS/MS Shotgun Proteomics of Lung Cancer Pleural Effusions Identifies the Prognostically Relevant Epithelial-to-Mesenchymal Transition Protein Periostin
SOLTERMANN A ¹ , OSSOLA R ² , TISCHLER V ¹ , AEBERSOLD R ² , MOCH H ¹
¹ University Hospital Zürich, Zürich, Switzerland; ² Swiss Federal Institute of Technology, Zürich, Switzerland |

02:00 - 03:40 PM Pharmaceutics - Drug delivery - Part II

Room 406

Chairmen: G. Jones, Boston, USA
N. Thomas, Nottingham, UK
E. Nieddu, Genoa, Italy

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 02:00 PM | 1250 | Bioconjugated Cytotoxin Prodrugs and Imaging Agents in Anticancer Research
JONES GB
Department of Chemistry & Chemical Biology, Northeastern University, Boston, MA 02115 USA |
| 02:20 PM | 1160 | Magnetic Resonance Imaging 'Pathfinder' Molecules For Use in Optimizing Antibody and Gene-Directed Enzyme-Prodrug Therapy (ADEPT/GDEPT) Treatments
THOMAS NR ¹ , GALLIARD L ¹ , SPENCE D ¹ , KÖCKENBERGER W ² , MAYER A ³
¹ Centre for Biomolecular sciences, Univ. Nottingham, Nottingham, NG7 2RD UK; ² Sir Peter Mansfield MR Centre, Univ. Nottingham, Nottingham, NG7 2RD UK; ³ Dept of Oncology, Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London NW3 2PF |

02:40 PM	923	<i>Corpora Non Agunt Nisi Fixata</i> : Tailored Drug Targeting By Intelligent Active Principles Or Intelligent Transporters, State Of Art And Our Experience NIEDDU E ¹ , PASA S ² , AVALLE L ¹ , MERELLO L ¹ , SANNA VA ³ , BRIGATI C ² ¹ Univ. of Genoa, Genoa, Italy; ² Nat Cancer Inst, Genoa, Italy; ³ Prion DGN, Alghero (SS), Italy.
03:00 PM	1340	Recombinant Gas Vesicles: A Novel Display/Delivery System for Peptide Antigens (SIV) SREMAC M ¹ , STUART ES ¹ ¹ Univ. Massachusetts, Amherst, USA
03:20 PM	176	Targeted and Multifunctional Dendritic Polymers: Magic Bullets for Drug and Gene Delivery PALEOS CM ^{1,2} , TSIOURVAS D ² , SIDERATOU Z ² , TZIVELEKA L-A ² ¹ Dendrigen SA, Athens, Greece; ² NCSR "Demokritos", Aghia Paraskevi, Greece.

02:00 - 04:00 PM Erythropoietin - a Magic Bullet's quo vadis

Room 214

Chairmen: W. Krzyzanski, Buffalo, USA
C. Gilmartin, Chicago, USA
T. Lappin, Belfast, United Kingdom

Time	Abstr. No.	Title
02:00 PM	111	Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin. KRZYZANSKI W Department of Pharmaceutical Sciences, University at Buffalo, USA
02:20 PM	389	Erythropoietic Stimulating Proteins - What is the Optimal, Safe Hemoglobin Target? GILMARTIN C Univ. of Illinois, Chicago, USA
02:40 PM	69	Erythropoietin in Cancer Anaemia: Friend or Foe? LAPPIN TRJ Haematology Research Group, Centre for Cancer Research and Cell Biology, Queen's University, Belfast
03:00 PM	474	Erythropoietin-Binding Protein And Its Antibodies For Possible Clinical Application LEE MS, LEE JS, LEE JY Northwestern Univ. School of Medicine, Chicago, USA, Univ of MN School of Medicine, Minneapolis, USA.
03:20 PM	560	Erythropoietin: Bold Directions And Strategies For A "Magic Bullet" Destined For Neurovascular Disease MAIESE K Division of Cellular and Molecular Cerebral Ischemia, Departments of Neurology and Anatomy & Cell Biology, Center for Molecular Medicine and Genetics, Institute of Environmental Health Sciences, Barbara Anne Karmanos Cancer Center, Wayne State University School of Medicine UHC, St. Antoine, Detroit, MI, USA
03:40 PM	317	Erythropoiesis-stimulating agents may improve survival in low-risk MDS patients PARK S, KELAIDI C, GREENBERG P, FENAU P, DREYFUS F. For the GFM group (Groupe Francophone des Myélodysplasies). Hôpital Cochin, Paris, FRANCE.

02:00 - 04:20 PM Antibacterials - The rise of antibacterial resistance

Room 115

Chairmen: R. Aminov, Aberdeen, United Kingdom
T. Van, Melbourne, Vietnam
K. Inai, Eiheiiji, Japan

Time	Abstr. No.	Title
02:00 PM	695	Antibiotic resistance: what can we learn from evolution? AMINOV RI Rowett Inst. of Nutrition and Health, Univ. Aberdeen, Aberdeen, UK

02:20 PM	988	Molecular Characterization of Antibiotic Resistance in Selected Enteropathogens Isolated from Raw Food Samples in Vietnam VAN¹ TTH, MOUTAFIS¹ G, ISTIVAN¹ T, TRAN² LT AND COLOE¹ PJ ¹ RMIT University, Melbourne, VIC, Australia; ² University of Natural Sciences, HCM City, Vietnam
02:40 PM	861	Pathophysiological Approach Against Resistant Bacteria-Causing Infectious Diseases; - From Autopsy Findings To Clinical Applications – INAI K¹, Noriki S², IWASAKI H³, YAMASHITA M⁴, UEDA T³, NAIKI H¹ ¹ Div Mol Pathol, ² Div Tumor Pathol, ³ Div Hematol & Cardiol, ⁴ Div Clin Inspect, Univ. FUKUI, Fukui, Japan.
03:00 PM	1393	Antimicrobial Resistance by <i>Mycoplasma species</i> in Farm Animals. AYLING RD. Veterinary Laboratories Agency (Weybridge), Addlestone, Surrey, UK. KT15 3NB
03:20 PM	471	National Surveillance of Antibiotic Resistance in Iran SABERI M^{1,2}, HOSSEINIDOST-SR³, HOSSEINI-SGA³ ¹ Department of Pharmacology and Toxicology, ² Chemical Injuries Research Center, ³ Molecular Cell Investigation Center, Faculty of Medicine, Baqiyatallah University of Medical Sciences, P.O. Box 19568, Tehran, Iran
03:40 PM	1776	The impact of antimicrobial drug use and the use of alcohol-based hand rub on the emergence and spread of extended-spectrum β -lactamase (ESBL)-producing strains - A time series analysis KAIER K Universitätsklinikum Freiburg, Institut für Umweltmedizin und Krankenhaushygiene, Breisacher Straße 115b, 79106 Freiburg, Germany.
04:00 PM	1365	Antibody-Therapeutic Targeting Of Tolc For Growth-Combating Of Antibiotic-Resistant <i>Escherichia Coli</i> HUI LI¹, LIN XIANG-MIN¹, SAN-YING WANG², XUAN-XIAN PENG¹, ¹ Center for Proteomics, State key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, University City, Guangzhou, China; ² School of Life Sciences, Xiamen University, Xiamen, China.

02:00 - 04:20 PM Antineoplastic agents - Factors affecting cancer and cancer chemotherapy - Part II

Room 205

Chairmen: K. Norrby, Gothenburg, Sweden
 S. Yang, London, United Kingdom
 K. Matsumoto, Kanazawa, Japan

Time	Abstr. No.	Title
02:00 PM	815	Unexpected Effects On Angiogenesis By Type Of Low-Molecular-Weight Heparin (LMWH) And By Type Of Vehicle In Chemotherapy NORRBY K University of Gothenburg, Sweden
02:20 PM	762	Interfere IGF-I pathways to augment sensitivities of colorectal cancer cells to current therapeutic agents YANG SY, SALES KM, FULLER B, SEIFALIAN AM, WINSLET MC Department of Surgery, University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
02:40 PM	874	Inhibition Of Tumor Metastasis And Angiogenesis By NK4, Bifunctional Inhibitor Of HGF-Met And Angiogenesis MATSUMOTO K Cancer Research Institute, Kanazawa University, Kanazawa, Japan
03:00 PM	729	CYP1A1, GST Gene Polymorphisms and Risk of Chronic Myeloid Leukaemia TASPINAR M¹, Erdogan Aydos S¹, Comez O¹, Elhan AH², Karabulut HG³, Sunguroglu A¹ ¹ Ankara University Faculty of Medicine, Department of Medical Biology, Ankara, Turkey ² Ankara University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey ³ Ankara University Faculty of Medicine, Department of Medical Genetics, Ankara, Turkey

03:20 PM	291	The effects of cytochrome P450 enzyme polymorphisms on bladder cancer and prostate cancer GUNES S¹ , BAGCI H ² , SARIKAYA S ³ ¹ Department of Medical Biology, School of Medicine, Ondokuz Mayıs University, Samsun, Turkey ² Department of Medical Biology, School of Medicine, Ondokuz Mayıs University, Samsun, Turkey ³ Department of Urology, School of Medicine, Ondokuz Mayıs University, Samsun, Turkey
03:40 PM	169	Distinct Cell Cycle Proteins Control Schwann Cell Proliferation in Health and Disease ATANASOSKI S University of Basel, Basel, Switzerland
04:00 PM	42	The Role OF Heat Shock Proteins IN Oral Cancer: A Possible New Target IN Antineoplastic Therapy? MARKOPOULOS AK , DELIGIANNI E, ANTONIADES DZ School of Dentistry, Aristotle University, Thessaloniki, Greece

02:00 - 04:20 PM **Antivirals - General issues and their solutions - Part II**

Room 111

Chairmen: A. Hellden, Stockholm, Sweden
 N. Urosevic, Perth, Australia
 B. Roca, Castellon, Spain

Time	Abstr. No.	Title
02:00 PM	529	Aciclovir- a Nearly Atoxic Antiviral Drug with Severe Neurotoxic Side Effects- a Retrospective Review of 280 Cases and the Importance of Analysing the Aciclovir Metabolite CMMG. HELLDÉN A Laboratory Medicine, Stockholm, Sweden
02:20 PM	84	Principal parallels between Interferon type I- and small inhibitory (si)RNA- based therapies UROSEVIC N^{1,2,3} and PANTELIC L ¹ ¹ University of Western Australia, Microbiology & Immunology; ² School of Psychiatry and Clinical Neurosciences, Nedlands, WA and ³ Edith Cowan University, Joondalup, WA, Australia
02:40 PM	15	Present Knowledge On Pharmacogenetics Of Antiretrovirals ROCA B Infectious Disease Division, Departmen of Medicine, Hospital General of Castellón, University of Valencia, Spain
03:00 PM	1335	The impact of highly active antiretroviral therapy on cytomegalovirus retinitis: triumphs and future challenges KEDHAR SR^{1,2,3} ¹ The New York Eye & Ear Infirmary, New York, United States; ² New York Medical College, Valhalla, United States; ³ The Johns Hopkins University School of Medicine, Baltimore, United States.
03:20 PM	209	Clinical importance of drug resistance in antiviral therapy for Hepatitis B Infection AMARAPURKAR DN Bombay Hospital, Mumbai
03:40 PM	1019	Rapid intervention: the role of antivirals in containing or controlling pandemic influenza SMITH JR International Medical Leader: Tamiflu, F. Hoffmann-La Roche Ltd, Basel, Switzerland
04:00 PM	733	Bilirubin: An Endogenous Molecule With Antiviral Activity <i>In Vitro</i> MANCUSO C¹ , MARCHETTI S ² , FADDA G ² , SANTANGELO R ² Institutes of ¹ Pharmacology and ² Microbiology, Catholic University School of Medicine, Roma, Italy

02:00 - 04:20 PM Drug-drug and drug-nutrient interactions - Part I

Room 412

Chairmen: L. Liebovitch, Boca Raton, USA
S. Popescu, Craiova, Romania
D. Endringer, Freiburg, Germany

Time	Abstr. No.	Title
02:00 PM	137	Advantages of Multiple Drug Interactions: Combinatorial Treatments Using Neural Networks LIEBOVITCH LS, PANDYA A Florida Atlantic University, Boca Raton, FL, USA.
02:20 PM	485	Pharmacokinetic and pharmacodynamic interactions between mepivacaine and antihypertensive drugs POPESCU SM¹, BANICERU M², POPESCU F³, NECHIFOR M⁴ ^{1,2,3} University of Medicine and Pharmacy Craiova, Romania; ⁴ University of Medicine and Pharmacy "Gr.T.Popa" Iassy, Romania
02:40 PM	1270	Natural products from plants and its derivatives as CYP19 (aromatase) inhibitors: flavonoids and dihydroisocoumarin ENDRINGER, DC¹, MAITI, A², GUIMARÃES, KG¹, CUENDET, M³, CROY, VL², CUSHMAN, M², KONDRATYUK, TP⁴, PEZZUTO, JM⁴, BRAGA, FC¹ ¹ Faculdade de Farmácia, Universidade Federal de Minas Gerais, MG, 31270-90, Brazil ² Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmaceutical Sciences, and ³ The Purdue Cancer Center, Purdue University, IN, 47907, USA ⁴ College of Pharmacy, University of Hawaii at Hilo, HI, 96720, USA
03:00 PM	582	Factors That Influence The Prevalence Of Drug-Drug Interactions Between Antiretroviral Drugs Prescribed To Patients Of Different Age Groups In A Section Of Private Healthcare Sector In South Africa KATENDE-KYENDA NL¹, LUBBE MS², SERFONTEIN JHP³, Truter I⁴ ¹ Walter Sisulu University, Mthatha; ²⁻³ Northwest University, Potchefstroom; ⁴ Nelson Mandela Metropolitan University, Port Elizabeth, South Africa
03:20 PM	1353	Let Food Be Thy Medicine And Medicine Be Thy Food MAHGOUB SEO University of Botswana, Gaborone, Botswana
03:40 PM	286	The effect of some endogenous substances (Cl ⁻ , oleate and Ca ²⁺) on the albumin binding of triflupromazine (TFZ), trifluoperazine (TFPZ) and bendroflumethiazide (BFZ). An in vitro spectrometric study Kitamura K¹, Takegami S¹, Omran AA^{1,2}, Kitade T¹ ¹ Kyoto Pharmaceutical University, Kyoto, Japan, ² Al-Azhar University, Assiut, Egypt
04:00 PM	791	Application of the Fluorescence Quenching Method to the Study of the Interaction of the Anti-psychotic Drug Chlorpromazine with Serum Albumin SILVA D, CORTEZ CM, BASTOS JC. Rio de Janeiro State University, Rio de Janeiro, Brazil

02:00 - 04:40 PM Psychoactive drugs - Part I

Room 101

Chairmen: L. Monassier, Strasbourg, France
D. Pinault, Strasbourg, France
R. Wu, Shantou, China

Time	Abstr. No.	Title
02:00 PM	740	Ketanserin And Dexfenfluramine: Angels Or Demons For 5-HT _{2B} Receptors? MONASSIER L¹, MAROTEAUX L² ¹ Faculty of Medicine Inserm715, Strasbourg, France; ² Institut du Fer à Moulin Inserm839, Paris, France
02:20 PM	265	Psychotomimetic Action of Ketamine and MK-801: Behavioral, Network and Cellular Features PINAULT D INSERM U666, Faculté de Médecine, ULP, Strasbourg, France

02:40 PM	306	Feasibility of Mapping Brain pH Using 31P MR Spectroscopy WU RH ^{1,2} , CHEN YW ¹ , LIU WW ¹ , WANG H ³ , QIU QC ¹ , TERBRUGGE K ² , MIKULIS DJ ² ¹ Shantou University Medical College, Shantou, China; ² University of Toronto, Toronto, Canada; ³ Southeast University, Nanjing, China
03:00 PM	1454	Neurodevelopment Of Children Following Exposure To Psychotropic Medications During Gestation: A Novel Approach To Behavioral Teratology NULMAN I University of Toronto, Toronto, Canada; Division of Clinical Pharmacology, The Motherisk Program, The Hospital for Sick Children, Toronto, Canada
03:20 PM	1142	Nicotinic acetylcholine receptor containing an alpha6 subunit: target for a magic bullet? SALMINEN O ¹ , GRADY SR ² , MARKS MJ ² , COLLINS AC ² ¹ University of Helsinki, Faculty of Pharmacy, Finland ² University of Colorado, Institute for Behavioral Genetics, CO, USA
03:40 PM	1357	Substance Use and Its Functions, Dysfunctions, and Alternative Functions in Contemporary Society SHAW VN California State University-Northridge, Northridge, USA
04:00 PM	978	Neuropeptides in Stress-Related Disorders: Possible Interaction of Vasopressin and Corticotropin Releasing Hormone ZELENA D ¹ , PINTÉR O ¹ , MERGL Zs ¹ , BARNA I ¹ , MAKARA GB ¹ ¹ Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary
04:20 PM	1774	Pharmacogenetic diagnostics for optimization of psychotropic drug treatment KIRCHHEINER J Institute of Pharmacology of Natural Products & Clinical Pharmacology, Helmholtzstr. 20, D-89081 Ulm, Germany

02:30 - 03:50 PM Blood brain barrier physiology and diseases - Part II

Room Paul Ehrlich Hall

Chairmen: I. Krizbai, Szeged, Hungary
 R. Raghavan, Baltimore, USA

Time	Abstr. No.	Title
02:30 PM	716	Molecular Changes Induced by Stress Factors in Cerebral Endothelial Cells KRIZBAI IA , FARKAS AE, NAGYOSZI P, FAZAKAS C, WILHELM I Institute of Biophysics, Biological Research Centre, Szeged, Hungary
02:50 PM	49	Breaching The Barriers Of The Brain: From Physics To Cures RAGHAVAN R , BRADY M Therataxis LLC, Baltimore, USA
03:10 PM	623	Effects of Intracarotid Injection of Methylprednisolone on Cellular Oedema after Osmotic Opening of the Blood-Brain Barrier in Rats KOZLER P ¹ , POKORNÝ J ² ¹ Department of Neurosurgery, Central Military Hospital, 1 st Faculty of Medicine, Charles University, Prague, CZ, Czech Republic ² Institute of Physiology, 1 st Faculty of Medicine, Charles University, Prague, CZ, Czech Republic
03:30 PM	577	The impact of interferon-β treatment on the blood-brain barrier KRAUS J ¹ Paracelsus Private Medical University and Salzburger Landeskliniken, Christian-Doppler-Klinik, University Hospital of Neurology, Ignaz-Harrer-Straße 79, 5020 Salzburg, Austria., Phone: +43-662-4483-0, Fax: +43-662-4483-3074, email: joerg.kraus@salk.at

03:00 - 04:00 PM Mechanisms of inflammation and anti-inflammatory agents - Part II

Room 213

Chairman: A. Hartog, Wageningen, The Netherlands

Time	Abstr. No.	Title
03:00 PM	1164	Advent of Pharmacology of Nociceptors Initiated by Capsaicin Has Opened Also a New World in Neurohumoral Regulation SZOLCSÁNYI J , PETHO G, PINTÉR E, HELYES ZS Department of Pharmacology, University of Pécs, Hungary
03:20 PM	1173	Orally Ingested Lactoferrin and Glycine Display <i>in vivo</i> Synergistic Anti-Inflammatory Activity HARTOG A ^{1,2} , GARSSSEN ^{1,2} , ¹ Danone Research, Centre for Specialised Nutrition, Wageningen, The Netherlands. ² Department of Pharmacology & Pathophysiology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands
03:40 PM	1277	Insulin Suppresses High Mobility Group-B1 (HMG-B1) Protein and Toll Like Receptor Expression: Further Evidence of its Anti-Inflammatory Effect DANDONA P Kaleida Health, State University of New York at Buffalo

03:00 - 04:00 PM Nerve diseases, mechanisms, and pathophysiology - Part II

Room 218

Chairman: NN Zolotov, Moscow, Russia

Time	Abstr. No.	Title
03:00 PM	928	Glucose Transporter Type 2 - Does It Pave the Way to Sporadic Alzheimer's Disease? SALKOVIC-PETRISIC M ¹ , GRÜNBLATT E ² , OSMANOVIC J ¹ , HOYER S ³ , RIEDERER P ² ¹ Dept. Pharmacol., Sch. Med., Univ. Zagreb, Croatia; ² Dept. Clin. Neurochem., Univ. Dept. Psychiat. Psychother., Univ. Würzburg, Würzburg, Germany; ³ Dept. Pathol., Univ. Heidelberg, Heidelberg, Germany
03:20 PM	1114	Proline Specific Peptidases as New Targets for Drug Development. Pharmacology and Pathophysiology ZOLOTOV NN , GARIBOVA TL, LEBEDEVA MA, VORONINA TA, SEREDENIN SB Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia
03:40 PM	886	The Role of PPAR? Agonist in Alzheimer's disease. DASH SK , CHANDY MJ Department of Neurosciences, Apollo Hospitals Dhaka, Bangladesh.

03:20 - 04:20 PM Immunosuppressants - Part II

Room 206

Chairman: R. Tesse, Bari, Italy

Time	Abstr. No.	Title
03:20 PM	402	Is Cyclosporine The Magic Bullet In Dermatology? JOVANOVIĆ M ^A , BRKIC S ^B , KARADAGLIĆ D ^C ^A Faculty of Medicine, University of Novi Sad, Clinical Centre of Vojvodina, Novi Sad, Serbia; ^B Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia; ^C Private Clinic "Professor Karadaglić", Belgrade, Serbia
03:40 PM	340	Efficacy of 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood SPADAVECCHIA L, TESSE R , FANELLI P, ARMENIO L Department of Biomedicina dell'Età Evolutiva- Pediatric Clinic "Maggiore"-University of Bari, Bari, Italy

04:00 PM 29 Nephrotoxicity of immunosuppressive drugs, new insight
THERVET E
Hopital Necker, Paris, France

03:20 - 04:20 PM Pharmaceutics - Drug delivery - Part III

Room 217

Chairmen: C. Wang, Singapore, Singapore
C. Vijaya Raghavan, Coimbatore, India
R.J. Babu, Tallahassee, USA

Time	Abstr. No.	Title
03:20 PM	12	On the Delivery of Carmustine, Paclitaxel, and Etanidazole to Brain Tumors: An integrated study on the novel fabrication methods of pharmaceutical particles and 3-D computer simulations for chemotherapy and radiotherapy applications WANG CH Department of Chemical and Biomolecular Engineering National University of Singapore
03:40 PM	333	Study of Tenoxicam on Various Drug Delivery Systems VIJAYA RAGHAVAN C¹ , JUDITH JUSTIN² ¹ PSG College of Pharmacy, Coimbatore, India; ² Avinashilingam University, Coimbatore, India
04:00 PM	820	Transdermal Drug Delivery into and Beneath the Skin - Application to Anti Inflammatory Drugs BABU RJ¹ , CHADHA GS¹ , PARSONS DL¹ , PATLOLLA RR² , SINGH M² ¹ Harrison School of Pharmacy, Auburn University, Auburn, USA; ² College of Pharmacy, Florida A&M University, Tallahassee, USA.

02:00 - 04:47 PM Antineoplastic agents - Approaches to optimize therapy - Part II

Room 112

Chairmen: U. Jaehde, Bonn, Germany
M. Rocchetti, Nerviano, Italy
D. Chow, Houston, USA

Time	Abstr. No.	Title
02:00 PM	10006	Optimizing therapy by platinum compounds via PK/PD JAEHDE U Institute of Pharmacy, An der Immenburg 4, D-53121 Bonn, Germany
02:27 PM	347	Predicting The Active Doses Of New Anticancer Agents In Humans Directly From Preclinical Data ROCCHETTI M¹ , PESENTI E² , DE NICOLAO G³ ¹ Pharmacokinetics&Modeling, Accelera, Nerviano Medical Sciences, Nerviano (MI), Italy. ² Pharmacology Department, Oncology, Nerviano Medical Sciences, Nerviano (MI), Italy. ³ Dipartimento di Informatica e Sistemistica, University of Pavia, Pavia, Italy
02:47 PM	53	Nanomedicines - Self Nanoemulsifying Drug Delivery System (SNEDDS) and Nanosuspension for Oral and Parenteral Formulations in Cancer Therapy with Significant Impacts on Pharmacokinetics and Biodistributions CHOW DSL¹ , GUPTA P^{1,2} , QI Y^{1,3} , LIANG D⁴ , WISNIECKI P⁵ , SHAH JC⁵ ¹ Univ. Houston, Houston, TX, USA; ² Schering-Plough, Kenilworth, NJ, USA; ³ BioMarin, Novato, CA, USA; ⁴ Texas Southern Univ., Houston, TX, USA; ⁵ Pfizer Global Research and Development, Groton, CT, USA
03:07 PM	1127	Targeted Therapy of Human Neuroblastoma Cells using Auger Electrons of Indium-111-labeled N-myc Antisense Oligonucleotide WATANABE N National Institute of Radiological Sciences, Chiba, Japan, International Atomic Energy Agency, Human Health Division, Vienna, Austria

03:27 PM	220	Which ABC-transporters should we target in leukemia? STEINBACH D University Children's Hospital Ulm, Eythstrasse 24, 89075 Ulm, Germany, Phone No.: +49 (0) 731 50057126, FAX No.: +49 (0) 731 50057485, Daniel@Steinba.ch
03:47 PM	1107	Synergistic or Antagonistic Interaction between Taxanes and G1/S Arresting Agents in Combination Therapy FAN W ^{1,2} , SUI M ² , ZENG S ¹ and ZHENG SS ¹ ¹ Zhejiang Univ., Hangzhou, China; ² Med. Univ. of SC, Charleston, USA
04:07 PM	835	A Novel Anti-Angiogenic Glycotherapeutic for Breast Cancer BANERJEE DK Department of Biochemistry, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR. USA
04:27 PM	28	Inhibitory Effects of Demecolcine on NK Cell Functions: Implications for Cancer Therapy SUCK G ¹ , KOH MBC ^{1,2} Blood Services Group, Health Sciences Authority ¹ and Department for Haematology Singapore General Hospital ² , Singapore

04:45 - 05:45 PM Vaccines - Antiinfectives - Herpes

Room 112

Chairman: J. Rajcani, Bratislava, Slovak Republic

Time	Abstr. No.	Title
04:45 PM	832	Preventing Immune Evasion as a Strategy for Enhancing the Effectiveness of Herpes Simplex Virus Vaccine. AWASTHI S, LUBINSKI J M, AND FRIEDMAN H M Infectious Disease Division, Department of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
05:05 PM	794	The Herpes Simplex Virus (HSV) Vaccines: Old Problems, New Challenges RAJCANI J Alpha medical a.s., Institute of Laboratory Diagnostic, Martin; Institute of Virology, Bratislava, Slovak Republic
05:25 PM	1379	Vaccination with Recombinant MHV68 Producing IFN? Effectively Protects Mice Against Infection With Wild Type MHV-68 and Dramatically Reduces the Establishment of Long-term Spleen Latency. ARICO' E ¹ , MONQUE DM ¹ , MOSCHELLA F ¹ , D'AGOSTINO G ¹ , VENDITTI M ¹ , KALINKE U ² , ALLEN D ³ , NASH A ³ , BELARDELLI F ¹ , FERRANTINI M ¹ . ¹ Istituto Superiore di Sanità, Rome, Italy; ² Paul Ehrlich Institute, Langen, Germany; ³ University of Edinburgh, Edinburgh, UK.

04:45 - 05:45 PM Antineoplastic agents - Genomic approaches to optimize therapy - Part I

Room 404

Chairman: Y Gong, Brussels, Belgium

Time	Abstr. No.	Title
04:45 PM	359	Generation of Human Gene Knockout Cell Lines: Application to Assessment of Genotoxic Anticancer Drugs ADACHI N International Graduate School of Arts and Sciences, Yokohama City University, Yokohama, Japan.
05:05 PM	364	Development of Prognostic and Predictive Variables in Breast Cancer: Personalized Approach Using Gene Expression Profiling Microarray GONG Y ¹ , YAN K ¹ , LIN F ¹ , ANDERSON K ¹ , SOTIRIOU C ² , ANDRE F ³ , HOLMES FA ⁴ , VALERO V ¹ , BOOSER D ¹ , PIPPEN JE ⁵ , VUKELJA S ⁶ , GOMEZ H ⁷ , MEJIA J ¹ , BARAJAS LJ ⁸ , HESS KR ¹ , SNEIGE N ¹ , HORTOBAGYI GN ¹ , PUSZTAI L ¹ , SYMMANS WF ¹ ¹ The University of Texas M. D. Anderson Cancer Center, Houston TX, USA; ² Institut Jules Bordet, Brussels, Belgium; ³ Institut Gustave Roussy, Villejuif, France; ⁴ US Oncology-Texas Oncology, Houston, TX, USA; ⁵ US Oncology-Texas Oncology, Sammons Cancer, Dallas, TX, USA; ⁶ US Oncology-Texas Oncology, Tyler Cancer Center, Tyler, TX; ⁷ Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; ⁸ Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico

05:25 PM 1227 Treatment Prospects For Breast Cancer: Lessons Learnt From A Decade Of Research On
Maspin
KHALKHALI-ELLIS Z, HENDRIX MJC
Children's Memorial Research Center, Robert H. Lurie Comprehensive Cancer Center,
Northwestern University Feinberg School of Medicine, Chicago, USA

04:45 - 06:05 PM Antiparasitic compounds – Discovery

Room Paul Ehrlich Hall

Chairmen: J. Akue, Franceville, Gabon
V. Duschak, Ciudad de Buenos Aires, Argentina

Time	Abstr. No.	Title
04:45 PM	477	<i>In vitro</i> Activities of Extracts from Natural Plants on the Human Filaria <i>Loa loa</i> MENGOME LE¹, FEUYA TCHOUYA GR¹, SOUZA A¹, NSI EMVO E¹, AKUE JP² ¹ Institut de Pharmacopée et de Médecine Traditionnelle (IPHAMETRA), Libreville, Gabon ; ² Centre International de Recherches Médicales de Franceville (CIRMF), Franceville , Gabon.
05:05 PM	842	Sulfated oligosaccharides as main targets in cruzipain, the major cysteine proteinase of <i>Trypanosoma cruzi</i> ACOSTA DM¹, SOPRANO LL¹, ESTEVA MI¹, KOVENSKY J², COUTO AS³ DUSCHAK VG¹ ¹ Inst Nac Parasitol "Dr Mario Fatała Chaben", Ministerio de Salud, Argentina; Laboratoire des glucides, Université Joules Verne, Amiens, France; ² CHIDECAR, FCEyN, UBA, Argentina.
05:25 PM	604	Drug-Peptide Conjugates with Antitumor or Anti Parasite Activity HUDE CZ F^{1,2}, ORBÁN E¹, MIKLÁN ZS¹, SZABÓ R¹, BÁNÓCZI Z¹, REMÉNYI J¹, GAÁL D² ¹ Research Group of Peptide Chemistry, Hungarian Academy of Sciences, Eötvös L. University, Budapest, Hungary. ² Department of Organic Chemistry, Eötvös L. University, Budapest, Hungary. ³ National Institute of Oncology, Budapest, Hungary
05:45 PM	1484	A Novel, Safe, and Effective Clinical Treatment to Eliminate Resistance in Ectoparasites MEINKING T, VILLAR ME, RIVERA H, PAQUET D, EYERDAM D, VICARIA M Institution: Global Health Associates of Miami, 7800 SW 57 th Ave Suite 219, 33143 Miami FL, USA

04:45 - 06:05 PM Antineoplastic agents - Tyrosine Kinase Inhibitors - Part II

Room 212

Chairmen: G. Wcislo, Warszawa, Poland
E. Razi, ATHENS, Greece

Time	Abstr. No.	Title
04:45 PM	512	Early Results of Imatinib as the Active Agent in Control of Aggressive Fibromatosis. An Attempt of Metaanalysis WCISLO G, BODNAR L, SZARLEJ-WCISLO K, SZCZYLIK C Department of Oncology, Military Institute of Medicine, Warsaw, Poland Email: gabrielwcislo@yahoo.pl
05:05 PM	145	Lapatinib: New Expectations RAZIS E Hygeia Hospital, Athens, Greece
05:25 PM	766	Receptor Protein Tyrosine Phosphatase Beta/Zeta as a Possible New Target to Regulate Endothelial and Tumor Cell Migration PAPADIMITRIOU E, MIKELIS C, KOUTSIOMPA M AND THEODOROPOULOU C Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, 26504 Patras, Greece
05:45 PM	198	<i>In vitro</i> hypothesis, <i>in vivo</i> veritas. Success and failure of Imatinib in cancer target therapy PRICL S MOSE Laboratory, DICAMP, University of Trieste, Trieste, Italy

04:45 - 06:05 PM Antivirals - New compounds and their mechanisms - Part II

Room 412

Chairmen: R. Geiben Lynn, Boston, USA
 T. Bell, Reno, USA

Time	Abstr. No.	Title
04:45 PM	1283	Development of Serpin drugs for the treatment of HIV/HCV co-transfections LETVIN NL and GEIBEN-LYNN R Division of Viral Pathogenesis, BIDMC and Harvard Medical School, Boston, MA 02115, USA.
05:05 PM	749	Synthesis and QSAR Studies of CADA Analogs with CD4 Down-modulating and anti-HIV Activities BELL TW ¹ , SCHOLS D ² , VERMEIRE K ² ¹ Univ. of Nevada, Reno, NV, USA; ² Katholieke Univ. Leuven, Belgium.
05:25 PM	750	System approach to Magic Bullets: tissue and cell targeted delivery of HIV and cancer drugs HO Rodney J.Y. University of Washington, Seattle, Washington 98195-7610, USA
05:45 PM	951	Anti-HIV activity of lectins from marine invertebrates MOLCHANOVA V ¹ , LI W ² , CHIKALOVETS I ¹ , WANG J-H ³ , ZHENG Y-T ³ , LUKYANOV P ¹ ¹ Pacific Institute of Bioorganic Chemistry, Vladivostok, Russia; ² Dalian Fisheries University, Dalian, China; ³ Kunming Institute of Zoology, Kunming, China.

04:45 - 06:05 PM Parkinson's disease, mechanism of disease and treatment - Part II

Room 405

Chairmen: K. Magyar, Budapest, Hungary
 B. Szende, Budapest, Hungary

Time	Abstr. No.	Title
04:45 PM	51	Four Decades In Selegiline Research; Historical Aspects, Further Perspectives MAGYAR K Dept. of Pharmacodyn., Semmelweis Univ., Neurochem. Res. Unit., Hung. Acad. Sci.
05:05 PM	1354	Anti-apoptotic and apoptotic action of (-)deprenyl (Selegiline) and its metabolites SZENDE B (1) , MAGYAR K(2) 1 st Department of Pathology and Experimental Cancer Research (1) and Department of Pharmacodynamics (2) Semmelweis University, Budapest, Hungary
05:25 PM	782	Manganese (Mn) Transport at the Blood-Brain Barrier: Implications for Parkinson's-Like Disease ASCHNER M ^{1,2} , BENEDETTO A ¹ , AU C ¹ ¹ Dept. Pediatrics and ² Dept. Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA
05:45 PM	292	<i>N</i> -Oleoyl-Dopamine: A Potential Novel Deliverer of Dopamine to the Brain POKORSKI M , ZAJAC D , REKAWEK A. Department of Respiratory Research, Medical Research Center, Polish Academy of Sciences, Warsaw, Poland

04:45 - 06:05 PM Pharmaceuticals - Nanoparticles and their latest developments - Part II

Room 403

Chairmen: S. Mueller, Muenster, Germany
 N. Bhogal, Nottingham, United Kingdom

Time	Abstr. No.	Title
04:45 PM	1604	Investigations Into Sulfur Nanoparticles As Drug Carriers MUELLER RS Westfälische Wilhelms-Universitaet, Muenster, Germany
05:05 PM	1259	Nanodevices for targeted delivery: An evaluation of toxicological models BHO GAL N FRAME, Russell & Burch House, 96-98 North Sherwood Street, Nottingham, UK
05:25 PM	917	Polyethylene Glycol Gold Coated Nanoparticles for the Enhancement of the Efficacy of a Specific Nutrient Synergy HARAKEH S¹ ; PARAK W³ ; SPERLING R³ ; NIEDZWIECKI A¹ ; RATH M¹ ; BAYDOUN E² 1 Dr.Rath Research Institute, Santa Calra, CA, USA 2 Biology Department, American University of Beirut, Beirut, Lebanon 3 Philipps University Marburg, Physics Department, Renthof 7, 35037 Marburg, Germany
05:45 PM	887	One Bullet, Two Targets! A Nano-Particle With Two Key Medical Applications MOREIN B¹ , HU K¹ , LARSSON R² , NYGREN P³ , LÖVGREN K⁴ ¹ Department of Medical Sciences, Section of Virology, Uppsala University; ² Department of Sciences, Uppsala University; ³ Department of Oncology, Uppsala University; ⁴ Isconova AB, Uppsala, Sweden

04:45 - 06:05 PM Sex steroids

Room 406

Chairmen: B. Wallner, Vienna, Austria
 H. Van Veen, CAMBRIDGE, United Kingdom

Time	Abstr. No.	Title
04:45 PM	66	Chronic Levonorgestrel Treatment in a Macaque Species (<i>Macaca sylvanus</i>): effects on sex steroids and secondary sex characteristics WALLNER B^{1,2} , MÖSTL E³ , DITTAMI J^{1,4} ¹ Univ. of Vienna, Vienna, Austria; ² Dept. of Anthropology; ³ Veterinary Univ. of Vienna, Vienna; Austria; Institute of Biochemistry; ⁴ Depart. Behavioural Biology
05:05 PM	737	A functional steroid-binding element in an ATP-binding cassette multidrug transporter VAN VEEN HW Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge CB2 1PD, United Kingdom
05:25 PM	1108	Metals as Endocrine Disruptors in Women's Reproduction: Assessment of Effect and Mechanism of Action in Different Steroidogenic Cells PIASEK M¹ , HENSON MC² , CHEDRESE PJ³ ¹ Institute for Medical Research and Occupational Health, Zagreb, HR, Croatia; ² Purdue University Calumet, Hammond, IN, USA; ³ University of Saskatchewan, Saskatoon, CA, Canada.
05:45 PM	177	Role of estradiol and testosterone in the regulation of bone metabolism in men and women SZULC P INSERM 831 Research Unit, Hôpital Edouard Herriot, University of Lyon, Lyon, France

04:45 - 06:05 PM Therapy with monoclonal antibodies - Part I

Room 215

Chairmen: C. Montalban, Madrid, Spain
R. Stebbings, Hertfordshire, United Kingdom

Time	Abstr. No.	Title
04:45 PM	518	First-Line Treatment With Rituximab Combined With Intravenous Or Oral Fludarabine For Patients With Extranodal Mucosa Associated Lymphoid Tissue (MALT) Lymphoma MONTALBÁN C , ¹ DOMINGO-DOMENECH DE, ² ESTANY C, ³ CANALES MA, ⁴ SALAR A ⁵ Department of Clinical Hematology, Hospital del Mar; ⁵ Department of Clinical Hematology (ICO), Hospitalet de Llobregat, ² Department of Hematology, Mutua de Terrasa; ³ Barcelona and Department of Hematology, Hospital La Paz, Madrid ⁴ and Department of Internal Medicine, Hospital de Ramón y Cajal, Madrid; ¹ Spain
05:05 PM	596	New Medicines, New Problems: Understanding the Failure of the Phase I Clinical Trial of Tgn1412 STEBBINGS R , EASTWOOD D, FINDLAY L, BURNS C, POOLE S, THORPE R Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), Potters Bar, Hertfordshire, United Kingdom
05:25 PM	245	Infliximab: Beyond the primary expectatives SCALI JJ Hospital L Duran, AV.San Martin 1750, CP :1602, Buenos Aires, Argentina
05:45 PM	245	The Impact Of Non-Fucosylated Therapeutic Antibodies In Humans <i>In Vivo</i> SHIGERU IIDA , MITSUO SATOH Antibody Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan

04:45 - 06:12 PM Treatment of severe infections including sepsis

Room 213

Chairmen: C. Joukhadar, Boston, USA
V. Bondar, Atlanta, USA

Time	Abstr. No.	Title
04:45 PM	10015	What we have learned in recent years in the therapy of life threatening Staphylococcus aureus infections! JOUKHADAR C Harvard Medical School.; BIDMC, Dept. of Infec. Diseases, 330 Brookline Ave, 02215 Boston, MA, USA
05:12 PM	412	Current systemic and local therapies of intra-abdominal sepsis BONDAR VM Department of Surgery, Coffee Regional Medical Center, Medical College of Georgia, Douglas, Georgia, USA
05:32 PM	1368	Bone Marrow Stromal Cells Attenuate Sepsis And Sepsis-Induced Acute Kidney Injury (AKI) Via A Novel Mechanism Of Action ² NEMETH K, ¹ LEELAHAVANICHKUL A, ¹ DOI K, ¹ HU X, ³ WEISS JM, ² ROBEY PG, ¹ YUEN PST, ¹ STAR RA, ² E MEZEY ¹ Renal Diagnostics and Therapeutics Unit, NIDDK, NIH; ² NIDCR, NIH, Bethesda, MD; ³ NCI, NIH, Frederick MD, USA
05:52 PM	950	New Anti-Endotoxins Agents against Gram-Negative Bacterial Infections YERMAK IM ^A , DAVYDOVA VN ^A , BARABANOVA AO ^A , GORBACH VI ^A , KHASINA EI. ^B , SOLOV'EVA TF. ^A , MALEEV VV ^C a-Pacific Institute of Bioorganic Chemistry, FED of RAS, Vladivostok, Russia b-Institute of Marine Biology, FED of RAS, Vladivostok, Russia c-Central Research Institute of Epidemiology, Moscow, Russia

04:45 - 06:05 PM Nerve diseases, mechanisms, and pathophysiology - Part III

Room 205

Chairmen: M. Ohadi, Tehran, Iran
F. Shad, Karachi, Pakistan

Time	Abstr. No.	Title
04:45 PM	195	A Novel Polymorphic Purine Complex At The 1.5 kb Upstream Region Of The Human Caveolin-1 Gene And Risk Of Alzheimer?s Disease; Extra-Short Alleles And Accumulated Allele Homozygosity OHADI M University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
05:05 PM	612	Drug Cell Interaction at Molecular Level SHAD FK Panjwani Center for Molecular Medicine and Drug Research International Center for Chemical Sciences, University of Karachi, Karachi-75270, ftmshad@yahoo.com
05:25 PM	539	Blood-brain barrier P-glycoprotein function in aging and neurological disease: <i>in vivo</i> measurements in humans with [¹¹ C]-verapamil PET BARTELS AL, WILLEMSSEN ATM, BART J, KORTEKAAS R, LEENDERS KL Depts of Neurology and Nuclear Medicine & Molecular Imaging, University Medical Centre Groningen, The Netherlands
05:45 PM	836	Innovative Nanopharmaceutical Strategies for Neuronal Survival and Regeneration After Traumatic Brain Injury PENKOWA M University of Copenhagen, Faculty of Health Sciences, Section of Neuroprotection Copenhagen, Denmark.

04:45 - 06:15 PM Cytochrome P450 drug metabolism

Room 216

Chairmen: M. Unger, Würzburg, Germany
D. Terziivanov, Sofia, Bulgaria

Time	Abstr. No.	Title
04:45 PM	10000	New Substrates for the Major Drug Metabolising Cytochrome P450 Enzymes UNGER M Institute of Pharmacy, Am Hubland, 97074 Würzburg, Germany
05:15 PM	185	Application of Population Pharmacokinetic Analysis and Monte Carlo Simulations Method in Drug Phenotyping. Assessment of Cytochrome P450 1A2 Activity in a Population of Adult Non-Related Caucasians from Sparse Data TERZIIVANOV DN and BOZHINOVA KV Clinic of Clinical Pharmacology and Pharmacokinetics, Univ Hosp"St.Ivan Rilski", Med Univ, Sofia, Bulgaria
05:35 PM	1273	The gut, the forgotten metabolic organ: the story of testosterone and dextromethorphan. LUEDTKE D Bayer Schering Pharma AG, Berlin, Germany.
05:55 PM	1371	Cytochrome P450 Inactivation by Pharmaceuticals and Phytochemicals: Therapeutic Relevance JOHNSON WW Drug Metabolism and Pharmacokinetics, OSI Pharmaceuticals, Boulder, CO 80301, USA

04:45 - 06:25 PM Antineoplastic agents - Biochemical approaches

Room 207

Chairmen: M. Dabrowska, Warszawa, Poland
J. Hiratake, Uji, Japan
H. Mizutani, Nagoya, Japan

Time	Abstr. No.	Title
04:45 PM	742	Methotrexate (MTX) Induces Permanent Growth Arrest in Human Adenocarcinoma Cells DABROWSKA M¹ , MOSIENIAK G ¹ , SIKORA E ¹ , RODE W ¹ ¹ Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
05:05 PM	877	Rational Design of Specific Inhibitors of γ -Glutamyl Transpeptidase (GGT) and γ -Glutamylcysteine Synthetase (GCS) for Modulating Cellular Glutathione and Redox Status HIRATAKE J¹ , NAKAJIMA M ¹ , HAN L ¹ , KAWAMURA N ¹ , HIBI T ² , NAKAJIMA Y ² ¹ Institute for Chemical Research, Kyoto University, Uji, Japan; ² Fukui Prefectural University, Fukui, Japan.
05:25 PM	693	Mechanism Of Oxidative DNA Damage And Apoptosis Induced By Doxorubicin Through Generation Of Reactive Oxygen Species MIZUTANI H¹ , HIRAKU Y ² , TADA-OIKAWA S ² , OIKAWA S ² , IKEMURA K ¹ , MURATA M ² , KAWANISHI S ³ ¹ College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan; ² Department of Environmental and Molecular Medicine, Mie University Graduate School of Medicine, Tsu, Japan; ³ Faculty of Pharmaceutical Science, Suzuka University of Medical Science, Suzuka, Japan
05:45 PM	990	Citrate Transport Mechanism In Prostate And Its Changes In Malignant Transformation. Implications For Fatty Acid Synthesis In Cancer MYCIELSKA ME , DJAMGOZ MBA Division of Cell and Molecular Biology, Neuroscience Solutions to Cancer Research Group, Sir Alexander Fleming Building, Imperial College London, South Kensington Campus, London, UK
06:05 PM	1296	The cytostatic treatment effect on nucleoli of leukaemia cells at the single cell level SMETANA K Institute of Haematology and Blood Transfusion, Prague

04:45 - 06:25 PM Steroid receptor - Jensen symposium

Room 214

Chairmen: P. Purohit, London, United Kingdom
P. Schoenlein, Augusta, USA
B. Bhavnani, TORONTO, Canada

Time	Abstr. No.	Title
04:45 PM	1185	Steroid Sulfatase Inhibitors – Novel Therapeutic Agents for Hormone Dependent Cancers PUROHIT A¹ , WOO LWL ² , STANWAY SJ ¹ , POTTER BVL ² , REED MJ ¹ ¹ Imperial College London, London, UK; ² University of Bath, Bath, UK.
05:05 PM	386	A Role for Macroautophagy in Antiestrogen Resistance SCHOENLEIN PV¹ , BARRETT JT ² , SAMUUELS T ¹ , BIEBERICH E ¹ ¹ Medical College of Georgia, Augusta, Ga., ² Watson Clinic, Lakeland, FL
05:25 PM	1202	Mechanisms that Explain the Lower Incidence of Breast Cancer in Postmenopausal Women Treated with Conjugated Estrogens (CEE). Role of Estrogen Receptor α and β . BHAVNANI BR^{1,2} ^{1,2} Univ. of Toronto and The LKSKI of St. Michael Hospital, Toronto, Ontario, Canada.
05:45 PM	559	Competing Causes of Death from a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer: NCIC CTG MA.17 CHAPMAN JW¹ , MENG D ¹ , SHEPHERD L ¹ , PARULEKAR W ¹ , INGLE JN ² , MUSS HB ³ , PALMER M ¹ , YU C ¹ , GOSS PE ⁴ ¹ NCIC Clinical Trials Group, Kingston, Canada; ² Mayo Clinic, Rochester, USA; ³ University of Vermont, Burlington, USA; ⁴ Harvard University, Boston, USA.

06:05 PM 1361 New Steroidal Hormones Promise to Become a Multi-Purpose "Magic Bullet"
KHRIPACH VA¹, **ZHABINSKII VN**¹, **ALTSIVANOVICH KK**², **SAMUSEVICH MP**²,
ZAVADSKAYA MI¹, **TARAZEVIKH EV**³, **SEMENOV AP**³.
¹Inst. Bioorganic Chemistry, Minsk; ²Mikonik Technologies Ltd, Minsk; Fish Industry Inst,
Minsk, Belarus.

04:45 - 06:25 PM Antiparasitic compounds - Leishmaniasis and its intricacies

Room 218

Chairmen: P. De Vries, Amsterdam, The Netherlands
T. Dorlo, Amsterdam, The Netherlands
S. Emadi, Nairobi, Kenya

Time	Abstr. No.	Title
04:45 PM	1027	The Pharmacokinetics and Pharmacodynamics of Miltefosine for Leishmaniasis. DE VRIES PJ ¹ , DORLO TPC ^{1,2} , BEIJNEN JH. ² ¹ Div, Infectious Diseases, Tropical Medicine & AIDS, Academic Medical Center, Amsterdam, the Netherlands; ² Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam the Netherlands
05:05 PM	1307	The Role of ABC Transporters in the Pharmacokinetics of Miltefosine for Leishmaniasis DORLO TPC ^{1,2} , VAN TELLINGEN O ³ , DE VRIES PJ ² , BEIJNEN JH ¹ ¹ Department of Pharmacy & Pharmacology, Slotervaart Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands; ² Division of Infectious Diseases, Tropical Medicine & AIDS, Academic Medical Center, Amsterdam, The Netherlands; ³ Department of Clinical Chemistry, Netherlands Cancer Institute, Amsterdam, The Netherlands.
05:25 PM	1366	New Strategic treatment for cutaneous leishmaniasis by local injection (Glucantime + triamcinolone 1/20ratio) in 250 patient in Bam-Iran EMADI SN 1- Red Crescent Society Research Center, Tehran, Iran 2- Baqiatallah University of Medical Sciences, Tehran, Iran
05:45 PM	1321	Antiplasmodial And Immunomodulating Activity Of Some Sudanese Herbal Medicine With Emphasis On Pristimerin As Antiplasmodial And Antileishmanial Agent IDRIS A eIT M ^{1,2} , SATTI G M H. ¹ , THEANDER T ³ , CHRISTENSEN S B. ⁴ , KHALID S A. ⁵ ¹ Faculty of Medicine, King Fahad Medical City, Kingdom of Saudi Arabia, ² Dept. of Biochemistry, Faculty of Medicine, University of Gezira, Sudan, ³ Panum Institute, University of Copenhagen, Copenhagen, Denmark, ⁴ Department of Medicinal Chemistry, Natural Products Research, The Danish University of Pharmaceutical Sciences, DK-2100 Copenhagen, Denmark, ⁵ Dept. of Pharmacognosy, Faculty of Pharmacy, University of Khartoum, Sudan
06:05 PM	1046	Photodynamic therapy as a new method for the treatment of cutaneous leishmaniasis GHAFFARIFAR F* ¹ , JORJANI O ¹ , MIRSHAMS M ² ¹ Parasitology Dept., School of medical science, Tarbiat Modarres University, Tehran, Iran ² Department of Dermatology, Tehran Medical University, Medical School, Razi hospital, Laser clinic Tehran, Iran

04:45 - 06:25 PM Therapeutic Proteins - clinical studies - Part II

Room 111

Chairmen: N. Biermasz, Leiden, The Netherlands
A. Safdar, Houston, USA
S. Makinoda, Uchinada, Japan

Time	Abstr. No.	Title
04:45 PM	404	Treatment Outcome And Management Of Acromegaly Before And After The Introduction Of Somatostatin Analogs A long term follow-up study BIERMASZ NR , PEREIRA AM , ROMIJN JA Leiden University Medical Center, Dept. of Endocrinology and Metabolism, Leiden, The Netherlands.

05:05 PM	74	Vaccination in Patients with Cancer: Strategies to Prevent Influenza and Pneumococcal Disease SAFDAR A M.D. Anderson Cancer center
05:25 PM	8	A New Application Of Granulocyte Colony-Stimulating Factor (G-CSF) In The Female Reproductive Medicine - For Prevention Of Luteinized Unruptured Follicle (LUF) - MAKINODA S, TOMIZAWA H, FUJITA S, WASEDA T, FUJII R Kanazawa Med. Univ., Uchinada, Japan
05:45 PM	538	Recombinant Factor VIIa (rFVIIa) For The Treatment Of Bleeding In Abdominal Surgery And Cardiac Surgery MICHALSKA GM, HAMERA I University Hospital nr1, Szczecin, Poland
06:05 PM	371	Pharmacokinetics and Biological Effects of the Recombinant Human Bone Morphogenetic Protein-7 in Vivo SMAJILAGIC A(1), REDZIC A (2), FILIPOVIC S (3) 1. University Clinic Center Sarajevo, Clinic for Maxillofacial Surgery, Sarajevo, Bosnia and Herzegovina; 2. Medical Faculty University in Sarajevo, Institute for Biology and Human Genetic, Sarajevo, Bosnia and Herzegovina; 3. Faculty of Veterinary Medicine University in Sarajevo, Clinic for Surgery, Orthopedic and Ophthalmology, Sarajevo, Bosnia and Herzegovina

04:45 - 06:40 PM Antineoplastic agents - Clinical trials and approaches- Part II

Room 206

Chairmen: H. Shimada , Yokohama, JAPAN
 T. Muir, Ingleby Arncliffe, United Kingdom
 B. Maisch, Marburg, Germany

Time	Abstr. No.	Title
04:45 PM	667	Treatment strategies for multiple liver metastases from colorectal cancer SHIMADA H¹⁾²⁾, TANAKA K¹⁾, ENDO I¹⁾ Dept. of Gastroenterological Surgery, Yokohama City Univ. Graduate School of Medicine, Yokohama, Japan Harue General Hospital, Fukui, Japan
05:05 PM	1184	Teaching An Old Dog New Tricks: Intralesional Bleomycin Injection (IBI) Treatment Of Vascular Birthmarks MUIR T¹⁾, SAINSBURY D , KESSELL G , FALL A , GUHAN A , MILLER V James Cook University Hospital, Middlesbrough, United Kingdom
05:25 PM	277	Intrapericardial Cisplatin Treatment Prevents Effectively The Recurrence Of Neoplastic Pericardial Effusion MAISCH B, PANKUWEIT S, RUPP H, RISTIC A Philipps Universität Marburg, Internal Medicine–Cardiology, Germany
05:45 PM	1755	Systems-directed targeted therapies in metastatic tumors: Equitable to reductionist therapy approaches? REICHLER A, VOGELHUBER M, VOGT T, BERAND A, BROSS K, WIEST R, KLEBL F, KULLMANN F, ROGENHOFER R, WALTER B, HAU P, ANDREESSEN R University Hospital of Regensburg, Regensburg, Germany
06:05 PM	1474	Correlation Between Clinicopathological Features and Allelic Loss at Tp53 In Metastatic Endometrial Cancer SEMCZUK A¹⁾, OLCHA P¹⁾, SEMCZUK M²⁾, CYBULSKI M³⁾, PRZADKA-RABANIUK D¹⁾, FILIP A⁴⁾, SKOMRA D⁵⁾, SZEWCZUK W¹⁾ ^{1)IND} Department of Gynecology, ²⁾ Department of Obstetrics, ³⁾ Department of Biochemistry and Molecular Biology, ⁴⁾ Department of Human Genetics, and ⁵⁾ Department of Pathology, Lublin Medical University, Lublin, Poland
06:25 PM	1329	Capecitabine-associated coronary vasospasm: a case report PAPADOPOULOS CA, WILSON H. Emergency Assessment Unit Medicine, Norfolk and Norwich University Hospital, Colney Lane, Norwich, England

04:45 - 06:41 PM Antibacterials - PK/PD of antibiotics in serious infections

Room 101

Chairmen: J. Mouton, Nijmegen, The Netherlands
 R. Jelliffe, Los Angeles, USA
 J. Roberts, Herston, Australia

Time	Abstr. No.	Title
04:45 PM	1642	[Title to be finalized.] MOUTON J Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, Nijmegen, The Netherlands.
05:17 PM	10008	Therapeutics: New Protocols For Instituting Continuous Intravenous Vancomycin Therapy JELLIFFE R Laboratory of Applied Pharmacokinetics, USC Keck School of Medicine, Los Angeles, CA, USA
05:41 PM	425	Piperacillin Dosing In ICU Patients – New Magic For Old Bullets ROBERTS JA ¹ , KIRKPATRICK CMJ ¹ , ROBERTS MS ¹ , LIPMAN J ¹ ¹ Univ. of Queensland, Queensland, Australia
06:01 PM	912	High-dose Levofloxacin to Reduce Duration of Therapy and Slow Emergence of Resistance PETERSON J ¹ , NICHOLSON S ¹ ¹ . Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA
06:21 PM	348	Value of pharmacokinetic/pharmacodynamic in dose management of ceftazidime and imipenem in ICUs AUBERT G ¹ , CARRICAJA A ¹ , AUBOYER C ² , ZENI F ³ ¹ Antibiology Laboratory, Univ. North Hosp. - Saint-Etienne - France; ² Intensive Care Unit, Univ. North Hosp. - Saint-Etienne - France; ³ Intensive Care Unit, Univ. Bellevue Hosp. - Saint-Etienne. - France.

04:45 - 06:45 PM Resistance - a Global Issue for diverse therapeutic areas - Part II

Room 115

Chairmen: S. Dei, Sesto Fiorentino, Italy
 M. Pasquini, ROME, Italy
 I. Tatischeff, Evry cedex, France

Time	Abstr. No.	Title
04:45 PM	1084	<i>N,N</i> -bis(alkanol)amine aryl esters and <i>N,N</i> -bis(cyclohexanol)amine aryl esters: identification of a new class of Pgp-dependent multidrug resistance (MDR) reverters endowed with potencies in the nanomolar range DEI S ¹ , MARTELLI C ¹ , TEODORI E ¹ , MANETTI D ¹ , CORONNELLO M ² , SALERNO M ³ , SGARAGLI G ⁴ , GUALTIERI F ¹ ¹ Dipartimento di Scienze Farmaceutiche, Università di Firenze, via U. Schiff 6, 50129 Sesto Fiorentino (FI), Italy; ² Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, viale G. Pieraccini 6, 50139 Firenze, Italy; ³ Laboratoire BioMoCeTi, Université Paris 13, 73 rue Marcel Cachin , 93017 Bobigny, France; ⁴ Dipartimento di Neuroscienze, Università di Siena, via A. Moro 2, 53100 Siena, Italy
05:05 PM	524	Central glutamatergic dysfunction as an explanation of resistance and refractoriness in Obsessive-Compulsive Disorder PASQUINI M , BERARDELLI I Department of Psychiatry and Psychological Medicine SAPIENZA University of ROME
05:25 PM	767	And what if we used for therapeutic drug delivery, the "magic bullets" that Dictyostelium discoideum cells expel as a multidrug resistance mechanism? TATISCHEFF I , LAVIALLE ¹ F AND ALFSEN ² ¹ BioMoCeTi, CNRS UMR 7033, Université Pierre et Marie Curie, Génopole campus 1, 91030 Evry cedex ² CNRS, UMR 8104, INSERM, U567, Institut Cochin, Département de Biologie Cellulaire, Université Paris-Descartes, 75014 Paris, France
05:45 PM	764	Aspirin resistance myth or reality? COX D ¹ , MCCALL ¹ M, TEDESCO A ¹ , PEACE A ¹ AND FOLEY D ² . ¹ Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, and ² Department of Cardiology, Beaumont Hospital, Dublin, Ireland

- 06:05 PM 307 The Inverse Relationship between Cisplatin and Paclitaxel Resistance: Two 'Magic Bullets' are Needed
STORDAL B^{1,2}, PAVLAKIS N¹, DAVEY R¹
¹Bill Walsh Cancer Research Laboratories, Department of Medical Oncology, Royal North Shore Hospital, St. Leonards NSW 2065, AUSTRALIA
²National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, IRELAND
- 06:25 PM 549 Effect of Genetic Polymorphisms in ABCG2 (BCRP) on Inhibition and Potential Drug Resistance
WANG M, EMERICK RM, SAWADA GA, PAK YA, RAUB TJ, HILLGREN KM
Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46285 (* currently at Bristol-Myers Squibb Company, Pennington, NJ)

04:45 - 07:04 PM Anti-infectives - PK/PD modeling strategies and applications

Room 217

Chairmen: A. Forrest, Latham, USA
E. Schuck, Andover, USA
J. Bulitta, Buffalo, USA

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 04:45 PM | 10005 | Mechanistic PK/PD modeling of anti-infectives - what does this approach have to offer?
FORREST A
ICPD-Ordway Research Institute, 43 British American Blvd., Latham, NY 12110, USA |
| 05:17 PM | 283 | PK/PD Modeling of Time-Kill Curves: Addressing Biphasic Killing Patterns
SCHUCK EL ¹ & DERENDORF H ²
¹ Eisai Research Institute, Andover, MA, USA; ² University of Florida, Gainesville, FL, USA |
| 05:37 PM | 10000 | Inverse and normal inoculum effects of antibiotics? a new paradigm for co-modeling the time-course of bacterial killing across a range of initial inocula
BULITTA J
University at Buffalo, NY, USA |
| 06:04 PM | 551 | Predicting Fluoroquinolones Ability To Kill Resistant <i>Streptococcus Pneumoniae</i> Isolates Expressing Different Genetic Mutations: Target Attainment Analysis Simulating Therapeutic Doses To Patients With Community Acquired Pneumonia
NOREDDIN AM ¹ , HOBAN D ² , ZHANEL GG ²
¹ University of Minnesota, Duluth, USA; ² Univeristy of Manitoba, Winnipeg, Canada |
| 06:24 PM | 1043 | Computational Investigation Of Infectious Disease Mechanisms: From HIV-1 Virus Inhibition To Bacterial Resistance To Antibiotics
RAUGEI S
International School for Advanced Studies, Trieste, Italy |
| 06:44 PM | 1553 | <i>In Vitro</i> Pharmacodynamic Evaluation Of Intracellular Activity Of Antibiotics (ABs) Alone Or In Combination Against A Small Colony Variant (SCV) Of <i>Staphylococcus Aureus</i>
NGUYEN HA ¹ , DENIS O ² , VERGISON A ² , TULKENS PM ¹ , STRUELENS MJ ¹ , VAN BAMBEKE F ¹
¹ Université catholique de Louvain, ² Université libre de Bruxelles, Brussels, Belgium |

06:25 - 06:45 PM Antineoplastic agents - Effectiveness and resistance in patients - Part III

Room 206

- | Time | Abstr. No. | Title |
|----------|------------|---|
| 06:25 PM | 1056 | The insulin-like growth factor pathway- the key to overcoming resistance in cancer therapy?
HALUSKA P
Division of Medical Oncology, Mayo Clinic, Rochester, MN |

08:45 - 09:25 AM Analgesia & analgetic drugs – Part III

Room 218

Chairman: Grossherr, Luebeck, Germany

Time	Abstr. No.	Title
08:45 AM	136	A Concerted Approach Using Physical Chemical Methodologies, Computational Chemistry And 3D QSAR Studies Aiming To Develop Novel Analgesic Cannabinoid Analogs MAVROMOUSTAKOS T ^{1,2} , DURDAGI S ^{2,3} , REIS H ² , KOUKOULITSA C ² , PAPADOPOULOS ² ¹ Department of Chemistry, University of Athens, Zographou, Athens, Greece, ² Institute of Organic and Pharmaceutical Chemistry, The National Hellenic Research Foundation, Greece, ³ Department of Biology Chemistry and Pharmacy, Freie Universitat Berlin, Germany
09:05 AM	14	Infusion Monitoring of Anesthetic Drugs: Propofol in Respiratory Gas GROSSHERR ¹ , HENGSTENBERG ² , VARADARAJAN B ² , DIBBELT ³ , SCHMUCKER ¹ , GEHRING ¹ ¹ Dept. of Anaesthesiology and ³ Central Laboratory, Department of Clinical Chemistry; UK S-H, Campus Luebeck, Luebeck, ² Research Unit, Draegerwerk Drägerwerk AG Co. KGaA, Germany

08:45 - 10:05 AM Antibacterials - Clinical Aspects - Part III

Room 205

Chairmen: D. Maharaj, Wellington South, New Zealand
S. Saxena, ABU DHABI, United Arab Emirates

Time	Abstr. No.	Title
08:45 AM	141	Infectious Pregnancy Complications MAHARAJ D Dept. of O&G, University of Otago, Wellington, New Zealand
09:05 AM	171	Intraluminal Cefotaxime – Heparin Lock' Placement in the Primary Prevention of Hemodialysis Catheter-Related bloodstream Infections among the Elderly and Diabetics SAXENA AK ¹ , PANHOTRA BR ² , AL-HAFIZ A ² , SUNDARAM DS ² , NAGUIB M ² , ABU OUN BA ² ¹ Al-Rahba Hospital- Johns Hopkins Medicine International, Abu Dhabi, United Arab Emirates (UAE), ² King Fahad Hospital and Tertiary Care Center, King Faisal University, Al-Hasa, Eastern Province, Saudi Arabia
09:25 AM	755	Chlorhexidine Gluconate - Local Antimicrobial Agent in Aid of Prevention and Treatment of Periodontal and Peri-implant Diseases KOZLOVSKY A , ISRAELI-TOBIAS CH, BAR-NESS GREENSTEIN R, HIRSHBERG A The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
09:45 AM	570	The prognostic value of genetic and phenotypic markers of drug metabolism and host and exposure factors for antituberculous drug induced hepatotoxicity VAVILIN VA ¹ , MAKAROVA SI ¹ , KOLPAKOVA TA ² , KUDRYASHOV AV ⁴ , MUTAIKHAN J ² , NIKISHINA MV ¹ , KOJANOVA LA ³ , POLYANSKAYA LV ³ , KRASNOV VA ² , LYAKHOVICH VV ¹ ¹ Institute of Molecular Biology and Biophysics, Novosibirsk, Russia, ² Novosibirsk Institute of Tuberculosis, Novosibirsk, Russia, ³ Close comany Institute Chromatography "EcoNova", Novosibirsk, Russia, ⁴ Novosibirsk state University, Novosibirsk, Russia

08:45 - 10:05 AM Drug-drug and drug-nutrient interactions - Part II

Room 215

Chairmen: L. Ajaimé Azzalis, São Paulo, Brazil
B. Astrand, Kalmar, Sweden

Time	Abstr. No.	Title
08:45 AM	1508	Effects of Alcohol and Sucrose Intake on Rat Liver Cyp2e1 AZZALIS LA ¹ , FONSECA FLA ² , SCHINDLER F ² , GIAVAROTTI L ¹ , MONTEIRO HP ³ , VIDELA LA ⁴ , JUNQUEIRA VBC ⁵ ¹ Universidade Anhembi Morumbi, São Paulo, Brasil, ² Faculdade de Medicina do ABC, Departamento de Hematologia e Oncologia, Santo André, Brasil, ³ Departamento de Bioquímica, UNIFESP, São Paulo, Brasil, ⁴ Programa de Farmacologia Molecular y Clínica, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile. ⁵ Disciplina de Geriatria, Departamento de Medicina, UNIFESP, São Paulo, Brasil.
09:05 AM	534	How to avoid drug—drug interactions ÅSTRAND B ¹ , MONTELIUS E ² , ANTONOV K ³ , HOVSTADIUS B ¹ , PETERSSON G ² ¹ School of Pure and Applied Natural Sciences, University of Kalmar, Kalmar, Sweden ² School of Human Sciences, University of Kalmar, Kalmar Sweden ³ The Association of Pharmaceutical Industry, Stockholm, Sweden
09:25 AM	675	Are Grapefruit, Orange, Lime, Pummelo and Apple the Forbidden Fruits of Drug Interactions? BAILEY DG , DRESSER GK , KIM RB University of Western Ontario, London, Canada
09:45 AM	301	Frovatriptan - the triptan with the least drug/drug interactions GOLDSTEIN J Director, San Francisco Clinical Research Center, San Francisco Headache Clinic, and San Francisco Alzheimer's and Dementia Clinic

08:45 - 09:45 AM Metabolic Diseases

Room 216

Chairman: C. Lugnier, Strasbourg, France

Time	Abstr. No.	Title
08:45 AM	506	A potential molecular link for metabolic stress and carcinogenesis: AMP-activated protein kinase CHING YP The University of Hong Kong, Pokfulam, Department of Anatomy, LKS medical school Hong Kong
09:05 AM	757	Specific Inhibitors of the Cyclic Nucleotide Phosphodiesterases PDE2 and PDE4 Overcome <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis KERAVIS T , LUGNIER C CNRS UMR 7175, Université Louis Pasteur de Strasbourg, France
09:25 AM	263	Selective inhibition of signal peptide-dependent cotranslational translocation by the cyclopeptolide CAM741 HARANT H , OBERHAUSER B , de VRIES JE , LINDLEY, IJD Novartis Institutes for BioMedical Research, A-1235 Vienna, Austria

08:45 - 10:25 AM CNS - Pharmacological options in disease of the central nervous system - Part IV

Room 403

Chairmen: M. Abdulrazik, EAST-JERUSALEM, Israel
J. Yip, Boston, USA

Time	Abstr. No.	Title
08:45 AM	1223	Non-Systemic Delivery of Ocular Brimonidine to the Brain: Extending the Therapeutic Benefits of Brimonidine to the CNS ABDULRAZIK M ^{1,2} , TAMILVANAN S ¹ , BENITA S ¹ ¹ Pharmaceutics Department, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel, and ² Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
09:05 AM	1554	Inhibitory balance of γ -aminobutyric acid in cerebellar circuitry in autism: a circuit-centered approach to drug target design for developmental neurobiological disorders YIP J , SOGHOMONIAN JJ, BLATT GJ Department of Anatomy and Neurobiology, Boston University School of Medicine, Boston MA 02118
09:25 AM	639	Valproate (VPA): unrecognized value from an old molecule KASTELEIJN-NOLST TRENITÉ DGA ¹ , REED RC ² , O'BRIEN TJ ³ , VAN RAAY L ³ , HOGAN RE ⁴ , MORRIS MJ ⁵ , DEDEURWAERDERE S ⁶ , PICCIOLI M ⁷ , PARISI P ¹ , TISEI P ¹ , PIA VILLA M ¹ , BUTTINELLI C ¹ 1. Universita di Roma, Sapienza II, Rome, Italy, 2. Abbott, Global Pharmaceutical Research & Development, Neuroscience, Abbott Park, IL, USA, 3. University of Melbourne, Australia, 4. Washington University, St Louis, USA, 5. University of New South Wales, Kensington, Australia, 6. Australian Nuclear Science & Technology Organisation, Lucas Heights, Australia, 7. San Filippo Neri hospital, Rome, Italy
09:45 AM	553	Application of Prodrug Strategies to Create Magic Bullets for the Treatment of CNS Maladies PROKAI L Department of Molecular Biology & Immunology, University of North Texas Health Science Center at Fort Worth, USA.
10:05 AM	1071	Peripherally Administered TrkB Agonists Cause Appetite Enhancement and Weight Gain in Non-Human Primates LIN JC ¹ , TSAO D ¹ , BARRAS P ³ , BASTARRACHEA R ² , BOYD B ⁴ , CHOU J ¹ , ROSETE R ¹ , LONG H ¹ , FORGIE A ¹ , ABDICHE Y ¹ , DILLEY J ¹ , STRATTON J ¹ , GARCIA C ¹ , SLOANE D ¹ , COMUZZIE A ² , ROSENTHAL A ¹ 1 Rinat, Pfizer Inc., S. San Francisco, USA, 2 SW Foundation for Biomedical Research, San Antonio, USA, 3 Alpha Genesis, Inc., Yemassee, USA, 4 Northern Biomedical Research, Muskegon, USA.

08:45 - 10:05 AM Treatment of asthma, COPD, and other lung diseases - Part III

Room 115

Chairmen: J. Kim, Boston, USA
G. Hochhaus, Gainesville, FL 32608, USA
H. Högger, Würzburg, Germany

Time	Abstr. No.	Title
08:45 AM	1075	Tumor Necrosis Factor (TNF)-? Inhibitors Effectively Treat Asthma. KIM J , REMICK DG Department of Pathology and Lab Medicine, Boston University School of Medicine Boston, USA
09:05 AM	671	Pharmacokinetic/pharmacodynamic considerations for inhaled glucocorticoids HOCHHAUS G Univ. of Florida, College of Pharmacy, Gainesville, FL
09:25 AM	1807	Explaining pulmonary pharmacokinetics of inhaled corticosteroids: how close to in vivo reality can we get? HÖGGER P Julius-Maximilians-Universität Würzburg

09:45 AM 1055 EM703 a New Derivative of Erythromycin, Inhibits Lung Fibrosis Induced by TGF-? Signaling in Murine and Human Lung Fibroblasts
AZUMA A, LI YJ, YU CH, ABE S AND USUKI J
Department of Internal Medicine - Pulmonary Medicine, Infection, and Oncology, Nippon Medical School, Tokyo, JAPAN

08:45 - 10:05 AM Vaccines - Antiinfectives - Bacteria, parasites, and HPV – Part II

Room 404

Chairmen: BG Stiles, Maryland, USA
T. Horii, Osaka, Japan

Time	Abstr. No.	Title
08:45 AM	636	Staphylococcal Enterotoxin Vaccines: Future Utility for Fighting Staphylococcus aureus? STILES BG USAMRIID, Integrated Toxicology Division, Fort Detrick, Maryland, USA
09:05 AM	908	The Clinical Pipeline of a Candidate Malaria Vaccine that Targets the Achilles' Heel Antigen of <i>Plasmodium falciparum</i> HORII T. Res. Inst. for Microbial Dis., Osaka University, Japan
09:25 AM	1099	Change in Knowledge of Women about Cervix Cancer, Human Papilloma Virus (HPV) and HPV Vaccination due to Introduction of HPV Vaccines DONDERS GGG¹⁻⁴ , BELLEN G ⁴ , DECLERQ A ¹ , BERGER J ¹ , VAN DEN BOSCH T ^{1,2} , RIPHAGEN I ¹ , VERJANS M ¹ Department of Obstetrics and Gynecology, of the 1) H Hart Hospital Tienen, 2) University Hospital Gasthuisberg Leuven, 3) University of Liège, and 4) Femicare vzw, Clinical Research for Women, Tienen, Belgium
09:45 AM	1126	Development Of A Novel DNA Vaccine Targeting Macrophage Migration Inhibitory Factor And Its Efficacy On Murine Models Of Inflammatory Diseases ONODERA S¹ , KOYAMA Y ² , NISHIHIRA J ² , ABE R ¹ , TOHYAMA H ¹ , YASUDA K ¹ ¹ Hokkaido Univ. Graduate School of Medicine, Sapporo, Japan; ² Hokkaido Information Univ., Ebetsu, Japan

08:45 - 10:25 AM Antineoplastic agents - New strategies and new compounds- Part III

Room 207

Chairmen: DS. Matteson, Pullman, USA
BK. Banik, Edinburgh, USA
MJRP. Queiroz, Braga, Portugal

Time	Abstr. No.	Title
08:45 AM	670	Innovations In Organoboron Chemistry Essential To The Discovery Of Bortezomib MATTESON DS Department of Chemistry, Washington State University, Pullman, WA, USA
09:05 AM	467	Synthesis and Biological Evaluation of Anticancer β -Lactams BANIK BK¹ , BANIK I ² AND BECKER FF ² ¹ Department of Chemistry, The University of Texas-Pan American, Edinburg, USA; ² University of Texas M. D. Anderson Cancer Center; Houston, USA.
09:25 AM	683	Synthesis Of Fluorescent Heteroaromatic Compounds Using Dehydroamino Acids As Building Blocks, Studies Of DNA And Biomembranes Interactions. Evaluation Of Antiproliferative Effects On Tumor Cell Lines QUEIROZ MJRP¹ , FERREIRA PMT ¹ , ABREU AS ¹ , CARVALHO MSD ¹ , CASTANHEIRA E ¹ , VALE-SILVA L ² , PINTO E ² , NASCIMENTO MSJ ² ¹ Univ. do Minho, Braga, Portugal; ² Univ. do Porto, Porto, Portugal
09:45 AM	606	DNA Conformation In Complexes With Coordination Compounds KASYANENKO N. Faculty of Physics, St.-Petersburg State University, Russia

10:05 AM 872 Temozolomide Acid Hexyl Ester (TMZA-HE) as a Topical Bullet for Skin and Cervical Cancers
WANG YF¹, LI DX², SUPPASANSATORN P¹, CONWAY BR¹, WANG GC²
¹Univ. ASTON, BIRMINGHAM, UNITED KINGDOM; ²TASLY GROUP, TIANJIN, CHINA

08:45 - 10:25 AM Antineoplastic agents - Combination therapy to optimize effectiveness

Room 212

Chairmen: H. Tsuchiya, Kanazawa-shi, Japan
J. Haveman, Amsterdam, The Netherlands
J. Denham, Newcastle, Australia

Time	Abstr. No.	Title
08:45 AM	953	Revolutionary impacts of caffeine-potentiated chemotherapy on osteosarcoma treatment H. TSUCHIYA¹ , H. NISHIDA ^{1,2} , M. KAWANO ¹ , K. TOMITA ¹ ¹ Kanazawa Univ., Kanazawa, Japan; ² Fujii Hosp., Kanazawa, Japan
09:05 AM	1207	Combination with hyperthermia and radiation contributes to the magic of cisplatin in cancer treatment. HAVEMAN J , FRANKEN NAP, STALPERS L Department of Radiotherapy, Academisch Medisch Centrum, University Hospital Amsterdam, The Netherlands.
09:25 AM	457	Magical interactions between cisplatin, fluorouracil and radiation benefit oesophageal cancer patients DENHAM JW¹ ¹ University of Newcastle, Newcastle, Australia
09:45 AM	1251	Apatone [®] , a Combination of Vitamins, with <i>In Vitro</i> , <i>In Vivo</i> and Clinical Effectiveness against Prostate Cancer JAMISON JM¹ , GILLOTEAUX J ² , TAPER HS ³ , VERRAX J ³ , NEAL D ¹ , MCGUIRE K ¹ , TAREEN B ¹ , GERSON L ¹ , BUC-CALDERON P ³ , DIOKNO A ⁴ , SUMMERS JL ¹ ¹ Summa Health System, Akron, OH, USA, ² St. George's International School of Medicine, Newcastle-upon-Tyne, UK, ³ Université Catholique de Louvain, Brussels, Belgium, ⁴ William Beaumont Hospital, Royal Oak, MI, USA
10:05 AM	779	Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer TSUNODA A , YASUDA N, NAKAO K, NARITA K, YAMAZAKI K, WATANABE M, SUZUKI N, KUSANO M Department of General and Gastroenterological Surgery, Showa University School of Medicine, Tokyo, Japan

08:45 - 10:25 AM Brain physiology, biochemistry, and drugs acting on the brain - Part I

Room 214

Chairmen: L. Lampson, Cambridge, USA
A. Jaubert, LONDON, United Kingdom
S. Park, Seoul, Korea

Time	Abstr. No.	Title
08:45 AM	587	Magic Bullets And Vaccines: Learning From The Brain LAMPSON LA Brigham & Women's Hospital and Harvard Medical School, Boston MA, USA
09:05 AM	971	A New Physiological Role for Dopamine and its Transporter in the Pituitary: Induction of Prolactin Cells Apoptosis at Weaning. JAUBERT A¹ , DRUTEL G ² , LESTE-LASSERRE T ² , ICHAS F ³ , and BRESSON-BEPOLDIN L ³ ¹ Division of Molecular Neuroendocrinology, National Institute for Medical Research, The Ridgeway, Mill Hill, London, UK; ² Physiopathologie de la plasticité neuronale, INSERM U862, Institut Européen de Chimie et de Biologie, Université Bordeaux 2, Pessac, France; ³ VINCO, INSERM U916, Institut Bergonié and Université Victor Segalen Bordeaux 2, Bordeaux, France.

09:25 AM	1198	Glial Cell Line-derived Neurotrophic Factor Family Artemin-Transcriptional Regulation, Neurite Outgrowth and Actin Polymerization in Mature Dorsal Root Ganglia Neurons PARK S, JEONG DG Dongduk Women's University, Seoul, Korea.
09:45 AM	584	Gene Expression In Brain And Kidney In Response To Aluminum In Drugs MESHITSUKA S Tottori University Institute of Regenerative Medicine and Biofunction, Yonago, Japan
10:05 AM	668	Chemical chaperone therapy: magic bullet to the brain in G _{M1} -gangliosidosis SUZUKI Y¹, NANBA E², HIGAKI K², SAKAKIBARA Y³, OGAWA S³, IIDA M⁴ ¹ Internat Univ Health Welfare, Otawara, Japan; Tottori Univ, Yonago, Japan; Keio Univ, Yokohama, Japan; Seikagaku Corp, Higashi Yamato, Japan

08:45 - 10:25 AM Bioanalytics - The cutting edge of LC-MS/MS - Part III

Room 217

Chairmen: J. Yin, Cambridge, USA
A. Pal, Kolkata, India
K. Boos, München, Germany

Time	Abstr. No.	Title
08:45 AM	332	Pharmacokinetic and Drug Metabolism: A Bioanalytical Perspective YIN J PharmaMar USA, Inc., Cambridge, MA, USA
09:05 AM	501	HPLC and MALDI TOF MS analysis of novel antileishmanial compounds from <i>Quassia amara</i> PAL A¹, CHAKRABORTY D¹, BHATTACHARJEE S², MAJUMDAR S² ¹ Plant Molecular & Cellular Genetics, ² Molecular Medicine, Bose Institute, Kolkata-700054, India.
09:25 AM	1653	A generic, multidimensional SPE-platform for undisturbed LC-MS/MS analysis of basic drugs in native biofluids BOOS K-S, MORELLO R Laboratory of BioSeparation, Institute of Clinical Chemistry, Medical Center of the University of Munich, Munich, Germany.
09:45 AM	1654	A Unique SPE-LC-MS/MS Platform For Fully Automated Analysis Of Drugs In Native Whole Blood MORELLO R, MILOJKOVIC J, BERGER I, BOOS KS Laboratory of BioSeparation, Institute of Clinical Chemistry, Medical Center of the University of Munich, Munich, Germany
10:05 AM	1194	Assessing the Metabolic Liabilities of Aromatic Amines using <i>In Vitro</i> Metabolism and Mass Spectral Techniques WANG J, LU W, MUTILIB A and TALAAT R Drug Safety & Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA

08:45 - 10:25 AM Illicit drugs & similar agents, doping and performance enhancement drugs

Room 406

Chairmen: S. Grabherr, Lausanne, Switzerland
C. Rousseaux, Wakefield, Canada
V. King, BALTIMORE, USA

Time	Abstr. No.	Title
08:45 AM	1324	Radiological Detection of Dissolved Cocaine by Computed Tomography GRABHERR S¹, THALI M², BERNHARD W², AUGSBURGER M¹, MANGIN P¹ ¹ Institute of Forensic Medicine, University of Lausanne, Rue du Bugnon 21, CH-1005 Lausanne; ² Institute of Forensic Medicine, University of Bern, Bülhstrasse 20, CH-3012 Bern

09:05 AM	565	Cannabis And Cannabinoids: The Forgotten Magic Bullet? ROUSSEAU CG University of Ottawa, Ottawa, Canada
09:25 AM	650	Opioid Agonist or Opioid Antagonist: Magic Bullets in the Treatment of Opioid Addiction KING VL, KIDORF MS, BROONER RK Johns Hopkins University School of Medicine, Baltimore, MD, USA
09:45 AM	484	The Role of the Dopamine Transporter Gene in Smoking and Other Addictive Behaviors VANDENBERGH DJ¹, VASILOPOULOS T¹, VOGLER GP¹, GREENBERG MT¹, BIERMAN KL¹, COIE JD², DODGE KA², LOCHMAN JE³, MCMAHON RJ⁴, PINDERHUGHES EE⁵ ¹ Pennsylvania State Univ. XYZ, Univ. Park, PA, USA; ² Duke University, Durham, NC, USA; ³ Univ of Alabama, Tuscaloosa, AL, USA; ⁴ Univ. of Washington, Seattle WA, USA; ⁵ Tufts Univ, Boston MA, USA
10:05 AM	398	Anabolic Androgenic Steroids (AAS) Elicit Aggression by Selectively Decreasing Neurosteroid Biosynthesis in Corticolimbic Glutamatergic Neurons PINNA G, PIBIRI F, NELSON M, AGIS-BALBOA RC The Psychiatric Institute, Dept. Psychiatry, College of Medicine, UIC, Chicago, IL, USA

08:45 - 10:25 AM Therapeutic Proteins - discovery and manufacturing - Part III

Room 405

Chairmen: W. Chen, Worcester, USA
S. Uriarte, Louisville, USA
M. Konaklieva, Washington, DC, USA

Time	Abstr. No.	Title
08:45 AM	1134	From Mono- to Dimeric-IRFs: The Heart of the Matter in Activation of the Interferon Regulatory Factors CHEN W, LAM SS, SRINATH H, SCHIFFER CA, LIN K, ROYER WE Dept. of Biochemistry and Mol. Pharm., Univ. of Massachusetts Med. School, Worcester, MA 01605
09:05 AM	180	Inhibition of Neutrophil Granule Exocytosis by a Novel Cell-Penetrating SNAP23 Fusion Protein: A Potential Magic Bullet? URIARTE SM¹, LUERMAN GC¹, LE J¹, WARD RA¹, MCLEISH KR^{1,2}. ¹ University of Louisville, Louisville, KY, United States, ² Dept Veterans Affairs, Louisville, KY, United States
09:25 AM	840	Serine Protease Inhibitors: Cross Inhibitors of Prokaryotic and Eukaryotic Systems KONAKLIEVA, M.I.¹ AND PLOTKIN, B.J.² ¹ American University, Washington DC, U.S.A; ² Midwestern University, Downers Grove, IL, U.S.A
09:45 AM	1145	Prospective, Structured Data Collection For Recombinant FVIIa: The STER Experience On 55 Surgical Interventions In Patients With Congenital FVII Deficiency MARIANI G, DOLCE A and INGERSLEV J for the STER and the IRF7 Study Group Haematology, University of L'Aquila, Italy
10:05 AM	1097	Therapeutic protein engineering via the incorporation of non- natural amino acids WANG A, NAIRN N, GRADDIS T, SHANEBECK K, THORNTON K, GRABSTEIN K Allozyne Corporation, 1600 Fairview Ave E, Suite 300, Seattle, WA 98102

08:45 - 10:45 AM Antineoplastic agents - Metal-based compounds to combat cancer

Room 206

Chairmen: R. Sun, Hong Kong, Hong Kong
T. Matsui, Tokyo, Japan
D. Deubel, Wien, Austria

Time	Abstr. No.	Title
08:45 AM	1230	Some Uses of Metal-Based Complexes as Anti-Tumor Agents SUN RWY, CHE CM* Department of Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Hong Kong, China
09:05 AM	754	Global And Local Structure Of Cisplatin And DNA Base Pair Complex: A Theoretical Study MATSUI T¹, SHIGETA Y², HIRAO K¹ ¹ Univ. of Tokyo, Tokyo, Japan; ² Univ. of Hyogo, Aioi, Japan
09:25 AM	17	Platinum and Non-Pt Anticancer Drugs: Insights from High-Level Computations DEUBEL DV¹, CHIORESCU I¹, ARION VB¹, KEPLER BK¹, CHIFOTIDES HT² ¹ University of Vienna, Austria; ² Texas A&M University, College Station, TX, USA. <i>metals-in-medicine@phys.chem.ethz.ch</i>
09:45 AM	677	Development of Unique Cisplatin Analogs for Site-Specific Treatment of Hormone-Dependent Female Cancers BÉRUBÉ G Univ. du Québec à Trois-Rivières, Trois-Rivières, Canada.
10:05 AM	922	Amidinoanthracyclines – Perspectives to Promising Modification of Known Anticancer Drugs WASOWSKA-LUKAWSKA M¹, OSZCZAPOWICZ I¹, AND OSZCZAPOWICZ J² ¹ Institute of Biotechnology and Antibiotics, Warsaw, ² Chemistry Department, Warsaw University, Warsaw, Poland
10:25 AM	10	Ruthenium Complexes In Cancer Therapy: In Vitro And In Vivo Studies MISHRA L¹, KOIRI R², TRIGUN SK² ¹ Department of Chemistry, Faculty of Science, Banaras Hindu University, Varanasi, India; ² Department of Zoology, Faculty of Science, Banaras Hindu University, Varanasi, India

08:45 - 10:45 AM Antineoplastic agents - Compounds and approaches - Part IV

Room 213

Chairmen: K. Bloch, Petach Tikva, Israel
J. Gilloteaux, Newcastle upon Tyne, United Kingdom
D. Banerjee, San Juan, USA

Time	Abstr. No.	Title
08:45 AM	1006	Therapeutic Differentiation of Insulinoma Cell Lines Treated with Streptozotocin BLOCH K, VARDI P. Tel Aviv University, Felsenstein Medical Research Center, Petach Tikva, Israel
09:05 AM	189	A new mode of cell death for tumor cells after ascorbate : menadione treatment in vitro and in vivo. GILLOTEAUX J¹, JAMISON JM², TAPER HS³, SUMMERS JL² ¹ St George's International School of Medicine, Newcastle-upon-Tyne, NE1 8ST, U.K., ² Department of Uro-Oncology, Summa Research Foundation, Akron OH., U.S.A. ³ Unité de Pharmacologie, Métabolisme, Nutrition & Toxicologie, Université Catholique de Louvain, B-1200 Brussels, Belgium
09:25 AM	545	A Novel Anti-Angiogenic Glycotherapeutic for Breast Cancer BANERJEE DK Department of Biochemistry, School of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR. USA

09:45 AM	424	Firing the “Magic Bullets” at Brain Tumors: From Bench-to-Bedside and Back Again SATHORN SUMETEE S¹ , POUNGVARIN N ¹ , RICH JN ² ¹ Department of Medicine (Neurology), Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700 THAILAND; ² Departments of Medicine, Surgery, Pharmacology and Cancer Biology; Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
10:05 AM	1327	ODAM As A Diagnostic And Therapeutic Target For Human Breast Cancer KESTLER DP , FOSTER JS, PATTON AL, SIDDIQUI S, BELL JL, PANELLA TJ, MURPHY CL, MACY SD, WALL J, SOLOMON A University of Tennessee Graduate School of Medicine, Knoxville, USA
10:25 AM	1753	Argyrisin A A New Type Of Proteasome Inhibitor With Potent Anti-Proliferative And Anti-Angiogenic Activities NICKELEIT I , MALEK NP Institute for Molecular Biology, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School

08:45 - 11:05 AM Psychoactive drugs - Part II

Room 412

Chairmen: P. Prolo, Bellinzona, Switzerland
 N. Popova, Novosibirsk, Russia
 S. Yamada, Shizuoka, Japan

Time	Abstr. No.	Title
08:45 AM	811	Cellular Immune Toxicity of Alcohol and Cocaine: Medical Practice Based on the Evidence vs. Evidence-Based Medical Practice PROLO P¹ , CHIAPPELLI F ² 1. Dip. Sanità e Socialità Canton Ticino, CH & Div. Oral Biol & Med, UCLA, 2. Division Oral Biology & Medicine, UCLA, Los Angeles, CA USA (fchiappelli@dentistry.ucla.edu)
09:05 AM	1000	The Role of the Genotype in the MAGIC BULLET Effect of Psychotropic Drugs POPOVA NK , NAUMENKO VS, TIKHONOVA MA Institute of Cytology and Genetics, Behavioral Neurogenomics Lab., Novosibirsk, Russia
09:25 AM	160	In Vivo Analysis of Brain Muscarinic Receptor (mAChR) Occupancy by Anticholinergic Agents Analyzed via Quantitative Autoradiography (ARG) and Positron Emission Tomography (PET) YAMADA S¹ , MARUYAMA S ¹ , ITO Y ¹ , OKU N ¹ , TSUKADA H ² ¹ Sch. of Pharm. Sci., Univ. of Shizuoka, Shizuoka; ² Central Res. Lab., Hamamatsu Photonics K.K., Shizuoka, Japan
09:45 AM	868	Lithium and vestibular function in Bipolar Disorder SOZA RIED AM^{1,2} , CERTANEC B ² , REYES J ² ¹ Universidad de los Andes, San Carlos de Apoquindo 2200, Santiago, Chile. ² Chilean Aerospace Medicine Centre
10:05 AM	515	Nicotine Dramatically Increases Impulsive Behavior—Can Nicotinic Acetylcholine Receptor Antagonist Suppress Impulsive Behavior? OHMURA Y¹ , TAKAHASHI T ² , TSUTSUI I ¹ , YAMAGUCHI T ¹ , IZUMI T, YOSHIOKA M ¹ Hokkaido Univ. Dept Neuropharmacol, Sapporo, Japan; ² Hokkaido Univ. Dept Behav Sci, Sapporo, Japan
10:25 AM	738	Neurosteroids in the treatment of neurodegeneration PAPADOPOULOS V , LECANU L The Research Institute of the McGill University Health Centre and Department of Medicine, McGill University, 1650 Cedar Avenue, Montreal, Quebec, Canada
10:45 AM	934	Differences in Plasma Levels of Risperidone: Causes and Consequences VAN OS SHG , MUNIZ PINIELLA P Synthron BV, Nijmegen, The Netherlands

09:25 - 10:25 AM Pharmaceuticals - Experimental and computational approaches - Part III

Room 218

Chairman: RF Latypov, Thousand Oaks, USA

Time	Abstr. No.	Title
09:25 AM	135	Interfacing Cell's Membrane And Drugs' Mechanical Properties To Control Bioavailability: Application To Lipinski's 2 nd Rule And Resistance To Drugs RAUCH C School of Veterinary Medicine and Science, Nottingham University, Sutton Bonington, Leicestershire, United Kingdom
09:45 AM	657	Temperature, Denaturant And Ligand Effects On Solution Stability And Conformational Properties Of Human Interleukin-1 Receptor Antagonist LATYPOV RF , LIU D, JACOB J, RAIBEKAS AA, KLEEMANN GR, BREMS DN and TREUHEIT MJ Amgen, Inc., Thousand Oaks, CA 91320, USA.
10:05 AM	790	Structure-Activity Relationships of Some 1,4-Dihydropyridine (DHP) Derivatives Evaluated by Interactions with the Physical Properties of Synthetic Lipid Bilayers and Rat Liver Mitochondrial Bioenergetics FERNANDES MAS¹ , PEREIRA SPS ¹ , JURADO AS ¹ , VIDEIRA RA ² , CUSTÓDIO JBA ¹ , SANTOS MA ¹ , MORENO AJM ¹ , DUBURS G ³ , VICENTE JAF ¹ ¹ Univ. Coimbra, Coimbra, Portugal; ² Esc. Sup. Tecnol. Viseu, Viseu, Portugal; ³ Latv. Inst. Org. Synth., Riga, Latvia.

10:05 - 10:45 AM Therapeutic Drug Monitoring, Personalized Medicine, and immunosuppressive agents

Room 215

Chairman: AA Vinks, Cincinnati, USA

Time	Abstr. No.	Title
10:05 AM	230	Effect of Diabetes Mellitus on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Immunosuppressive agents: Ciclosporin, Tacrolimus and Mycophenolic Acid AKHLAGHI F¹ , CHITNIS SD ¹ , MENDONZA AE ¹ , PATEL CG ¹ , GOHH RY ² ¹ Clinical Pharmacokinetics Research Laboratory, Uni. of Rhode Island, Kingston, RI, USA; ² Division of Transplantation, Brown Uni. Medical School, Providence, RI, USA.
10:25 AM	10013	Applications of Pharmacometrics to Immunosuppressive Therapy in Transplant Patients: Can we do better? VINKS AA College of Medicine and Pharmacy, Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

10:05 - 11:05 AM Antineoplastic agents - Effects of well known anti-tumor agents and drugs with other primary action - Part III

Room 205

Chairman: TM Weiger, Salzburg, Austria

Time	Abstr. No.	Title
10:05 AM	75	Increased Expression of Tumor-Specific Cyclin B1 Sensitizes Prostate Cancer Cells to Apoptosis Induced by Anti-Mitotic Drugs PEREZ-STABLE C 1, 2 , REINER T 2, DE LAS POZAS A 1, GOMEZ A 3, PARRONDO R 1 1Geriatric Research, Education, and Clinical Center and Research Service, VA Medical Center, Miami, Florida; 2Division of Gerontology & Geriatric Medicine, Department of Medicine and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami Florida; 3South Florida VA Foundation, Miami, Florida

- 10:25 AM 256 Antiproliferative Properties of Quinidine
WEIGER TM, HERMANN A
University of Salzburg, Salzburg, Austria
- 10:45 AM 107 Unprecedented Antitumor Effect of Irradiation Generated by 5-Trimethylsilyl-2-Trifluoroacetyl-furan Oxime in Fibrosarcoma Cells
VEINBERG G, DOMRACHEVA I, SHESTAKOVA I, VORONA M, IGNATOVICH L, LUKEVICS E, KALVINSH I
Latvian Institute of Organic Synthesis, Riga, Latvia

11:15 - 11:35 AM Treatment of diseases with involvement of the immune system - Part IV

Room 217

- Time Abstr. No. Title
- 11:15 AM 1387 Targeted Immunotherapy of Cancer Through TCR Gene Transfer
XUE SA, GAO L, THOMAS S, HART D, XUE JZ, MORRIS E, STAUSS HJ
University College London, London, United Kingdom

11:15 AM - 12:15 PM Antineoplastic agents - Effectiveness and resistance in patients - Part IV

Room 207

Chairman: HB Newton, Columbus, USA

- Time Abstr. No. Title
- 11:15 AM 489 Optimising High Dose Melphalan In Patients With Multiple Myeloma: Preliminary Results From A Multi-Centre Trial
NATH CE¹, SHAW PJ^{1,7}, TROTMAN J^{2,7}, ZENG L^{1,7}, TILEY C³, JOSHUA D^{4,7}, KERRIDGE I^{5,7}, KWAN Y², PRESGRAVE P⁶, GURNEY H^{5,7}, MCLACHLAN AJ^{2,7}, EARL JW¹
¹The Children's Hospital at Westmead, ²Concord Hospital, ³Gosford Hospital, ⁴Royal Prince Alfred Hospital, ⁵Westmead Hospital, ⁶Wollongong Hospital, ⁷University of Sydney, NSW, Australia
- 11:35 AM 56 Longterm Therapy Of Brain Tumors With Temozolomide: Review Of Tolerability And Efficacy In 53 Patients
NEWTON HB¹, DALTON J¹, FIGG G¹, VOLPI C¹, PEARL D²
Departments of ¹Neurology and ²Statistics; The Ohio State University Medical Center and James Cancer Hospital and Solove Research Institute, Columbus, OH, USA
- 11:55 AM 1064 Hyaluronan-Mediated Transformation And Relapse Of Prostate Cancer
LIN S-L
Department of Cell and Neurobiology, Keck School of Medicine, University of Southern California, Los Angeles, California, U.S.A.

11:15 AM - 12:15 PM Antineoplastic agents - Paclitaxel - a true Magic Bullet

Room 412

Chairman: I. Ojima, New York, U.S.A

- Time Abstr. No. Title
- 11:15 AM 1005 Incorporation of Paclitaxel into Well-Defined Amphiphilic Block Copolymer Micelle Having Phospholipid Polymer Sequence
YUSA S¹, Fukuda K¹, Ishihara K², Yotaro M³
¹Univ. of Hyogo, Himeji, Japan; ²The Univ. of Tokyo, Bunkyo-ku, Japan; ³Fukui Univ. of Tech., Fukui, Japan
- 11:35 AM 85 Taxane-Based Tumor-Targeting Anticancer Agents
OJIMA I
Institute of Chemical Biology & Drug Discovery, State University of New York, Stony Brook, New York, U.S.A

11:55 AM 787 Germ cell tumours, squamous cell carcinoma, urothelioma: Taxanes magic bullet in urologic cancers?
PIZZOCARO G
Studio Medico, Piazza Gorini 8, Milano, Italy.

11:15 AM - 12:15 PM Drug-drug and drug-nutrient interactions - Part III

Room 404

Chairman: G. Corona, Aviano, ITALY

Time	Abstr. No.	Title
11:15 AM	469	Neuromuscular blocking drugs and magnesium interactions FAWCETT WJ Royal Surrey County Hospital, Guildford GU2 7XX, UK
11:35 AM	119	Anti-HIV And Anti-Cancer Drug-Drug Interactions CORONA G Experimental and Clinical Pharmacology Unit, NATIONAL CANCER INSTITUTE CRO-IRCCS. Via Franco Gallini 2, 33081 Aviano (PN) ITALY
11:55 AM	848	Effect Of Commonly Prescribed Nsaids, Proton Pump Inhibitor And Newer Anti-Malarial Compound On Pharmacokinetics Of Different Antiepileptics MEDHI B, PRAKASH A, PRASADBYRAV DS Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

11:15 AM - 12:35 PM Analgesia & analgetic drugs IV

Room 205

Chairmen: F. Ariza, CALI, COLOMBIA
S. Ray, BROOKLYN, USA

Time	Abstr. No.	Title
11:15 AM	556	Remifentanyl: How it Relives Human and Earthly Pain, and New Perspectives. ARIZA F¹; TORRES G² ¹ Transplantation Anesthesiology, Fundación Valle del Lili, Cali, Colombia; ² Cardiovascular Anesthesiology, Fundación Valle del Lili, Cali, Colombia.
11:35 AM	399	Acetaminophen: The Global Pain Killing Magic Bullet Of The New Millennium RAY SD, BULKU E, ZINKOVSKY D, LAHOTI T Mol. Tox. Labs, A&M Schwartz Coll. of Pharmacy & HScs, Long Island University, Brooklyn, NY, USA
11:55 AM	1214	Development Of Novel γ -Conopeptide Inhibitors Of The Norepinephrine Transporter For The Treatment Of Severe Pain LEWIS RJ¹, BRUST A¹, PALANT E¹, COLLESS B¹, SCHMIDT P¹, DRINKWATER R¹, GIBBONS S¹, MARTIN W² ¹ Xenome Ltd, Brisbane, Queensland, Australia; ² Xenome Inc, San Diego, CA, USA
12:15 AM	376	Preoperative use of Analgesia in Appendicites ARAM FO Hadramout University, Mukalla, Yemen.

11:15 AM - 12:15 PM Antibacterials - Genomic strategies

Room 218

Chairmen: L. Good, Hatfield, United Kingdom
E. Ilina, Moscow, Russia

Time	Abstr. No.	Title
11:15 AM	635	Antibacterial RNA Silencing GOOD L Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London
11:35 AM	1432	Molecular Investigation Of Drug Resistant <i>Neisseria Gonorrhoeae</i> Clinical Isolates ILINA EN¹ , BOROVSKAYA AD ¹ , SIDORENKO SV ² , KUBANOVA AA ² , MAIER T ³ , KOSTRZEWA M ³ , GOVORUN VM ¹ . ¹ Res Inst Physical-Chemical Medicine, Moscow, Russia, ² Centr Res Inst of Dermatology and Venereology, Moscow, Russia, ³ Bruker Daltonik GmbH, Leipzig, Germany
11:55 AM	1377	An Arabidopsis Transcription Factor, AtNFXL1 Gene Negatively Regulates <i>Fusarium</i> Phytotoxin Trichothecene-Induced Defense Response ASANO T ¹ , YASUDA M ² , NAKASHITA H ² , KIMURA M ² , YAMAGUCHI K ¹ , NISHIUCHI T¹ ¹ Univ. KANAZAWA, Kanazawa, Japan; ² RIKEN, Wako, Japan

11:15 AM - 12:35 PM Antineoplastic agents - Genomic approaches to optimize therapy - Part II

Room 406

Chairmen: P. Lucas, Bethesda, USA
P. Chieffi, Naples, Italy

Time	Abstr. No.	Title
11:15 AM	575	TGF- β : A primary tumor suppressor gene involved in leukemogenesis LUCAS PJ¹ , MCNEIL N ¹ , HILGENFELD E ¹ , ECKHAUS MA ¹ , RIED T ¹ , GRESS RE ¹ National Institutes of Health, Bethesda, MD, USA
11:35 AM	768	PATZ1 gene has a critical role in the spermatogenesis and testicular tumors CHIEFFI P Department of Experimental Medicine, II University of Naples, Naples, Italy.
11:55 AM	468	Investigation of SGK-1 and Dexas1 expression in Human Embryonic Kidney (HEK 293) cells GHASSEM ATTRAZADEH YAZDI ¹ , MICHAEL SHIPSTON ² , FERENC ANTONI Department of Neuroscience, University of Edinburgh, EH8 9JZ, Scotland, United Kingdom, ¹ Hormozgan University of Medical Sciences, Iran, ² Membrane Biology Group, University of Edinburgh Medical School, Hugh Robson Building, Edinburgh, EH8 9XD. Scotland, United Kingdom
12:15 AM	741	Expression Of MAGE-A12 In Oral Squamous Cell Carcinoma MOLLAOGLU N^{1,2} , VAIRAKTARIS E ³ , NKENKE E ¹ , FRIEDRICH WN ¹ , RIES J ¹ ¹ Friedrich- Alexander University of Erlangen/Nuremberg, Germany; ² Gazi University, School of Dentistry, Ankara, Turkey; ³ University of Athens Medical School, Attikon Hospital, Athens, Greece

11:15 AM - 12:55 PM Anti-infectives - Reviews on Magic Bullets - Part II

Room 206

Chairmen: S. Nicholson, Raritan, USA
M. Trautmann, Stuttgart, Germany
S. Straus, Vancouver, Canada

Time	Abstr. No.	Title
11:15 AM	943	Doripenem, A New Carbapenem: Optimizing Dose To Treat Increasingly Resistant Gram-Negative Pathogens NICHOLSON SC¹ , PETERSON JA ¹ ¹ Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA
11:35 AM	1697	Use of Pharmacodynamic Modeling to Predict Efficacy of Doripenem, a Class 2 Carbapenem recently Licensed in Europe TRAUTMANN M Institute of Hospital Hygiene, Klinikum Stuttgart, Stuttgart, Germany
11:55 AM	415	Daptomycin: Old drug, New data, Endless Puzzles HO SW ¹ , JUNG D ² , BAEK SB ¹ , SCOTT WRP ¹ , CALHOUN JR ³ , LEAR JD ³ , CHENG JTJ ¹ , HANCOCK REW ² , STRAUS SK¹ ¹ Dept. Chemistry, University of British Columbia, Vancouver, BC, CANADA; ² Dept. of Microbiology and Immunology, University of British Columbia, Vancouver, BC, CANADA; ³ Dept. Biochemistry, University of Pennsylvania, PA, USA.
12:15 AM	873	Organ protective effects of tunicamycin as an endoplasmic reticulum stress inducer INAGI R¹ , NANGAKU M ¹ ¹ Div Nephrol & Endocrinal, Univ Tokyo Shc Med, Tokyo, Japan.
12:35 AM	649	Significant Interactions between some Antibiotics and Antimalarial Drugs BABALOLA C.¹ , OLANIYI A. ¹ , IWHEYE G., FASHEDEMI T. ¹ , AJOKU C. ¹ , ADENIYI B. ² ¹ Department of Pharmaceutical Chemistry, ² Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Ibadan, Nigeria

11:15 AM - 12:55 PM New / known targets & mechanisms - Part I

Room 215

Chairmen: C. Heaysman, Farnham, Surrey, United Kingdom
P. Fernandes, Chapel Hill, USA
S. Cheung, Hong Kong, Hong Kong

Time	Abstr. No.	Title
11:15 AM	1677	Chemoembolisation Using Drug Eluting Beads: Magic Bullets Targeted by Arterial Guidance. HEAYSMAN C Biocompatibles UK Ltd, Chapman House, Farnham Business Park, Farnham, Surrey, UK.
11:35 AM	681	Blocking the Peptide Tunnel- Is the Magic Still There? FERNANDES P¹ , MATSA S ¹ , ROMERO A ² , BAKER W ³ , ICHIKAWA Y ² , PEREIRA D ¹ ¹ Cempra Pharmaceuticals, Chapel Hill, NC 27517. USA. ² Optimer Pharmaceuticals, San Diego, USA. ³ Advisor, Cempra Pharmaceuticals
11:55 AM	436	From Gene Expression Profile to Identification of Molecular Target Granulin-Epithelin Precursor for Liver Cancer CHEUNG ST, FAN ST Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong.
12:15 AM	952	Structure Based Development of Selective Inhibitors for Individual Cathepsins and Their Medical Applications for Therapeutic purposes KATUNUMA N¹ , TURK V ² ¹ Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan, ² Jozef Stefan Institute, Ljubljana, Slovenia
12:35 AM	99	The Path from Colles' Law to the "Magic Bullet" BENEDEK TG University of Pittsburgh, Pittsburgh, Pennsylvania

11:15 AM - 12:55 PM Resistance - a Global Issue for diverse therapeutic areas - Part III

Room 216

Chairmen: K. Lounsbury, Burlington, USA
M. Spigelman, London, United Kingdom
S. Goncharova, Chernogolovka, Russia

Time	Abstr. No.	Title
11:15 AM	153	Proposed antiangiogenic agents with mechanisms that prevent tumor cell survival and resistance to cytotoxic therapies LOUNSBURY, KM¹ , HALE, SA ¹ , HATLE, K ² , RINCON, M ² Departments of ¹ Pharmacology and ² Medicine, University of Vermont, College of Medicine, Burlington, VT, USA
11:35 AM	689	The Uncertain Future or the End of Modern Medicine?: A Clinicians View of Antibiotic Resistance-Way to Prevent the Inevitable SPIGELMAN M Visiting Professor Centre for Infectious Diseases and International Health, Department of Infection, Windeyer Institute of Medical Sciences, UCL, 46, Cleveland Street, London W1T 4JF
11:55 AM	87	No-Donors As Modulators of Antitumor Drugs Resistance. GONCHAROVA SA , RAJEWSKAYA TA, KONOVALOVA NP Institute of Problems of Chemical Physics, RAS, Russia
12:15 AM	1025	Overcoming Multidrug Resistance In Human Cancer Cells By Dietary Phytochemicals NABEKURA T¹ , YAMAKI T ¹ , UENO K ¹ , KITAGAWA S ² ¹ Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan; ² Kobe Pharmaceutical University, Kobe, Japan.
12:35 AM	400	Inhibition Of Drug Resistance Of Bacteria And Cancer Cells MOLNÁR J , MÁNDI Y, ENGI H, SCHELZ ZS AND MUCSI I Department of Medical Microbiology and Immunobiology, University of Szeged, Hungary

11:15 AM- 12:55 PM Atherosclerosis and stroke - mechanisms and treatment

Room 405

Chairmen: ML. Higuchi, Sao Paulo, Brazil
JD. Adams, Los Angeles, USA
P. Luoma, Helsinki, Finland

Time	Abstr. No.	Title
11:15 AM	1023	A new focus on atherosclerosis treatment: transialidase from <i>Trypanosoma cruzi</i> as an anti-proliferative drug. HIGUCHI ML , FAGUNDES R, IKEGAMI R, REIS MM, PALOMINO S, DAMY S, SAMBIASE N, STOLF N. Heart Institute of School of Medicine of São Paulo University , Sao Paulo, Brazil
11:35 AM	1370	Nicotinamide Mechanisms of Neuroprotection in Stroke ADAMS JD University of Southern California, School of Pharmacy, Los Angeles, CA, USA
11:55 AM	309	Cytochrome P450 and Gene-activating Agents – Cholesterol Elimination and Regression of Atherosclerosis LUOMA PV Institute of Biomedicine, Pharmacology, FIN-00014 University of Helsinki, Finland
12:15 PM	937	Neonatal Abstinence Syndrome And Cerebral Infarction Following Maternal Codeine Use During Pregnancy REYNOLDS EW¹ , REIL-ROMERO RMS ² , BADA HS ¹ ¹ University of Kentucky, Lexington KY USA. ² Louisiana State University, Shreveport LA USA

12:35 PM 101 Pro-Atherogenic and Pro-Inflammatory Alterations in Mononuclear Cell Populations Induced by Oxidized Low Density Lipoprotein (oxLDL) and High Glucose Levels in Type II Diabetic Patients. Anti-Inflammatory Drugs, an Alternative?
BUSTAMANTE, M¹, DÍAZ, F¹, MUÑOZ, M¹, GUZMÁN, C¹, LLANCAQUEO, A¹, NÚÑEZ, L¹, CAMPOS, L¹, RIVAS, CI², VERA, JC², GROSS, H-C³ & BACHEM, M³.
¹Laboratory of Molecular Diagnosis, Catholic University of Concepción, Concepción, Chile; ²Department of Pathophysiology, University of Concepción, Concepción, Chile; ³Einrichtung Klinische Chemie, Uni-Klinikum, Ulm, Germany

11:15 AM - 01:15 PM Antineoplastic agents - New mechanisms & compounds - Part III

Room 212

Chairmen: V. Pistoia, Genoa, Italy
J. Gariepy, Toronto, Canada
BC Baguley, Auckland, New Zealand

Time	Abstr. No.	Title
11:15 AM	1049	IL-12 receptor expression and function on human lung adenocarcinoma: identification of a new potential therapeutic target AIROLDI I¹ , DI CARLO E ² , COCCO C ¹ , CACI E ¹ , CILLI M ³ , SORRENTINO C ² , SOZZI G ⁴ , FERRINI S ³ , ROSINI S ⁵ , GALIETTA L ¹ , RIBATTI D ⁶ and PISTOIA V¹ ¹ G. Gaslini Institute, Genova, Italy, ² G. d'Annunzio" University Chieti, Italy, ³ Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, ⁴ Fondazione IRCCS Istituto Nazionale Tumori, Italy, ⁵ SS Annunziata" Hospital, Chieti, ⁶ University of Bari, Bari, Italy
11:35 AM	1070	Combinatorial Ribosome-Inactivating Protein Libraries: Part of a New Arsenal in Combating Cancer GARIEPY J , PERAMPALAM S, WEI X, KIARASH R, GREEN E, ZHANG QH, CHEUNG M, ABDUL-WAHID A, REVERS L University of Toronto, Ontario, Canada
11:55 AM	134	The action of a new drug that targets a cancer's blood supply: the story of DMXAA (ASA404) BAGULEY BC Auckland Cancer Society Research Centre, the University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
12:15 PM	1229	A New Molecular Mechanism of Action of a Leading Chemotherapeutic Drug—Cisplatin and Its Novel Applications LU QB , NGUYEN J, WANG CR, CHAN P University of Waterloo, Waterloo, ON, Canada.
12:35 PM	1373	Nucleotide Excision Repair (NER) in cisplatin-induced cellular responses WANG G Institute of Environmental Health Sciences, Wayne State University, 2727 Second Avenue, Room 4325, Detroit, MI 48201, USA
12:55 PM	865	Enhancing Radiotherapy Of Cancer Using Agents That Target Thrombospondin-1 Signaling Via CD47 ROBERTS DD¹ , ISENBERG JS ¹ , MAXHIMER JB ¹ , HYODO F ² , PENDRAK ML ¹ , RIDNOUR LA ² , DEGRAFF WG ² , TSOKOS M ¹ , WINK DA ² ¹ Laboratory of Pathology & ² Radiation Biology Branch, NCI, NIH, Bethesda, MD, USA

11:15 AM - 01:15 PM Cardiovascular - Drugs acting on the cardiovascular system - Part IV

Room 214

Chairmen: M. Vavlukis, Skopje, Republic of Macedonia
D. Vesely, Tampa, USA
V. Baudin-Creuzat, Le Kremlin-Bicêtre, France

Time	Abstr. No.	Title
11:15 AM	344	Can Cardiovascular Drugs Influence Clinical outcome in CABG patients VAVLUKIS M1 , BOROZANOV V1, GEORGIEVSKA-ISMAIL Lj1, POP-GORCEVA D2, MAJSTOROV V2, KOSTOVA N1, ZDRAVKOVSKA M2 1Clinic for cardiology, Skopje, MK, 2 Institute for Pathophysiology and Nuclear Medicine, Skopje, MK

11:35 AM	773	Cardiac Hormones: Magic Bullets for the Treatment of Congestive Heart Failure, Renal Failure and Cancer VESELY DL University of South Florida Health Sciences Center, Tampa, FL, USA; J. A. Haley Veterans Hospital, Tampa, FL, USA
11:55 AM	454	Cell-free octameric hemoglobin as a blood substitute BAUDIN-CREUZA V¹ , VASSEUR C ¹ , DOMINGUES E ¹ , HO C ² , MARDEN MC ¹ ¹ INSERM U779, University of Paris XI, 78 rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France. ² Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.
12:15 PM	129	Water Channel Proteins (Aquaporins): From their Discovery in 1985 in Cluj-Napoca, Romania (By the use of a Doping Nmr Method and Specific Labeling) to the use of their Inhibitors as Magic Bullets BENGA G Dept. of Cell and Molecular Biology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
12:35 PM	900	Serum hepcidin level (HEPC) is a significant predictor of arterial stiffness in maintenance hemodialysis patients (mHD) KURAGANO T⁽¹⁾ , SHIMONAKA Y ⁽²⁾ , YASUNO H ⁽²⁾ , KIDA A ⁽¹⁾ , ITOH K ⁽¹⁾ , FURUTA M ⁽¹⁾ , NANAMI M ⁽¹⁾ , OTAKI Y ⁽¹⁾ , HASUIKE Y ⁽¹⁾ , NONOGUCHI H ⁽¹⁾ , NAKANISHI H ⁽¹⁾ , (1) Department of Internal Medicine Division of nephrology and dialysis. Hyogo College of Medicine. (2) Chugai pharmaceutical CO., LTD.
12:55 PM	544	Genetic Variant Of <i>KIF6</i> Predicts Both Increased Risk For Coronary Events And Greater Benefit From Statin Therapy: An Overview Of Genetic Studies Of The CARE, WOSCOPS, And PROVE IT - TIMI 22 Trials IAKOUBOVA OA¹ , SABATINE MS ² , ROWLAND CM ¹ , TONG CH ¹ , CAMPOS H ⁴ , PFEFFER MA ² , KIRCHGESSNER TG ⁵ , PLOUGHMAN LM ⁵ , SIMONSEN KL ⁵ , RANADE K ⁵ , WHITE TJ ¹ , PACKARD CJ ³ , SACKS FM ^{2,4} , SHEPHERD J ³ , DEVLIN JJ ¹ AND BRAUNWALD E ² ¹ Celera, Inc., Alameda, CA, USA, ² Brigham & Women's Hospital, Harvard Medical School, Boston, USA, ³ University of Glasgow and Royal Infirmary, Glasgow, UK., ⁴ Harvard School of Public Health, Boston, USA, ⁵ Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, USA

11:15 AM - 01:55 PM Biomarkers & personalized medicine

Room 213

Chairmen: CM Helgason, Chicago, USA
 A. Pradeep, BANGALORE, India
 J. Smith Sonneborn, Laramie, USA

Time	Abstr. No.	Title
11:15 AM	1382	Matching the Individual Patient to the Results of Large Clinical Trials and Testing the Null Hypothesis Using Fuzzy Theory HELGASON CM¹ , JOBE TH² ^{1,2} Univ. Illinois College of Medicine @Chicago, Chicago, IL., USA
11:35 AM	374	Exploring Leukotriene B ₄ (LTB ₄) as a periodontal biomarker: A time to focus. PRADEEP AR , MANJUNATH SG, SWATI PP, SHIKHA C, SUJATHA PB. Department of Periodontics, Government Dental College and Research Institute, Bangalore, India.
11:55 AM	680	Activation of Ancient Stress-resistance Pathways by Molecular Triggers, Age and Disease Intervention SMITH SONNEBORN J University of Wyoming, Laramie, WY USA
12:15 PM	989	Integrated 'OMIC' Analyses Of The Rat Brain: Novel Biomarker Candidates For Mental Disorders And Stress MASUO Y , HIRANO M, SHIBATO J, RAKWAL R National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan
12:35 PM	255	Small Lipoprotein A-I subclasses (42,000-70,000) are Promising Biomarkers in Cardiovascula Disease ATMEH RF , KASASBEH AZ, ABUODEH MR Jordan University of Science and Technology, Irbid, Jordan

12:55 PM	1760	Circulating epithelial tumor cells (CETC) allow gene analysis of the residual tumor burden individual chemosensitivity testing and monitoring of the adjuvant setting in a curative PACHMANN K^{1,2} and PACHMANN U² ¹ Clinic for Internal Medicine II University Hospital Friedrich Schiller University Jena Germany and ² Center for Transfusion Medicine Bayreuth Germany
01:15 PM	1506	Alpha-1-antitrypsin and IgA in Serial Meconium and Faeces for Date Newborn's Faeces Formed during Intrauterine and Extrauterine Maturation. LISOWSKA-MYJAK B, PACHECKA J Medical University, Warsaw , Poland
01:55 PM	795	Prognostic and predictive biomarkers in thyroid diseases: "magic bullets" for a personalized therapeutic strategy. TROVATO M Department of Human Pathology, Policlinico Universitario, via Gazzi, 98100, Messina, Italy, mariatrovato@tin.it, University of Messina, Italy

11:35 AM - 12:35 PM Recent progress and development in nanotechnology

Room 217

Chairman: SS Mohapatra, Tampa, USA

Time	Abstr. No.	Title
11:35 AM	414	Targeted Delivery of Magic Bullets by the Use of Mechanized Nanoparticles TAMANOI F California NanoSystems Institute, University of California, Los Angeles, CA, USA
11:55 AM	188	Targeted Therapeutics: From Magic Bullets To Multifunctional Nanoparticles MOHAPATRA SS, MOHAPATRA S, LOCKEY RF Joy McCann Culverhouse Airway Disease and Nanomedicine Research Center, VA Hospital and USF College of Medicine, Tampa, FL, USA

12:15 - 01:15 PM Antineoplastic agents - Search and Development of new Magic Bullets - Part II

Room 412

Chairman: S. Chen, Surrey, UK

Time	Abstr. No.	Title
12:15 PM	46	Induction of Complete Tumor Remission by DNA-Directed Alkylating Agents SU TL¹, CHOU TC², CHIOU SH³ ¹ Institute of Biomedical Sciences, Academia Sinica, Laboratory of Bioorganic Chemistry, Taipei, Taiwan; ² Memorial Sloan-Kettering Cancer Center, Molecular Pharmacology & Chemistry Program, NY, NY, USA; ³ Taipei Veterans General Hospital and National Yan-Ming University, Department of Medical and Research and Education, Taipei, Taiwan
12:35 PM	1410	Synergistic inhibition of taxol- resistance primary ovarian cancer cells by oridonin and wogonin CHEN S¹, WADES J¹, JONES M¹, BUTLER-MANUEL S² ¹ Ovarian and Prostate Cancer Research Trust Laboratory, Guildford, Surrey, UK, ² St. Luke Cancer Centre, Guildford, Surrey, UK
12:55 PM	590	Molecular Targeting of the <i>bcl-2</i> Oncogene for Staging and Therapy of B-Cell Lymphoma LEWIS MR¹, JIA F², BALKIN ER², DAIBES FIGUEROA S¹, BALAJI BS², GALLAZZI F³, STATHAM KA², HOFFMAN TJ¹ ¹ Research, Harry S Truman Memorial Veterans' Hospital, Columbia, MO, USA; ² Veterinary Medicine and Surgery, ³ Molecular Biology, University of Missouri, Columbia, MO, USA.

12:15 - 01:15 PM Pharmaceuticals - Pharmacokinetics and drug formulations - Part II

Room 404

Chairman: RC Reed, USA

Time	Abstr. No.	Title
12:15 PM	637	On the Need for Fractal Modeling of Renal Clearance, <i>G</i> (ml/min), of Radiolabeled Pentatate WESOLOWSKI CA , PUETTER RC, BABYN PS MUN, St. John's, Canada; UCSD, La Jolla, USA; The Hospital for Sick Children, Toronto, Canada
12:35 PM	546	Divalproex-Valproate: Is The Discovery, Research & Development With This Molecule And Its Formulations Complete? REED RC ¹ , KASTELEIJN-NOLST TRENITE DGA ² , O'BRIEN TJ ³ , VAN RAAY L ³ , HOGAN RE ⁴ , MORRIS MJ ⁵ , DEDEURWAERDERE S ⁶ , DUTTA S ¹ , ROSENFELD W ⁷ and ABOU-KHALIL B. ⁸ ¹ Abbott, Global Pharmaceutical R&D, Abbott Park, USA, ² Universita di Roma, Sapienza II, Rome, Italy, ³ University of Melbourne, Australia, ⁴ Washington University, St Louis, USA, ⁵ University of New South Wales, Kensington, Australia, ⁶ Australian Nuclear Science & Technology Organisation, ⁷ Comprehensive Epilepsy Center, St. Louis, USA, ⁸ Vanderbilt University, Nashville, USA
12:55 PM	648	Mannitol, a Key Probe Molecule in the Assessment of Small Intestinal Permeability? BIJLSMA PB ¹ , TAMINIAU JAJM ¹ , JODAL M ² ¹ Academic Medical Center, Amsterdam, The Netherlands; ² University of Göteborg, Göteborg, Sweden.

12:15 - 01:55 PM Therapy with monoclonal antibodies - Part II

Room 207

Chairmen: Y. Seo, San Francisco, USA
 C. Kloft, Halle, Germany
 E. Gosselin, Albany, USA

Time	Abstr. No.	Title
12:15 PM	380	In Vivo Molecular Imaging of Capromab Pendetide in Humans and Small Animals Using Combined Dual-Modality SPECT/CT and microSPECT/CT Systems SEO Y ¹ ¹ University of California, San Francisco, USA
12:35 PM	1639	Monoclonal antibodies: potent therapeutic proteins - not only in cancer treatment KLOFT C Martin-Luther-Universitaet Halle-Wittenberg, Germany.
12:55 PM	962	Monoclonal Antibodies as Vaccine Adjuvants: From Potential to Protection BITSAKTIS C, RAWOOL DB, IGLESIAS B, DRAKE JR, GOSELIN EJ Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY, USA.
13:15 PM	411	Potential use of denosumab in the treatment of giant cell tumor of bone SKUBITZ KM Masonic Cancer Center and University of Minnesota, Minneapolis, MN, USA
13:35 PM	423	Intracavitary-administered Nimotuzumab labeled with 188Re in adult recurrent high-grade glioma. CASACÓ A, LÓPEZ G , FERNÁNDEZ R, TORRES L, PERERA A, BATISTA J, LEYVA R, PEÑA Y, AMADOR Z, GONZÁLEZ A, ESTUPIÑAN B, COCA M, HERNÁNDEZ A, PUIG M, IGLESIAS M, HERNÁNDEZ A, RAMOS M, RODRÍQUEZ L, SUAREZ N.

12:35 - 01:15 PM Antibacterials - Adverse events and mechanisms of toxicity - Part III

Room 217

Chairman: G. Slapsyte, Lithuania

Time	Abstr. No.	Title
12:35 PM	656	Potential Reproductive and Developmental Damage Induced by Metronidazole PALERMO AM ¹ , MERANI MS ² , MUDRY MD ³ ¹ CITEFA, Buenos Aires; ² FMed-UBA; ³ FCEyN-UBA, Universidad de Buenos Aires. Buenos Aires, Argentina.
12:55 PM	164	Chromosome Damage in Peripheral Lymphocytes of Children with Urinary Tract Infection after Antimicrobial Therapy with Nitroheterocyclic Compounds SLAPSYTE G , MIERAUSKIENE J Department of Botany and Genetics, Vilnius University, Lithuania

12:15 - 12:55 PM Antibacterials - New antibiotic and antineoplastic compound

Room 218

Chairman: AK Mishra, Johannesburg, South Africa

Time	Abstr. No.	Title
12:35 PM	1281	Functional characterization of outer membrane proteome in response to antibiotic resistance SAN-YING WANG ² , XIANG-MIN LIN ¹ , CHANG-XIN XU ² , HUI LI ¹ , XUAN-XIAN PENG ¹ ¹ Center for Proteomics, State key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, University City, Guangzhou, 510006, China; ² School of Life Sciences, Xiamen University, Xiamen, 361005, China
12:55 PM	1356	Chemistry Of Nitrogen And Sulphur Based Compounds: An Approach Towards The Discovery Of Magic Bullets MISHRA AK Department of Chemical Technology, University of Johannesburg, Doornfontein Campus, Johannesburg, South Africa

12:35 - 01:15 PM Antineoplastic agents - New promising mechanisms - Part II

Room 406

Chairman: IV Sorokina, Novosibirsk, Russia

Time	Abstr. No.	Title
12:35 PM	1261	Elesclomol: A Novel Oxidative Stress Inducer for the Treatment of Metastatic Melanoma BARSOUM J ¹ , FOLEY KP ¹ , WILLIAMS A ¹ , JACOBSON E ¹ , O'DAY S ² , 4783-03 STUDY GROUP ¹ Synta Pharmaceuticals Corp., Lexington, MA, USA; ² The Angeles Clinic and Research Institute, Santa Monica, CA, USA.
12:55 PM	1048	Betulonic acid and its alanine amide derivatives - a new multy-target agents for tumor chemotherapy SOROKINA IV , TOLSTIKOVA TG, ZHUKOVA NA, BAEV DS, SCHULTZ EE Novosibirsk Institute of Organic Chemistry of Siberian Branch of Russian Academy of Science, Novosibirsk, Russia

12:35 - 01:55 PM Antibacterials - Discovery - Peptide antibiotics - Part III

Room 205

Chairmen: S. Anastasiadou, Greece, Greece
 A. Zamyatnin , Moscow, Russia

Time	Abstr. No.	Title
12:35 PM	505	Production, isolation, partial characterization and antimicrobial spectrum of a novel bacteriocin produced by a <i>Lactobacillus plantarum</i> strain in fermentation ANASTASIADOU S* , PAPAGIANNI M, AMBROSIADIS I, KOIDIS P Department of Hygiene and Technology of Food of Animal Origin, School of Veterinary Medicine, Aristotle University of Thessaloniki. Thessaloniki 54006, Greece
12:55 PM	609	Structural and Functional Diversity of Endogenous Antimicrobial Oligopeptides ZAMYATNIN AA ^{1,2} ¹ A.N.Bach Institute of Biochemistry, Russian Academy of Sciences, Moscow, Russia; ² Universidad Tecnica Federico Santa Maria, Valparaiso, Chile
01:15 PM	228	Are the tropical forests the new frontier for antibiotics discovery? Novel peptidomics insights on the screening of plant antimicrobial peptides. FRANCO OL ¹ , MOREIRA JS ¹ , PELEGRINI PB ¹ , COSTA FT ¹ , NETO SM ¹ , LIMA TB ¹ ¹ Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, UCB, Brasília-DF, Brazil.
01:35 PM	97	Isolation, purification, partial characterization, biochemical properties and stability of two novel antimicrobial peptides produced by <i>Pediococcus</i> strains PAPAGIANNI M Department of Hygiene and Technology of Food of Animal Origin, School of Veterinary Medicine, Aristotle University of Thessaloniki

12:55 - 02:15 PM Antineoplastic agents - Clinical trials and approaches- Part III

Room 206

Chairmen: Y. Takakura, Kyoto, Japan
 J. Lambert, Waltham, USA

Time	Abstr. No.	Title
12:55 PM	814	Interferon Gene Therapy against Metastatic Cancer TAKAKURA Y , NISIKAWA M Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.
01:15 PM	335	Magic Bullets: Beynod Selective Targeting to Selective Killing Using Armed Antibodies LAMBERT JM ImmunoGen, Inc., Waltham, MA, USA.
01:35 PM	303	New Approaches for the Use of Old Drugs – Preclinical and Clinical Pharmacological Evaluation of the Pyrimidine Anti-neoplastics: 5-fluorouracil, zebularine, 5-fluoro-2'-deoxycytidine, gemcitabine, and THU. BEUMER JH ¹ , EISEMAN JL ¹ , NEWMAN EM ² , DOROSHOW JH ³ , SYNOLD TW ² , ZEH HJ ¹ , BARTLETT DL ¹ , KUMMAR S ³ , EGORIN MJ ¹ ¹ Univ. of Pittsburgh, Pittsburgh, USA; ² City of Hope National Medical Center, Duarte, USA; ³ National Cancer Institute, Bethesda, USA.
01:55 PM	1228	Is there a magic bullet for prostate cancer? COREY E ¹ , KORECKIJ T ¹ , MORRISSEY C ¹ , VESSELLA RL ^{1,2} ¹ University of Washington, Seattle, WA, USA, ² Veteran Administration, Seattle, WA, USA

02:15 - 02:55 PM Blood-brain barrier - History and most recent finding - Part III

Room 205

Chairman: L Masaichi-Chang-II, Yokosuka, Japan

Time	Abstr. No.	Title
02:15 PM	712	Bile Acid Derivatives As BBB Modifiers MIKOV M¹ , TUCKER I ¹ , YANG L ¹ , VASOVIC V ² , GOLOCORBIN-KON S ² , KUHAJDA K ² , KEVRESAN S ² , POSHA M ² , JAKOVLJEVIC V ² ¹ School of Pharmacy, Univ. of Otago, Dunedin, New Zealand; ² Department of Pharmacology and Toxicology, Medical Faculty, Univ. of Novi Sad, Serbia
02:35 PM	1300	Biomedical Application Of Electron Spin Resonance (ESR) Spectroscopy Using Blood-Brain-Barrier (BBB) Permeable Nitroxyl Spin Probe MASAICHI-CHANG-IL L Department of Clinical Care Medicine, Division of Pharmacology & ESR Laboratories, Kanagawa Dental College, Yokosuka, Japan

02:15 - 02:55 PM Pharmaceutics - Nanoparticles and their latest developments - Part III

Room 213

Chairman: AP Taylor, Sydney, Australia

Time	Abstr. No.	Title
02:15 PM	1106	A Preparation of NI-Lipid Nanoparticles by Combination of Roll Mill and High Pressure Homogenization, and Stabilization of the Nanoparticles by Gel Solidification Method -- Aiming at preparation methods of the nanoparticle without using organic solvent— KAMIYA S^{1,2} , MIYAGISHIMA A ² , SONOBE T ² , ITAI S ² , ARAKAWA M ¹ ¹ Univ. Nagasaki International University, City, Sasebo, Country; Japan, ² Univ. University of Shizuoka, City, Shizuoka, Country; Japan
02:35 PM	1121	Magic Bullets Made Easily Using Nano-particulate Membrane Bioreactors TAYLOR AP^{1,2} ¹ Australian Membrane Technologies Pty. Ltd. (AMT), Sydney, Australia; ² Australian Nuclear Science and Technology Organisation (ANSTO), Sydney, Australia.

02:15 - 03:15 PM Cytochrome P450 - in vitro studies - Part II

Room 206

Chairman: JC McGiff, Valhalla, USA

Time	Abstr. No.	Title
02:15 PM	829	Interactions between Cytochrome P4504A, Cyclooxygenase and Nitric Oxide Synthase during Endotoxemia: Therapeutic Implications for Inflammatory Diseases TUNCTAN B¹ , KORKMAZ B ¹ , CUEZ T ¹ , BUHARALIOGLU CK ¹ , SAHAN-FIRAT S ¹ , FALCK J ² , MALIK KU ³ ¹ Mersin Univ., Mersin, Turkey; ² Univ. of TX, Southwestern Med. Ctr., Dallas, TX, USA; ³ Univ. of TN, HSC, Memphis, TN, USA.
02:35 PM	562	Eicosanoids: The Endless Parade: Enter The Cytochrome P450 System, EETs And HETEs CARROLL MA ¹ , FERRERI NR ¹ , JIANG H ¹ , McGIFF JC¹ , MINUZ P ² , QUILLEY J ¹ , SACERDOTI D ³ ¹ New York Medical College, Valhalla, NY, USA; ² University of Verona, Verona, Italy; ³ University of Padova, Padova, Italy
02:55 PM	1061	Activated iron(IV)-oxo structures in intermediates of heme enzymes and their models TERNER J¹ Dept. of Chemistry, Virginia Commonwealth University, Richmond, VA 23284-2006. USA

02:15 - 03:15 PM Vaccines - Antineoplastic - Role of immune cells - Part II

Room 215

Chairman: R. Kircheis, Vienna, Austria

Time	Abstr. No.	Title
02:15 PM	1238	T-cells as Magic Bullets: Recombinant Vaccine Strategies for Cancer Immunotherapy HODGE JW Director, Recombinant Vaccine Group, Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda MD.
02:35 PM	314	Anti-Carbohydrate Specific Immune Response And Tumor Cell Lysis Correlate With Vaccination-Induced Systemic Release Of Stimulatory Cytokines KIRCHEIS R, SIEGL P, HALANEK N, NECHANSKY A Vela Laboratories, Vienna, Austria
02:55 PM	73	Therapeutic Vaccination For Lymphomas: Challenges And Opportunities NEELAPU SS Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

02:15 - 03:35 PM Anti-infective Magic Bullets

Room 207

Chairman: S. Hsieh, Taipei, Taiwan
ZS Pawlowski, Poznan, Poland

Time	Abstr. No.	Title
02:15 PM	547	Targeting CLEC5a/MDL1-1 for the Treatment of Dengue Hemorrhagic Fever CHEN ST ¹ , LIN YL ^{2,3} , HUANG MT ¹ , WU MF ¹ , CHENG SC ¹ , LEI HY ⁴ , LEE CK ⁵ , CHIOU TY ⁶ , WONG CH ³ , HSIEH SL ^{1,3,7} . ¹ Dept. and Inst. of Microbiol. and Immunol, Natl. Yang-Ming Univ.; ² Inst. of Biomed. Sciences, Academia Sinica; ³ Genomics Research Center, Academia Sinica; ⁴ Dept. and Inst. of Microbiol. and Immunol., National Cheng Kung University; ⁵ Inst. of Immunol, National Taiwan University; ⁶ Dept. of Life Science and Inst. of Biotech., National Dong Hwa University; ⁷ Immunology Research Center, National Yang-Ming University & Taipei Veterans General Hospital, Taiwan
02:35 PM	1089	Discovery and Use of the Magic Bullets in Human Taeniosis (Niclosamide, Praziquantel) PAWLOWSKI ZS Medical University, Poznan, Poland
02:55 PM	1157	Transfer factors - Magic Bullets for preventing and treating viruses and mycobacteria in the 21st century WHITE A Department of Psychiatry, Division of Medical Psychology, Duke University Medical Center, Durham, NC 27713 USA
03:15 PM	1810	CAPNET - The German approach of attacking a serious infection problem WELTE T Depart. of Respiratory Medicine, Medizinische Hochschule, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.

02:55 - 03:35 PM Therapeutic Proteins - discovery and manufacturing - Part IV

Room 213

Chairman: T. Akamizu, Suita, JAPAN

Time	Abstr. No.	Title
02:55 PM	1154	Multifunctionality of Native and Recombined Proteins of Honeybee Royal Jelly: Assumptions for Application in Pharmacy ŠIMŮTH J, BÍLIKOVÁ K Institute of Molecular Biology, Slovak Academy of Sciences, Bratislava, Slovakia

03:15 PM 32 Clinical Applications of Ghrelin
AKAMIZU T¹, IWAKURA H¹, ARIYASU H¹, KANGAWA K^{1,2}
¹ Kyoto University, Kyoto, JAPAN; ² National Cardiovascular Center, Suita, JAPAN.

02:55 - 03:35 PM Cardiovascular - Magic Bullets & the cardiovascular system - Part II

Room 205

Chairman: J. Ker, Pretoria, South Africa

Time	Abstr. No.	Title
02:55 PM	210	Xenon: a magic bullet for the treatment of acute brain ischemia? ABRAINI JH^{1,2} , DAVID HN ² , HAELEWYN B ² , RISSO JJ ³ ¹ ERT 1083 "Pharmacologie et Formulation de Gaz-Médicaments", UMR 6232, Université de Caen, CNRS, CEA, Centre CYCERON, Caen, France; ² NNOXe Pharmaceuticals, Quebec, Canada ; ³ IMNSSA, Toulon, France.
03:15 PM	218	The ACE-Inhibitor: True Magic Bullet From Myocardium To Endocardium KER J University of Pretoria, Pretoria, South Africa

02:15 - 03:15 PM Vaccines - History, Reviews, and Future Perspectives - Part II

Room 212

Chairman: P Nara, Frederick, USA

Time	Abstr. No.	Title
02:15 PM	1276	Vaccine-derived polioviruses (VDPVs) - a grey cloud around a magic bullet SHULMAN, LM^{1,2} , MANOR Y ¹ , SOFER D ¹ , MENDELSON E ^{1,3} ¹ Central Virology Laboratory, Tel Hashomer, Israel ² Univ. Tel Aviv , Tel Aviv, Israel ³ Univ. Bar Ilan, Ramat Gan, Israel
02:35 PM	561	Immune Refocusing Technology - Improving On Mother Nature's Immunogenicity NARA P^{1,2} , CHAUDURI R ¹ , LIN G ^{1,3} , TOBIN G ¹ ¹ Biological Mimetics, Inc., Frederick, MD., USA; ² Iowa State University, Ames, IA.,USA, ³ Brigham's and Women's Hosp., Boston Mass., USA
02:55 PM	1178	Whooping cough vaccines: a public health and producer's perspective THALEN M¹ , DE GRAAF T ² ¹ SynCo Bio Partners, Amsterdam, the Netherlands, Netherlands Vaccine Institute, The Hague, the Netherlands

03:15 - 03:35 PM Resistance - a Global Issue for diverse therapeutic areas - Part IV

Room 206

Time	Abstr. No.	Title
03:15 PM	1630	Hydrophilic hexapeptides – a new class of ATF – dependent transport proteins of multiple drug resistance LEBEDEV VV Central Research Institute of Epidemiology, Russia, Moscow

03:35 - 04:35 PM Transporters of physiological compounds and drugs - Part II

Room 214

Chairman: D. Takara, Buenos Aires, Argentina

Time	Abstr. No.	Title
03:35 PM	235	Acetazolamide Inhibits Electrogenic Sodium Bicarbonate Flux through kNBC1. Molecular Mechanisms and Computer Simulations. GROSS E Department of Physics and Astronomy, University of Arkansas, Fayetteville, AR, 72703, USA.
03:55 PM	1304	Interaction Between Local Anesthetics, Specially Articaine, and the Sarcoplasmic Reticulum Ca ²⁺ -Adenosine Triphosphatase TAKARA D; SÁNCHEZ GA and ALONSO GL University of Buenos Aires, Buenos Aires, Argentina.
04:15 PM	116	Novel Modular Nanotransporters which Significantly Enhance Efficacy of Transported Drugs and Impart Cell Specificity to Them SOBOLEV AS ^{1,2} ¹ Institute of Gene Biology, Moscow Russia; ² Moscow State University, Moscow, Russia

Poster presentations

- Abstr. No. Title
- 5 Expression Of Estrogen Receptors During Postnatal Development Of The Brain
IKEDA Y¹, IKEDA M-A²
¹Yokohama City University School of Medicine, Yokohama, Japan; ²Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
- 11 Dopaminergic Receptors: Potential Therapeutic Applications
VELASCO M¹, ISRAILI ZH²
¹Clinical Pharmacology Program, Vargas Medical School, Central University of Venezuela, Caracas, Venezuela; ²Department of Medicine, Emory University, Atlanta, GA USA
- 21 Misoprostol and Postpartum Hemorrhage
ABDEL-ALEEM H
Department of Obstetrics and Gynecology, Faculty of Medicine ,Assiut University, Assiut , Egypt.
- 22 Antibiotic Resistance of Food Chain Related Bifidobacteria
DOMIG KJ, MAYRHOFER S, MAIR C, AMTMANN E, KNEIFEL W
BOKU – University of Natural Resources and Applied Life Sciences, Vienna, Department of Food Sciences and Technology, Division of Food Microbiology and Hygiene
- 24 Aminoglycosides: Deadly Bullets In The Hands Of Unexperienced
NEEF C¹, CROES S^{1,3}, KOOP AH², van GILS SA²
¹Maastricht University Medical Center, Maastricht, The Netherlands; ²University of Twente, Enschede, The Netherlands. ³presenting author
- 47 Effectiveness of Nystatin in Polysymptomatic Patients
A randomized, double-blind study in 116 individuals selected by a 7-item questionnaire (FRDQ-7)
SANTELMANN H¹, LAERUM E², ROENNEVIG J³, FAGERTUN H⁴
¹Holistic Center, Oslo, Norway; ²University of Oslo, Oslo, Norway; ³National Hospital, Oslo, Norway; ⁴Medstat Research, Stroemmen, Norway
- 57 Organ Independent Drug Elimination
KISOR DF
Ohio Northern University College of Pharmacy, Ada, Ohio, USA
- 79 Antitumor Effect of a Novel NF-κB Targeting Therapy in Bladder Cancers
HORIGUCHI Y¹, KIKUCHI E², OZU C¹, YOSHIOKA K¹, NAKASHIMA J², UMEZAWA K³, TACHIBANA M¹,
¹Tokyo Medical Univ., Tokyo, Japan; ²Keio Univ., Schl. of Med., Tokyo, Japan; ³Faculty of Science and Technology, Keio Univ., Yokohama, Japan.
- 80 Soluble Leishmanial Antigen and Plasmid Expressing Interleukin-12 Protects BALB/c Mice from *Leishmania major* Infection
YAMAKAMI K¹, TADAKUMA T²
¹Department of Preventive Medicine and Public Health, National Defense Medical College, Tokorozawa, Saitama, Japan; ²Faculty of Health Care, Kiryu University, Midori-shi, Gunma, Japan
- 83 Comparison of the Pharmacodynamics of Imipenem in Patients with Ventilator-Associated Pneumonia following Administration by 2 h or 0.5 h Infusion
JARURATANASIRIKUL S, SUDSAI T
Prince of Songkla Univ., Songkla, Thailand.
- 89 The study of the adhesion molecules in Non Small Cell Lung Cancer (NSCLC) treated with epidermal growth factor (EGF) can generate a new drugs targets and developing new approaches for systemic treatment in lung cancer
FONSECA FLA^{1,2}, AZZALIS LA³, NOGOCEKE E²
¹Oncology/Hematology Department, ABC Medical School, Santo André, Brazil; ²Roche Center for Medical Genomics, Basel, Switzerland; ³Anhembi Morumbi University, São Paulo, Brazil.
- 90 Exploiting Biochemical Differences Between Parasite And Host In Development Of Antiparasitic Agent
OGBUNDE POJ
University of Nigeria, Enugu-campus, Nigeria
- 112 PKC- η inhibition by ICA-1 reduces cell proliferation in Neuroblastoma
PILLAI P, DESAI S, WIN H, OSTROV D AND **ACEVEDO-DUNCAN M**
Department of Chemistry, University of South Florida, Tampa, FL, James A. Haley Veteran's Hospital, Tampa, FL, *University of Florida, Gainesville, FL
- 114 Physiology and Pharmacology of Gonadotropin-Inhibitory Hormone
UBUKA T1, TSUTSUI K2, BENTLEY GE1
1Univ. of California at Berkeley, Berkeley, CA, USA; 2Waseda Univ., Shinjuku-ku, Tokyo, Japan
- 122 Influence Of Etiology On Host Immunity In Liver Cirrhosis Patients With Advanced Hepatocellular Carcinoma Treated By Combined Intra-Arterial Chemotherapy
NAGAI H, MATSUI T, KANAYAMA M, HIGAMI K, WAKUI N, MOMIYAMA K, IKEHARA T, WATANABE M, IIDA K, ISHII K, SUMINO Y
Division of Gastroenterology and Hepatology, Toho University School of Medicine.

Abstr. No.	Title
157	Treosulfan-Containing Regimens – an Option to Overcome Transplant-Related Toxicity in Children with Refractory Leukemia SKVORTSOVA YV , DISHLEVAYA ZM, MASCHAN AA, MASCHAN MA, SKOROBOGATOVA EV Russian Children's Hospital, Moscow, Russia
173	Starvation and Oxidative Stress as an Inductor of Ciprofloxacin Resistance BIROŠOVÁ L , MIKULÁŠOVÁ M Slovak University of Technology, Bratislava, Slovakia
196	Clinical Guidelines For The Use Of Extended Interval Dosage Regimens Of Gentamicin In Neonates. LANAO JM ¹ , CALVO MV ² , MARTÍN-SUÁREZ A ¹ , MESA JA ² , HERAS MI ³ , CARBAJOSA T ³ , DOMINGUEZ-GIL A ² ¹ Pharmacy and Pharmaceutical Technology, University of Salamanca, ² Pharmacy Service, ³ Paediatric Service, University Hospital
202	Data review on Medicines utilization and expenditure in Serbia from 2004-2007 STEFANOVIĆ D ¹ , SOLAROVIC T ¹ , RADONJIC V ¹ ¹ Medicines and Medical Devices Agency of Serbia (ALIMS), Belgrade, Republic of Serbia
212	Extremely High Natriuretic Effect of 1-Desamino-8-homoarginine Vasotocin in Rats KUTINA AV , NATOCHIN JuV Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Science, Saint-Petersburg, Russia.
224	Antimicrobial Resistance Among Re Treatment TB Patients; Sri Lankan Experience MAGANA-ARACHCHI DN ^{1,2} , PERERA AJ ² , SENARATNE V ³ , DE SILVA K ³ ¹ Institute of Fundamental Studies, Sri Lanka, ² Department of Microbiology, University of Colombo, Sri Lanka, ³ Central Chest Hospital, Welisara, Sri Lanka
227	Tacrolimus: a highly effective new therapy for chronic glomerular diseases? BUTANI L Professor and Chief, Pediatric Nephrology, Co-Instructor of Record, 3rd year Pediatric Clerkship, UC Davis Medical Center, 2516 Stockton Boulevard, Sacramento, CA 95817, USA
243	Culture, Susceptibility Testing And Genotyping Of <i>Mycobacterium Tuberculosis</i> Isolated From Tuberculosis Patient In Bangladesh RAHIM Z ¹ , ZAMAN K ¹ , van SOOLINGEN D ² , LUBY SP ¹ , ENDTZ HP ¹ , SUZUKI Y ³ , van der Zanden AGM ⁴ ¹ International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; ² National Mycobacteria Reference Laboratory, National Institute of Public Health and the Environment, Bilthoven, The Netherlands; ³ Research Center for Zoonosis Control, Hokkaido University, Sapporo, Japan; ⁴ Medisch Microbiologisch, Onderzoeker, Laboratorium Microbiologie, Enschede, The Netherlands
257	Treatment of Agitation in Dementia: Polypharmacy for symptom relief as the Magic Bullet SOMMER, BR ¹ , FENN ² , HH, KETTER TA ¹ ¹ Stanford University School of Medicine, Stanford, CA, USA ² Acute Geropsychiatry Unit, Menlo Park Division, Palo Alto VA Health Care System, Palo Alto CA, USA
266	Activity of Antimalarial Constituents of <i>Spathodea campanulata</i> AMUSAN OOG University of Swaziland, Private Bag 4, Kwaluseni, Swaziland.
272	Targeting Cellular Mechanisms with Natural Antioxidants from Red Palm Oil in order to enhance Cardioprotection ESTERHUYSE AJ ¹ , BESTER DJ ¹ , DU TOIT EF ² , ENGELBRECHT AM ² , TRUTER EJ ¹ , VAN ROOYEN J ¹ ¹ Univ. Cape Peninsula, Bellville, SA; ² Univ. Stellenbosch, Stellenbosch, SA.
275	Quinolone Resistance in <i>Campylobacter</i> isolates Originating from Chicken in Senegal. KINANA AD ¹ , CARDINALE E ² , TALL F ³ , BAHOUN I ¹ , SIRE JM ¹ , BREUREC S ¹ , GARIN B ¹ , BOYE CSB ⁴ , PERRIER-GROS-CLAUDE JD ⁵ . ¹ Institut Pasteur, Dakar, Sénégal; ² CIRAD, Montpellier, France; ³ ISRA, Dakar, Sénégal; ⁴ Université Cheikh Anta Diop, Dakar, Sénégal; ⁵ Institut Pasteur, Casablanca, Maroc
285	Practice of PK/PD theory with no measuring medicine for new quinolones injectable agents in Japan- As an example of the liver abscess - HAMADA Y ¹ , IMAIZUMI H ¹ , SUNAKAWA K ¹ , YAGO K ¹ ¹ Kitasato University Hospital, Kanagawa, Japan
290	From Classic Autohemotherapy To Autologous Hemoderivative Cancer Vaccine Through A Drug And Drug-Carrier Immunomodulatory Adjuvant System LASALVIA-PRISCO E ^{1,3} , GARCIA-GIRALT E ² , VÁZQUEZ J ^{1,3} , CUCCHI S ¹ , LASALVIA- GALANTE E ^{1,3} , LARRAÑAGA J ^{1,3} ¹ Interdoctors MP, Uruguay; ² Centre Cancérologie Hartmann, France; ³ Natl. Ins. of Oncology, Uruguay
302	Dehydroepiandrosterone (DHEA) reduced adiposity and insulin resistance ISHIZUKA T , KAJITA K, IKEDA T, MORI I, FUJIOKA K, UNO Y, MORITA H Department of General Internal Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
310	Multiple Targets of Pyrvinium Pamoate in Mammalian and Parasite Mitochondria TOMITSUKA E ¹ , KITA K ² , ESUMI H ¹ ¹ Natl. Cancer Center Res. Inst. East, Chiba, Japan; ² Univ, Tokyo, Tokyo, Japan.
324	Characterization of an Active Pharmaceutical Ingredient by Its Dissolution Properties: Amoxicillin Trihydrate as a Model Drug HORKOVICS-KOVATS S ¹ ¹ Sandoz GmbH, Kundl, Austria.

- Abstr. No. Title
- 331 Antileishmanial Efficacy of Amphotericin B bearing Emulsomes against Experimental Visceral Leishmaniasis
GUPTA S¹, DUBE A², VYAS SP^{1,3}
¹Indo Soviet Friendship College of Pharmacy, Moga (PB), India; ²Central Drug Research Institute, Lucknow (UP), India; ³Dr. Hari Singh Gour Vishwavidyalaya, Sagar (MP), India.
- 334 The Tissue Specific Choice of Anti-cancer Drugs on the Basis of Polyamine Level
WATANABE S¹, NAGASE S², SATO S², OHKUMA S¹
¹Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama Japan
²Kawasaki College of Allied Health Professions, 316 Matsushima, Kurashiki City, Okayama Japan
- 336 Use of retinoids as environmental contamination biomarkers in aquatic ecosystems
EL BOUHALI B¹, NASRI I²
¹National Laboratory of Forensic Science, Casablanca, Morocco; ²Hassan II University, FST, Laboratory of Biochemistry, Mohammedia, Morocco.
- 341 Some New Derivatives Of Vindoline, Monoindole Catharanthus Alkaloid
RUSZKOWSKA J, CHROBAK R, ZERO P, STUDZIAN M, CZARNOCKI Z
Laboratory of Natural Products, Faculty of Chemistry, Warsaw University, Warszawa, PL
- 352 Polypharmacy: A Major Risk In The Life Of The Elderly
LABAULT-CABEZA NM
Gerontology Program, Graduate School of Public Health, University of Puerto Rico.
- 354 Acetylsalicylic Acid: an Immune-Modulator in HIV Infection
STANCZUK GA¹ and SIBANDA EN²
^{1,2} Medical School, University of Zimbabwe, P.O. Box A 178, Avondale, Harare, Zimbabwe
- 355 Plant Alkamides Bioactive Molecules On A Wide Range Of Organisms
MOLINA-TORRES J¹, LOPEZ-BUCIO J², RAMÍREZ-CHÁVEZ E¹, HERRERA-ESTRELLA L³
¹Cinvestav U, Irapuato, Irapuato, Gto, México. ²Instituto de Investigaciones Químico-Biológicas, Universidad Michoacana de San Nicolás de Hidalgo., Ciudad Universitaria. Morelia, Mich, México. ³LaNGeBio, Cinvestav-Guanajuato Libramiento Norte, Irapuato, Gto, México
- 357 *In Vitro* Pharmacodynamic Evaluation Of Intracellular Activity Of Antibiotics (ABs) Alone Or In Combination Against A Small Colony Variant (SCV) Of *Staphylococcus Aureus*
NGUYEN HA¹, DENIS O², VERGISON A², TULKENS PM¹, STRUELENS MJ¹, VAN BAMBEKE F¹
¹Université catholique de Louvain, ²Université libre de Bruxelles, Brussels, Belgium
- 370 The trypanicidal Effects of Amiodarone and the Azoles: From the Skin to the Heartbeat of a Continent
PANIZ MONDOLFI AE^{1,2}, PÉREZ ÁLVAREZ AM¹, MÁRQUEZ E³, CONCEPCIÓN JL³
1 Laboratorio de Bioquímica, Instituto de Biomedicina, Caracas, Venezuela.
2 Hospital "José Gregorio Hernández", Instituto Venezolano de los Seguros Sociales, Caracas, Venezuela.
3 Laboratorio de Enzimología de Parásitos, Facultad de Ciencias, Universidad de Los Andes, Mérida, Venezuela.
- 383 Telephone counseling of athletes abusing anabolic-androgenic steroids and the state of drugabuse in Japanese athletes
TAKAHASHI M¹, Tatsug Y¹, Kohno T²
1. International Budo University, Katsuura, Japan
2. Ryotokuji University, Urayasu, Japan
- 388 Oxfendazole: A novel strategy to control Cystic Echinococcosis by targeting the intermediate host (sheep)
GAVIDIA CM¹, GONZALEZ AE¹, BARRON E¹, LLAMOSAS M¹, VERASTEGUI MR², GILMAN RH³
¹Universidad Nacional Mayor de San Marcos, Facultad de Medicina Veterinaria, Lima, Peru; ²Universidad Peruana Cayetano Heredia, Lima, Peru; ³Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, USA.
- 390 Antimicrobial Resistance in South Africa: 'Craving for a Magic Bullet'
WALUBO A, VAN WYK R
Department of Pharmacology, University of the Free State, Bloemfontein, South Africa
- 391 Chloroquine is Therapeutic in Murine Experimental Model of Paracoccidiodomycosis
DIAS-MELICIO LA, CALVI SA, BORDON AP, GOLIM MA, PERAÇOLI MTS, SOARES AMVC.
Department of Microbiology and Immunology, Biosciences Institute, São Paulo State University, Botucatu, São Paulo, Brazil.
- 403 Anti-leishmanial effect of Hydroxyurea
GALINDO-SEVILLA N¹, MARTINEZ-ROJANO H^{2,3}, MANCILLA-RAMIREZ J^{1,2}, QUIÑONEZ-DIAZ L^{2,4}
¹Instituto Nacional de Perinatología, Mexico City, Mexico; ²Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City; ³Hospital de Gineco-Pediatría 3A, IMSS, Mexico City; ⁴UJAT, Villahermosa, Tabasco.
- 407 Comprehensive HIV/AIDS Care And Treatment As A Need For Quality Provision Of Antiretroviral Therapy: A Case Study From Dar Es Salaam Region, Tanzania
MAPUNJO SG¹ AND URASSA DP²
¹Ministry of Health and Social Welfare. DSM, Tanzania, ²Muhimbili University of Health and Allied Sciences, DSM, Tanzania
- 408 The influence of cytarabine and myristic acid on aspirin binding with serum albumin. Spectroscopic study
BOJKO B¹, SULKOWSKA A¹, MACIAZEK-JURCZYK M¹, RÓWNICKA J¹, ZUBIK-SKUPIEN I¹ AND SULKOWSKI WW²
¹Department of Physical Pharmacy, Faculty of Pharmacy, Medical University of Silesia, Sosnowiec, Poland
²Department of Environmental Chemistry and Technology, Institute of Chemistry, University of Silesia, Katowice, Poland

- Abstr. No. Title
- 409 Antimicrobial Resistance In Major Pathogens Of Surgical Site Infection In Iran Hospitals
MOBASHERIZADEH S¹, MEMARZADEH M², IRAJ B¹, KHORVASH F³, MOSTAFAVIZADEH K³, ABNESHAHIDI SA⁴, RASTI SJ¹
¹Isfahan University of Medical Science, Isfahan, Iran, ²Department of Surgery Isfahan University of Medical Science, Isfahan, Iran, ³ Department of Infectious Disease and Research Center Isfahan University of Medical Science, Isfahan, Iran, ⁴ Research and Development Center of Saadi Hospital, Isfahan, Iran
- 410 SAPPHERE: A Structural-energetic Approach to B-cell Epitope Prediction
CAOILI SE
University of the Philippines Manila, Manila, Philippines.
- 441 The Knowledge And Expectations Of Parents About The Role Of Antibiotic Treatment In Upper Respiratory Tract Infection (URTI) – A Survey Among Parents Attending Tertiary Care Institution With Their Sick Child
PREMARATNA R, RAJINDRAJITH S, **METTANANDA KCD**, BALASOORIYA H, FONSEKA J, RANDENY S, DE SILVA HJ
Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka
- 442 Treatment Outcome Of Otolomycosis With 1% Clotrimazole Cream
OLOGE FE, NWABUISI C
University of Ilorin, Ilorin, Nigeria
- 459 Magic Bullets and the Nosocomial Nemesis – the KwaZulu-Natal Experience
ESSACK SY
School of Pharmacy and Pharmacology, University of KwaZulu-Natal, Durban, South Africa
- 475 Cytogenetic Response of Imatinib Mesylate in Chronic Phase Chronic Myeloid Leukemia
SHARMA KD, HA CB, KARKI P
BP Koirala Institute of Health Sciences, Dharan, Nepal
- 478 Association of Fluoroquinolone and ESBL-Resistance in Gram-Negative Organisms from Oncology Patients of Lagos University Teaching Hospital (LUTH), Nigeria
AIBINU, IE, ADENIPEKUN, EO, NWAKA, DUC, ADELOWOTAN, AO, AJEKIGBE, AT. ADEYEMI, OF AND ODUGBEMI, TOLU
College Of Medicine, University Of Lagos. Nigeria
- 480 Bacteriocin substance producing by *Lactococcus lactis* against *Listeria monocytogenes* isolated in ready-to-use fish fillets
BARILE M.¹, PALOMBA S.², CERES C.¹, MURRU N.¹, PEPE O²
¹Department of Zootechnical Sciences and Food Inspection, Faculty of Veterinary Medicine, Napoli, Italy; ²Department of Food Sciences, Faculty of Agricultural, Portici, Italy
- 493 Antihormonal and liposomal carriers as novel strategies for chemo-radiotherapy based on cisplatin in cervical cancer.
GARCIA-LÓPEZ P¹, JURADO R¹, GUERRERO-VARGAS N¹, MEDINA LA²
¹Subdirección de Investigación Básica, Instituto Nacional de Cancerología; ²Instituto de Física, Universidad Nacional Autónoma de México. México, D.F., México
- 494 Peroral Colon-Specific Delivery Of Insulin Based On Novel Acrylic-Terpolymer Microcapsular Devices
ICHIKAWA H¹, ARIMOTO M^{1,2}, FUKURMORI Y¹
¹Kobe Gakuin Univ., Kobe, Japan; ²Arfresa Pharma Corporation, Osaka, Japan.
- 508 The Frequency-Dependent Effect of Infrasound on Bull Sperm Velocity
BAGHDASARYAN N, AYRAPETYAN S
UNESCO Chair-Life Sciences International Postgraduate Educational Center, Yerevan, Armenia
- 509 **The Effect of 4Hz (30dB) Infrasound on Heart Muscle Contractility**
DADASYAN E, AYRAPETYAN G
UNESCO Chair-Life Sciences International Postgraduate Educational Center, Yerevan, Armenia
- 511 Synthesis of Unnatural Ceramide Analogs and Their Antiproliferative Properties Against a Panel of Cancer Cells
BITTMAN R¹ AND ARTHUR G²
¹Department of Chemistry and Biochemistry, Queens College and The Graduate Center of CUNY, Flushing, NY 11367, USA
²Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba, CANADA
- 523 Buccal Delivery of Carbamazepine (CBZ): a New Scenario in Management of Trigeminal Neuralgia (TN)
GIANNOLA LI, DE CARO V, GIANDALIA G, SIRAGUSA MG
University of Palermo, Italy
- 526 Nature's Magic: Antiteratogenic Potential of Blue-green Algae Spirulina
JAHANGIR SM¹, **ISLAM AFM S²**
¹Chittagong Medical College, Chittagong, Bangladesh; ² Comilla Medical College, Comilla, Bangladesh
- 542 Online method for measuring of the activities of antibiotic efflux pumps in *Escherichia coli* and *Pseudomonas aeruginosa*
BUIVYDAS A^{1,2}, SENCILIO A^{1,2}, STUKAITE S¹, BAMFORD D², DAUGELAVICIUS R¹
¹Ciurlionio 21/27, Department of Biochemistry and Biophysics, Vilnius University, Vilnius, Lithuania LT-03101;
²Viihinkaari 5 (PO Box 56), Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
- 552 Determination of Modafinil (Provigil) in Plasma and Urine by High-Performance Liquid-Chromatography
SCHWERTNER HA
Clinical Research, Wilford Hall Medical Center, San Antonio, Texas USA 78236

Abstr. No.	Title
567	Pathogenesis of Osteoarthritis: possible target molecules for new therapeutic strategies. ALMONTE-BECERRIL M , CRUZ R, GONZALEZ EC, MIRANDA M, ROJAS-ORTEGA M, KOURI JB Investigation center and advanced studies of National Polytechnic Institute (CINVESTAV-IPN); México, DF.
569	Comparison of therapeutic effects of Reboxetine and Methylphenidate in children and adolescents with Attention-Deficit/Hyperactivity Disorder TEHRANI-DOOST M , MOALLEMI SH, SHAHRIVAR Z Roozbeh Hospital, Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
603	Conceptual basis for cancer treatment: from single drugs to kits with serial programmed actions of multiple substances-drugs BURLAKA D Department of Biotechnical Problems of Diagnostics, Institute of Cryobiology and Cryomedicine National Academy of Sciences of Ukraine, Kyiv, Ukraine.
605	Validation of a RP-HPLC Method with Fluorescence Detection for the Bioequivalence Study of Norfloxacin in Plasma Samples MARIA BERNADETE de SOUSA MAIA ^A , ISMAEL LEITE MARTINS ^B , DEMÉTRIO FERNANDES do NASCIMENTO ^B , ADRIANO NUNES CUNHA ^B , FRANCISCO EVANIR GONÇALVES de LIMA ^B , FERNANDO ANTÔNIO FROTA BEZERRA ^B , MANOEL ODORICO MORAES ^B , MARIA ELISABETE AMARAL MORAES ^B , ^A Departamento de Fisiologia e Farmacologia, Universidade Federal de Pernambuco-UFPE, Cidade Universitária, 50670-901, Recife-PE, Brazil; ^B Unidade de Farmacologia Clínica (UNIFAC) – Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Rua Cel. Nunes de Melo, 1127, Rodolfo Teófilo, 60431-970, Fortaleza-CE, Brazil
608	Combined targeting of growth-promoting genes with antisense oligonucleotides in human colorectal cancer cells: Chemosensitization potential ABAZA M-S . AND BAHMAN A M Department of Biological Sciences, Faculty of Science, Kuwait University, P. Box 5969, 13060 Safat, State of Kuwait.
617	Cardiac side effects of psychotrop (antidepressant, antipsychotic) drugs KECSKEMETI V Semmelweis University, Budapest, Hungary
627	Success story of the first regulatory approval of safety biomarkers, Part II: Consortia, regulatory submissions and translation to human DIETERLE F , MARRER E Novartis Institutes for BioMedical Research
633	Antibacterial Activity Of Glucosamine Sulfate And Chondroitine Sulfate? ROZIN AP ¹ , GOLDSTEIN M ² , SPRECHER H ² ¹ B. Shine Department of Rheumatology, ² Department of Microbiology, Rambam Health Care Campus and Technion, Haifa, Israel
634	Immunogenicity of mucosally delivered Lactococcus lactis expressing a malaria protein in rabbits YASAWARDENE SG ¹ , RAMASAMY R ² ¹ Faculty of Medical Sciences, University of Sri Jayawardenepura, Nugegoda, Sri Lanka; ² Institute of Medicine, University Brunei Darussalam surangiy@hotmail.com
660	Digoxin plasma concentrations of four different dosing schedules commonly used in clinical settings. REINBACH R ¹ , VILLA L ² , FERNANDEZ P ² , GIRAUDDO P ³ , VENEGAS R ¹ . ¹ Universidad de Concepción, Facultad de Medicina, Concepción, Chile ² Universidad de Concepción, Facultad de Farmacia, Concepción, Chile ³ Laboratorio Clínico Diagnomed, Concepción, Chile
676	A New Paradigm Of Endocrine Systems That Enables The Development Of Selective Hormonal Therapies MANDOKI JJ ¹ , JIMÉNEZ-OROZCO A ¹ , GARCÍA-MONDRAGÓN MJ ¹ , MALDONA-DO-ESPIÑOZA A ¹ , CASA-TIRAO B ² ¹ Facultad de Medicina, ² Facultad de Filosofía y Letras, Universidad Nacional Autónoma de México
682	Combined Therapy With Pitavastatin And Eicosapentaenoic Acid Improve Platelet Activation Markers In Hyperlipidemic Patients With Type 2 Diabetes Mellitus NOMURA S ¹ , INAMI N ² , SHOUZU A ² , IWASAKA T ² ¹ Kishiwada City Hospital, Osaka, Japan; ² Kansai Medical University, Osaka, Japan
702	AntiJEd: A possible therapeutic and immunomodulatory drug for Japanese encephalitis SAXENA SK ¹ ¹ Centre for Cellular and Molecular Biology, Uppal Road, Hyderabad 500007 (AP), INDIA
703	The Outer Membrane Vesicles Of An Antarctic Bacterium <i>Pseudomonas Syringae</i> Lz4W JAGANNADHAM MV , DHOPLE VM and SUNDARAM CS Centre for Cellular and Molecular Biology, Uppal road, Tarnaka, Hyderabad-500 007, India.
707	Toxins and Adhesion Factors Associated with <i>Staphylococcus Aureus</i> Isolated from Urinary Tracts Infections BABA MOUSSA L ¹ , ANANI L ² , HAÏKOU N ¹ , HOUNSOU F ² , COUTURIER M ³ , SANNI A ¹ , MONTEIL H ³ , PREVOST G ³ ¹ FAST-University of Abomey-Calavi, Bénin; ² LNSP, Cotonou, Bénin ; ³ UPRES EA-3432, Institut de Bactériologie, Strasbourg France
707	Panton-Valentine leucocidin as a major virulence factor associated to furuncles BABA MOUSSA L ¹ , PREVOST G ² , COUTURIER M ² , MONTEIL H ² , MOREAU B ³ , PRADINAUD R ⁴ , COUPPIE P ⁴ ¹ FAST-University d'Abomey-Calavi, Bénin ; ² UPRES EA-3432, Institut de Bactériologie, Strasbourg ; ³ Bactériologie ; ⁴ Dermatologie, C.H.G. Cayenne, France

Abstr. No.	Title
708	Seropositivity for Hepatitis B Virus, Vaccination Coverage, and Vaccine Response in Dentists from <i>Campo Grande, Mato Grosso do Sul, Brasil</i> . BATISTA SMF ¹ , ANDREASI MSA , BORGES AM , LINDENBERG AS , SILVA AL , FERNANDES TD , PEREIRA EF , BASMAGE EA , CARDOSO DDP . ¹ Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brasil ² Universidade Federal de Goiás, Goiânia, GO, Brasil
710	Synthesis And Biological Evaluation Of Some New 2-Cinnamamidobenzamides As Potential Antagonists Of The HDM2-P53 Protein-Protein Interactions RAFFA D ¹ , PLESCIA S ¹ , CASCIOFERRO S ¹ , CUSIMANO MG ¹ , TOLOMEO M ² ¹ Dipartimento di Chimica e Tecnologie Farmaceutiche, Palermo, Italy, ² Centro Interdipartimentale di Ricerca in Oncologia Clinica (C.I.R.O.C.), Policlinico, Università di Palermo, Palermo, Italy
713	Superoxide Dismutase Activity in the Kidney of Mice Exposed to Acute Cadmium Intoxication: Protective Effect of Magnesium Pretreatment DJUKIC-COSIC D ¹ , CURCIC M ¹ , NINKOVIC M ² , MALICEVIC Ž ² , PLAMENAC BULAT Z ¹ , MATOVIC V ¹ ¹ Institute of Toxicology, Faculty of Pharmacy, Belgrade, Serbia; ² Institute of Medical Research, Military Medical Academy, Belgrade, Serbia.
732	Malaria-induced up and down-regulation of Cytochrome P450: Implications for Pharmacotherapy DE-OLIVEIRA ACAX , PAUMGARTTEN FJR , DA-MATTA AC , POÇA KS , SANTOS MJS . Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil.
792	The Interaction of the Organophosphorous Pesticide Methyl-Parathion with Serum Albumin by Fluorescence Spectroscopy CORTEZ CM , SILVA D , BASTOS JC . Rio de Janeiro State University, Rio de Janeiro, Brazil.
796	Treatment of chronic myeloid leukaemia (CML) by imatinib mesilate in Togo KUEVIAKOE MI * ; SEGBENA AY* ; PADARO E* ; DORKENOO M* ; BORIÉS D** * Laboratories of the Campus Teaching Hospital (Lomé, Togo) ** Cellular and Molecular Haematology Laboratory of Henri Mondor Teaching Hospital (Créteil, France)
805	Chitosan-Ca-Alginate Microparticles As Carriers For Colon Delivery Of 5-Aminosalicylic Acid After Peroral Administration MLADENOVSKA K ¹ , CRUAUD O ² , GORACINOVA K ¹ , EFREMOVA D ¹ , DAVITKOVSKA E ¹ , VENIER-JULIENE MC ² , POPOVSKI E ³ , RICHOMME P ⁴ ¹ Ss "Cyril and Methodious University", Faculty of Pharmacy, Skopje, Macedonia; ² University d'Angers, Angers, France; ³ Ss "Cyril and Methodious University", Faculty of Natural Science, Skopje, Macedonia; ⁴ SONAS, UFR des Sciences Pharmaceutiques, Angers, France
819	Impact of Cisplatin potentiation by Cytarabine in the 5-FU-CDDP regimen for dismal- prognosis head and neck cancer (HNC) patients; a meta-analysis of 3 local trials involving 492 patients. JELIC S , KREACIC M , URSLOVIC T , VUCICEVIC S , GAVRILOVIC D , JOVANOVIC N , BABOVIC N , PETROVIC Z , MIKIC A Institute for Oncology and Radiology of Serbia, Belgrade
867	Clinical Pharmacokinetics of Gentamicin: Estimation of Initial Dosing Parameters in Hospitalized Patients at Kuwaiti Hospital. AL-LANQAWI Y ¹ , CAPPS P ² , ABUDLMALEK K ³ , AL-ANEZI K ⁴ , THUSU A ⁵ , AND SHARMA P ^{1,3,4,5} AL-Amiri Hospital, Ministry of Health, Kuwait, and ^{2,6} Faculty of Pharmacy - Kuwait University, Kuwait.
879	Synbiotics: An Important Tool For Preventing Enterocolitis And Promoting Physical Growth In Severely Ill Pediatric Patients –10 Years' Experience In One Institute- KANAMORI Y ¹ , IWANAKA T ¹ , SUGIYAMA M ¹ , YUKI N ² , TAKAHASHI T ² , MOROTOMI M ² , TANAKA R ² ¹ The University of Tokyo Hospital, Tokyo, Japan, ² Yakult Central Institute for Microbiological Research, Tokyo, Japan
880	Antioxidant and Antiglycation Potential of Some Sudanese Medicinal Plants and their Isolated Compounds KOKO WS ¹ , OSMAN EA ² , GALA M ¹ ¹ Medicinal and Aromatic Plants Research Institute, National Center for Research, P. O. Box 2404, Khartoum, Sudan; ² Faculty of Pure and Applied Sciences, International University of Africa, Khartoum, Sudan
881	Metalloantibiotics: Synthesis and Antibacterial Activity of Metal(II) Complexes Containing Cephalosporin and Sulfathiazole ANACONA JR Universidad de Oriente. Departamento de Química, Cumana. Venezuela
884	The prevalence and the resistance mechanism of fluoroquinolones in bacteria isolated from Bangladesh AKHTER F , OSMAN KT , AMIN R , AKHTER F , ADNAL N , HOSSAIN MA Department of Microbiology, University of Dhaka, Dhaka 1000, Bangladesh
889	The Hyperglycaemic Effect Of S-Nitrosoglutathione And S-Nitroso-N-Acetylpennicillamine – Possible Mechanism Of Action McGROWDER D , BROWN P , RAGOOBIRSINGH D University of the West Indies, Kingston, Jamaica
901	Protective effect of plant polyphenols-containing azuki bean (<i>Vigna angularis</i>) on renal damage SATO S ¹ , MUKAI Y ¹ , AND YAMATE J ² ¹ Aomori Univ. Health Welfare, Aomori, Japan; ² Osaka Pref. Univ, Sakai, Japan
929	Associative learning induces selective changes in the quantitative distribution of GAT-1, a high-affinity γ -aminobutyric acid transporter, in adult mice barrel cortex SIUCINSKA E Nencki Institute, Warsaw, Poland

- Abstr. No. Title
- 958 Role of Endothelial Cells and Treatment with Gentamicin in Septic Shock
HASWANI DK¹, OETTINGER CW² and D'SOUZA MJ³
¹Patheon Pharmaceuticals, 2110 E Galbraith Road, Cincinnati, OH, United States; ²Dialysis Clinic, Atlanta, GA, United States; ³College of Pharmacy & Health Sciences, Mercer University, Atlanta, GA, United States.
- 1037 Do parasitic nematodes regulate cell apoptosis in the host
DONSKOW-SCHMELTER K, DOLIGALSKA M.
University of Warsaw, Warsaw, Poland;
- 1038 Computed Tomographic Study Of The Paranasal Sinuses And Nasal Washings In Atopic Children Without Sinusitis Symptoms
ROSARIO NA; KOVALHUK LC; CARVALHO A; CALLEFE LG
Federal University of Parana, Curitiba – Brazil
- 1050 The VesiVax[®] System: Vaccinology's Magic Bullet?
FUJII, G¹, ERNST WA¹, ADLER-MOORE, J²
¹Molecular Express, Inc., Rancho Dominguez, USA; ²California State Polytechnic University Pomona, Pomona, USA.
- 1083 Two Passengers on the Cancer Road: Clomipramine and Lithium Chloride
BILIR A¹, ERGUVEN M², YAZIHAN N³
Istanbul University, Istanbul, Turkey ¹Istanbul Faculty of Medicine, ² Istanbul Faculty of Medicine and Faculty of Pharmacy; ³ Ankara University, Faculty of Medicine, Ankara, Turkey.
- 1091 Methicillin Resistance In *Staphylococcus Aureus* And Coagulase-Negative Staphylococci
RIBEIRO de SOUZA da CUNHA ML, MARTINS A, USTULIN DR, PEREIRA VC
Instituto de Biociências, Universidade Estadual Paulista - UNESP, Botucatu-SP, Brasil
- 1091 Coagulase-Negative Staphylococci Oxacillin Resistant And Toxigenic Isolated In Brazil
RIBEIRO de SOUZA da CUNHA ML, CALSOLARI RAO, ARAÚJO-JÚNIOR JP
Instituto de Biociências, Universidade Estadual Paulista - UNESP, Botucatu-SP, Brasil
- 1092 Polymyxins: Differences & Similarities between Polymyxin B and Polymyxin E (Colistin), and their recent developments
KWA AL¹, KASIAKOU SK³, TAM VH², FALAGAS ME^{3,4}
1. Department of Pharmacy, Singapore General Hospital, Singapore, 2. Department of Clinical Sciences and Administration, University of Houston College of Pharmacy, Houston, Texas, USA, 3. Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece, 4. Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA.
- 1104 Anti-mycobacterial compounds: effects on the microbe and its host cell
GARCIA RC¹, OLIVEIRA RAS¹, AZEVEDO-XIMENES E², BANFI E³, LUZZATI R⁴
Leukocyte Biology Group, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy¹; Department of Antibiotics, Universidade Federal de Pernambuco, Recife, Brazil²; Department of Biomedical Sciences, University of Trieste, Italy³ and Department of Infectious Diseases, University Hospital, Trieste, Italy⁴
- 1118 Novel Diastereoselective Synthetic Routes to Tamoxifen, Toremifene, and Droloxifene, Anti-Breast Cancer Agents via Organoboranes
BHAT NG, CAVAZOS E, ORTIZ O, ELIZONDO D
Department of Chemistry, The University of Texas-Pan American, 1201 West University Drive, Edinburg, Texas 78539-2999 USA;
- 1131 The Application of Early Bactericidal Activity (EBA) studies in Assessing Antituberculosis Drugs
SIRGEL FA
Medical Research Council, Cape Town, South Africa
- 1136 Pain Relief Without Side Effects: Methylalntrexone (MNTX) and Alvimopan (ALV) are Silver Bullets In the Use of Opioids for Analgesia
FOSS JF
Cleveland Clinic, Cleveland, OH, USA
- 1140 Crosstalk Between TNF α and NGF: Potential Implications for Alzheimer's Disease and Neuroblastoma
YOSHINORI TAKEI and RONALD LASKEY
MRC Cancer Cell Unit, Hutchison/MRC Research Centre,
Hills Road Cambridge CB2 0XZ, UK.
- 1147 B16 And Cloudman S91 Mouse Melanoma Cells Susceptibility To Apoptosis After Dacarbazine And Doxorubicin Treatment Examined In Three Cytotoxicity Tests: Cell Counting, MTT And Flow Cytometry
OLSZEWSKA-SLONINA D, STYCZYNSKI J, DREWA T
Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland

- Abstr. No. Title
- 1156 Cefquinome and Amoxicillin in Goats: PK/PD Integration
BATZIAS GC
Laboratory of Veterinary Pharmacology, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, 54 124 Thessaloniki, Greece
- 1179 Ciprofloxacin Induces Oxidative Stress and Exerts Biphasic Cytotoxicity in Primary Culture of Rat Astrocytes and Human Fibroblast Cells.
GÜRBAY A1,2, GONTHIER B2, FAVIER A3, HINCAL F1
1Univ. of Hacettepe, Ankara, Turkey; 2Univ. Joseph Fourier, La Tronche, France; 3CEA/Grenoble, Grenoble, France
- 1209 Lipid Nanocarriers for delivery of antimalarial drug Primaquine
SINGH KK, VINGKAR S
C.U.Shah College of Pharmacy, SNTD Women's University, Mumbai, India
- 1286 Application of Superparamagnetic Nanoparticles in Purification of Plasmid DNA and Recombinant Protein from Bacterial Cells
CHIANG CL, CHEN CY
Department of Chemical and Materials Engineering, Southern Taiwan University, 710 Yung-Kang City, Tainan Hsien, Taiwan
- 1299 Serum Alcohol Dehydrogenase: A Sensitive Biomarker of Ongoing Graft Function After Liver Transplantation
SHIMOJIMA N¹, SHIMAZU M¹, KIKUCHI H², KAWACHI S¹, TANABE M¹, HOSHINO K¹, WAKABAYASHI G¹, MORIKAWA Y¹, KITAJIMA M¹
¹Department of Surgery and ²Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan
- 1306 Chemotherapy of Duchenne's muscular dystrophy
URADE Y, ARITAKE K
Osaka Bioscience Institute, Osaka, Japan
- 1330 Immunogenic and Adjuvant Activities of *Bordetella pertussis* proteins
CAINELLI GEBARA VCB, LOPES APY, WOLF PS, FERREIRA VRF, QUINTILIO W, RAW I
Instituto Butantan, São Paulo, SP, Brasil
- 1332 Trends in Co-Occurring Diseases in Patients Treated for Alcohol and Drug Problems in Canada.
ADRIAN M
Nova Southeastern University, Ft. Lauderdale, FL, USA
- 1338 Effect of caffeine on quinidine transport to the central nervous system in rats
VASOVIC V, JAKOVLJEVIC V, BANIC B, SABO A, VUKMIROVIC S, MILIJASEVIC B
Medical faculty of Novi Sad, Novi Sad, Serbia
- 1349 Biomedical Research at The University of The West of England, Bristol
JACKSON SK, AVENT ND, XU J
Centre for Research in Biomedicine, Faculty of Health and Life Sciences, University of the West of England, Bristol, U.K
- 1349 Disturbance in energy metabolism induced by hepatotoxins in a liver spheroid model
XU J, JACKSON SK
Centre for Research in Biomedicine, Faculty of Health and Life Sciences, University of the West of England, Bristol, U.K.
- 1355 Laticins, Antimicrobial Peptides from Spider Venom: a Variety of the Mechanisms of Action
DUBOVSKII PV
Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia
- 1358 The Strong Growth Advantage in Stationary Phase Phenomenon in Mixed Cultures of Antimicrobial Resistant *Escherichia* and *Salmonella*
BACUN-DRUZINA V¹, BUTORAC A¹, HALEC I¹, GJURACIC K²
Faculty of Food Technology and Biotechnology, Zagreb, Croatia; ²GSK Research Centre Zagreb Ltd., Zagreb, Croatia.
- 1405 SWAZILAND DEMOGRAPHIC AND HEALTH SURVEY 2006–2007 WITH SPECIAL FOCUS ON THE PREVALENCE OF HIV
MASUKU R¹, MNGADI PT²
¹Swaziland Central Statistics Office, Mbabane, Swaziland, ²University of Swaziland, Faculty of Health Sciences, Mbabane, Swaziland
- 1406 Cytokine Profiles Of Patients With Cutaneous Leishmaniasis
OZBILGE H, KAYA E
University of Erciyes, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Kayseri, Turkey.
- 1414 Ascorbic acid and dietary selenium bioavailability in rats
GROSICKI A, KOWALSKI B.
National Veterinary Research Institute, Department of Radiobiology, 24-100 Pulawy, Poland.

- Abstr. No. Title
- 1419 A Novel And Effective Antibody Therapy For Brain Infarction Targeting Alarmin/HMGB1
NISHIBORI M¹, LIU K¹, TAKAHASHI HK, WAKE H¹, ZHANG J¹, TOMONO Y⁴, ADACHI N⁵, YOSHINO T, OHTSUKA A, MORI S^{1,6}
Department of Pharmacology¹, Pathology² and Human Morphology³, Okayama Univ Grad Schl Med, Okayama, Japan; ⁴Shigei Medical Inst, Japan; ⁵Ehime Grad Schl Med, Matsuyama, Japan; ⁶Shujitsu Univ Schl Pharmacy, Okayama, Japan
- 1426 Fentanyl Analogues: Structure-Activity-Relationship (SAR) Study
VUCKOVIC S, TODOROVIC Z, NEŠIC Z, IVANOVIC M, STOJANOVIC R, DIVAC N, PROSTRAN M
University of Belgrade, Belgrade, Serbia
- 1428 Analysis of fish immune response through bacterial stimulation and its application to oral vaccination for the cultured marine fishes
TAMARU Y^{1,2*}, OHTSUKA M¹, MATSUDA T¹, KATO K³, MANABE S⁴, KURODA K⁵, SANADA M⁵, AND UEDA M⁵
¹Dept. of Life Science, Grad. Sch. of Bioresources and ²Venture Business Lab., Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
³Fisheries Lab. of Kinki Univ., 3153 Shirahama, Nishimuro, Wakayama 649-2211, Japan
⁴Kan-on-ji Inst., The Research Foundation for Microbial Disease of Osaka Univ., 2-9-41 Yahata, Kanonji, Kagawa 768-0061, Japan
⁵Dept. Appl. Biochem., Grad. Sch. of Agriculture, Kyoto Univ., Kitashirakawa-Oiwake, Sakyo, Kyoto 606-8502, Japan
- 1436 Nonmedical factor influencing the prescribing of antibacterials
SABO A, TOMIC Z, HORVAT O, MIKOV M, VASOVIC V, JAKOVLJEVIC V, RAŠKOVIC A
Faculty of Medicine Novi Sad Serbia
- 1436 The impact of non medical factors on prescription rate and the structure of antibacterials in Serbia
SABO A, TOMIC Z, HORVAT O, MIKOV M, VASOVIC V, JAKOVLJEVIC V, RAŠKOVIC A
Faculty of Medicine Novi Sad Serbia
- 1450 Progesterone and its Metabolites have Functional Effects on Processes other than Pregnancy, such as those involving Stress, Affect, and Cognition
WALF AA¹, FRYE CA¹⁻⁴
¹Psychology, ²Biology, ³Center for Neuroscience, ⁴Center for Life Science Research, Univ. at Albany-SUNY, Albany, NY, USA
- 1452 Proteomic analysis of human breast cancer cells derived from metastatic versus non-metastatic tumors
VYDRA J¹, SELICHAROVA I², SMUTNA K², SANDA M², MATOUSKOV E³, BURSÍKOVA E³, PRCHALOVA M³, VELENSKA Z⁴, COUFAL D⁵, JIRACEK J²
¹Department of Oncology, ^{1st} Faculty of Medicine, Charles University Prague, Czech Republic; ²Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic; ³Institute of Biochemistry and Experimental Oncology, ^{1st} Faculty of Medicine, Charles University Prague, Czech Republic; ⁴Institute of Pathology ^{1st} Faculty of Medicine, Charles University Prague and General Teaching Hospital, Prague, Czech Republic; ⁵Institute of Computer Science, Academy of Sciences of the Czech Republic, Prague, Czech Republic
- 1455 Antioxidant Supplementation Impacts upon Electronegative Low Density Lipoprotein Plasma Levels and Cardiovascular Risk
GOMES LF¹, SIMON KA², MELLO-ALMADA FILHO C², CENDOROGLIO MS², QUIRINO LM², RAMOS LR², JUNQUEIRA VBC²
¹Universidade de São Paulo; ²Universidade Federal de São Paulo, São Paulo, Brazil.
- 1462 Endovascular Stenting for Malignant Superior Vena Cava Syndrome is Essential Therapy but not Approved in Japan
FUKUDA M, MOTOSHIMA K, HISATOMI K, FUTSUKI Y, HARADA T, OGAWARA D, IMAMURA S, IKEDA K, YAMAMURA M, YAMAKAWA M, MINAMI K, NAKAMURA Y, KOHNO S
- 1470 Protective effects of *Nigella sativa* extract and its components against chromium VI-induced toxicity in Nile tilapia (*Oreochromis niloticus*) and zebrafish (*Danio rerio*)
KHALIL WKB^{1*}, **ALI Fagr K**², BELATTAR N³, SENATOR A², ABDEL-WAHAB MA^{4**}
¹Cell Biology Department, ²Water Pollution Department, ⁴Food Toxicology & Contaminants Department, National Research Centre, 12622 Dokki, Cairo, Egypt
²Laboratory of Applied Biochemistry, Biology Department, Faculty of Sciences, Ferhat Abbes University, 19000 Sétif, Algeria.
- 1475 Multiple antibiotic resistance of heterotrophic bacteria from Siberian lakes as an indicator of anthropogenic influence on the ecosystems
LOBOVA TI
International Centre for Research of Extremal States of Organisms, Krasnoyarsk Scientific Center of Siberian Branch of Russian Academy of Sciences, Krasnoyarsk, Russia.
- 1475 Specificity of multiple antibiotic resistance appearance by luminous bacteria inhabiting the Pacific and Indian oceans
MEDVEDEVA SE¹, **ZAKHAROVA NV**¹, **LOBOVA TI**², **POPOVA LYU**²
¹Institute of Biophysics of SB RAS, Krasnoyarsk, ²Russia; International Centre for Research of Extremal States of Organisms, Krasnoyarsk Scientific Center of SB RAS, Krasnoyarsk, Russia.
- 1476 Development of Agonists and Antagonists of Human Thyrotropin Using Site-Directed Mutagenesis and Gene Transfer
FARES F, BAR-SHALOM R, AZZAM N
Department of Molecular Genetics, Carmel Medical Center and the Faculty of Science and Science Education, University of Haifa, Haifa, Israel.
- 1476 Designing a new agonist of Erythropoietin by Fusing the Carboxyl-Terminal Peptide of Human Chorionic Gonadotropin β Subunit to the Coding Sequence of Human Erythropoietin
FARES F^{1,2}, **GANEM S**², **HAJOUJ T**², **AGAI E**²
¹Department of Molecular genetics, Carmel Medical Center and the Faculty of Science, University of Haifa, Haifa, 31905, and ²ModigeneTech, Weizmann Science Park, Nes-Ziona, 74140, Israel

- Abstr. No. Title
- 1479 The Antagonistic Role of Curcumin against Nicotine induced Genotoxicity on different Organs of Female Rats under Restricted Dietary Protein
BANDYOPADHYAYA G¹, SINHA S¹, CHATTOPADHYAY K², **CHATTOPADHYAY BD¹**
¹Jadavpur University, Kolkata, India; ²University of Calcutta, Kolkata, India.
- 1490 Therapeutics: A New Control Strategy Using The Doses As Well As The Serum Concentrations To Optimize Learning About The Patient While Treating Him/Her At The Same Time
BAYARD D^{1,2}, SCHUMITZKY A^{1,3}, **JELLIFFE R¹**
¹Laboratory of Applied Pharmacokinetics, USC Keck School of Medicine, Los Angeles, CA, USA. ²Guidance and Control Section, Jet Propulsion Laboratory, Pasadena CA, USA. ³Department of Mathematics, USC, Los Angeles CA USA.
- 1490 Therapeutics: Two New Bayesian Methods For Parameter Updating In Individual Patients
BAYARD D^{1,2}, SCHUMITZKY A^{1,3}, BOTNEN A¹, THOMSON A⁴, **JELLIFFE R¹**
1. Laboratory of Applied Pharmacokinetics, USC Keck School of Medicine, Los Angeles CA, USA. 2. Guidance and Control Section, Jet propulsion Laboratory, Pasadena CA USA. 3. Department of Mathematics, USC. 4. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
- 1495 Renal Afferent Arteriolar Vasodilator Action of Adenosine Predominantly Involves A2b Receptor Activation
FENG M-G, NAVAR LG
Tulane University, New Orleans, LA. USA
- 1498 Matrix metalloproteinases at BBB and beyond in Multiple Sclerosis and HIV-dementia. New perspectives for therapeutical interventions
LIUZZI GM
Department of Biochemistry and Molecular Biology "E. Quagliariello", University of Bari, Italy
- 1504 Surface-modified polyamidoamine (PAMAM) dendrimers for site-specific gene delivery
KUMAR A, YELLEPEDDI VK, **PALAKURTHI S**
Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, TX, USA
- 1509 A Potential Anti-Cancer Drug From a Plant Extract, *Tillandsia recurvata*
LOWE H¹, BRYANT JL²
¹Environmental Health Foundation; ²University of Maryland (IHV) School of Medicine
- 1518 Cryoimmunology Induced After Reimplantation Of Malignant Bone Tumor Treated With Liquid Nitrogen
NISHIDA H^{1,2}, TSUCHIYA H¹, KAWANO M¹, TOMITA K¹
¹Kanazawa Univ., Kanazawa, Japan; ²Fujii Hosp., Kanazawa, Japan
- 1528 Change in Immunisation Schedule and Sudden Infant Death Syndrome in Hungary
TÖRO K
Department of Forensic Medicine Semmelweis University, Budapest, Hungary
- 1533 New Approaches in the Treatment of Lymphoma Patients, R-Chop: Rapid Infusion Rituximab
SANCHEZ- RUIZ A, CANTOS B, MAXIMIANO C, MENDEZ M, GALAN L, HUELVES M, LOPEZ A, PROVENCIO M
Medical Oncology Service. University Hospital Puerta de Hierro. Madrid, Spain.
- 1572 Some Aspects On Xenobiotic Metabolism, From Hepatic Function To Prospective Drugs
REKKA EA, KOUROUNAKIS PN
Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki, Greece
- 1573 Discovery of the HCV NS3/4A Protease Inhibitor, Boceprevir (SCH503034). Key Steps in Structure-Based Optimization.
PRONGAY AJ
Schering Plough Research Institute, Cambridge, United States of America.
- 1579 Drugs Legeslation and Regulation in Pakistan
GUL R, IFTIKHAR ALAM KHATTAK
Department of Human Nutrition, Faculty of Nutrition Sciences, NWFP Agricultural University, Peshawar, NWFP-Pakistan, Email: romanticadil@yahoo.com
- 1581 Dual Inhibitors Targeting Matrix Metalloproteinases And Carbonic Anhydrases As Potential Anticancer Drugs
MARQUES SM, SANTOS MA
Centro de Química Estrutural, Instituto Superior Técnico, Lisboa, Portugal
- 1586 The Long Term Follow up Results of Hydatid Cysts after Albendazole and Mebandazole Treatment
ARSLAN A¹, ÖDEV K², PAKSOY Y², ARIKOGLU H², and SAHIN M²
¹Gaziantep University, Gaziantep, Turkey, ²Selçuk University, Meram Campus, Konya, Turkey
- 1598 Central Nervous Systems involvement in dogs naturally infected by *Leishmania chagasi/infantum*
ABREU-SILVA AL¹, DE CARVALHO DA SILVA AP¹, DE MACEDO AA¹, DE CARVALHO NETA AV², AND DA SILVA CALABRESE K³
¹Departamento de Patologia da Universidade Estadual do Maranhão, São Luís – Maranhão Brazil.,
²Departamento de Química e Biologia da Universidade Estadual do Maranhão, São Luís – Maranhão Brazil.,
³Laboratório de Imunomodulação, Departamento de Protozoologia do Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.

- Abstr. No. Title
- 1614 Screening Phage Genomes to Identify Novel Antimicrobial Targets in Mycobacteria and Related Organisms
SHIBAYAMA Y, DABBS ER
Univ. of the Witwatersrand, Johannesburg, South Africa
- 1608 Then - Macrocirculation and Antibacterial Treatment – and Now: Microcirculation and Antiviral Treatment
VOGEL GE, BACK TH, BLASINI R, BRANDL R, HECKLER R, VON ITZSTEIN M, KOMM CH, MANYCH M, MÖLLER R, SCHÖTTLER M, SCHREIBER M, SCHWAIGER M
- 1624 Therapeutic effects of *Crocus sativus* (saffron) on respiratory diseases
BOSKABADY MH, ASLANI MR, AHMADZADEH H, GHASEMZADEH RAHBARDAR M, NEMATI A
Dept. of Physiology and Pharmacological Research Centre, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran
- 1624 Different therapeutic effects of *Nigella sativa*
BOSKABADY MH, MOHSENPOOR N, TAKALOO L, JAVAN H, FARHADI J
Dept. of Physiology, Medical School, Azadi Square, Mashhad University of Medical Sciences, Mashhad, IR Iran
- 1631 Targeting of nitric oxide-donors to the phagosomal compartment of macrophages and the release of NO mediate killing of intracellular Leishmania parasites within the host cell
SCHLEICHER U¹, VALDEZ CA³, MAMMATO R², EL-GAYAR S¹, KEEFER LK³, BOGDAN C¹
¹Institute of Clinical Microbiology, Immunology and Hygiene, University Clinic of Erlangen, Germany
²Institute of Medical Microbiology and Hygiene, University Clinic of Freiburg, Germany
³Laboratory of Comparative Carcinogenesis, National Cancer Institute at Frederick, U.S.A.
- 1640 Gold Nanoparticles as Model System for the Targeting of Colloids
Tessmar J
University of Regensburg-Pharmaceutical Technology, Universitätsstr 31, 93040 Regensburg, Germany
- 1647 Vancomycin Resistant Enterococcus faecium Under Constant Linezolid Exposure
GLOEDE J, SCHEERANS, C., KLOFT C
Martin-Luther-Universität Halle-Wittenberg, Halle, Germany
- 1657 Tolerability of pyrimethamine/sulpha chemotherapy in children with congenital toxoplasmosis treated in Department of Pediatrics and Infectious Disease, Medical University in Wrocław, Poland.
KUCHAR E, KUCHAR I, SZENBORN L, JASONEK J, ZYZAK K.
Department of Pediatrics and Infectious Disease, Medical University in Wrocław (Breslau), Poland.
- 1661 Population Pharmacokinetics for Nevirapine in Black Newborns to Prevent HIV Transmission
FRANK M¹, KUNZ A², HARMS G², KLOFT C¹
¹Martin-Luther-Universität Halle-Wittenberg, Halle, Germany; ²Institute of Tropical Medicine, Charité, Berlin, Germany.
- 1671 Development of a new 3D-Human Airway Epithelium/ Whole-blood Co-culture Model Combined with Multi-Analyte Profile (MAP) Analyses for Assessing Drug Effects
BLUM M¹, STEIN GM¹, CONSTANT S², WISZNIOWSKI L², HUANG S², MAPES J³, SPAIN M³, SCHMOLZ M¹
¹EDI GmbH, Reutlingen, Germany, ²Epithelix Sàrl, Plan-Les-Quates, Genève Suisse, ³Rules-Based Medicine Inc., Austin, TX, USA
- 1674 Fluorescent Biosensors to Detect Magic Bullets against Multi-Drug Resistant Bacteria
I. MECKLENBRÄUKER, C. SCHLEBERGER, C. HAHN, Y. WILLER, N. Q. LE, C. KÖNIG, L. WILKEN, A. BECHTHOLD, D. BUMANN and C. LIPPUNER
Albert-Ludwigs Universität Freiburg, Freiburg, Germany
- 1679 *In situ* Photopolymerized Coatings for pH-Specific Drug Delivery from Pellets
CONCHEIRO A, MAYO-PEDROSA M
Univ. Santiago de Compostela, Santiago de Compostela, Spain.
- 1685 Intrapericardial Cisplatin Treatment Prevents Effectively The Recurrence Of Neoplastic Pericardial Effusion
MAISCH B, PANKUWEIT S, RUPP H, RISTIC A
Philipps Universität Marburg, Internal Medicine–Cardiology, Germany
- 1691 Cytotoxic Platinum(II) Complexes With Quaterpyridine Ligands As A New Class Of Topoisomerase I Inhibitors
LAI-MING WONG E¹, MA DL¹, LEUNG CH¹, SIU FM¹, WU P¹, CHE CM¹, YANG M²
¹Department of Chemistry and Open Laboratory of Chemical Biology of the Institute of Molecular Technology for Drug Discovery and Synthesis, The University of Hong Kong, Hong Kong; ²Department of Biology and Chemistry, City University of Hong Kong, Kowloon, Hong Kong SAR (China)
- 1692 Calreticulin, a novel B-cell molecular target in gastrointestinal malignancies
SÁNCHEZ D¹, PEKÁRIKOVÁ A¹, PALOVÁ-JELÍNKOVÁ L¹, BENEŠ Z², HOFFMANOVÁ I³, MOTHEŠ T⁴, TLASKALOVÁ-HOGENOVÁ H¹, TUCKOVÁ L¹
¹Department of Immunology, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; ²Thomayer's Faculty Hospital, Prague, Czech Republic; ³rd Medical Faculty of Charles University, Prague, Czech Republic; ⁴Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics of the University Hospital, Leipzig, Germany
- 1698 Value of High Resolution Real Time Imaging (HRRTI) to assess gut absorption of antibiotics
WEITSCHIES JW², SCHMIDTMANN M³, KOSCH O⁴, KINZIG M¹, HORKOVICS-KOVATS S⁵, WEDEMEYER R-S², SCHWARZ F⁵, FRIEDRICH C², TRAHMS L⁴, MÖNNIKES H³, RODAMER M¹, RANEBURGER J⁵, SÖRGE F¹
¹IBMP – Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, ²Germany. Dep. Biopharm. & Pharmaceut Technol, Univ. of Greifswald,
³Dep. of Gastroenterol & Hepatol, Univ. Hosp. Charité, ⁴Physik.-Techn. BA, Berlin, ⁵Sandoz, Kundl, Austria.

- Abstr. No. Title
- 1698 Dosing of Antiinfectives – “One Size Fits All” vs. Individualized Therapy
SÖRGE L F¹, **BULITTA J**¹, **KINZIG M**¹, **LANDERSDORFER C**¹, **TOMALIK-SCHARTE D**², **JETTER A**², **FUHR U**², **CASCORBI I**³
1: IBMP – Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, D-90562 Heroldsberg, Germany.
2: Institute for Pharmacology, University of Köln, Gleueler Str. 24, 50931 Köln, Germany.
3: Institute for Pharmacology, Friedrich-Loeffler-Str. 23D, 17487 Greifswald, Germany
- 1699 Incurred Samples – Practical Experience from Four Drugs and Two Metabolites
KINZIG M, **SÖRGE L F**, **RODAMER M**, **JAKOB AV**
IBMP -Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
- 1699 Validation of an ELISA for Recombinant Human Erythropoietin According to FDA Requirements
KINZIG M, **SÖRGE L F**, **HÜTTNER S**, **RODAMER M**
IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
- 1699 Validation of an ELISA for Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) according to FDA-Requirements
KINZIG M, **SÖRGE L F**, **JAKOB AV**, **HÜTTNER S**
IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
- 1705 Use of ELISAs in the Pharmacokinetics (Pk) of Recombinant Proteins - A Critical Reappraisal
RODAMER M, **JAKOB AV**, **HÜTTNER S**, **KINZIG M**, **SÖRGE L F**
Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, 90562 Nürnberg-Heroldsberg, Germany.
- 1705 Determination of Loratadine and Desloratadine in Human Plasma by LC-MS/MS
RODAMER M, **KINZIG M**, **JAKOB AV**, **HÜTTNER S**, **SÖRGE L F**
Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, 90562 Nürnberg-Heroldsberg, Germany.
- 1706 Use of Flow-Cytometry in the Pharmacodynamic Assessment of G-CSF in Humans
JAKOB AV, **SIEBE S**, **KINZIG M**, **HÜTTNER S**, **SÖRGE L F**
Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, 90562 Nürnberg-Heroldsberg, Germany.
- 1706 Determination of Tigecycline in Human Tissue by LC-MS/MS
JAKOB AV, **KINZIG M**, **RODAMER M**, **HÜTTNER S**, **SÖRGE L F**
Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, 90562 Nürnberg-Heroldsberg, Germany.
- 1709 Pharmacokinetic (PK) / Pharmacodynamic (PD) Comparison of Ciprofloxacin (CIP) and Levofloxacin (LEV) by a Population PK Meta-Analysis and Monte Carlo Simulation (MCS)
BULITTA JB¹, **KINZIG M**¹, **LANDERSDORFER CB**¹, **NABER KG**², **RODAMER M**¹, **JAKOB AV**¹, **WAGENLEHNER FM**², **DRUSANO GL**³, **HOLZGRABE U**⁴, **SÖRGE L F**^{1,5}
¹IBMP, Nürnberg, Germany; ²St. Elisabeth Hospital, Straubing, Germany; ³Ordway Res. Inst., Albany, NY; ⁴Univ. of Würzburg, Germany; ⁵Univ. of Duisburg-Essen, Germany.
- 1710 Penetration into Bone and Pharmacodynamic Profile of Amoxicillin and Clavulanic Acid evaluated by Population Pharmacokinetics and Monte Carlo Simulation
LANDERSDORFER CB¹, **KINZIG M**¹, **BULITTA JB**¹, **JAKOB AV**¹, **HOLZGRABE U**², **DRUSANO GL**³, **SÖRGE L F**^{1,4}
¹IBMP, Nürnberg-Heroldsberg, Germany. ²University of Würzburg, Germany. ³Ordway Research Institute, Albany, NY, USA. ⁴University of Duisburg-Essen, Germany.
- 1721 Etoposide And Irinotecan Choice On The Basis Of Regional Brain's Polyamine Levels
NAGASE S, **WATANABE S**, **SATO S**, **OHKUMA S**
¹Kawasaki College of Allied Health Professions, Kurashiki City, Okayama Japan, ¹Kawasaki Medical School, Kurashiki City, Okayama Japan
- 1726 Bacteriologic and therapeutic aspects of paediatrics osteo-articular infections.
KOUAME B, **OUATTARA O**, **ODEHOURE T**, **GOULI JC**, **DIETH A**, **ANOMA DS**, **KREH Y**, **TEMBELY S**, **DICK R**
Department of general paediatric surgery at the university hospital of Yopougon: Abidjan COTE D'IVOIRE
- 1753 Argirin A A New Type Of Proteasome Inhibitor With Potent Anti-Proliferative And Anti-Angiogenic Activities
NICKELEIT I, **MALEK NP**
Institute for Molecular Biology, Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School
- 1758 Inhaled H₂S for suspended animation in anesthetized and ventilated mice
BAUMGARTK¹, **WAGNER F**¹, **SIMKOVA S**¹, **WEBER S**¹, **CALZIA E**¹, **RADERMACHER P**¹, **SENFTLEBENU**¹, **HUBER-LANGM**², **KNÖFERLM**², **GEORGIEFF M**¹
¹Klinik für Anästhesiologie und ²Unfallchirurgie, Universitätsklinikum, Ulm, Germany
- 1770 Synthesis and Biological Evaluation of New Duocarmycin Prodrugs for a Selective Cancer Therapy
- 1771 Luminescent Lanthanide Complexes as Probes for Phosphates and their Applications to Monitor Enzyme Activities
- 1772 Investigations Into Sulfur Nanoparticles As Drug Carriers
MUELLER RS
Westfälische Wilhelms-Universitaet, Muenster, Germany
- 1775 Pharmaceutical Research Made in Germany: Adenosine Receptors, Neuroprotection and Antiinflammation
- 1779 Conscious drug selection and dosing by genotyping and phenotyping of alleles with mutations, deletion and/or duplication of the CYP2D6 gene
ARNETH B¹, **SHAMS M**², **HIEMKE C**², and **HÄRTTER S**²
Departments of Clinical Chemistry¹ and Psychiatry², University of Mainz, Germany

Abstr. No.	Title
1798	Operation as a motivation for smoking cessation WEISS-GERLACH E, TURINI S, LINNEN H, SPIES CD Charité – Universitätsmedizin, Department of Anesthesiology and Intensive Care Medicine, Berlin, Germany
1802	Intravascular fluid replacement in the critically ill: Is it the substance or the timing that makes the difference? GOEPFERT MS, KUBITZ JC, GOETZ AE, REUTER DA Department of Anesthesiology, Hamburg-Eppendorf University Hospital, University of Hamburg, Germany

Abstr. No.	Title
1	A Study of Capecitabine and Cisplatin in the Treatment of Recurrent Carcinoma of the Uterine Cervix BENJAPIBAL M , THIRAPAKAWONG C, LEELAPHATANADIT C, THERASAKVICHAYA S, INTHASORN P Mahidol University, Bangkok, Thailand.
18	Magnetic Alginate Nanospheres: a Novel Vector for Targeted Drug Delivery CIOFANI G ¹ , RAFFA V ¹ , MENCIASSI A ^{1,2} , MICERA S ¹ , CUSCHIERI A ¹ ¹ Scuola Superiore Sant'Anna, Pisa, Italy; ² IT Network, Genova; Italy.
31	Glomerular nephrotoxicity of aminoglycosides SALGADO CM Unidad de Investigacion, Hospital Universitario de Salamanca, and Unidad de Fisiopatologia Renal y Cardiovascular, Departamento de Fisiologia y Farmacologia, Universidad de Salamanca
41	Pharmacokinetics (PK) And Pharmacodynamics (PD) Of Fosfomycin (FOF) For Central Nervous System (CNS) Infections RIBES S ¹ , CABELLOS C ² , GUDIOL F ² , NAU R ^{1,3} ¹ Department of Neurology, University of Göttingen, Göttingen, Germany; ² Laboratory of Experimental Infection, Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L'Hospitalet, Spain; ³ Department of Geriatrics, Evangelisches Krankenhaus Göttingen-Weende, Göttingen, Germany
48	Dendritic Cell Immunotherapy Of Malignant Gliomas LEPLINA O ¹ , STUPAK VV ² , PENDURIN IV ² , NIKONOV SD ¹ , OSTANIN AA ¹ , CERNYKH ER ¹ ¹ Institute of Clinical Immunology Siberian Branch of the Russian Academy of Medical Sciences, ² Institute of traumatology and orthopaedy, Novosibirsk, Russia.
61	Reduced Vancomycin Clearance Despite Unchanged Creatinine Clearance In Patients Treated With Vancomycin For Longer Than 4 Weeks NAKAYAMA H ¹ , ECHIZEN H ² , SATO M ¹ , TANAKA M ¹ , ORII T ¹ ¹ Kanto Medical Center NTT East Corporation, Tokyo, Japan, ² Meiji Pharmaceutical University, Kiyose, Japan
64	Liquid Chromatography-Mass Spectrometry: A Unique Tool In Drug Development And Patient Care Via Quality Assurance, Validation Of Biomarkers And Databases, Tissue Analysis, Assessing Prognosis And Monitoring Drug Interactions RITCHIE M ^{1,2} , WONG V ³ , GILMOUR A ⁴ , GATES S ⁵ , BREACH R ² , MORTON M ⁶ ¹ Napier University, Scotland, ² Arbroath High School, Scotland, ³ Aberdeen University, Scotland, ⁴ Manchester University, England, ⁵ Cambridge University, England, ⁶ Cardiff University, Wales
71	Cefepime Neurotoxicity in Perspective BRAGATTI JA ¹ , SILVA D ¹ , CASTILHOS RM ¹ , AZAMBUJA M ¹ , GARCÉS EO ¹ , BARROS EG ² , THOMÉ FS ² , BIANCHIN MM ² ¹ Hospital de Clínicas de Porto Alegre, Brazil ² Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
72	Neurotoxicity Related to Lithium Combination Treatment in a Patient with Schizoaffective Disorder SEIDL A , SCHOPPER C, BRANDENBERGER M, BOEKER H University Hospital Zürich, Switzerland
81	Protective effects of minocycline on methamphetamine-induced dopaminergic neuronal damage: a positron emission tomography (PET) study with conscious monkeys TSUKADA H , NISHIYAMA S, FUKUMOTO D, KAKIUCHI T PET Center, Central Research Laboratory, Hamamatsu Photonics, Hamamatsu, JAPAN
121	Radiotherapy And Multi-Agent Chemotherapy (Procarbazine, ACNU And Vincristine) For High-Grade Gliomas: A Prospective Study OGAWA K ¹ , YOSHII Y ² , INOUE O ³ , TUCHIDA Y ² , SUGIMOTO K ² , IRAHA S ¹ , TOITA T ¹ , KAKINOHANA Y ¹ , TAMAKI W ¹ , ARIGA T ¹ , KASUYA G ¹ , MURAYAMA S ¹ ¹ Department of Radiology, University of the Ryukyus, Okinawa, Japan, ² Department of Neurosurgery, University of the Ryukyus, Okinawa, Japan, ³ Department of Hyperbaric Medicine, University of the Ryukyus, Okinawa, Japan
123	Is there a magic bullet in antiviral therapy? PEUSCHEL KE Hopital psychiatrique de Prefargier, 2000 Marin/NE, Switzerland
128	Phenotypization of Cyclosporine A in Stable Renal Transplant Patients DURICOVA J , MARSALKOVA P, KOMZAKOVA I, BROZMANOVA H, GRUNDMANN M Univ. Hospital and Medico Social Faculty Ostrava Univ., Ostrava, Czech Republic
159	Comparison And Evaluation Of The Antiviral Potentials Among Different Soluble Forms Of Nectin-1 To Herpesvirus Infection ONO E ¹ , TOMIOKA Y ² , OZAKI K ¹ , MORIMATSU M ² , CHEREL P ³ ¹ Kyushu University, Fukuoka, Japan; ² Hokkaido University, Sapporo, Japan; ³ France Hybrids, St Jean De Braye, France
163	Preoperative chemoradiation with concurrent Capecitabine for Locally Advanced Resectable Rectal Cance (LARC): a Phase II study VELENIK V ¹ , ANDERLUH F ¹ , OBLAK I ¹ , SEGEDIN B ¹ , ZAKOTNIK B ¹ , STROJAN P ¹ ¹ Institute of Oncology, Ljubljana, Slovenia
165	Therapeutic Control Chart As A Tool To Aid Drug Monitoring. A Comparison Between The Acenocoumarol And Digoxin Laboratory Control. INTROCASO G , RAGGI M, CAVALLERO A Laboratory Medicine Service, Cardiological Center "Monzino", Milan, Italy
175	Red Blood Cell Membrane Fatty Acid Analysis in Never-Medicated First-Episode and Chronic Medicated-Schizophrenic Patients BURETIC-TOMLJANOVIC A ¹ , GIACOMETTI J ¹ , NADALIN S ¹ , RUBEŠA G ² , VULIN M ³ , TOMLJANOVIC D ¹ ¹ School of Medicine, University of Rijeka, Rijeka, Croatia; ² Clinical Medical Centre, Rijeka, Croatia; ³ Psychiatric Hospital Lopaca, Rijeka, Croatia; ⁴ Private psychiatric practice, Rijeka, Croatia
186	Epinephrine Vasoconstrictor Drug-Drug Interactions Revisited BROWN RS Howard University College of Dentistry, Washington, DC, USA

Abstr. No.	Title
190	Synthesis, Anti-rhinovirus Activity and Mechanism of Action of New Chromene and Chroman Derivatives DESIDERI N and CONTI C Università "Sapienza", P.le A. Moro, 00185 Rome, Italy.
199	Oxytress-induced antitumor therapeutics via targeted-inhibiting heme oxygenase-1 (HSP32) in tumor FANG J¹ , SEKI T ² , BHARATE GY ¹ , QING HB ¹ , NAKAMURA H ¹ , MAEDA H ¹ ¹ Sojo University, Kumamoto, Japan; ² Venture Business Laboratory, Kumamoto University, Kumamoto, Japan.
200	Glucagon-like Peptide-1: Broadening the Incretin Concept to Involve Gut Motility: a New Target for Treatment of IBS HELLSTRÖM PM¹ , KRISTENSEN J ² , BJÖRNSSON E ³ , BYTZER P ⁴ , HEIN J ⁵ , SCHAMBYE H ² ¹ Gastrocenter Medicine, Karolinska University Hospital Solna, Stockholm, Sweden, ² Gastrotech Pharma A/S, Copenhagen, Denmark, ³ Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁴ Department of Medical Gastroenterology, Køge University Hospital, Køge, Denmark and ⁵ Gastroenterology Clinic, Marburg, Hessen, Germany.
216	ATP and adenosine as biomarkers for drug development YEUNG PKF , DAUPHINEE J, SIMONSON K, BEATON S, GOUZOULES T Dalhousie University, Halifax, Nova Scotia, Canada
223	action on Mycobacterium tuberculosis DASTIDAR SG , DASGUPTA A Herbicare Healthcare Bio-Herbal Research Foundation, Metro Garden City, D.H. Road, Kolkata 700 104, India
225	Effect Of A Subtoxic Dose Of Acetaminophen On The Toxicity Of Chemicals That Are Metabolically Activated KIM YC , PARK HK, KIM SJ, KWON DY Seoul National University, College of Pharmacy, Seoul, Korea
229	Carbapenem –resistant Bacteroides isolated in Japan TANAKA K , Goto T, Watanabe K Division of Anaerobe Research, Life Science Research Center, Gifu University, Gifu, Japan.
231	Tumor Necrosis Factor-alpha Antibody Reduces Pain Related Behavior Induced by both Epidural Application of Nucleus Pulposus and Nerve Root Compression in Rats SASAKI N^{1,2} , KIKUCHI S ² , KONNO S ² ¹ Minamisouma City General Hospital, Fukushima, Japan; ² Department of Orthopedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan
236	Pharmacokinetics (PK)/Pharmacodynamics (PD) Of Infliximab In Treatment For Patients With Rheumatoid Arthritis: Characterization Of Infliximab-Resistant Cases And PK-Based Modified Therapy MORI S National Kumamoto Saishunsou Hospital, Kohshi, Japan
237	Paroxetine-induced CYP2D6 Phenotype Conversion and Clinical Outcomes ŽOURKOVÁ A^a , JURICA J ^b ^a Department of Psychiatry, ^b Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech republic
240	Design Of Aquasomes Loaded With Indomethacin And Their Released Profiles ROJAS-OVIEDO I¹ , LÓPEZ-TORRES A ¹ , REYES-GASCA J ² , QUIRINO-BARRERA C T ¹ , GARCÍA-GARCÍA R ² ¹ Universidad Autónoma Metropolitana-Xochimilco, México D.F., ² Universidad Nacional Autónoma de México, México, D.F.
246	Phase III Study Of Combined Neoadjuvant Chemotherapy And Letrozol In Locally Advanced Breast Cancer MOHAMMADIANPANAH M , OMIDVARI SH, AHMADLOO N, MOSALAEI A Shiraz University of Medical Sciences, Shiraz, Iran
252	Competition of Sulindac with Specific Markers for the Major Binding Sites on Human Serum Albumin Studied by High Performance Liquid Affinity Chromatography ZHIVKOVA Z , RUSSEVA V Faculty of Pharmacy, Medical University, Sofia, Bulgaria
280	Successful Treatment Of Methicillin-Resistant Staphylococcus Aureus Meningitis Using Linezolid Without Removal Of Intrathecal Infusion Pump: Three Years Follow-Up KALLWEIT U^{1,2} , HARZHEIM M ² , WIETHOELTER N ² , MARKLEIN G ³ , POEHLAU D ² ¹ University Hospital Zurich, Department of Neurology, Zurich, Switzerland, ² Kamillus Klinik, Department of Neurology, Asbach, Germany, ³ University Hospital Bonn, Department of Microbiology and Immunology, Bonn, Germany
287	Association between Alpha-2a-Adrenergic Receptor Gene and Methylphenidate Response in Korean Children and Adolescents with ADHD CHEON K-A¹ , CHO D-Y ² , SHIM J-O ¹ , KOO M-S ¹ ¹ Univ. Kwandong, Koyang City, South Korea; ² Labgenomics, Seoul, South Korea.
296	Magic Bullets With Multiple Warheads: Multi-Targeted Antineoplastic Agents RUSSU WA , SHALLAL HM School of Pharmacy, University of the Pacific, Stockton, CA, USA
319	Portal Haemodynamics and Plasma Transaminase Levels before and after Prostacyclin Analog Administration in Patients with Chronic Viral Hepatitis ZARDI EM¹ , VECILE E ² , BARTOLOZZI F ¹ , AFELTRA A ¹ , DOBRINA A ² ¹ Area of Clinical Medicine "Campus Bio-Medico", Rome, Italy ² Department of Physiology and Pathology, Trieste University, Italy
320	Paclitaxel works nicely with molecular targeting cancer therapy via RNA interference YOSHIFUMI TAKEI Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, JAPAN
325	A New Strategy to Inhibit Foam Cell Formation in Atherosclerosis Using the Soluble Immunoadhesion CD68-Fc DAUB K , SCHOENBERGER T, GAWAZ M, SIEGEL-AXEL D Medical Clinic III, Dept. of Cardiology, Eberhard-Karls-University, Tuebingen, Germany

- Abstr. No. Title
- 326 Pyrrole Hydrazones as a reliable Starting Platform in anti-tuberculosis Drugs Development
BIJEV A, PRODANOVA P, VLADIMIROVA S, **GEORGIEVA M**
University of Chemical Technology and Metallurgy, Sofia, Bulgaria
- 338 Nitrendipine as a putative probe for CYP3A phenotyping
PASTERA J, ZOULOVÁ J, KOPECKÝ J and KVETINA J
Institute of Experimental Biopharmaceutics, Joint Research Center of PRO.MED.CS Praha a.s. and Academy of Sciences of the Czech Republic, Heyrovského 1207, 500 03 Hradec Králové, Czech Republic
- 342 Glucose transporters in the blood-brain barrier
HUSSAR P, BENNO I, HUSSAR Ü
University of Tartu, Tartu, Estonia
- 366 Factors Affecting Toxicity And Efficacy Of Injectable Nanomedicines: Significance On Particle Size
IGARASHI E¹
¹Nanosion Co., Ltd., Kashiwa, Japan.
- 369 Composition Of Essential Oil Of *Nigella sativa* (L.) Seeds And Inhibition Of Human Neutrophil Elastase
KACEM R¹, BUHLING F², WELTE T²
¹Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Sciences, University Ferhat Abbas, Setif, Algeria;
²Institut für Immunologie, Medizinische Fakultät, Otto-Von-Guericke-Universität Magdeburg, Germany.
- 372 Rho-Kinase Inhibitors Augment the Inhibitory Effect of Anesthetic Agents on Rat Airway Smooth Muscle Contraction
HANAZAKI M¹, YOKOYAMA M¹, MORITA K¹, KOHJITANI A², SAKAI Y³, CHIBA Y³, MISAWA M³
¹Okayama University, Okayama, Japan; ²Kagoshima University, Kagoshima, Japan; ³Hoshi University, Tokyo, Japan.
- 375 Antitumor Activity of New Combination Chemotherapy with Iirinotecan Hydrochloride(CPT-11) and Nedaplatin(NDP) against Human Cervical Cancer Cell Lines
YAMAMOTO K¹, SHIMAOKA M¹, ABE K², HOSHIAI H², NODA K²
¹ Sakai Hospital, Kinki University, Sakai, Japan; ² Kinki University, Osakasayama, Japan
- 377 Synthesis and Evaluation of Highly Potent Antimicrobial Chromanyl-1,2,4-dithiazoles
ISHAR MPS¹, RAJ T,¹ BHATIA RK^A, KUMAR R²
¹Bio-Organic and Photochemistry Laboratory, Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar-143 005, Punjab, India. ²Department of Microbiology, Guru Nanak Dev University, Amritsar-143 005, Punjab, India
- 382 Clinical Role of Fluorouracil Metabolizing Enzymes and Optimal Duration in Chemotherapy with Tegafur
TOKUNAGA Y, MD PhD, SASAKI H, MD PhD, SAITO T, MD PhD
Department of Surgery
Osaka North Japan Post Hospital
Osaka, JAPAN
- 384 Effect Of Formulations On Clopidogrel Bioactivity And Bioavailability In Vivo
MASRI MA, JAALOUK G, RIZK S, BARBOUCH H, ATTIA M
Transmedical Research Institute Beirut, Lebanon
- 387 Effective Drugs In Psychiatry: Magic Bullets Or Hand Grenades?
MARKS DM¹, PATKAR AA¹
¹Duke Clinical Research Institute. Durham, North Carolina, USA
- 392 Alpha1-Adrenoceptor-Mediated Pronociception Attenuates Induced Analgesia in Rat
HOLDEN JE
Univ. Illinois at Chicago, Chicago, IL, USA
- 417 New View of Retroviruses; Consequences in Aids Diagnostics and Therapy
ZAJAC V¹, MEGO M², MATELOVA L¹, SCHREINER A³, STEVURKOVA V¹, STANEKOVA D⁴
¹Cancer Research Institute, Vlarska 7, 83391 Bratislava, Slovakia
²National Cancer Hospital, Bratislava, Slovakia
³Ardeypharm, Herdecke, Germany
⁴Slovak Medical University, National HIV/AIDS Centre, Bratislava, Slovakia
- 428 The distribution of antimicrobial resistance patterns of nasopharyngeal *Haemophilus influenzae* isolated from healthy preschool children
KOSIKOWSKA U, MALM A
Department of Pharmaceutical Microbiology, Medical University of Lublin, 1 Chodzki Str., 20-093 Lublin, Poland
- 432 Cutaneous Microdialysis As A Useful Tool To Evaluate Skin Penetration Of Antiinfective Agents
KLIMOWICZ A¹, BIELECKA-GRZELA S²
¹Division of Dermatopharmacotherapy, Dept. Dermatology, Pomeranian Medical University, Szczecin, Poland; ²Division of Aesthetic Dermatology, Dept. Dermatology, Pomeranian Medical University, Szczecin, Poland
- 433 Pituitary Resistance To Thyroid Hormone
ZIELENIEWSKI W, JAGODZINSKA A
Department of Endocrinology, Medical University of Lodz, Sterlinga 3, 91425 Lodz, Poland, e-mail: wz1964@wp.pl
- 438 Prokinetic Effect Of Erythromycin: The Benefit Of A Common Side Effect
PETRAKIS IE, GRISBOLAKI EE
University Hospital of Herakleion Crete, Greece, Department of General Surgery
- 450 PK/PD Relationship of Antibiotics in Local Treatment of Prosthetic Infections
BERTAZZONI MINELLI E and BENINI A
University of Verona, Verona, Italy
- 465 *In silico* Approaching to Cisplatin Toxicity
KUDUK-JAWORSKA J¹, JAROSZEWICZ¹ I, JANSKI¹ J, CHOJNACKI² H
¹Faculty of Chemistry Wroclaw University, Wroclaw, Poland
²Institute of Physical and Theoretical Chemistry, Wroclaw University of Technology, Wroclaw, Poland

Abstr. No.	Title
472	Pharmacogenetic screening and drug susceptibility and fetal malformations, past, present, and future VAN DYKE DC , Skhal KJ Department of Pediatrics, University of Iowa Children's Hospital, Carver College of Medicine, Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa, USA
486	Activation Of Exploratory Behavior In Senescence Accelerated OXYS Rats By Stimulation Of Cell-Mediated Immune Response With BCG Vaccine MARKOVA EV ¹ , KOLOSOVA NG ² , ABRAMOV VV ¹ , KOZLOV VA ¹ ¹ Inst. of Clinical Immunology, Novosibirsk, Russia; ² Inst. of Cytology and Genetics, Novosibirsk, Russia
488	Clinical trial of immunochemotherapy (personalized peptide vaccination and gemcitabine) for metastatic pancreatic cancer patients YANAGIMOTO H ¹ , SATOI S ¹ , MINE T ² , YAMAMOTO T ¹ , HIROOKA S ¹ , TOYOKAWA H ¹ , YAMADA A ² , KWON AH ¹ , ITOH K ² ¹ Department of Surgery, Kansai Medical University ² Department of Immunology, Kurume University School of Medicine
498	Mifepristone Acts as Progesterone Antagonist of Non-genomic Responses but Agonist of Immunosuppression in Human T Cells CHIEN EJ ¹ , LAI JN ² , CHIEN C-H ¹ , SHIE MC ¹ , LEE WF ¹ ¹ University, National Yang-Ming, Taipei; ² Hospital, Taipei Municipal Yang-Ming, Taipei, Republic of China.
499	Pathological Studies on Thymic Lymphoma in Medaka Fish CHIEN C-H , CHIEN EJ ¹ , LIN T-L ² , AND LIAO CF ^{1,2} ¹ University, National Yang-Ming, Taipei, ROC; ² Institution Academia Sinica, Taipei, ROC
500	Genetic And Epigenetic Effects Of Pharmacological Doses Of Gamma-Hydroxybutyrate (GHB) In The Rat Brain KLEIN C , KEMMEL V, TALEB O, AUNIS D, MAITRE M Department of Biochemistry and INSERM U-575, Faculty of Medicine, Strasbourg, France
502	Plasmodial Plasma Membrane: isolation and its implication in drug transport ELANDALOUSSI LM ^{1,2} , LINDT M ¹ , SMITH PJ ¹ ¹ Division of clinical pharmacology of the Univ. of Cape Town and Groote Schuur Hospital, Cape Town, South Africa; ² IRTA, Sant Carles de la Rapita, Spain.
514	In Vitro Preclinical Studies For A Rational Design Of Cancer Chemotherapy Combinations KANO Y ¹ , AKUTSU MIYUKI ¹ , FURUKAWA Y ² ¹ Division of Hematology, Tohigi Cancer Center, Tohigi, Japan, ² Division of Stem Cell Regulation, Jichi Medical University, Tohigi, Japan
517	Aerosolized Liposomal Antifungal Agents LAMBROS MP ¹ , JOHNSON DL ² , BOURNE DW ² ¹ Western University of Health Sciences, Pomona, CA, USA; University of Oklahoma HSC, Oklahoma City, OK, USA.
519	Effects Of Central Penicillin Administration On Neuronal Response Of The Nucleus Reticularis Gigantocellularis LEBEDEVA MA Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russia.
519	The Role Of Central Vagal Control In The Action Of Lipophilic And Hydrophilic Beta-Adrenoblockers LEBEDEVA MA ¹ , KAVERINA NV ² , LYSKOVTSSEV VV ² ¹ Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow, Russia, ² Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
525	Treatment of ovarian cancer cells with drug combinations targeting ErbB receptor tyrosine kinases and fatty acid synthase GRUNT TW ^{1,3} , WAGNER R ¹ , SHABBI R ¹ , BERGER W ¹ , MARIAN B ² , GRUSCH M ² , ZIELINSKI C ^{1,3} , LUPU R ⁴ ¹ Div. Oncology and ² Inst. Cancer Res., Dept. Med. I, Med. Univ. Vienna, ³ Ludwig Boltzmann Cluster Oncology, Vienna, Austria; ⁴ Dept. Med., Evanston Northwestern Healthcare Res. Inst., Evanston, IL, USA.
525	The PI3K/AKT pathway determines EGFR/HER/ErbB drug efficacy in breast cancer cells. SHABBI R ^{1,3} , BRÜNNER-KUBATH C ¹ , GRUSCH M ² , BERGER W ² , MARIAN B ² , WAGNER R ¹ , LÖTSCH D ² , ZIELINSKI C ^{1,3} , GRUNT TW ^{1,3} ¹ Div. Oncology and ² Inst. Cancer Res., Dept. Med. I, Med. Univ. Vienna, ³ Ludwig Boltzmann Cluster Oncology, Vienna, Austria
537	Changes in Plasma Protein Binding of an Extensively Bound and Highly Extracted Drug, Propofol, Have Clinical Relevance HIRAOKA H ^{1,2} , HIRAOKA T ¹ ¹ Department of Anesthesiology, Medical & Art Office Takasaki, Takasaki, Japan, ² Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan.
548	Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment KUBOTA Takahiro ¹ and UCHIYAMA Kan ² ¹ Chiba Institute of Science, Chiba, Japan; ² The Jikei University School of Medicine (Kashiwa Hospital), Chiba, Japan
549	Effect of Genetic Polymorphisms in ABCG2 (BCRP) on Inhibition and Potential Drug Resistance WANG M , EMERICK RM, SAWADA GA, PAK YA, RAUB TJ, HILLGREN KM Drug Disposition, Eli Lilly and Company, Indianapolis, IN 46285 (* currently at Bristol-Myers Squibb Company, Pennington, NJ)
574	New Drug Development Outside of G8: Ready, Shoot, Aim VALDIVIA-ALCOTA R ¹ , KATO M ¹ ¹ Universidad de Chile, Genotoxic Risk Assessment Center, CERIG-Facultad de Odontología, Santiago, Chile
581	The Effects Of Single-Dose Ethanol Administration To Aldehyde Dehydrogenase 2 Knock-Out Mice: Down-Regulation Of Expression Of Cytochrome P450 2E1 Mrna And Amelioration Of Oxidative Stress In Liver Tissue MATSUMOTO A ¹ , KAWAMOTO T ² , ISSE T ² , OYAMA T ² , OISHI H ¹ , ICHIBA M ¹ ¹ Saga University, Saga, Japan; ² University of Occupational and Environmental Health, Kitakyushu, Japan
601	3-O-Methylfunicone, A Fungitoxic And Antitumor Extritol Produced By <i>Penicillium Pinophilum</i> NICOLETTI R ¹ , DE STEFANO M ² , BUOMMINO E ² , CIAVATTA ML ³ , TUFANO MA ² ¹ Council for Research and Experimentation in Agriculture (CRA), Scafati, Italy; ² The Second University of Naples, Italy; ³ CNR-Institute of Biomolecular Chemistry, Pozzuoli, Italy.

- Abstr. No. Title
- 628 Searching For A Tool To Improve The Anti-Doping Action: The Project AR.I.E.T.T.A. (Artificial Intelligence Evoking Target Testing In Antidoping)
MANFREDINI F^{1,2}, MALAGONI AM², LITMANEN H¹, ZHUKOVSKAJA L¹, JEANNIER P¹, DAL FOLLO D², BESSEBERG A¹, GEISTLINGER M¹, BAYER P¹, FELISATTI M², CARRABRE JE¹
¹International Biathlon Union, Salzburg, Austria; ²Department of Biochemistry and Molecular Biology-Center Biomedical Studies applied to Sport-University of Ferrara, Ferrara, Italy
- 640 Girolinone, a new antiparasmodial leader extracted from the sponge *Cymbastela cantharella*
BENOIT-VICAL F^{1,2}, SALERY M², NJOMNANG SOH P^{1,2}, AHOND A³, POUPAT C³
¹. Laboratoire de Chimie de Coordination du CNRS, UPR8241, 31077 Toulouse 4, France.
². Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rangueil, 31059 Toulouse 9, France.
³. Institut de Chimie des Substances Naturelles du CNRS, 91198 Gif-sur-Yvette cedex, France
- 645 Liquid Chromatography and Capillary Electrophoresis as a Tools to Study Ligand-Receptor Interactions
BIELEJEWSKA A
Institute of Physical Chemistry PAS, Kasprzaka 44/52, Warsaw 01-224, Poland
- 646 New Calcipotriol Analogs, their Toxicity and Antitumor Activity in vivo in Comparison to the Affinity with VDR and DBP
PELCZYNSKA M¹, FILIP B², MILCZAREK M², KUDUK-JAWORSKA J³, KUTNER A⁴, WIETRZYK J²
1. Karkonosze College, Higher Professional State School, Jelenia Góra, Poland
2. Polish Academy of Sciences, Institute of Immunology and Experimental Therapy (IITD), Wrocław Poland
3. Wrocław University, Wrocław Poland
4. Pharmaceutical Research Institute, Warszawa, Poland
- 685 Sugammadex A Novel Cyclodextrin For The Reversal Of Neuromuscular Blockade
NICHOLSON WT, SPRUNG J, JANKOWSKI CJ
Mayo Clinic, Rochester, MN, USA
- 731 Verapamil Reverts Acute Renal Functional Impairment Induced by Angiotensin II Converting Enzyme Inhibitors
ALVAREZ GREGORI JA^{1,2}, **BOUCHOUTROUCH Y²**, MACIAS NUÑEZ JF²
¹CS. Casto Prieto. UDMFYC. SACYL. Salamanca;
²Faculty of Medicine. University of Salamanca
- 733 Bilirubin: An Endogenous Molecule With Antiviral Activity *In Vitro*
MANCUSO C¹, MARCHETTI S², FADDA G², SANTANGELO R²
Institutes of ¹Pharmacology and ²Microbiology, Catholic University School of Medicine, Roma, Italy
- 735 Role of the cell envelope in the antibacterial activities of cyclic polypeptides against *Escherichia coli*
DIXON RA
Department of Forensic and Biomedical Sciences
University of Lincoln, Lincoln, United Kingdom
- 747 The two main problems in evaluating resistance to antiparasitic drugs in populations of naturally infected hosts: efficacy variability and cut-off value for resistance
CABARET J, ANTOINE T
INRA, IASP 1232, 37380 Nouzilly, France
- 753 Metalloporphyrin-Loaded Liposomes as Anticancer Drug Delivery System. Novel Drug Bearing SOD-like and Fenton-reaction Activities
YUASA M, MURATA H, YUKI R, TATEISHI T
Tokyo Sci. Univ., Noda 278-8510, Japan
- 758 TOPICAL IMMUNOTHERAPY WITH DIPHENYLCYCLOOPENONE IN VITILIGO: A PRELIMINARY EXPERIENCE
AGHAEI S, MD¹, SAFAEE-ARDEKANI GR, MD²
1- Jahrom University of Medical Sciences, School of Medicine, Jahrom, Iran
2- Shiraz University of Medical Sciences, School of Medicine, Shiraz, Iran
- 771 New Chemical Entities For The Treatment Of Estrogen Receptor Negative Breast Cancer: *In Vitro* Mechanisms Of Action
SOMERS-EDGAR, TJ¹, SCANDLYN MJ¹, LARSEN L², **ROSENGREN RJ¹**
¹University of Otago, Dunedin, New Zealand. ²New Zealand Institute for Crop and Food Research Ltd., Dunedin, New Zealand
- 778 Tetracycline Biosynthesis: How to Overcome Nature's Potential in Developing Novel Anti-infectives?
PETKOVIC H^{1*}, LEŠNIK U¹, HUNTER IS², RASPOR P¹
¹University of Ljubljana, Biotechnical Faculty, Slovenia, ²University of Strathclyde, Scotland, UK
- 784 Increased PGC-1? expression exhibits protective effects against age-related neurodegenerative and metabolic disease processes
WARD WF^{1,3}, LIANG H^{2,3}, RICHARDSON A^{2,3,4}, VAN REMMEN H^{2,3,4}
Departments of Physiology¹ and Cellular & Structural Biology². The Barshop Institute for Longevity and Aging Studies³, The University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Center⁴. San Antonio, TX, USA, 78229
- 788 Properties Of The Key Reaction Steps In Demeclocycline Biosynthesis Of The Engineered *Streptomyces Aureofaciens* Strains
NAKANO T¹, DAIRI T², MIYAKE K¹, KATSUMATA R³
¹Kyowa Hakko Bio Co.,Ltd., Tokyo, Japan; ²Tohoku Univ., Sendai, Japan; ³Toyama Pref. Univ., Imizu, Japan
- 822 Pharmacokinetic interactions of drugs and fruit juices with carbamazepine in Rat
HIDAKA M¹, NAGATA M¹, AIMORI K²
¹School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, 1714-1 Yoshinocho, 882-8508, Miyazaki, Japan;
²Department of Pharmacy, University of Miyazaki Hospital, 5200 Kihara, Kiyotake-cho, Miyazaki-gun, 889-1692, Miyazaki, Japan.

- Abstr. No. Title
- 825 Racial Disparity In Stroke Risk Factors: The Berlin–Ibadan Experience; A Retrospective Study
OWOLABI MO¹, PLATZ T²
¹Department of Medicine, University College Hospital, Ibadan, Nigeria; ²Ernst-Moritz-Arndt Universität, Greifswald, Germany
- 851 Driving Under Influence In France (2007) : Performance Of Accurate Emergency Forensic Procedures With Drug Urine Detection (Nal-Von Minden) Assessed By Blood GC/MS
MARC B¹, LECLERC J¹, ZANDER T², FUCHE C³, COLLOT D³, LEROY N³, GOND A³
¹Emergency Forensic Unit, Compiègne Hospital, France, ²Nal von minden, Regensburg, Germany, ³CTSI (Interior Security Technical Centre, Ministry of Interior, France)
- 851 Is Cannabidiol (CBD) An Accurate Marker For Cannabis Use? Analysis Of 2007-2008 Blood GC/MS Analysis From Drivers Under Influence
MARC B¹, LECLERC J¹, FUCHE C², COLLOT D², LEROY N², GOND A²
¹Emergency Forensic Unit, Compiègne Hospital, France, ²CTSI (Interior Security Technical Centre, Ministry of Interior, France)
- 860 Molecular Epidemiology of Quinolone Resistant *Salmonella* Typhi: South Africa 2003-2007
KEDDY KH^{1,2}, GOVENDER N^{1,2}, SOOKA A¹, SMITH AM^{1,2} FOR GERMS-SA*
¹Enteric Diseases Reference Unit, National Institute for Communicable Diseases, Johannesburg, South Africa and ²University of the Witwatersrand, Johannesburg, South Africa
- 863 Purification and properties of a chemotherapeutic enzyme, L-asparaginase, from *Pectobacterium carotovorum* MTCC 1428.
KUMAR S, DASU VV, PAKSHIRAJAN K
Biochemical Engineering Laboratory, Department of Biotechnology, Indian Institute of Technology Guwahati, Guwahati 781309, Assam, INDIA
- 883 Cost Implications of Oral Treatment of Colorectal Cancer in Germany**
HIEKE K
NEOS Health, Binningen, Switzerland
- 888 IM28 Inhibiting HIV1 Replication, Glucose, Lipids, Hemoglobin Levels And Nitric Oxide (NO) In HIV1 Patients: Study From Gabon
MAKA G, MAVOUNGOU VP, AKOUME NDONG MY, ONGALI B, MAVOUNGOU E, **MAVOUNGOU D**
Centre de Recherche sur les Pathologies Hormonales (CRPH), Université des Sciences de la Santé, Libreville, Gabon
- 902 Benzimidazoles and surgery in cardiac hydatidosis: efficacy in prevention of disease relapse
KUDAIBERDIEV T
National Center of Cardiac Surgery and Organ Transplantation, Bishkek, Kyrgyz Republic
- 905 Metallic gold reduce TNF α expression, oxidative DNA damage and pro-apoptotic signals in brain injured mice
PEDERSEN MØ, LARSEN A, PEDERSEN DS, PENKOWA M
The University of Copenhagen, Section of Neuroprotection
- 924 Telomerase as a Possible new Target for Cancer Treatment
SARETZKI GC
Newcastle University, Newcastle upon Tyne, UK
- 926 Plumbagin: A Candidate for Targeted Anticancer Therapy
SRINIVAS GOPALA¹, ASOKE BANERJI², MADHAVAN RADHAKRISHNA PILLAI³, PRIYA SRINIVAS³
¹Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India; ²Centre for Biotechnology, Kollam, India; ³Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India
- 931 A Climate for Change? A Statistical Analysis of General Practitioners' Relationship with Chiropractic Care.
GATES SEE¹, COCHRAN KD¹, RITCHIE MM^{2,3}, GIBBS TJ⁴, GILMOUR A⁵, WONG V⁶.
¹Cambridge University, Cambridge, England, ²Napier University, Edinburgh, Scotland, ³Arbroath High School, Angus, Scotland, ⁴Chinese University of Hong Kong, Hong Kong, China, ⁵Manchester University, Manchester, England, ⁶Aberdeen University, Aberdeen, Scotland
- 939 HIV Protease Inhibitor: An Antifungal Agent?
TSANG CSP, I Hong
The University of Hong Kong
- 946 Alpha2-Antiplasmin Is A Critical Regulator On Bleomycin-Induced Fibrosis
KANNO Y, MATSUNO H
Doshisha Women's Collage of Liberal Arts, Kyoto, Japan.
- 977 Chelating Agents for Treatment of Uranium-induced Toxicity in Radiation Emergency Medicine
FUKUDA S¹, IKEDA M¹, YAN Y², XIE Y²
¹National Institute of Radiological Sciences, Chiba, Japan, ²Shanghai Institute of Materia Medica, Shanghai, China.
- 995 Chemical agents in root canal therapy. Key of the success
PÉREZ-HEREDIA M¹, GONZÁLEZ-RODRÍGUEZ MP¹, ARIAS-MOLIZ MT¹, NAVARRO-ESCOBAR E¹, FERRER-LUQUE CM¹
¹Univ. Granada, Spain.
- 1002 Anti-tumour Vaccination in Advanced Malignancy with Class I & II hTERT Peptide-pulsed Dendritic Cells (DCs) Generates Suboptimal Antigen Specific CD8+Cytotoxic T Cell (CTL) Responses and Induces Regulatory T Cells in the Circulation
ALOYSIUS MM¹, VERMA C², ROBINS RA², EREMIN JM³, SREENIVASAN T³, FARZANEH F⁴, HARDWICK N⁴, HABIB N⁵, KECHNIE AMC¹, HARRISON PR⁶, EL-SHEEMY M⁴, AND EREMIN O^{1,4}.
¹Section of Surgery and ²Institute of Infection and immunity, School of Molecular Medical Sciences, Nottingham University Hospitals, University of Nottingham, NG7 2RD, UK.
³Lincoln Oncology Centre and ⁴Research and Development Department, Lincoln County Hospital, Lincoln, UK.
⁵Department of Haematological & Molecular Medicine, Rayne Institute, King's College, 123 Coldharbour Lane, London, SE5 9NU.
⁶Surgery Section, Department of Surgical Oncology and Technology, Imperial College London, Du Cane Road, London, W12 0NN, UK.
⁶The Liver Unit, King's College Hospital, Denmark Hill, London SE5 9RS, UK.

Abstr. No.	Title
1008	Locked and Bowed Over: Infections Down the Line FENNELL JP ¹ , CORMICAN M ¹ and LYNCH M ² ¹ National University of Ireland Galway, Galway, Ireland, ² Mater Misericordiae University Hospital, Dublin, Ireland
1008	Smoking, Streptococci and Sputum FENNELL JP ¹ , GREINER B ² , CORCORAN GD ³ , CRYAN B ³ , ¹ UHG, Galway, Ireland, ² UCC, Cork, Ireland, ³ Cork University Hospital, Cork, Ireland
1010	Corticotrophin releasing factor as drug target for modifying dopaminergic system neuroplasticity in cocaine addiction COROMINAS M ¹ , RONCERO C ¹ , CASTELLS X ² , CASAS M ¹ . ¹ Department of Psychiatry, Vall d'Hebron University Hospital, Barcelona, Spain; ² Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Barcelona, Spain.
1010	BDNF and Its Intracellular Signaling Pathways as Drug Targets in Addiction COROMINAS M ¹ , RONCERO C ¹ , RIBASES M ¹ , CASTELLS X ² , CASAS M ¹ . ¹ Department of Psychiatry, Vall d'Hebron University Hospital, Barcelona, Spain; ² Department of Clinical Pharmacology, Vall d'Hebron University Hospital, Barcelona, Spain.
1017	Disulfiram As a New Promising Anticancer Drug CVEK B Palacky University, Olomouc, Czech Republic
1044	Genes commonly upregulated in immortal cancer cells but not in immortalized non-cancerous cells are novel molecular targets for universal anti-cancer strategy HIYAMA K ¹ , TANIMOTO K ¹ , HIYAMA E ¹ , NISHIYAMA M ^{1,2} ¹ Hiroshima Univ., Hiroshima, Japan; ² Saitama Medical Univ. Saitama, Japan.
1044	Genes commonly upregulated in immortal cancer cells but not in immortalized non-cancerous cells are novel molecular targets for universal anti-cancer strategy HIYAMA K ¹ , TANIMOTO K ¹ , HIYAMA E ¹ , NISHIYAMA M ^{1,2} ¹ Hiroshima Univ., Hiroshima, Japan; ² Saitama Medical Univ. Saitama, Japan.
1057	Opening of Blood-Brain Tumor Barrier by Phosphodiesterase Type 5 (PDE5) Inhibitors in a Mice Metastatic Brain Tumor Model HU J , SHU Y, KO MH K, PHILLIPS DJ, KONDA BM, ESPINOZA A, YUAN X, LJUBIMOVA J, BLACK KL Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
1072	Gastrointestinal Prokinetic 5-HT ₄ Agonists; Receptor Selectivity and Benefit-to-Risk Profile BEATTIE DT, SMITH, JAM Theravance, Inc., South San Francisco, CA, USA
1099	Change in Knowledge of Women about Cervix Cancer, Human Papilloma Virus (HPV) and HPV Vaccination due to Introduction of HPV Vaccines DONDERS GGG ¹⁻⁴ , BELLEN G ⁴ , DECLERQ A ¹ , BERGER J ¹ , VAN DEN BOSCH T ^{1,2} , RIPHAGEN I ¹ , VERJANS M ¹ Department of Obstetrics and Gynecology, of the 1) H Hart Hospital Tienen, 2) University Hospital Gasthuisberg Leuven, 3) University of Liège, and 4) Femicare vzw, Clinical Research for Women, Tienen, Belgium
1105	Novel BINOL Derivatives as Photoactivatable Carriers of DNA-Targeted Potent Cytotoxic Agents FRECCERO M ¹ , DI ANTONIO M ² , PALUMBO, M ² ; DORIA F ¹ , VERGA D ¹ ¹ Univ. Pavia, Pavia, Italy; ² Univ. Padova, Padova, Italy.
1111	Albendazole Sulphoxide Levels in Endemic Normals and Filariasis Patients from a Lymphatic Filariasis Endemic Region of India Administered with Albendazole Using Liquid Chromatography SARIN R IPE Global, 81/82 Mona Villa, Ekamra Marg, Forest Park Area, Bhubaneswar, Orissa, India
1152	Molecularly Imprinted Polymers (MIPs) for the Drug Targeting PUOCI F Università della Calabria, Arcavacata di Rende (CS), Italia;
1153	Ames Test And Gene Expression Analysis For Polyhydroxybutyrate – A Biomaterial KANNAN TP, ABDULAZIZ QA, AZLINA A, SAMSUDIN AR School of Dental Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
1188	Drug-Drug and Drug-Biomolecule Photoinduced Reactions in Preparations for Topical Use ALBINI A ¹ , FASANI E ¹ , DONDI D ² , SERPONE N, ¹ FAGNONI M ¹ ¹ Dep. Org. Chem., Univ. PAVIA; ² Dep. Gen. Chem., Univ. PAVIA, Pavia, Italy.
1203	Pharmacokinetics and pharmacodynamics of meloxicam in rats and humans FLORES-MURRIETA FJ ^{1,2} , AGUILAR-MARISCAL H ³ , RODRÍGUEZ-SILVERIO J ^{1,2} , CARRASCO-PORTUGAL MC ¹ ¹ Unidad de Investigación en Farmacología, INER, Mexico City, Mexico; ² Escuela Superior de Medicina del IPN, Mexico City, Mexico; ³ Universidad Juárez Autónoma de Tabasco, Villahermosa Tabasco, Mexico.
1204	Comparison of oral pharmacokinetics of nifedipine in different populations CARRASCO-PORTUGAL MC ¹ , FLORES-MURRIETA FJ ^{1,2} ¹ Unidad de Investigación en Farmacología, INER, Mexico City, Mexico; ² Escuela Superior de Medicina del IPN, Mexico City, Mexico
1209	Surface Modified Nanostructured Carriers of Nevirapine for Brain Targeting SINGH KK, SHEGOKAR R C U Shah College of Pharmacy, S N D T Women's University, Juhu Road, Santacruz West Mumbai, India
1233	Akt Inhibitors: A New Strategy Targeting Long-Living HIV Macrophage Reservoirs CHUGH P, RIVERA-PABON O, KIM B University of Rochester, Rochester, NY, USA

- Abstr. No. Title
- 1264 Effects of neurotoxic and neuroprotective compounds on cholinergic neurons are mediated by alterations in acetyl-CoA metabolism
SZUTOWICZ A¹, BIELARCZYK H, DYS A, RONOWSKA A, KLIMASZEWSKA J, JANKOWSKA-KULAWY A
Department of Laboratory Medicine, Medical University of Gdansk, Gdansk, Poland
- 1289 Antisecretory Factor (AF) - an inducible antisecretory and antiinflammatory protein
LONNROTH I, JOHANSSON E, LANGE S
University of Goteborg, Sweden.
- 1290 Recombinant Expression of the Biosynthetic Enzyme for the Biotechnological Production of Tetrahydrocannabinol, a Revisited Magic Bullet from Marijuana
TAURA F
Kyushu Univ., Fukuoka, Japan
- 1293 Extensive Necrosis of Visceral Melanoma Metastases after Immunotherapy
STOETER D¹, DI LIGUORI CARINO N¹, MARSHALL E², POSTON GJ¹, WU A¹
¹The Department of Hepatobiliary Surgery, Aintree University Hospital NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool, L9 7AL, UK, ²The Clatterbridge Centre for Oncology NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY, UK
- 1316 Rectal Delivery of Ceftriaxone Sodium-loaded Mucoadhesive Gelatin-Mucin Microspheres
OFOKANSI KC, ADIKWU MU
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, 410001 Nsukka, Enugu State, Nigeria
- 1320 Efficacy of amoxicillin/clavulanic acid in preventing infectious and inflammatory complications following impacted mandibular third molar extraction.
ARTEAGOITIA I¹, DIEZ A², BARBIER L¹², SANTAMARIA G¹, SANTAMARIA J¹²
¹University of the Basque Country. Leioa, Spain ²Cruces Hospital. Osakidetza. Spain
- 1331 Synthesis And Biological Evaluation Of Novel Pyrazole And Pyrazolo[3,4-D]Pyrimidines As Anti-Inflammatory Agents
ABD-EL-AZIZ AS¹, YOUSSEF AM², **NEELAND EG¹**, KLEGERIS A¹
¹University of British Columbia Okanagan, Kelowna, British Columbia, Canada, ²Faculty of Pharmacy, University of Alexandria, Alexandria, Egypt
- 1360 High Dose Ascorbic Acid in Burn Resuscitation
DUBICK MA
US Army Institute of Surgical Research, San Antonio, TX 78234, USA
- 1362 Trial Of Lamivudine In Hepatitis B Surface Antigen Carriers With Persistence Hepatitis B Core IgM Antibody
MOHAMMED ALI HY
Dean, Technical & Health Institute-Zakho, Department of Microbiology & Immunology, College of Medicine, University of Dohuk, Kurdistan Region-Iraq
- 1378 Aptamers As Magic Bullets And Delivery Vehicles In Disease Imaging And Therapy
MISSAILIDIS S
Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK
- 1384 The Thyroid Gland Function Assessment In Women After Mastectomy And Chemotherapy During Breast Cancer Therapy.
MAJKOWSKA-MLYNARCZYK A^{1,3}, KINALSKI M², ZACZEK-KUCHARSKA E³
¹Endocrinological Clinic of District Hospital, Kielce, ²Department of Gynecology of District Hospital, Bialystok, ³Department of Health Natural –Humanistic Uniwwersity, Kielce, Poland
- 1390 Expression of Topoisomerase I and IIa Protein in Primary Colorectal Cancer; is That the Culprit of Recurrent Disease Following 5-Fluorouracil-based Adjuvant Chemotherapy?
TSAVARIS N¹, LAZARIS A², GOUVERIS P¹, KOSMAS C³, KAVANTZAS N², KOPTERIDES P¹, PAPATHOMAS T², ARAPOGIANNIS G², ZORZOS H², KYRIAKOU V², PATSOURIS E²
¹Medical Oncology Unit, "Laikon" University General Hospital, Athens, Greece ²First Department of Pathology, "Laikon" University General Hospital, Athens, Greece ³"Metaxa" Cancer Hospital, Piraeus
- 1412 Comparison of susceptibility against MRSA isolates to the brand vancomycin and manufactured generic drugs
FUJIMURA S¹, FUSE K², WATANABE A¹.
¹ Research Division for Development of Anti-Infective Agents, Institute Development Aging and Cancer, Tohoku University, Sendai, Japan.
² Department of Pharmacy, Tohoku KoseiNenkin Hospital, Sendai, Japan
- 1415 Safety of Etanercept in Elderly Subjects With Rheumatoid Arthritis
LURATI A¹, SCARPELLINI M, RE KA, MARRAZZA MG
Rheumatology Unit, Fornaroli Hospital Magenta italy
- 1422 The ADAM9 Disintegrin Domain (ADAM9D) Inhibits Platelet and Tumor Cell Adhesion to Subendothelial Matrix under Dynamic Flow Conditions
COMINETTI MR¹, MARTIN ACBM¹, RIBEIRO JU¹, FAUVEL-LAFÈVE F², CRÉPIN M², SELISTRE-DE-ARAUJO, HS¹
¹Federal University of São Carlos, SP, Brazil; ²INSERM Unit 553, Paris, France.
- 1422 Inhibition of angiogenesis and melanoma metastasis by DisBa-01, an alphavbeta3-blocking RGD-disintegrin from *Bothrops alternatus* snake venom
SELISTRE-DE-ARAUJO, HS¹, RIBEIRO, JU¹, COMINETTI, MR¹, RAMOS, OHP¹, PONTES, CLS¹, SOUZA, DHF², CREPIN, M³, FAUVEL-LAFEVE, F³ AND BONNEFOY, A^{3,4}
¹Dep. Ciências Fisiológicas, ²Dep. Chemistry, Universidade Federal de São Carlos, São Carlos, SP, Brazil, ³INSERM Unit 553, Paris, France; ⁴INSERM Unit 743, Montreal, QC, Canada
- 1427 The Chick Embryo as a Tool to Discover and Validate New Therapeutic Targets Against Tumor Angiogenesis
JAVERZAT, S^{1,2}, BIKFALVI, A^{1,2}, **HAGEDORN M^{1,2}**
¹ INSERM U920, ELAT (European Laboratory for Angiogenesis and Translational Research), Talence, F-33405, France; Univ Milan, Milan I-20122, Italy; ² Univ Bordeaux 1, Talence, F-33405, France

Abstr. No.	Title
1437	Desipramine and Panic: Complex Approaches to Understand Complex Interactions in Psychopharmacology VIGLIECCA NS ¹ , MOLINA SC ² , PEÑALVA MC ² ¹ Consejo Nacional de Investigaciones Científicas y Técnicas de la Argentina (CONICET) y Servicio de Neurología y Neurocirugía del Hospital Córdoba ^{1,2} Centro de Investigaciones de la Facultad de Filosofía y Humanidades (CIFYH) Córdoba, Argentina
1438	Vitamin K ₃ Is A Potent Inhibitor Of Angiogenesis And DNA Polymerase MATSUBARA K ^{1,2} , KAYASHIMA T ¹ , MIZUSHINA Y ^{2,3} ¹ Hiroshima Univ., Higashihiroshima, Japan; ² Cooperative Research Cent. Life Sci., Kobe-Gakuin Univ., Kobe, Japan; ³ Kobe-Gakuin Univ., Kobe, Japan
1439	Recombinant Viral Vectors as Suitable Surrogates for Antiviral Screening Studies ESIMONE CO ^{1,3} , ECK G ² , DUONG TN ⁴ , ÜBERLA K ³ , PROKSCH P ² ¹ University of Nigeria, Nsukka, Nigeria, ² Heinrich-Heine University, Düsseldorf, Germany, ³ Ruhr University, Bochum, Germany, ⁴ Vietnamese Academy of Science and Technology, Hanoi, Vietnam.
1439	Novel Phyto-antiviral Leads from Aglaia Species ESIMONE CO ^{1,3} , ECK G ² , DUONG TN ⁴ , ÜBERLA K ³ , PROKSCH P ² ¹ University of Nigeria, Nsukka, Nigeria, ² Heinrich-Heine University, Düsseldorf, Germany, ³ Ruhr University, Bochum, Germany, ⁴ Vietnamese Academy of Science and Technology, Hanoi, Vietnam.
1440	<i>Pneumocystis jirovecii</i> Dihydropteroate Synthase Gene Mutations and Sulfa Resistance de la HORRA C ^{1,2} , MORILLA R ¹ , RIVERO L ² , FRIAZA V ¹ , GUTIERREZ S ² , RESPALDIZA N ¹ , MARTIN-JUAN J ³ , MONTES-CANO MA ^{1,4} , MEDRANO FJ ^{1,2} , VARELA JM ^{1,2} , CALDERÓN EJ ^{1,2} ¹ CIBER of Epidemiology and Public Health, ² Internal Medicine, ³ Pneumology and ⁴ Immunology Services, Virgen del Rocío University Hospital, Seville, Spain.
1442	Memorabilia of Paul Ehrlich in modern Strzelin (Strehlen) and Wrocław (Breslau). KUCHAR E , KUCHAR I, SZENBORN L Department of Pediatrics and Infectious Disease, Medical University in Wrocław (Breslau), Poland.
1446	Primary CMF Chemotherapy in Operable Breast Cancer. FALO C , MORENO A, BENITO E, LLOVERAS B, VARELA M, M ^a SERRA J, PRIETO L, AZPEITIA D, ESCOBEDO A. UNITAT FUNCIONAL DE MAMA. Institut Català d'Oncologia. Hospital Duran i Reynals, Hospital Universitari de Bellvitge (Barcelona). Spain.
1447	Isatin (2,3-dioxo-indole) and its Analogues as New Antipyretic Agents TELEGDY G , ADAMIK A, GLOVER V ¹ . Department of Pathophysiology, University of Szeged, Szeged, Hungary, ¹ Institute of Reproductive and Developmental Biology, Imperial College, London, UK.
1459	Combined Targeting of IL6 and VEGF Potently Inhibits Glioma Growth and Invasiveness SAIDI A ^{1,2} , HAGEDORN M ^{1,2} , ALLAIN N ^{1,2} , BIKFALVI A ^{1,2} , JAVERZAT S ^{1,2} ¹ INSERM U920, ELAT (European Laboratory for Angiogenesis and Translational Research), Talence, F-33405, France; Univ Milan, Milan I-20122, Italy; ² Univ Bordeaux 1, Talence, F-33405, France
1460	The role of corticosteroids, male and female sex hormones in a complex with apolipoprotein A-I in the regulation of gene expression PANIN LE State Research Institute of Biochemistry SD RAMS, Timakov str. 2, Novosibirsk, Russia
1466	Cardiological medicines: allowed and prohibited pharmacological helping for athletes PILKOWSKI SM ¹ , POKRYWKA A ² , KWIATKOWSKA D ² , MAMCARZ A ¹ ¹ III Department of Internal Medicine and Cardiology, II Medical Faculty of Warsaw Medical University, Warsaw, Poland ² Department of Anti-Doping Research, Institute of Sport, Warsaw, Poland
1472	Isoaspartate-glycine-arginine (isoDGR): a new tumor vascular targeting motif CURNIS F ¹ , SACCHI A ¹ , GASPARRI A ¹ , LONGHI R ² , BACHI A ¹ , DOGLIONI C ¹ , BORDIGNON C ³ , CATIA TRAVERSARI ³ , RIZZARDI G-P ³ , CORTI A ¹ ¹ DIBIT-Department of Oncology, CIGT Program and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, Milan, Italy; ¹ Istituto di Chimica del Riconoscimento Molecolare, CNR, Milan, Italy; ³ MolMed SpA, Milan, Italy.
1472	Spontaneous Formation of L-isoAspartate and Gain-of-Function in Fibronectin CURNIS F , LONGHI R ¹ , CRIPPA L, CATTANEO A, DONDOSSOLA E, BACHI A, CORTI A DIBIT-Department of Oncology, CIGT Program and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, Milan, Italy; ¹ Istituto di Chimica del Riconoscimento Molecolare, CNR, Milan, Italy.
1477	Anti-Inflammatory, Analgesic And Antipyretic Activities Of Physalis Minima Linn KHAN MA ^{1,2} , KHAN H ³ , KHAN S ⁴ , MAHMOOD T ² , KHAN PM ⁴ , JABAR A ⁵ ¹ Department of Chemistry, Kohat University of Science and Technology, Kohat Pakistan, ² Pakistan Council of Scientific and Industrial Research Laboratories Complex, Peshawar, Pakistan, ³ Gandhara College of Pharmacy, Gandhara University, Peshawar, Pakistan, ⁴ Department of Chemistry, Jehanzeb Postgraduate College, Swat, Pakistan, ⁵ Department of Chemistry, Islamia University, Bahawalpur, Pakistan
1486	Altered Morphine Metabolism In Asphyxiated Term Neonates During Prolonged, Moderate Whole Body Hypothermia Treatment ROKA A ¹ , KELEN D ¹ , VASARHELYI B ² , AZZOPARDI D ³ , SZABO M ¹ ¹ First Department of Paediatrics, Semmelweis University, Budapest, Hungary, ² Research Group of Paediatrics and Nephrology, Hungarian Academy of Sciences, Budapest, Hungary, ³ Division of Clinical Sciences, Hammersmith Campus, Imperial College, London, UK
1487	Peritoneal Transport Dynamics of Icodextrin and Its Influence on The Membrane Permeability In Vitro CZYZEWSKA K , GRZELAK T, SZARY B Poznan Univ. Med. Sci., Poznan, Poland

Abstr. No.	Title
1488	Rationale for the use of memantine in the treatment of glaucoma and other neurodegenerative disease. HARE WA, WHEELER L Allergan Inc.; Irvine, CA; USA
1489	Nongenomic Corticosteroid-adrenergic Drug Interactions in the Airway HORVATH G ^{1,2} , MENDES ES ² , SCHMID N ² , SCHMID A ² , CONNER GE ² , SALATHE M ² , WANNER A ² ¹ Semmelweis Univ., Budapest, Hungary; ² Univ. of Miami, Miami, FL, USA
1530	Engineering Human Bak Proteoliposomes: a New Approach for the Treatment of Glioblastoma LIGUORI L, LENORMAND J-L HumProTher laboratory, TheRex-GREPI, TIMC-IMAG Laboratory, University Joseph Fourier, UFR de Medecine, Domaine de la Merci, 38706 La Tronche, France.
1532	How To Implement Pharmaceutical Care In The Curriculum?: The Cuban Pharmacy Education Experiences MARTINEZ-SANCHEZ AM Pharmacy Department, University of Oriente, Santiago de Cuba - Cuba
1535	Designing Material of Particular Equilibrium and Transport Properties by <i>Ab Initio</i> Molecular Dynamics GHATEE, MH ¹ and ZARE, M, JAHROMI, F, MOOSAVI, F ¹ ¹ Shiraz University, Shiraz, Iran
1542	Association between Polymorphisms of Vitamin D Metabolizing Enzymes and Colorectal Cancer Incidence FLÜGGE J ^{1,2} , KRUSEKOPF S ¹ , GOLDAMMER M ¹ , KLARE S ³ , MALZAHN U ¹ , ROOTS I ¹ ¹ Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany; ² Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany ³ CENiMED GmbH, Center for Individualized Medicine – Clinical Pharmacogenomics, Berlin, Germany
1548	Magic bullets in prostate cancer ABDELBAKY A, HUSSAIN M, KAISARY AV Department of Urology, The Royal Free NHS Trust, London, U.K.
1550	Limitations of Non-magic Bullets Compounds in Bioequivalence Assessment. How Can this Enhance Knowledge Towards the Development of Generic Products. The Mycophenolate Mofetil Case. FRANCO SPINOLA AC ¹ , ALMEIDA S ¹ , FILIPE A ¹ , NEVES R ¹ ¹ Grupo Tecnimede, Sintra, Portugal.
1558	Identification of the anti-inflammatory targets of interactive constituents of <i>Hypericum perforatum</i> (Hp). BIRT DF and HAMMER KDP Dept. of Food Sci. & Human Nutr., Iowa State Univ., Ames, IA.
1559	Is The Induction Chemotherapy Response- And Recurrence Rate Depend On N0 Or N+ Stage In Oral Squamous Cell Cancer? OLASZ L ¹ , NYARADY Z ^{1,2} , SZALMA J ¹ , ORSI E ¹ ¹ University Pécs, Department of Oral and Maxillofacial Surgery, Hungary; ² University Szeged, Department of Dentistry, Oral and Maxillofacial Surgery, Hungary
1559	Is The Induction Chemotherapy Response- And Recurrence Rate Depend On N0 Or N+ Stage In Oral Squamous Cell Cancer? OLASZ L ¹ , NYARADY Z ^{1,2} , SZALMA J ¹ , ORSI E ¹ ¹ University Pécs, Department of Oral and Maxillofacial Surgery, Hungary; ² University Szeged, Department of Dentistry, Oral and Maxillofacial Surgery, Hungary
1560	Detemir Insulin in Type 1 and Type 2 Diabetes PETERSON GE Diagnostic & Critical Care Medicine, The Diabetes Center, 411 Laurel Street, Suite 3275, Des Moines, USA
1564	Psychoncology And Psychoneuroendocrinology (PNEI): Relation Between The Anticancer Immunity And The Psychospiritual Status Of Cancer Patients MESSINA G ¹ , LISSONI P, BRIVIO F ¹ Psychological Service, Policlinico Maggiore Hospital, University of Milan Department of Oncology, San Gerardo Hospital, Monza, Milan
1568	Toxic Effect Of Homocysteine On Nervous And Immune System KARPOVA L (1,2), BRYUSHKOVA E (2), MAKHRO A (2), MASHKINA A (1,2), SOLENAYA O (2), BULYGINA E (1,2), VLADYCHENSKAYA E (2), STEPANOVA M (1), FEDOROVA T (1), BOLDYREV A(1,2) 1 - Research Center of neurology, Russian Academy of medical sciences, Moscow, Russia 2 – International Biotechnological Center of M.V. Lomonosov Moscow state University
1569	H pylori: Treatment for the patient only or the whole family? SARI YS, CAN D , TUNALI V, SAHIN O, KOC O, BENDER O. SB Istanbul Training Hospital, Istanbul, Turkey
1582	Pharmacokinetics And Effects On Adenosine Concentration Of A New 4-Anilinoquinazoline Derivative In Rats ROCCO SA ¹ , MARIN RM ¹ , THEIZEN TH ¹ , LIMA J ¹ , GUIDO, MC ¹ , FRANCHINI KG ¹ ¹ State University of Campinas, Campinas, Brazil
1583	17-year Survey of Triclosan Efficacy on Supragingival Plaque HARASZTHY V ¹ , ZAMBON JJ ¹ , SREENIVASAN PK ² , DE VIZIO W ² ¹ University at Buffalo, NY, USA, ² Colgate Palmolive Company, Piscataway, NJ, USA
1584	Effect of Inoculum Size on the Antibiotic Susceptibilities of Enterobacteriaceae Producing Shv and Ctx-M Extended-Spectrum Beta-Lactamases BEDENIC B ^{1,2} , VRANES J ^{1,3} , PLECKO V ^{1,2} , MATULIC-BEDENIC I ⁴ , KALENIC S ^{1,2} ¹ School of Medicine, University of Zagreb, Zagreb; ² Department of Clinical and Molecular Microbiology, Clinical Hospital Center Zagreb ³ Zagreb Institute of Public Health, Zagreb; ⁴ Trg Bana Jelacica 3 (retired)

Abstr. No.	Title
1591	Mast cells infiltrate the thalamus as part of the CNS nociceptive response DUBAYLE D* , MENETREY D CNRS UMR 8119, Neurophysique et Physiologie Université Paris Descartes, UFR Biomédicale, 45 rue des Saints Pères, 75270 Paris Cedex 06, France
1596	Paul Ehrlich And The Search For Magic Bullets McKENZIE MW College of Pharmacy, University of Florida, Gainesville, FL USA
1597	Naked Models of Compound I of Heme Enzymes CRESTONI ME , FORNARINI S Università "La Sapienza", Roma, Italy
1602	Magic Bullets in Removing <i>Enterococcus faecalis</i> Biofilms. ARIAS-MOLIZ MT ¹ , FERRER-LUQUE CM ¹ , ESPIGARES-RODRÍGUEZ E ² , PÉREZ-HEREDIA M ¹ , BACA-GARCÍA P ¹ ¹ School of Dentistry, University of Granada, Spain; ² School of Pharmacy, University of Granada, Spain.
1606	The in vitro effects of Thymoquinone on human endometrial adenocarcinoma cells TIMURKAN H ¹ , BULUT H ¹ , RISVANLI A ¹ , AYDIN S ¹ , GURATES B ¹ , YEKELER H ² , TIMURKAN O ³ ¹ University of Firat, Elazig, Turkey; ² Hospital of Research and Education Elazig, Turkey; ³ University of Ankara, Ankara, Turkey
1607	Capitalizing on CYP450 polymorphism in HIV treatment optimization TO KW ¹ , LEE SS ^{2,3} , Chan DPC ³ , LIU ST ⁴ , LEE KCK ¹ , CHEUNG SW ² , CHAN CY ² . ¹ Department of Medicine and Therapeutics, ² Department of Microbiology, ³ Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong; ⁴ East Lake Hospital, Shenzhen, PRC
1613	Gold activates mast cells through L- type calcium channels. HAYAMA K ^{1,2} , SUZUKI Y ¹ , YOSHIMARU T ¹ , INOUE T ¹ , RA C ¹ 1:Nihon University Graduate School of Medical Science, Tokyo, Japan 2:Department of Dermatology, Nihon university School of Medicine, Tokyo ,Japan
1621	Estradiol as Membrane Targeting Modulator of Neuronal Cell Functions HORVAT A , PETROVIC S Institute of Nuclear Sciences "Vinca", Belgrade, Serbia
1723	Development of Nonviral Gene Vectors for Gene Delivery to the Lungs and Blood Cells ÜZGÜN, S ^{1,2} , GEIGER, JP ^{1,2} , ANEJA, MK ¹ , RUDOLPH, C ^{1,2} ¹ Ludwig-Maximilians University Munich, Germany ² Free University of Berlin, Germany
1743	Bringing Light Into the Dark: Influence of Fluorescence Labeling on Protein Nanoparticles for <i>in-vivo</i> Use BROERMANN P, SCHULTES S , COESTER C Ludwig Maximilians University, Munich, Germany
1766	Si Quantum Dots functionalized for siRNA delivery in Caco-2 cells KLEIN S ¹ , KRYSCHI C ¹ , NEUHUBER W ² , SCHRÖDL F ² , ZOLK O ³ ¹ Dept. Chemistry and Pharmacy, ² Chair of Clinical Pharmacology and Clinical Toxicology, ³ Chair of Anatomy 1, University of Erlangen, Erlangen, Germany.
1768	A Novel Biomimetical Transformation to Construct Natural Product Frameworks T.Muljati , M.Kalesse Institute for Organic Chemistry, Leibniz University of Hannover, Hannover, Germany.
1777	Consequences to morphology of primary neurons as an effect of Nitric Oxide on plasma membrane fluidity HIPPE S Ruhr-Universität Bochum, Lehrstuhl für Molekulare Neurobiochemie, Universitätsstraße 150, 44780 Bochum Germany

Symposia in German

Satellitensymposium MSD

Samstag, 04.10.2008 09.30 – 11.00 Uhr

Alexander - Fleming - Hall

Wyeth Satellitensymposium

Neue Optionen in der Resistenzeindämmung auf der Intensivstation

Samstag, 4.10.2008 11.00 - 12.30 Uhr

Alexander - Fleming - Hall

Lunchsymposium Pfizer

Neue Optionen in der Resistenzeindämmung auf der Intensivstation

Samstag, 4.10.2008 13.00 - 14.30 Uhr

Alexander - Fleming – Hall

Satellitensymposium MSD

Samstag, 04.10.08 09.30 – 11.00 Uhr

Alexander - Fleming - Hall

"Antiiinfektive Therapiestrategien bei kritisch kranken Patienten auf der ICU"

Vorträge:

"Antiiinfektive Therapie aus Sicht der Mikrobiologie"

Prof. Dr. med. Franz-Josef Schmitz
Johannes Wesling Klinikum Minden
Zweckverband Kliniken im Mühlkreis
Hans-Nolte-Straße 1
32429 Minden

"Aktuelle Aspekte zur Antibiotischen Therapie schwerer Infektionen"

Dr. med. Klaus Friedrich Bodmann
Klinik für Kardiologie, Angiologie, Intensivmedizin (Medizinische Klinik I)
Klinikum Hildesheim GmbH
Weinberg 1
31134 Hildesheim

"Antimykotische Therapiestrategien bei kritisch kranken Patienten auf der ICU"

Dr. med. Rainer Höhl
Klinik für Anästhesiologie und operative Intensivmedizin
Klinikum Nürnberg Nord
Prof.-Ernst-Nathan-Straße 1
90419 Nürnberg

Wyeth Satellitensymposium

Neue Optionen in der Resistenz Eindämmung auf der Intensivstation

4.10.2008, 11.00 - 12.30 Uhr

Chair: K.-F. Bodmann, Hildesheim

Referenten:

F.-J. Schmitz, Minden

Vorteile der Klassenerweiterung bei Antibiotika aus mikrobiologischer Sicht

K.-F. Bodmann, Hildesheim:

"Neue Aspekte in der Therapie schwerer nosokomialer Infektionen".

F. Sörgel, Nürnberg:

Betrachtung der Guidelines unter PK / PD Gesichtspunkten

Lunchsymposium Pfizer

Multiresistente Erreger: Neue Aspekte in Therapie und Diagnostik

Samstag, 4. Oktober 2008
13:00 – 14:30 Uhr
Alexander-Fleming-Hall

Moderation: Prof. Dr. Fritz Sörgel, Nürnberg

Mikrobiologische Aspekte Prof. M. Trautmann, Stuttgart

100 Jahre Antibiotika seit Ehrlich und die Resistenzentwicklungen gegen sie – Wie wir heute mit Pharmakokinetik und Pharmakodynamik der Resistenzsituation Herr werden wollen.
Prof. F. Sörgel, Nürnberg

Therapeutische Optionen des Kliniklers Dr. K.-F. Bodmann, Hildesheim

Fortbildung der Bayerischen Landesapothekerkammer

Samstag, **04.Oktober** von 10:00 bis ca. 17:15 Uhr,

Georg-Simon-Ohm Hochschule, Bahnhofstr. 87, 90402 Nürnberg.

Raum Paul Karrer Hall

Kursnummer: BYA084151

Programm

(Die Themen sind als Arbeitstitel geführt, Abweichungen im Ablauf und Umstellungen bei den Referenten sind möglich)

10:00 – 10:10 Uhr	Begrüßung
10:10 – 10:45 Uhr	Was gibt es neues auf dem Markt der Antiinfektiva? Prof. Dr. Ulrike Holzgrabe
10:45 – 11:30 Uhr	Pharmakokinetik und Pharmakodynamik von Antiinfektiva Prof. Hartmut Derendorf, Gainesville, Florida
11:30 – 12:15 Uhr	HNO – Infektionen und ihre Leitlinien konforme Behandlung - Für die Apothekenpraxis relevantes Wissen. Prof Dr. W. Elies, Berlin
12:15 – 13:00 Uhr	Harnwegsinfektionen im Alter – der immer wieder kehrende Patient Prof. Dr. Kurt Naber, Straubing
13:00 – 14:00 Uhr	Mittagspause
14:00 – 14:45 Uhr	Ambulant erworbene Pneumonie – die üblichen Fehler in der ambulanten Therapie. - Wie der Apotheker die Therapie unterstützen kann Privatdozent Dr. Strauß
14:45 – 15:30 Uhr	Wichtige Arzneimittelinteraktionen von Antiinfektiva in der Praxis Prof. Dr. F. Sörgel, Nürnberg
15:30 – 16:15 Uhr	Die vielen Facetten einer Antiviralen Therapie – vom Lippen-Herpes bis zur Vakzinierung gegen HPV-Infektion N.N.
16:15 – 17:00 Uhr	Die nächste Grippewelle kommt bestimmt – und der Apotheker ist gefragt! Prof. Dr. E. Vogel, München
17:00 – 17:10 Uhr	Diskussion und Schlusswort

HNO-INFEKTIOLOGISCHE FORTBILDUNGSVERANSTALTUNG der Arbeitsgemeinschaft HNO-Infektiologie der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie

am Sonntag, den 5. Oktober 2008 von 9.00 – 15.00 Uhr
in Nürnberg, Georg-Simon-Ohm-Hochschule, Bahnhofstrasse 87
Raum Paul Karrer Hall

im Rahmen der Veranstaltung „World Conference on Magic Bullets“
zum 100. Jahrestag der Verleihung des Nobel Preises an Paul Ehrlich

V o r s i t z:

Prof. P. Federspil, Homburg / Saar, Prof. W. Elies, Berlin

P r o g r a m m

- | | |
|-----------|---|
| 09.00 Uhr | Empfang der Teilnehmer Eröffnung der Industrieausstellung |
| 09.15 Uhr | Begrüßung und Einleitung: HNO-Antibiotikatherapie kritisch betrachtet,
Prof. P. Federspil, Homburg/Saar |
| 09.30 Uhr | Derzeitige Empfindlichkeit der häufigsten HNO-Erreger in Deutschland,
Prof. M. Fischer, Heidelberg |
| 09.55 Uhr | In der Praxis wichtige Nahrungs- und Arzneimittelinteraktionen,
Prof. F. Sörgel, Nürnberg |
| 10.15 Uhr | Aktuelles zur Pneumokokken-Impfung und zum Impfkalendar,
Prof. D. Adam, München |
| 10.35 Uhr | Pause / Fachausstellung / Paul – Ehrlich - Ausstellung |
| 10.50 Uhr | Antibiotikatherapie bei immunsupprimierten Patienten,
Dr. F. Waldfahrer, Erlangen |
| 11.15 Uhr | Neue Antibiotika, Prof. D. Adam, München |
| 11.30 Uhr | Aktuelles zur Therapie der akuten Otitis media und Mastoiditis,
PD A. Koch, Luxemburg |
| 12.00 Uhr | Kontroversen zur Therapie der akuten Pharyngitis,
Prof. J. Strutz, Regensburg |
| 12.20 Uhr | Imbiß / Fachausstellung / Paul – Ehrlich - Ausstellung |
| 13.00 Uhr | Epidemiologie und notwendige Antibiotikatherapie der akuten und chronischen
Rhin sinusitis, Prof. W. Elies, Berlin |
| 13.30 Uhr | Zur neuen Antibiotika-Endokarditisprophylaxe, PD Ch. Naber, Essen. |
| 13.50 Uhr | Unerlässliche Hygienestandards in der HNO-Praxis und Ambulanz im Zeitalter von
MRSA, Dr. I. Johnscher, Nürnberg |
| 14.20 Uhr | Warum KISS (Krankenhaus-Infektions-Surveillance System) in der HNO, Prof. P.
Federspil, Homburg/Saar |
| 14.40 Uhr | Aktuelles zur Therapie der Otitis externa, Prof. P. Federspil, Homburg/Saar |
| 15.00 Uhr | Ausgabe der Zertifikate (6 Punkte) und Verabschiedung |